EP2398793B1 - Novel substituted benzoxazole, benzimidazole, oxazolopyridine and imidazopyridine derivatives as gamma secretase modulators - Google Patents
Novel substituted benzoxazole, benzimidazole, oxazolopyridine and imidazopyridine derivatives as gamma secretase modulators Download PDFInfo
- Publication number
- EP2398793B1 EP2398793B1 EP10706973.4A EP10706973A EP2398793B1 EP 2398793 B1 EP2398793 B1 EP 2398793B1 EP 10706973 A EP10706973 A EP 10706973A EP 2398793 B1 EP2398793 B1 EP 2398793B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- alkyl
- methyl
- halo
- substituents
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- VHNYOQKVZQVBLC-RTCGXNAVSA-N (4r,7e,9as)-7-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]-4-(3,4,5-trifluorophenyl)-1,3,4,8,9,9a-hexahydropyrido[2,1-c][1,4]oxazin-6-one Chemical compound C1([C@@H]2COC[C@@H]3CC\C(C(N32)=O)=C/C=2C=C(C(=CC=2)N2C=C(C)N=C2)OC)=CC(F)=C(F)C(F)=C1 VHNYOQKVZQVBLC-RTCGXNAVSA-N 0.000 title abstract description 7
- 229940124648 γ-Secretase Modulator Drugs 0.000 title abstract description 7
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical class C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 title abstract description 4
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical class C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 title abstract description 3
- BFPLMTPHDFFMTG-UHFFFAOYSA-N [1,3]oxazolo[5,4-b]pyridine Chemical class C1=CN=C2OC=NC2=C1 BFPLMTPHDFFMTG-UHFFFAOYSA-N 0.000 title abstract description 3
- 125000004857 imidazopyridinyl group Chemical class N1C(=NC2=C1C=CC=N2)* 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 286
- 239000003814 drug Substances 0.000 claims abstract description 20
- 239000004480 active ingredient Substances 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 201
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 167
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 153
- -1 C1-4alkyloxy Chemical group 0.000 claims description 142
- 229910052739 hydrogen Inorganic materials 0.000 claims description 136
- 239000001257 hydrogen Substances 0.000 claims description 136
- 125000001424 substituent group Chemical group 0.000 claims description 125
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 104
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 63
- 150000003839 salts Chemical class 0.000 claims description 62
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 58
- 125000002757 morpholinyl group Chemical group 0.000 claims description 50
- 125000003386 piperidinyl group Chemical group 0.000 claims description 49
- 208000024827 Alzheimer disease Diseases 0.000 claims description 44
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 40
- 239000012453 solvate Substances 0.000 claims description 38
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 30
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 29
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 25
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims description 19
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 17
- 125000001544 thienyl group Chemical group 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 125000004076 pyridyl group Chemical group 0.000 claims description 16
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 15
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 15
- 206010012289 Dementia Diseases 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 14
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 12
- 125000002971 oxazolyl group Chemical group 0.000 claims description 12
- 125000000335 thiazolyl group Chemical group 0.000 claims description 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 12
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 11
- 125000002541 furyl group Chemical group 0.000 claims description 11
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 11
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 11
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 11
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 11
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 11
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 11
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 11
- 125000004946 alkenylalkyl group Chemical group 0.000 claims description 10
- IOIDROQCESKQOG-UHFFFAOYSA-N 2-(4-fluoro-3-methoxyphenyl)-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methylbenzimidazol-4-amine Chemical compound C1=C(F)C(OC)=CC(C=2N(C3=CC=CC(NC=4N=C(OC)C(=CC=4)N4C=C(C)N=C4)=C3N=2)C)=C1 IOIDROQCESKQOG-UHFFFAOYSA-N 0.000 claims description 9
- ZQYDYFCAHHBFKE-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methylbenzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=C(F)C=C1 ZQYDYFCAHHBFKE-UHFFFAOYSA-N 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 9
- 201000010374 Down Syndrome Diseases 0.000 claims description 8
- 208000010877 cognitive disease Diseases 0.000 claims description 8
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 8
- UWYCETWPMNHOLB-UHFFFAOYSA-N n-[3-fluoro-4-(4-methylimidazol-1-yl)phenyl]-2-(4-fluorophenyl)-1,6-dimethylimidazo[4,5-c]pyridin-4-amine Chemical compound C1=NC(C)=CN1C(C(=C1)F)=CC=C1NC1=NC(C)=CC2=C1N=C(C=1C=CC(F)=CC=1)N2C UWYCETWPMNHOLB-UHFFFAOYSA-N 0.000 claims description 8
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims description 7
- 208000005314 Multi-Infarct Dementia Diseases 0.000 claims description 7
- 206010039966 Senile dementia Diseases 0.000 claims description 7
- 206010044688 Trisomy 21 Diseases 0.000 claims description 7
- 201000004810 Vascular dementia Diseases 0.000 claims description 7
- OITPWPVYACUEFN-UHFFFAOYSA-N 2-(2,3-difluorophenyl)-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methylbenzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=CC(F)=C1F OITPWPVYACUEFN-UHFFFAOYSA-N 0.000 claims description 6
- BVTQXWYJRCHRAT-UHFFFAOYSA-N 2-(3,5-dimethoxyphenyl)-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methylbenzimidazol-4-amine Chemical compound COC1=CC(OC)=CC(C=2N(C3=CC=CC(NC=4N=C(OC)C(=CC=4)N4C=C(C)N=C4)=C3N=2)C)=C1 BVTQXWYJRCHRAT-UHFFFAOYSA-N 0.000 claims description 6
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 6
- 201000002832 Lewy body dementia Diseases 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 5
- 230000009529 traumatic brain injury Effects 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 229910006069 SO3H Inorganic materials 0.000 claims description 3
- 125000001475 halogen functional group Chemical group 0.000 claims 37
- 150000002431 hydrogen Chemical group 0.000 claims 18
- 238000000034 method Methods 0.000 abstract description 57
- 230000008569 process Effects 0.000 abstract description 7
- 239000000543 intermediate Substances 0.000 description 442
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 309
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 303
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 184
- 239000008279 sol Substances 0.000 description 167
- 238000002360 preparation method Methods 0.000 description 147
- 239000000203 mixture Substances 0.000 description 139
- 125000005843 halogen group Chemical group 0.000 description 126
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 92
- 239000000047 product Substances 0.000 description 91
- 239000002904 solvent Substances 0.000 description 91
- 238000006243 chemical reaction Methods 0.000 description 84
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 78
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 78
- 239000012044 organic layer Substances 0.000 description 77
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 76
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 66
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 66
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 65
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 57
- 239000003480 eluent Substances 0.000 description 57
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 56
- 239000012071 phase Substances 0.000 description 56
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 53
- 108010037444 diisopropylglutathione ester Proteins 0.000 description 52
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 50
- 238000003818 flash chromatography Methods 0.000 description 45
- 239000000741 silica gel Substances 0.000 description 45
- 229910002027 silica gel Inorganic materials 0.000 description 45
- 229960001866 silicon dioxide Drugs 0.000 description 45
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 44
- 239000012299 nitrogen atmosphere Substances 0.000 description 44
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 37
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 36
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 36
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 36
- 230000000694 effects Effects 0.000 description 34
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 34
- 239000007787 solid Substances 0.000 description 34
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 33
- 229910000024 caesium carbonate Inorganic materials 0.000 description 33
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 32
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 31
- 239000002585 base Substances 0.000 description 31
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 28
- 239000002253 acid Substances 0.000 description 28
- 235000019439 ethyl acetate Nutrition 0.000 description 28
- 238000002474 experimental method Methods 0.000 description 28
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 28
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 27
- 239000000706 filtrate Substances 0.000 description 27
- 239000000243 solution Substances 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 26
- 239000012074 organic phase Substances 0.000 description 26
- 238000002953 preparative HPLC Methods 0.000 description 26
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 25
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 25
- 239000005909 Kieselgur Substances 0.000 description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 102000005650 Notch Receptors Human genes 0.000 description 21
- 108010070047 Notch Receptors Proteins 0.000 description 21
- 229910052801 chlorine Inorganic materials 0.000 description 19
- 210000004556 brain Anatomy 0.000 description 18
- 229910052794 bromium Inorganic materials 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 18
- 229910000027 potassium carbonate Inorganic materials 0.000 description 18
- 239000003054 catalyst Substances 0.000 description 17
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 16
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 16
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 16
- 125000004432 carbon atom Chemical group C* 0.000 description 16
- 239000012298 atmosphere Substances 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 229920006395 saturated elastomer Polymers 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 239000002244 precipitate Substances 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 239000000758 substrate Substances 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 11
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 11
- 150000001412 amines Chemical class 0.000 description 11
- 239000012442 inert solvent Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 229910052740 iodine Inorganic materials 0.000 description 11
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 11
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 11
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 229910052751 metal Inorganic materials 0.000 description 10
- 239000002184 metal Substances 0.000 description 10
- 238000012545 processing Methods 0.000 description 10
- 230000002285 radioactive effect Effects 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- 229910052731 fluorine Inorganic materials 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- XLSZMDLNRCVEIJ-UHFFFAOYSA-N 4-methylimidazole Chemical compound CC1=CNC=N1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 description 8
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 8
- 0 C**=C(C(N)=C(*)N*)*#N Chemical compound C**=C(C(N)=C(*)N*)*#N 0.000 description 8
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 239000005457 ice water Substances 0.000 description 8
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 229930192474 thiophene Natural products 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 7
- 150000003840 hydrochlorides Chemical group 0.000 description 7
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 7
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 230000009261 transgenic effect Effects 0.000 description 7
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 6
- 229920000858 Cyclodextrin Polymers 0.000 description 6
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 229910004879 Na2S2O5 Inorganic materials 0.000 description 6
- 102000015499 Presenilins Human genes 0.000 description 6
- 108010050254 Presenilins Proteins 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 150000001298 alcohols Chemical class 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 6
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 6
- 239000003643 water by type Substances 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 238000005917 acylation reaction Methods 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 229960004853 betadex Drugs 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 238000009833 condensation Methods 0.000 description 5
- 230000005494 condensation Effects 0.000 description 5
- BERDEBHAJNAUOM-UHFFFAOYSA-N copper(i) oxide Chemical compound [Cu]O[Cu] BERDEBHAJNAUOM-UHFFFAOYSA-N 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 5
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Substances [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 238000004007 reversed phase HPLC Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- PKXWXXPNHIWQHW-RCBQFDQVSA-N (2S)-2-hydroxy-3-methyl-N-[(2S)-1-[[(5S)-3-methyl-4-oxo-2,5-dihydro-1H-3-benzazepin-5-yl]amino]-1-oxopropan-2-yl]butanamide Chemical compound C1CN(C)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](O)C(C)C)C2=CC=CC=C21 PKXWXXPNHIWQHW-RCBQFDQVSA-N 0.000 description 4
- KHGOIOOGUJMLBQ-UHFFFAOYSA-N 1-(4-bromo-2-methoxyphenyl)-4-methylimidazole Chemical compound COC1=CC(Br)=CC=C1N1C=C(C)N=C1 KHGOIOOGUJMLBQ-UHFFFAOYSA-N 0.000 description 4
- CZKLEJHVLCMVQR-UHFFFAOYSA-N 4-fluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1 CZKLEJHVLCMVQR-UHFFFAOYSA-N 0.000 description 4
- PZKFSRWSQOQYNR-UHFFFAOYSA-N 5-methyl-1h-1,2,4-triazole Chemical compound CC1=NC=NN1 PZKFSRWSQOQYNR-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 108090000331 Firefly luciferases Proteins 0.000 description 4
- 229940125373 Gamma-Secretase Inhibitor Drugs 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 229910004878 Na2S2O4 Inorganic materials 0.000 description 4
- 239000007832 Na2SO4 Substances 0.000 description 4
- 102000003992 Peroxidases Human genes 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 108010052090 Renilla Luciferases Proteins 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 4
- 230000010933 acylation Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 238000000423 cell based assay Methods 0.000 description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- IBTSWKLSEOGJGJ-UHFFFAOYSA-N (3-acetamidophenyl)boronic acid Chemical compound CC(=O)NC1=CC=CC(B(O)O)=C1 IBTSWKLSEOGJGJ-UHFFFAOYSA-N 0.000 description 3
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 3
- VFPAOFBPEYCAAZ-UHFFFAOYSA-N 1-bromo-3-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=C(F)C=CC=C1Br VFPAOFBPEYCAAZ-UHFFFAOYSA-N 0.000 description 3
- JXIJUAWSDBACEB-UHFFFAOYSA-N 1-chloro-2-methoxy-4-nitrobenzene Chemical compound COC1=CC([N+]([O-])=O)=CC=C1Cl JXIJUAWSDBACEB-UHFFFAOYSA-N 0.000 description 3
- XIRRDAWDNHRRLB-UHFFFAOYSA-N 2,6-dibromoaniline Chemical compound NC1=C(Br)C=CC=C1Br XIRRDAWDNHRRLB-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- 208000037259 Amyloid Plaque Diseases 0.000 description 3
- DWJXYEABWRJFSP-XOBRGWDASA-N DAPT Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)OC(C)(C)C)C=1C=CC=CC=1)C(=O)CC1=CC(F)=CC(F)=C1 DWJXYEABWRJFSP-XOBRGWDASA-N 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000001116 FEMA 4028 Substances 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- YNHIGQDRGKUECZ-UHFFFAOYSA-L PdCl2(PPh3)2 Substances [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 3
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 238000006069 Suzuki reaction reaction Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 229940125844 compound 46 Drugs 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000011977 dual antiplatelet therapy Methods 0.000 description 3
- 238000000132 electrospray ionisation Methods 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000000833 heterodimer Substances 0.000 description 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 150000002460 imidazoles Chemical class 0.000 description 3
- 229940127121 immunoconjugate Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 3
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 239000006199 nebulizer Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 229920000137 polyphosphoric acid Polymers 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 229950001900 semagacestat Drugs 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 3
- 150000003852 triazoles Chemical class 0.000 description 3
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 3
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
- RUBQQRMAWLSCCJ-UHFFFAOYSA-N 1,2-difluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C(F)=C1 RUBQQRMAWLSCCJ-UHFFFAOYSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- AZNKKZHZGDZSIF-UHFFFAOYSA-N 1-fluoro-2-methoxy-4-nitrobenzene Chemical compound COC1=CC([N+]([O-])=O)=CC=C1F AZNKKZHZGDZSIF-UHFFFAOYSA-N 0.000 description 2
- RTXYIHGMYDJHEU-UHFFFAOYSA-N 2,4-dichloro-3-nitropyridine Chemical compound [O-][N+](=O)C1=C(Cl)C=CN=C1Cl RTXYIHGMYDJHEU-UHFFFAOYSA-N 0.000 description 2
- JOAKHTWYUAHAOH-UHFFFAOYSA-N 2-(2-fluoro-5-methoxyphenyl)-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methylbenzimidazol-4-amine Chemical compound COC1=CC=C(F)C(C=2N(C3=CC=CC(NC=4N=C(OC)C(=CC=4)N4C=C(C)N=C4)=C3N=2)C)=C1 JOAKHTWYUAHAOH-UHFFFAOYSA-N 0.000 description 2
- JCSFFHFILQRTEF-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-1-propan-2-ylbenzimidazol-4-amine Chemical compound C=1C=C(N2N=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1N(C(C)C)C=2C1=CC=C(F)C=C1 JCSFFHFILQRTEF-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 2
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 2
- IOCXBXZBNOYTLQ-UHFFFAOYSA-N 3-nitrobenzene-1,2-diamine Chemical compound NC1=CC=CC([N+]([O-])=O)=C1N IOCXBXZBNOYTLQ-UHFFFAOYSA-N 0.000 description 2
- SVSUYEJKNSMKKW-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-prop-1-en-2-yl-1,3,2-dioxaborolane Chemical compound CC(=C)B1OC(C)(C)C(C)(C)O1 SVSUYEJKNSMKKW-UHFFFAOYSA-N 0.000 description 2
- NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 102100029470 Apolipoprotein E Human genes 0.000 description 2
- 101710095339 Apolipoprotein E Proteins 0.000 description 2
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 2
- UHNRLQRZRNKOKU-UHFFFAOYSA-N CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O Chemical compound CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O UHNRLQRZRNKOKU-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- MPXDAIBTYWGBSL-UHFFFAOYSA-N Cc(c(F)c1)ccc1F Chemical compound Cc(c(F)c1)ccc1F MPXDAIBTYWGBSL-UHFFFAOYSA-N 0.000 description 2
- OSIGJGFTADMDOB-UHFFFAOYSA-N Cc1cc(OC)ccc1 Chemical compound Cc1cc(OC)ccc1 OSIGJGFTADMDOB-UHFFFAOYSA-N 0.000 description 2
- 240000004307 Citrus medica Species 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 206010015719 Exsanguination Diseases 0.000 description 2
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 229910006124 SOCl2 Inorganic materials 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 2
- RYXZOQOZERSHHQ-UHFFFAOYSA-N [2-(2-diphenylphosphanylphenoxy)phenyl]-diphenylphosphane Chemical compound C=1C=CC=C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)C=1OC1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RYXZOQOZERSHHQ-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 2
- 238000010256 biochemical assay Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 229910052729 chemical element Inorganic materials 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000005595 deprotonation Effects 0.000 description 2
- 238000010537 deprotonation reaction Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- XWRLQRLQUKZEEU-UHFFFAOYSA-N ethyl(hydroxy)silicon Chemical class CC[Si]O XWRLQRLQUKZEEU-UHFFFAOYSA-N 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 239000003540 gamma secretase inhibitor Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 230000002140 halogenating effect Effects 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 102000046701 nicastrin Human genes 0.000 description 2
- 108700022821 nicastrin Proteins 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000001202 rhombencephalon Anatomy 0.000 description 2
- 108091006024 signal transducing proteins Proteins 0.000 description 2
- 102000034285 signal transducing proteins Human genes 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 239000003656 tris buffered saline Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- LUJMSRVFSBMEOY-UHFFFAOYSA-N (4-fluoro-3-methoxyphenyl)boronic acid Chemical compound COC1=CC(B(O)O)=CC=C1F LUJMSRVFSBMEOY-UHFFFAOYSA-N 0.000 description 1
- KNTLWQNGFDJSQN-UHFFFAOYSA-N 1-(2-methoxyethyl)-2-(2-methylpropyl)-n-[4-(3-methyl-1,2,4-triazol-1-yl)phenyl]benzimidazol-4-amine Chemical compound C1=CC=C2N(CCOC)C(CC(C)C)=NC2=C1NC(C=C1)=CC=C1N1C=NC(C)=N1 KNTLWQNGFDJSQN-UHFFFAOYSA-N 0.000 description 1
- ZAKJFPBFWJGXBH-UHFFFAOYSA-N 1-(2-methoxyethyl)-n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-2-(3-methoxyphenyl)benzimidazol-4-amine Chemical compound C1=CC=C2N(CCOC)C(C=3C=C(OC)C=CC=3)=NC2=C1NC(C=C1OC)=CC=C1N1C=NC(C)=C1 ZAKJFPBFWJGXBH-UHFFFAOYSA-N 0.000 description 1
- ZEKRKYSSKNGFNZ-UHFFFAOYSA-N 1-[4-[4-[3-methoxy-4-(4-methylimidazol-1-yl)anilino]-1,3-benzoxazol-2-yl]piperidin-1-yl]ethanone Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1OC=2C1CCN(C(C)=O)CC1 ZEKRKYSSKNGFNZ-UHFFFAOYSA-N 0.000 description 1
- RTCDDKAKVADEOS-UHFFFAOYSA-N 1-[4-[[2-(4-fluorophenyl)-1-methylbenzimidazol-4-yl]amino]-2-methoxyphenyl]imidazole-4-carbonitrile Chemical compound C=1C=C(N2C=C(N=C2)C#N)C(OC)=CC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=C(F)C=C1 RTCDDKAKVADEOS-UHFFFAOYSA-N 0.000 description 1
- XPMLJYNOEYCWGH-UHFFFAOYSA-N 1-[4-[[4-[3-methoxy-4-(4-methylimidazol-1-yl)anilino]-1-methylbenzimidazol-2-yl]methyl]piperidin-1-yl]ethanone Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1N(C)C=2CC1CCN(C(C)=O)CC1 XPMLJYNOEYCWGH-UHFFFAOYSA-N 0.000 description 1
- CYWCGNJMBWOQSV-UHFFFAOYSA-N 1-benzyl-2-(4-fluorophenyl)-n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]benzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(C=1N=C2C=3C=CC(F)=CC=3)=CC=CC=1N2CC1=CC=CC=C1 CYWCGNJMBWOQSV-UHFFFAOYSA-N 0.000 description 1
- IOZHETUAEWIECE-UHFFFAOYSA-N 1-benzyl-2-methyl-n-[4-(3-methyl-1,2,4-triazol-1-yl)phenyl]benzimidazol-4-amine Chemical compound N1=C(C)N=CN1C(C=C1)=CC=C1NC1=CC=CC2=C1N=C(C)N2CC1=CC=CC=C1 IOZHETUAEWIECE-UHFFFAOYSA-N 0.000 description 1
- XUGFUZXUDIHVOR-UHFFFAOYSA-N 1-benzyl-n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-2-(2-methylphenyl)benzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(C=1N=C2C=3C(=CC=CC=3)C)=CC=CC=1N2CC1=CC=CC=C1 XUGFUZXUDIHVOR-UHFFFAOYSA-N 0.000 description 1
- AHSIOKLWYYDJFF-UHFFFAOYSA-N 1-ethyl-n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-2-(3,3,3-trifluoropropyl)benzimidazol-4-amine Chemical compound C1=CC=C2N(CC)C(CCC(F)(F)F)=NC2=C1NC(C=C1OC)=CC=C1N1C=NC(C)=C1 AHSIOKLWYYDJFF-UHFFFAOYSA-N 0.000 description 1
- BTUGGGLMQBJCBN-UHFFFAOYSA-N 1-iodo-2-methylpropane Chemical compound CC(C)CI BTUGGGLMQBJCBN-UHFFFAOYSA-N 0.000 description 1
- KAENQIFYYIFFBF-UHFFFAOYSA-N 1-tert-butyl-2-(4-fluorophenyl)-n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]benzimidazol-4-amine Chemical compound C=1C=C(N2N=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1N(C(C)(C)C)C=2C1=CC=C(F)C=C1 KAENQIFYYIFFBF-UHFFFAOYSA-N 0.000 description 1
- GSSSPWWNAHYONK-UHFFFAOYSA-N 1-tert-butyl-2-(4-fluorophenyl)-n-[4-(3-methyl-1,2,4-triazol-1-yl)phenyl]benzimidazol-4-amine Chemical compound N1=C(C)N=CN1C(C=C1)=CC=C1NC1=CC=CC2=C1N=C(C=1C=CC(F)=CC=1)N2C(C)(C)C GSSSPWWNAHYONK-UHFFFAOYSA-N 0.000 description 1
- ZSJYSZWQVCWDQO-UHFFFAOYSA-N 2,4-dichloropyridin-3-amine Chemical compound NC1=C(Cl)C=CN=C1Cl ZSJYSZWQVCWDQO-UHFFFAOYSA-N 0.000 description 1
- JSWRVDNTKPAJLB-UHFFFAOYSA-N 2,4-difluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C(F)=C1 JSWRVDNTKPAJLB-UHFFFAOYSA-N 0.000 description 1
- VFUHTPHOHKMNPU-UHFFFAOYSA-N 2-(2,4-difluorophenyl)-n-[2-fluoro-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-1-methylimidazo[4,5-c]pyridin-4-amine Chemical compound N1=C(C)N=CN1C(C=C1F)=CC=C1NC1=NC=CC2=C1N=C(C=1C(=CC(F)=CC=1)F)N2C VFUHTPHOHKMNPU-UHFFFAOYSA-N 0.000 description 1
- JWSGSCIXIRUFCU-UHFFFAOYSA-N 2-(2,4-difluorophenyl)-n-[3-fluoro-4-(4-methylimidazol-1-yl)phenyl]-1-methylimidazo[4,5-c]pyridin-4-amine Chemical compound C1=NC(C)=CN1C(C(=C1)F)=CC=C1NC1=NC=CC2=C1N=C(C=1C(=CC(F)=CC=1)F)N2C JWSGSCIXIRUFCU-UHFFFAOYSA-N 0.000 description 1
- IAXPOYQINPGRTP-UHFFFAOYSA-N 2-(2,4-difluorophenyl)-n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-1-methylimidazo[4,5-c]pyridin-4-amine Chemical compound C=1C=C(N2N=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=NC=CC=1N(C)C=2C1=CC=C(F)C=C1F IAXPOYQINPGRTP-UHFFFAOYSA-N 0.000 description 1
- OABVPHMXGVFMQT-UHFFFAOYSA-N 2-(2,4-difluorophenyl)-n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-1-methylbenzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=C(F)C=C1F OABVPHMXGVFMQT-UHFFFAOYSA-N 0.000 description 1
- RBYJRERTDQENRR-UHFFFAOYSA-N 2-(2,4-difluorophenyl)-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methylbenzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=C(F)C=C1F RBYJRERTDQENRR-UHFFFAOYSA-N 0.000 description 1
- OPEILIJYCPBPPU-UHFFFAOYSA-N 2-(2,5-difluorophenyl)-1-ethyl-6-fluoro-n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]benzimidazol-4-amine Chemical compound C1=C(F)C=C2N(CC)C(C=3C(=CC=C(F)C=3)F)=NC2=C1NC(C=C1OC)=CC=C1N1C=NC(C)=N1 OPEILIJYCPBPPU-UHFFFAOYSA-N 0.000 description 1
- IIEWBNOFIBPVCT-UHFFFAOYSA-N 2-(2,6-dimethylmorpholin-4-yl)-n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-1-methylbenzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1N(C)C=2N1CC(C)OC(C)C1 IIEWBNOFIBPVCT-UHFFFAOYSA-N 0.000 description 1
- HTUKMTYMXXRAMS-UHFFFAOYSA-N 2-(2-chloro-3-methoxyphenyl)-n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-1-methylbenzimidazol-4-amine Chemical compound COC1=CC=CC(C=2N(C3=CC=CC(NC=4C=C(OC)C(=CC=4)N4N=C(C)N=C4)=C3N=2)C)=C1Cl HTUKMTYMXXRAMS-UHFFFAOYSA-N 0.000 description 1
- DVSOIRZJZXEGHN-UHFFFAOYSA-N 2-(2-chlorophenyl)-6-fluoro-n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-1-methylbenzimidazol-4-amine Chemical compound C=1C=C(N2N=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC(F)=CC=1N(C)C=2C1=CC=CC=C1Cl DVSOIRZJZXEGHN-UHFFFAOYSA-N 0.000 description 1
- YPAODXFGTASVHR-UHFFFAOYSA-N 2-(2-chlorophenyl)-6-fluoro-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methylbenzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC(F)=CC=1N(C)C=2C1=CC=CC=C1Cl YPAODXFGTASVHR-UHFFFAOYSA-N 0.000 description 1
- MIFOEPVAATZAER-UHFFFAOYSA-N 2-(2-chlorophenyl)-n-[3-fluoro-4-(4-methylimidazol-1-yl)phenyl]-1,6-dimethylimidazo[4,5-c]pyridin-4-amine Chemical compound C1=NC(C)=CN1C(C(=C1)F)=CC=C1NC1=NC(C)=CC2=C1N=C(C=1C(=CC=CC=1)Cl)N2C MIFOEPVAATZAER-UHFFFAOYSA-N 0.000 description 1
- BDPTWHFIMGMGPB-UHFFFAOYSA-N 2-(2-chlorophenyl)-n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-1,6-dimethylimidazo[4,5-c]pyridin-4-amine Chemical compound C=1C=C(N2N=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=NC(C)=CC=1N(C)C=2C1=CC=CC=C1Cl BDPTWHFIMGMGPB-UHFFFAOYSA-N 0.000 description 1
- NHWBJPVLTMPAQS-UHFFFAOYSA-N 2-(2-chlorophenyl)-n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-1-methylimidazo[4,5-c]pyridin-4-amine Chemical compound C=1C=C(N2N=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=NC=CC=1N(C)C=2C1=CC=CC=C1Cl NHWBJPVLTMPAQS-UHFFFAOYSA-N 0.000 description 1
- IBWOVNMBKJTOTL-UHFFFAOYSA-N 2-(2-chlorophenyl)-n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-1-propan-2-ylimidazo[4,5-c]pyridin-4-amine Chemical compound C=1C=C(N2N=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=NC=CC=1N(C(C)C)C=2C1=CC=CC=C1Cl IBWOVNMBKJTOTL-UHFFFAOYSA-N 0.000 description 1
- YKYIPXIDJXJZSG-UHFFFAOYSA-N 2-(2-chlorophenyl)-n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-1,3-benzoxazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1OC=2C1=CC=CC=C1Cl YKYIPXIDJXJZSG-UHFFFAOYSA-N 0.000 description 1
- HLHVBPDEXLTVOB-UHFFFAOYSA-N 2-(2-chlorophenyl)-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1,6-dimethylimidazo[4,5-c]pyridin-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=NC(C)=CC=1N(C)C=2C1=CC=CC=C1Cl HLHVBPDEXLTVOB-UHFFFAOYSA-N 0.000 description 1
- GWGZYNDZIORUFV-UHFFFAOYSA-N 2-(2-fluoro-4-methoxyphenyl)-n-[3-fluoro-4-(4-methylimidazol-1-yl)phenyl]-1,6-dimethylimidazo[4,5-c]pyridin-4-amine Chemical compound FC1=CC(OC)=CC=C1C(N(C1=CC(C)=N2)C)=NC1=C2NC1=CC=C(N2C=C(C)N=C2)C(F)=C1 GWGZYNDZIORUFV-UHFFFAOYSA-N 0.000 description 1
- WPHQAEZVMQUIQM-UHFFFAOYSA-N 2-(2-fluoro-4-methoxyphenyl)-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methylbenzimidazol-4-amine Chemical compound FC1=CC(OC)=CC=C1C(N(C1=CC=C2)C)=NC1=C2NC1=CC=C(N2C=C(C)N=C2)C(OC)=N1 WPHQAEZVMQUIQM-UHFFFAOYSA-N 0.000 description 1
- DECBHEFHQHWBHL-UHFFFAOYSA-N 2-(2-fluorophenyl)-n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-1-methylbenzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=CC=C1F DECBHEFHQHWBHL-UHFFFAOYSA-N 0.000 description 1
- HSUVZOKOFHMFPG-UHFFFAOYSA-N 2-(2-fluorophenyl)-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methylbenzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=CC=C1F HSUVZOKOFHMFPG-UHFFFAOYSA-N 0.000 description 1
- OUFQEFGTOZUXTQ-UHFFFAOYSA-N 2-(3,4-difluorophenyl)-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methylbenzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=C(F)C(F)=C1 OUFQEFGTOZUXTQ-UHFFFAOYSA-N 0.000 description 1
- NOGGZBXOIBGHND-UHFFFAOYSA-N 2-(3,5-difluorophenyl)-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methylbenzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC(F)=CC(F)=C1 NOGGZBXOIBGHND-UHFFFAOYSA-N 0.000 description 1
- NJIBSNLUIIMXBY-UHFFFAOYSA-N 2-(3-bromo-4-fluorophenyl)-n-[3-fluoro-4-(4-methylimidazol-1-yl)phenyl]-1,6-dimethylimidazo[4,5-c]pyridin-4-amine Chemical compound C1=NC(C)=CN1C(C(=C1)F)=CC=C1NC1=NC(C)=CC2=C1N=C(C=1C=C(Br)C(F)=CC=1)N2C NJIBSNLUIIMXBY-UHFFFAOYSA-N 0.000 description 1
- PLWRWSNUNARRRY-UHFFFAOYSA-N 2-(3-bromo-4-fluorophenyl)-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methylbenzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=C(F)C(Br)=C1 PLWRWSNUNARRRY-UHFFFAOYSA-N 0.000 description 1
- CSCLFWRLJCNUBU-UHFFFAOYSA-N 2-(3-chlorophenyl)-n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-1-propan-2-ylbenzimidazol-4-amine Chemical compound C=1C=C(N2N=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1N(C(C)C)C=2C1=CC=CC(Cl)=C1 CSCLFWRLJCNUBU-UHFFFAOYSA-N 0.000 description 1
- UELMJHMCZGUXDC-UHFFFAOYSA-N 2-(3-chlorophenyl)-n-[3-methoxy-4-(5-methyl-1,2,4-triazol-1-yl)phenyl]-1-methylbenzimidazol-4-amine Chemical compound C=1C=C(N2C(=NC=N2)C)C(OC)=CC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=CC(Cl)=C1 UELMJHMCZGUXDC-UHFFFAOYSA-N 0.000 description 1
- LPTROJVOWGCYAM-UHFFFAOYSA-N 2-(3-ethoxyphenyl)-n-[3-fluoro-4-(4-methylimidazol-1-yl)phenyl]-1,6-dimethylimidazo[4,5-c]pyridin-4-amine Chemical compound CCOC1=CC=CC(C=2N(C3=CC(C)=NC(NC=4C=C(F)C(=CC=4)N4C=C(C)N=C4)=C3N=2)C)=C1 LPTROJVOWGCYAM-UHFFFAOYSA-N 0.000 description 1
- OBUQFBNFGAZYSC-UHFFFAOYSA-N 2-(3-ethoxyphenyl)-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methylbenzimidazol-4-amine Chemical compound CCOC1=CC=CC(C=2N(C3=CC=CC(NC=4N=C(OC)C(=CC=4)N4C=C(C)N=C4)=C3N=2)C)=C1 OBUQFBNFGAZYSC-UHFFFAOYSA-N 0.000 description 1
- ORWAVHQUDYBEFD-UHFFFAOYSA-N 2-(3-fluoro-5-methoxyphenyl)-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methylbenzimidazol-4-amine Chemical compound COC1=CC(F)=CC(C=2N(C3=CC=CC(NC=4N=C(OC)C(=CC=4)N4C=C(C)N=C4)=C3N=2)C)=C1 ORWAVHQUDYBEFD-UHFFFAOYSA-N 0.000 description 1
- QDLQFCPWFXGJIX-UHFFFAOYSA-N 2-(3-fluorophenyl)-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methylbenzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=CC(F)=C1 QDLQFCPWFXGJIX-UHFFFAOYSA-N 0.000 description 1
- ROUCQEFWDOVQKF-UHFFFAOYSA-N 2-(3-methoxyphenyl)-1-methyl-n-[4-(3-methyl-1,2,4-triazol-1-yl)phenyl]benzimidazol-4-amine Chemical compound COC1=CC=CC(C=2N(C3=CC=CC(NC=4C=CC(=CC=4)N4N=C(C)N=C4)=C3N=2)C)=C1 ROUCQEFWDOVQKF-UHFFFAOYSA-N 0.000 description 1
- OSCFKEIMEYQDKH-UHFFFAOYSA-N 2-(3-methoxyphenyl)-n-[4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-1-propan-2-ylbenzimidazol-4-amine Chemical compound COC1=CC=CC(C=2N(C3=CC=CC(NC=4C=CC(=CC=4)N4N=C(C)N=C4)=C3N=2)C(C)C)=C1 OSCFKEIMEYQDKH-UHFFFAOYSA-N 0.000 description 1
- PLSYVAXIBDLBNM-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-1-methylbenzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1N(C)C=2N1CCC(F)(F)CC1 PLSYVAXIBDLBNM-UHFFFAOYSA-N 0.000 description 1
- HQQYSEBEDOPLDD-UHFFFAOYSA-N 2-(4-chloro-3-methoxyphenyl)-6-fluoro-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methylbenzimidazol-4-amine Chemical compound C1=C(Cl)C(OC)=CC(C=2N(C3=CC(F)=CC(NC=4N=C(OC)C(=CC=4)N4C=C(C)N=C4)=C3N=2)C)=C1 HQQYSEBEDOPLDD-UHFFFAOYSA-N 0.000 description 1
- IIQHAJRQSHMGKE-UHFFFAOYSA-N 2-(4-chloro-3-methoxyphenyl)-n-[3-fluoro-4-(1,2,4-triazol-1-yl)phenyl]-1-methylbenzimidazol-4-amine Chemical compound C1=C(Cl)C(OC)=CC(C=2N(C3=CC=CC(NC=4C=C(F)C(=CC=4)N4N=CN=C4)=C3N=2)C)=C1 IIQHAJRQSHMGKE-UHFFFAOYSA-N 0.000 description 1
- VRGQJNHNIHCYLO-UHFFFAOYSA-N 2-(4-chloro-3-methoxyphenyl)-n-[3-fluoro-4-(4-methylimidazol-1-yl)phenyl]-1,6-dimethylimidazo[4,5-c]pyridin-4-amine Chemical compound C1=C(Cl)C(OC)=CC(C=2N(C3=CC(C)=NC(NC=4C=C(F)C(=CC=4)N4C=C(C)N=C4)=C3N=2)C)=C1 VRGQJNHNIHCYLO-UHFFFAOYSA-N 0.000 description 1
- FTNRYVHBGWCTBB-UHFFFAOYSA-N 2-(4-chloro-3-methoxyphenyl)-n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-1,6-dimethylimidazo[4,5-c]pyridin-4-amine Chemical compound C1=C(Cl)C(OC)=CC(C=2N(C3=CC(C)=NC(NC=4C=C(OC)C(=CC=4)N4N=C(C)N=C4)=C3N=2)C)=C1 FTNRYVHBGWCTBB-UHFFFAOYSA-N 0.000 description 1
- KSEXVXAOAJGSLA-UHFFFAOYSA-N 2-(4-chloro-3-methoxyphenyl)-n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-1-methylbenzimidazol-4-amine Chemical compound C1=C(Cl)C(OC)=CC(C=2N(C3=CC=CC(NC=4C=C(OC)C(=CC=4)N4N=C(C)N=C4)=C3N=2)C)=C1 KSEXVXAOAJGSLA-UHFFFAOYSA-N 0.000 description 1
- NEXNTOHTHGMMLA-UHFFFAOYSA-N 2-(4-chloro-3-methoxyphenyl)-n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-1-methylimidazo[4,5-c]pyridin-4-amine Chemical compound C1=C(Cl)C(OC)=CC(C=2N(C3=CC=NC(NC=4C=C(OC)C(=CC=4)N4N=C(C)N=C4)=C3N=2)C)=C1 NEXNTOHTHGMMLA-UHFFFAOYSA-N 0.000 description 1
- LXMWIAMMSBVOFF-UHFFFAOYSA-N 2-(4-chloro-3-methoxyphenyl)-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methylbenzimidazol-4-amine Chemical compound C1=C(Cl)C(OC)=CC(C=2N(C3=CC=CC(NC=4N=C(OC)C(=CC=4)N4C=C(C)N=C4)=C3N=2)C)=C1 LXMWIAMMSBVOFF-UHFFFAOYSA-N 0.000 description 1
- GCARWMSSKVFSGT-UHFFFAOYSA-N 2-(4-chloro-3-methoxyphenyl)-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-propan-2-ylbenzimidazol-4-amine Chemical compound C1=C(Cl)C(OC)=CC(C=2N(C3=CC=CC(NC=4N=C(OC)C(=CC=4)N4C=C(C)N=C4)=C3N=2)C(C)C)=C1 GCARWMSSKVFSGT-UHFFFAOYSA-N 0.000 description 1
- RHOOYARYQDCLFL-UHFFFAOYSA-N 2-(4-ethoxy-2-methyl-5-propan-2-ylphenyl)-4-N-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-1-methyl-3H-benzimidazole-2,4-diamine Chemical compound C(C)OC1=CC(=C(C=C1C(C)C)C1(NC2=C(N1C)C=CC=C2NC1=CC(=C(C=C1)N1C=NC(=C1)C)OC)N)C RHOOYARYQDCLFL-UHFFFAOYSA-N 0.000 description 1
- VUSWJMRZZSNLNH-UHFFFAOYSA-N 2-(4-ethoxy-2-methyl-5-propan-2-ylphenyl)-n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-1,3-benzoxazol-4-amine Chemical compound C1=C(C(C)C)C(OCC)=CC(C)=C1C(OC1=CC=C2)=NC1=C2NC1=CC=C(N2N=C(C)N=C2)C(OC)=C1 VUSWJMRZZSNLNH-UHFFFAOYSA-N 0.000 description 1
- XVGGFYKTURTYQJ-UHFFFAOYSA-N 2-(4-ethoxy-2-methyl-5-propan-2-ylphenyl)-n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-1-methylbenzimidazol-4-amine Chemical compound C1=C(C(C)C)C(OCC)=CC(C)=C1C(N(C1=CC=C2)C)=NC1=C2NC1=CC=C(N2N=C(C)N=C2)C(OC)=C1 XVGGFYKTURTYQJ-UHFFFAOYSA-N 0.000 description 1
- NBEHGEYSPZTGPY-UHFFFAOYSA-N 2-(4-fluoro-2-methylphenyl)-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methylbenzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=C(F)C=C1C NBEHGEYSPZTGPY-UHFFFAOYSA-N 0.000 description 1
- IYUVEUROFQKUIY-UHFFFAOYSA-N 2-(4-fluoro-3-iodophenyl)-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methylbenzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=C(F)C(I)=C1 IYUVEUROFQKUIY-UHFFFAOYSA-N 0.000 description 1
- MZTSGMUCFDLCOB-UHFFFAOYSA-N 2-(4-fluorophenyl)-1-methyl-n-[2-(4-methylimidazol-1-yl)pyrimidin-5-yl]benzimidazol-4-amine Chemical compound C1=NC(C)=CN1C(N=C1)=NC=C1NC1=CC=CC2=C1N=C(C=1C=CC(F)=CC=1)N2C MZTSGMUCFDLCOB-UHFFFAOYSA-N 0.000 description 1
- MXGWSHSUMYTYPM-UHFFFAOYSA-N 2-(4-fluorophenyl)-1-methyl-n-[4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-6-(trifluoromethyl)benzimidazol-4-amine Chemical compound N1=C(C)N=CN1C(C=C1)=CC=C1NC1=CC(C(F)(F)F)=CC2=C1N=C(C=1C=CC(F)=CC=1)N2C MXGWSHSUMYTYPM-UHFFFAOYSA-N 0.000 description 1
- FDKDAHHAMXKBEI-UHFFFAOYSA-N 2-(4-fluorophenyl)-1-methyl-n-[4-(3-methyl-1,2,4-triazol-1-yl)phenyl]benzimidazol-4-amine Chemical compound N1=C(C)N=CN1C(C=C1)=CC=C1NC1=CC=CC2=C1N=C(C=1C=CC(F)=CC=1)N2C FDKDAHHAMXKBEI-UHFFFAOYSA-N 0.000 description 1
- NHNZNUPFJDLVRI-UHFFFAOYSA-N 2-(4-fluorophenyl)-1-methyl-n-[4-(4-methylimidazol-1-yl)phenyl]benzimidazol-4-amine Chemical compound C1=NC(C)=CN1C(C=C1)=CC=C1NC1=CC=CC2=C1N=C(C=1C=CC(F)=CC=1)N2C NHNZNUPFJDLVRI-UHFFFAOYSA-N 0.000 description 1
- SBMTYDPNLHAVKD-UHFFFAOYSA-N 2-(4-fluorophenyl)-1-methyl-n-[5-(4-methylimidazol-1-yl)pyridin-2-yl]benzimidazol-4-amine Chemical compound C1=NC(C)=CN1C(C=N1)=CC=C1NC1=CC=CC2=C1N=C(C=1C=CC(F)=CC=1)N2C SBMTYDPNLHAVKD-UHFFFAOYSA-N 0.000 description 1
- VVUVOICXTMWSCH-UHFFFAOYSA-N 2-(4-fluorophenyl)-1-methyl-n-[6-(3-methyl-1,2,4-triazol-1-yl)pyridin-3-yl]-6-(trifluoromethyl)benzimidazol-4-amine Chemical compound N1=C(C)N=CN1C(N=C1)=CC=C1NC1=CC(C(F)(F)F)=CC2=C1N=C(C=1C=CC(F)=CC=1)N2C VVUVOICXTMWSCH-UHFFFAOYSA-N 0.000 description 1
- NRBAKHFHMCVBJB-UHFFFAOYSA-N 2-(4-fluorophenyl)-1-methyl-n-[6-(3-methyl-1,2,4-triazol-1-yl)pyridin-3-yl]benzimidazol-4-amine Chemical compound N1=C(C)N=CN1C(N=C1)=CC=C1NC1=CC=CC2=C1N=C(C=1C=CC(F)=CC=1)N2C NRBAKHFHMCVBJB-UHFFFAOYSA-N 0.000 description 1
- XZGMRTZEDNSSBH-UHFFFAOYSA-N 2-(4-fluorophenyl)-1-methyl-n-[6-(4-methylimidazol-1-yl)pyridin-3-yl]benzimidazol-4-amine Chemical compound C1=NC(C)=CN1C(N=C1)=CC=C1NC1=CC=CC2=C1N=C(C=1C=CC(F)=CC=1)N2C XZGMRTZEDNSSBH-UHFFFAOYSA-N 0.000 description 1
- MRMPGRSXCSHKFX-UHFFFAOYSA-N 2-(4-fluorophenyl)-5-methoxy-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-3-methylimidazo[4,5-b]pyridin-7-amine Chemical compound C=12N=C(C=3C=CC(F)=CC=3)N(C)C2=NC(OC)=CC=1NC(N=C1OC)=CC=C1N1C=NC(C)=C1 MRMPGRSXCSHKFX-UHFFFAOYSA-N 0.000 description 1
- CMHJVNJGWXWDTI-UHFFFAOYSA-N 2-(4-fluorophenyl)-6-methoxy-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methylbenzimidazol-4-amine Chemical compound C=12N=C(C=3C=CC(F)=CC=3)N(C)C2=CC(OC)=CC=1NC(N=C1OC)=CC=C1N1C=NC(C)=C1 CMHJVNJGWXWDTI-UHFFFAOYSA-N 0.000 description 1
- PHFUYVPWWBGWJK-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-(4-imidazol-1-yl-3-methoxyphenyl)-1-methylbenzimidazol-4-amine Chemical compound C=1C=C(N2C=NC=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=C(F)C=C1 PHFUYVPWWBGWJK-UHFFFAOYSA-N 0.000 description 1
- BNBMNXXKTNAQBS-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[3-fluoro-4-(1,2,4-triazol-1-yl)phenyl]-1-methylbenzimidazol-4-amine Chemical compound C1=CC=C2N(C)C(C=3C=CC(F)=CC=3)=NC2=C1NC(C=C1F)=CC=C1N1C=NC=N1 BNBMNXXKTNAQBS-UHFFFAOYSA-N 0.000 description 1
- HAXFFRKFZWEGMA-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[3-methoxy-4-(1,2,4-triazol-1-yl)phenyl]-1-methylbenzimidazol-4-amine Chemical compound C=1C=C(N2N=CN=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=C(F)C=C1 HAXFFRKFZWEGMA-UHFFFAOYSA-N 0.000 description 1
- HGCUCSHSAOCCGR-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-1,6-dimethylimidazo[4,5-c]pyridin-4-amine Chemical compound C=1C=C(N2N=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=NC(C)=CC=1N(C)C=2C1=CC=C(F)C=C1 HGCUCSHSAOCCGR-UHFFFAOYSA-N 0.000 description 1
- RVBFGQBCCUPXDM-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-1-methyl-6-propan-2-ylimidazo[4,5-c]pyridin-4-amine Chemical compound C=1C=C(N2N=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=NC(C(C)C)=CC=1N(C)C=2C1=CC=C(F)C=C1 RVBFGQBCCUPXDM-UHFFFAOYSA-N 0.000 description 1
- IKPCKYHZXLJFRM-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-1-methylbenzimidazol-4-amine Chemical compound C=1C=C(N2N=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=C(F)C=C1 IKPCKYHZXLJFRM-UHFFFAOYSA-N 0.000 description 1
- BREMIXQPTMHJMF-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-1-methylimidazo[4,5-c]pyridin-4-amine Chemical compound C=1C=C(N2N=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=NC=CC=1N(C)C=2C1=CC=C(F)C=C1 BREMIXQPTMHJMF-UHFFFAOYSA-N 0.000 description 1
- QNPUEVNSGRBAPD-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-3,5-dimethylimidazo[4,5-b]pyridin-7-amine Chemical compound C=1C=C(N2N=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC(C)=NC=1N(C)C=2C1=CC=C(F)C=C1 QNPUEVNSGRBAPD-UHFFFAOYSA-N 0.000 description 1
- UHSROSFDCGYGSK-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-3-methyl-5-prop-1-en-2-ylimidazo[4,5-b]pyridin-7-amine Chemical compound C=1C=C(N2N=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC(C(C)=C)=NC=1N(C)C=2C1=CC=C(F)C=C1 UHSROSFDCGYGSK-UHFFFAOYSA-N 0.000 description 1
- TZBWTZVCIOEMPJ-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-3-methyl-5-propan-2-ylimidazo[4,5-b]pyridin-7-amine Chemical compound C=1C=C(N2N=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC(C(C)C)=NC=1N(C)C=2C1=CC=C(F)C=C1 TZBWTZVCIOEMPJ-UHFFFAOYSA-N 0.000 description 1
- MJUAZRLEZSWWMX-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-3-methylimidazo[4,5-b]pyridin-7-amine Chemical compound C=1C=C(N2N=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=NC=1N(C)C=2C1=CC=C(F)C=C1 MJUAZRLEZSWWMX-UHFFFAOYSA-N 0.000 description 1
- IGMAHJWPWNTAEZ-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-3-methylimidazo[4,5-c]pyridin-7-amine Chemical compound C=1C=C(N2N=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CN=CC=1N(C)C=2C1=CC=C(F)C=C1 IGMAHJWPWNTAEZ-UHFFFAOYSA-N 0.000 description 1
- JTGMRHVAZCQIEO-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-5-(3-methoxypropyl)-3-methylimidazo[4,5-b]pyridin-7-amine Chemical compound C=12N=C(C=3C=CC(F)=CC=3)N(C)C2=NC(CCCOC)=CC=1NC(C=C1OC)=CC=C1N1C=NC(C)=N1 JTGMRHVAZCQIEO-UHFFFAOYSA-N 0.000 description 1
- IORHEWUNLZVUCN-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-1,3-benzoxazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1OC=2C1=CC=C(F)C=C1 IORHEWUNLZVUCN-UHFFFAOYSA-N 0.000 description 1
- GDJPLNOSDZIINK-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-1-methylimidazo[4,5-c]pyridin-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=NC=CC=1N(C)C=2C1=CC=C(F)C=C1 GDJPLNOSDZIINK-UHFFFAOYSA-N 0.000 description 1
- PKOGOXGNANMYSK-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-1-propan-2-ylbenzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1N(C(C)C)C=2C1=CC=C(F)C=C1 PKOGOXGNANMYSK-UHFFFAOYSA-N 0.000 description 1
- PCAZIKURHILOSM-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-1h-benzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1NC=2C1=CC=C(F)C=C1 PCAZIKURHILOSM-UHFFFAOYSA-N 0.000 description 1
- WSHWFBSMZKAWHA-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-1h-imidazo[4,5-c]pyridin-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=NC=CC=1NC=2C1=CC=C(F)C=C1 WSHWFBSMZKAWHA-UHFFFAOYSA-N 0.000 description 1
- SNAXEGCXKYIQKD-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[3-methoxy-4-(5-methyl-1,2,4-triazol-1-yl)phenyl]-1-methylbenzimidazol-4-amine Chemical compound C=1C=C(N2C(=NC=N2)C)C(OC)=CC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=C(F)C=C1 SNAXEGCXKYIQKD-UHFFFAOYSA-N 0.000 description 1
- GWHKBSLGBNGZKP-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[3-methoxy-4-[4-(methoxymethyl)imidazol-1-yl]phenyl]-1-methylbenzimidazol-4-amine Chemical compound C1=NC(COC)=CN1C(C(=C1)OC)=CC=C1NC1=CC=CC2=C1N=C(C=1C=CC(F)=CC=1)N2C GWHKBSLGBNGZKP-UHFFFAOYSA-N 0.000 description 1
- ZNOKCGCYGUEWMC-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-1-propan-2-ylbenzimidazol-4-amine Chemical compound C1=CC=C2N(C(C)C)C(C=3C=CC(F)=CC=3)=NC2=C1NC(C=C1)=CC=C1N1C=NC(C)=N1 ZNOKCGCYGUEWMC-UHFFFAOYSA-N 0.000 description 1
- DMPZKHNQWVHPTQ-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[4-(5-methyl-1,2,4-triazol-1-yl)phenyl]-1-propan-2-ylbenzimidazol-4-amine Chemical compound C1=CC=C2N(C(C)C)C(C=3C=CC(F)=CC=3)=NC2=C1NC(C=C1)=CC=C1N1N=CN=C1C DMPZKHNQWVHPTQ-UHFFFAOYSA-N 0.000 description 1
- HZBCNIXRPWTDIM-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[4-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methylbenzimidazol-4-amine Chemical compound N=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=C(F)C=C1 HZBCNIXRPWTDIM-UHFFFAOYSA-N 0.000 description 1
- RSNNNLVZOQZOCE-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[5-(3-methyl-1,2,4-triazol-1-yl)pyridin-2-yl]-1-propan-2-ylbenzimidazol-4-amine Chemical compound C1=CC=C2N(C(C)C)C(C=3C=CC(F)=CC=3)=NC2=C1NC(N=C1)=CC=C1N1C=NC(C)=N1 RSNNNLVZOQZOCE-UHFFFAOYSA-N 0.000 description 1
- IPLJMLVASBJBRO-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[5-methoxy-6-(4-methylimidazol-1-yl)pyridin-3-yl]-1-methylbenzimidazol-4-amine Chemical compound C=1N=C(N2C=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=C(F)C=C1 IPLJMLVASBJBRO-UHFFFAOYSA-N 0.000 description 1
- FFHBNRGUGMISED-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[6-(3-methyl-1,2,4-triazol-1-yl)pyridin-3-yl]-1-propan-2-ylbenzimidazol-4-amine Chemical compound C1=CC=C2N(C(C)C)C(C=3C=CC(F)=CC=3)=NC2=C1NC(C=N1)=CC=C1N1C=NC(C)=N1 FFHBNRGUGMISED-UHFFFAOYSA-N 0.000 description 1
- QEPDAPPFDGNYMA-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[6-methoxy-5-(3-methyl-1,2,4-triazol-1-yl)pyridin-2-yl]-1-methylbenzimidazol-4-amine Chemical compound C=1C=C(N2N=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=C(F)C=C1 QEPDAPPFDGNYMA-UHFFFAOYSA-N 0.000 description 1
- GVJIEVCGSQIRLS-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1,6-dimethylimidazo[4,5-c]pyridin-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=NC(C)=CC=1N(C)C=2C1=CC=C(F)C=C1 GVJIEVCGSQIRLS-UHFFFAOYSA-N 0.000 description 1
- YGEKWAJMNNUENB-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-propan-2-ylbenzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC=CC=1N(C(C)C)C=2C1=CC=C(F)C=C1 YGEKWAJMNNUENB-UHFFFAOYSA-N 0.000 description 1
- OFLNNUDBLZGTKW-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-3,5-dimethylimidazo[4,5-b]pyridin-7-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC(C)=NC=1N(C)C=2C1=CC=C(F)C=C1 OFLNNUDBLZGTKW-UHFFFAOYSA-N 0.000 description 1
- UWZOXGIZQKJTHT-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-3-methyl-5-propan-2-ylimidazo[4,5-b]pyridin-7-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC(C(C)C)=NC=1N(C)C=2C1=CC=C(F)C=C1 UWZOXGIZQKJTHT-UHFFFAOYSA-N 0.000 description 1
- SPHHJGFNUMZBFI-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-3-methylimidazo[4,5-b]pyridin-7-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC=NC=1N(C)C=2C1=CC=C(F)C=C1 SPHHJGFNUMZBFI-UHFFFAOYSA-N 0.000 description 1
- ZASNNPFHAFOWIH-UHFFFAOYSA-N 2-(5-chlorothiophen-2-yl)-n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-1-propan-2-ylbenzimidazol-4-amine Chemical compound C=1C=C(N2N=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1N(C(C)C)C=2C1=CC=C(Cl)S1 ZASNNPFHAFOWIH-UHFFFAOYSA-N 0.000 description 1
- XTEFMKXGDXNFCG-UHFFFAOYSA-N 2-(cyclopropylmethyl)-1-ethyl-n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]benzimidazol-4-amine Chemical compound N=1C2=C(NC=3C=C(OC)C(=CC=3)N3C=C(C)N=C3)C=CC=C2N(CC)C=1CC1CC1 XTEFMKXGDXNFCG-UHFFFAOYSA-N 0.000 description 1
- OMRGQWGYZQCYNT-UHFFFAOYSA-N 2-(cyclopropylmethyl)-n-[3-methoxy-4-(5-methyl-1,2,4-triazol-1-yl)phenyl]-1-methylimidazo[4,5-c]pyridin-4-amine Chemical compound C=1C=C(N2C(=NC=N2)C)C(OC)=CC=1NC(C=1N=2)=NC=CC=1N(C)C=2CC1CC1 OMRGQWGYZQCYNT-UHFFFAOYSA-N 0.000 description 1
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 1
- NPYAHWBZOQFCKU-UHFFFAOYSA-N 2-[(4-fluorophenyl)methyl]-n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-1,3-benzoxazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1OC=2CC1=CC=C(F)C=C1 NPYAHWBZOQFCKU-UHFFFAOYSA-N 0.000 description 1
- NIPRNOLKWXJBCK-UHFFFAOYSA-N 2-[(4-fluorophenyl)methyl]-n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-1-methylbenzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1N(C)C=2CC1=CC=C(F)C=C1 NIPRNOLKWXJBCK-UHFFFAOYSA-N 0.000 description 1
- ZVUCWOZMNASVFT-UHFFFAOYSA-N 2-[1-(4-chlorophenyl)cyclopropyl]-n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-1-methylbenzimidazol-4-amine Chemical compound C=1C=C(N2N=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1(C=2C=CC(Cl)=CC=2)CC1 ZVUCWOZMNASVFT-UHFFFAOYSA-N 0.000 description 1
- ARDWSAHXQGHUIL-UHFFFAOYSA-N 2-[1-(4-chlorophenyl)ethyl]-n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-1-methylbenzimidazol-4-amine Chemical compound C=1C=C(N2N=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1N(C)C=2C(C)C1=CC=C(Cl)C=C1 ARDWSAHXQGHUIL-UHFFFAOYSA-N 0.000 description 1
- AONKLSWELHYSOP-UHFFFAOYSA-N 2-[2-fluoro-5-(trifluoromethyl)phenyl]-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methylbenzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC(C(F)(F)F)=CC=C1F AONKLSWELHYSOP-UHFFFAOYSA-N 0.000 description 1
- NKEXBFJGCZZEPI-UHFFFAOYSA-N 2-[3-(dimethylamino)phenyl]-n-[3-fluoro-4-(4-methylimidazol-1-yl)phenyl]-1,6-dimethylimidazo[4,5-c]pyridin-4-amine Chemical compound CN(C)C1=CC=CC(C=2N(C3=CC(C)=NC(NC=4C=C(F)C(=CC=4)N4C=C(C)N=C4)=C3N=2)C)=C1 NKEXBFJGCZZEPI-UHFFFAOYSA-N 0.000 description 1
- IVUDCBWFLUXYTK-UHFFFAOYSA-N 2-[3-(dimethylamino)phenyl]-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methylbenzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=CC(N(C)C)=C1 IVUDCBWFLUXYTK-UHFFFAOYSA-N 0.000 description 1
- QBTSYOIPLUCHLZ-UHFFFAOYSA-N 2-[3-fluoro-5-(trifluoromethyl)phenyl]-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methylbenzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC(F)=CC(C(F)(F)F)=C1 QBTSYOIPLUCHLZ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- DQEFSYWRGPPYQZ-UHFFFAOYSA-N 2-[4-(dimethylamino)phenyl]-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methylbenzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=C(N(C)C)C=C1 DQEFSYWRGPPYQZ-UHFFFAOYSA-N 0.000 description 1
- LZJFYPAJTNDKNR-UHFFFAOYSA-N 2-[4-fluoro-3-(trifluoromethyl)phenyl]-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methylbenzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=C(F)C(C(F)(F)F)=C1 LZJFYPAJTNDKNR-UHFFFAOYSA-N 0.000 description 1
- NHZOXEVQBKIVMY-UHFFFAOYSA-N 2-bromo-3-nitropyridin-4-amine Chemical compound NC1=CC=NC(Br)=C1[N+]([O-])=O NHZOXEVQBKIVMY-UHFFFAOYSA-N 0.000 description 1
- FYCRRMSGEDGSFS-UHFFFAOYSA-N 2-bromo-4-methoxy-6-nitroaniline Chemical compound COC1=CC(Br)=C(N)C([N+]([O-])=O)=C1 FYCRRMSGEDGSFS-UHFFFAOYSA-N 0.000 description 1
- XPMCSUIPJSYFFI-UHFFFAOYSA-N 2-butyl-n-[3-fluoro-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-1-methylbenzimidazol-4-amine Chemical compound C1=CC=C2N(C)C(CCCC)=NC2=C1NC(C=C1F)=CC=C1N1C=NC(C)=N1 XPMCSUIPJSYFFI-UHFFFAOYSA-N 0.000 description 1
- PLOHMGUEAHHTKK-UHFFFAOYSA-N 2-chloro-4-n-methylpyridine-3,4-diamine Chemical compound CNC1=CC=NC(Cl)=C1N PLOHMGUEAHHTKK-UHFFFAOYSA-N 0.000 description 1
- ONIKNECPXCLUHT-UHFFFAOYSA-N 2-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Cl ONIKNECPXCLUHT-UHFFFAOYSA-N 0.000 description 1
- LYYJQVJGRBVMSH-UHFFFAOYSA-N 2-cyclohexyl-n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-1,3-benzoxazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1OC=2C1CCCCC1 LYYJQVJGRBVMSH-UHFFFAOYSA-N 0.000 description 1
- HXHLWWBUMDZHTA-UHFFFAOYSA-N 2-cyclohexyl-n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-1-methylbenzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1CCCCC1 HXHLWWBUMDZHTA-UHFFFAOYSA-N 0.000 description 1
- IDLNLGMUINCSGS-UHFFFAOYSA-N 2-fluoro-5-(trifluoromethyl)benzaldehyde Chemical compound FC1=CC=C(C(F)(F)F)C=C1C=O IDLNLGMUINCSGS-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- GPZXFICWCMCQPF-UHFFFAOYSA-N 2-methylbenzoyl chloride Chemical compound CC1=CC=CC=C1C(Cl)=O GPZXFICWCMCQPF-UHFFFAOYSA-N 0.000 description 1
- OSASEJHIRSVWOB-UHFFFAOYSA-N 2-tert-butyl-n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-1,3-benzoxazol-4-amine Chemical compound COC1=CC(NC=2C=3N=C(OC=3C=CC=2)C(C)(C)C)=CC=C1N1C=NC(C)=C1 OSASEJHIRSVWOB-UHFFFAOYSA-N 0.000 description 1
- WWFOGMKDXRXGQG-UHFFFAOYSA-N 2-tert-butyl-n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-1-methylbenzimidazol-4-amine Chemical compound COC1=CC(NC=2C=3N=C(N(C)C=3C=CC=2)C(C)(C)C)=CC=C1N1C=NC(C)=C1 WWFOGMKDXRXGQG-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- QBUQQUOGXPOBAQ-UHFFFAOYSA-N 3,5-dibromo-1-oxidopyridin-1-ium Chemical compound [O-][N+]1=CC(Br)=CC(Br)=C1 QBUQQUOGXPOBAQ-UHFFFAOYSA-N 0.000 description 1
- YFSAWEMJTOLCMW-UHFFFAOYSA-N 3-[4-[[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]amino]-1-methylbenzimidazol-2-yl]benzonitrile Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=CC(C#N)=C1 YFSAWEMJTOLCMW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- FAHZIKXYYRGSHF-UHFFFAOYSA-N 3-bromo-4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1Br FAHZIKXYYRGSHF-UHFFFAOYSA-N 0.000 description 1
- OVGAPUVMLZWQQF-UHFFFAOYSA-N 3-bromo-5-(trifluoromethyl)benzene-1,2-diamine Chemical compound NC1=CC(C(F)(F)F)=CC(Br)=C1N OVGAPUVMLZWQQF-UHFFFAOYSA-N 0.000 description 1
- VCINLTLIJKUOQC-UHFFFAOYSA-N 3-bromo-5-fluorobenzene-1,2-diamine Chemical compound NC1=CC(F)=CC(Br)=C1N VCINLTLIJKUOQC-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- YACFFSVYSPMSGS-UHFFFAOYSA-N 3-methoxyprop-1-yne Chemical compound COCC#C YACFFSVYSPMSGS-UHFFFAOYSA-N 0.000 description 1
- OABUKBBBSMNNPM-UHFFFAOYSA-N 4,4-difluoropiperidin-1-ium;chloride Chemical class Cl.FC1(F)CCNCC1 OABUKBBBSMNNPM-UHFFFAOYSA-N 0.000 description 1
- ZPGVCQYKXIQWTP-UHFFFAOYSA-N 4,7-dimethoxy-1,10-phenanthroline Chemical compound C1=CC2=C(OC)C=CN=C2C2=C1C(OC)=CC=N2 ZPGVCQYKXIQWTP-UHFFFAOYSA-N 0.000 description 1
- PJUPTRYCQKQLCI-UHFFFAOYSA-N 4-(4-methylimidazol-1-yl)aniline Chemical compound C1=NC(C)=CN1C1=CC=C(N)C=C1 PJUPTRYCQKQLCI-UHFFFAOYSA-N 0.000 description 1
- FTZRLGDRISUULM-UHFFFAOYSA-N 4-[4-[3-methoxy-4-(4-methylimidazol-1-yl)anilino]-1,3-benzoxazol-2-yl]piperidine-1-carboxylic acid Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1OC=2C1CCN(C(O)=O)CC1 FTZRLGDRISUULM-UHFFFAOYSA-N 0.000 description 1
- FBEBVAQOMVWORE-UHFFFAOYSA-N 4-bromo-2-chloropyrimidine Chemical compound ClC1=NC=CC(Br)=N1 FBEBVAQOMVWORE-UHFFFAOYSA-N 0.000 description 1
- OXUUNDMDOOXPKY-UHFFFAOYSA-N 4-chloro-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1Cl OXUUNDMDOOXPKY-UHFFFAOYSA-N 0.000 description 1
- BBYDXOIZLAWGSL-UHFFFAOYSA-N 4-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C=C1 BBYDXOIZLAWGSL-UHFFFAOYSA-N 0.000 description 1
- FXTXKHGAAFZTAU-UHFFFAOYSA-N 5-[4-[3-fluoro-4-(4-methylimidazol-1-yl)anilino]-1-methylbenzimidazol-2-yl]-1-methylpyridin-2-one Chemical compound C1=NC(C)=CN1C(C(=C1)F)=CC=C1NC1=CC=CC2=C1N=C(C1=CN(C)C(=O)C=C1)N2C FXTXKHGAAFZTAU-UHFFFAOYSA-N 0.000 description 1
- SVLOVRUYDOQKCV-UHFFFAOYSA-N 5-[4-[[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]amino]-1-methylbenzimidazol-2-yl]-1-methylpyridin-2-one Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC=CC=1N(C)C=2C=1C=CC(=O)N(C)C=1 SVLOVRUYDOQKCV-UHFFFAOYSA-N 0.000 description 1
- WGOLHUGPTDEKCF-UHFFFAOYSA-N 5-bromopyridin-2-amine Chemical compound NC1=CC=C(Br)C=N1 WGOLHUGPTDEKCF-UHFFFAOYSA-N 0.000 description 1
- VXUBPWLAPYQRDM-UHFFFAOYSA-N 5-cyclopropyl-2-(4-fluorophenyl)-n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-3-methylimidazo[4,5-b]pyridin-7-amine Chemical compound C=1C=C(N2N=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC(C3CC3)=NC=1N(C)C=2C1=CC=C(F)C=C1 VXUBPWLAPYQRDM-UHFFFAOYSA-N 0.000 description 1
- RFFYRWKAJCVCTB-UHFFFAOYSA-N 5-cyclopropyl-n-[3-fluoro-4-(4-methylimidazol-1-yl)phenyl]-2-(4-fluorophenyl)-3-methylimidazo[4,5-b]pyridin-7-amine Chemical compound C1=NC(C)=CN1C(C(=C1)F)=CC=C1NC1=CC(C2CC2)=NC2=C1N=C(C=1C=CC(F)=CC=1)N2C RFFYRWKAJCVCTB-UHFFFAOYSA-N 0.000 description 1
- IVILGUFRMDBUEQ-UHFFFAOYSA-N 5-iodopyridin-2-amine Chemical compound NC1=CC=C(I)C=N1 IVILGUFRMDBUEQ-UHFFFAOYSA-N 0.000 description 1
- HSVYYOLSYNEVSP-UHFFFAOYSA-N 6-bromo-2-methoxypyridin-3-amine Chemical compound COC1=NC(Br)=CC=C1N HSVYYOLSYNEVSP-UHFFFAOYSA-N 0.000 description 1
- XTHKRYHULUJQHN-UHFFFAOYSA-N 6-bromopyridin-3-amine Chemical compound NC1=CC=C(Br)N=C1 XTHKRYHULUJQHN-UHFFFAOYSA-N 0.000 description 1
- FBNFOEWATUXCRJ-UHFFFAOYSA-N 6-chloro-2-(4-fluorophenyl)-n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-1-methylimidazo[4,5-c]pyridin-4-amine Chemical compound C=1C=C(N2N=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=NC(Cl)=CC=1N(C)C=2C1=CC=C(F)C=C1 FBNFOEWATUXCRJ-UHFFFAOYSA-N 0.000 description 1
- VXOYHOJQKYHNTD-UHFFFAOYSA-N 6-fluoro-2-(3-methoxyphenyl)-1-methyl-n-[4-(3-methyl-1,2,4-triazol-1-yl)phenyl]benzimidazol-4-amine Chemical compound COC1=CC=CC(C=2N(C3=CC(F)=CC(NC=4C=CC(=CC=4)N4N=C(C)N=C4)=C3N=2)C)=C1 VXOYHOJQKYHNTD-UHFFFAOYSA-N 0.000 description 1
- AINCZFLOUPZPFC-UHFFFAOYSA-N 6-fluoro-2-(4-fluorophenyl)-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methylbenzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC(F)=CC=1N(C)C=2C1=CC=C(F)C=C1 AINCZFLOUPZPFC-UHFFFAOYSA-N 0.000 description 1
- GXNJKYWLANBLQI-UHFFFAOYSA-N 6-fluoro-2-(4-fluorophenyl)-n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-propan-2-ylbenzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC(F)=CC=1N(C(C)C)C=2C1=CC=C(F)C=C1 GXNJKYWLANBLQI-UHFFFAOYSA-N 0.000 description 1
- FOAFKCIUGYCMQS-UHFFFAOYSA-N 6-fluoro-n-[3-fluoro-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-2-(3-methoxyphenyl)-1-methylbenzimidazol-4-amine Chemical compound COC1=CC=CC(C=2N(C3=CC(F)=CC(NC=4C=C(F)C(=CC=4)N4N=C(C)N=C4)=C3N=2)C)=C1 FOAFKCIUGYCMQS-UHFFFAOYSA-N 0.000 description 1
- YRHNDTOBVXNILB-UHFFFAOYSA-N 6-fluoro-n-[3-fluoro-4-(4-methylimidazol-1-yl)phenyl]-2-(4-fluorophenyl)-1-propan-2-ylbenzimidazol-4-amine Chemical compound C1=C(F)C=C2N(C(C)C)C(C=3C=CC(F)=CC=3)=NC2=C1NC(C=C1F)=CC=C1N1C=NC(C)=C1 YRHNDTOBVXNILB-UHFFFAOYSA-N 0.000 description 1
- DXHCARRBYHWYOA-UHFFFAOYSA-N 6-fluoro-n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-2-(3-methoxyphenyl)-1-methylbenzimidazol-4-amine Chemical compound COC1=CC=CC(C=2N(C3=CC(F)=CC(NC=4C=C(OC)C(=CC=4)N4N=C(C)N=C4)=C3N=2)C)=C1 DXHCARRBYHWYOA-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 101800001718 Amyloid-beta protein Proteins 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- HQPIILKGTFWSDJ-UHFFFAOYSA-N CC(C=C1)=CN(C)C1=O Chemical compound CC(C=C1)=CN(C)C1=O HQPIILKGTFWSDJ-UHFFFAOYSA-N 0.000 description 1
- NOGAAFSXFIEXQA-UHFFFAOYSA-N CC(CN(C=O)c(ccc(Br)n1)c1OC)=O Chemical compound CC(CN(C=O)c(ccc(Br)n1)c1OC)=O NOGAAFSXFIEXQA-UHFFFAOYSA-N 0.000 description 1
- QSWGSLWFQDIXSH-UHFFFAOYSA-N CCCC(C)(F)F Chemical compound CCCC(C)(F)F QSWGSLWFQDIXSH-UHFFFAOYSA-N 0.000 description 1
- GKRNCWKBRFZTQP-UHFFFAOYSA-N CCOc1cc(C)c(C)cc1C(C)C Chemical compound CCOc1cc(C)c(C)cc1C(C)C GKRNCWKBRFZTQP-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- KBRLTYHUJDMMLI-UHFFFAOYSA-N Cc(cc1)cc(OC)c1Cl Chemical compound Cc(cc1)cc(OC)c1Cl KBRLTYHUJDMMLI-UHFFFAOYSA-N 0.000 description 1
- LUGCLHQDNLONML-UHFFFAOYSA-N Cc(nc1)c[n]1-c(c(F)c1)ccc1Nc(nc(C)cc1[n]2C)c1nc2Cl Chemical compound Cc(nc1)c[n]1-c(c(F)c1)ccc1Nc(nc(C)cc1[n]2C)c1nc2Cl LUGCLHQDNLONML-UHFFFAOYSA-N 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101100348842 Mus musculus Notch2 gene Proteins 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 101000579647 Penaeus vannamei Penaeidin-2a Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 238000000297 Sandmeyer reaction Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- NWCVEINRAMWOFE-UHFFFAOYSA-N [1-[4-[[2-(4-fluorophenyl)-1-methylbenzimidazol-4-yl]amino]-2-methoxyphenyl]imidazol-4-yl]methanol Chemical compound C=1C=C(N2C=C(CO)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=C(F)C=C1 NWCVEINRAMWOFE-UHFFFAOYSA-N 0.000 description 1
- QQIRAVWVGBTHMJ-UHFFFAOYSA-N [dimethyl-(trimethylsilylamino)silyl]methane;lithium Chemical compound [Li].C[Si](C)(C)N[Si](C)(C)C QQIRAVWVGBTHMJ-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- QBYJBZPUGVGKQQ-SJJAEHHWSA-N aldrin Chemical compound C1[C@H]2C=C[C@@H]1[C@H]1[C@@](C3(Cl)Cl)(Cl)C(Cl)=C(Cl)[C@@]3(Cl)[C@H]12 QBYJBZPUGVGKQQ-SJJAEHHWSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000007792 alzheimer disease pathology Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000006933 amyloid-beta aggregation Effects 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 230000003941 amyloidogenesis Effects 0.000 description 1
- 230000003942 amyloidogenic effect Effects 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 101150089041 aph-1 gene Proteins 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 150000003940 butylamines Chemical class 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- WIKQEUJFZPCFNJ-UHFFFAOYSA-N carbonic acid;silver Chemical compound [Ag].[Ag].OC(O)=O WIKQEUJFZPCFNJ-UHFFFAOYSA-N 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- KRFJLUBVMFXRPN-UHFFFAOYSA-N cuprous oxide Chemical compound [O-2].[Cu+].[Cu+] KRFJLUBVMFXRPN-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- HXCKCCRKGXHOBK-UHFFFAOYSA-N cycloheptane Chemical class [CH]1CCCCCC1 HXCKCCRKGXHOBK-UHFFFAOYSA-N 0.000 description 1
- 125000003113 cycloheptyloxy group Chemical group C1(CCCCCC1)O* 0.000 description 1
- RVOJTCZRIKWHDX-UHFFFAOYSA-N cyclohexanecarbonyl chloride Chemical compound ClC(=O)C1CCCCC1 RVOJTCZRIKWHDX-UHFFFAOYSA-N 0.000 description 1
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 208000017004 dementia pugilistica Diseases 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 1
- WEHWNAOGRSTTBQ-UHFFFAOYSA-N dipropylamine Chemical compound CCCNCCC WEHWNAOGRSTTBQ-UHFFFAOYSA-N 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000317 environmental toxin Toxicity 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 208000015756 familial Alzheimer disease Diseases 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical class C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- QDYTUZCWBJRHKK-UHFFFAOYSA-N imidazole-4-methanol Chemical compound OCC1=CNC=N1 QDYTUZCWBJRHKK-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000005232 imidazopyridines Chemical class 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000003331 infrared imaging Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000010687 lubricating oil Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- KTMKRRPZPWUYKK-UHFFFAOYSA-N methylboronic acid Chemical compound CB(O)O KTMKRRPZPWUYKK-UHFFFAOYSA-N 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- IHCHOVVAJBADAH-UHFFFAOYSA-N n-[2-hydroxy-4-(1h-pyrazol-4-yl)phenyl]-6-methoxy-3,4-dihydro-2h-chromene-3-carboxamide Chemical compound C1C2=CC(OC)=CC=C2OCC1C(=O)NC(C(=C1)O)=CC=C1C=1C=NNC=1 IHCHOVVAJBADAH-UHFFFAOYSA-N 0.000 description 1
- HSYWROXNCXDIHZ-UHFFFAOYSA-N n-[3,5-difluoro-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-2-(4-fluorophenyl)-1-methylbenzimidazol-4-amine Chemical compound N1=C(C)N=CN1C(C(=C1)F)=C(F)C=C1NC1=CC=CC2=C1N=C(C=1C=CC(F)=CC=1)N2C HSYWROXNCXDIHZ-UHFFFAOYSA-N 0.000 description 1
- XUSAKMSAVGLMCQ-UHFFFAOYSA-N n-[3-[4-[3-fluoro-4-(4-methylimidazol-1-yl)anilino]-1,6-dimethylimidazo[4,5-c]pyridin-2-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2N(C3=CC(C)=NC(NC=4C=C(F)C(=CC=4)N4C=C(C)N=C4)=C3N=2)C)=C1 XUSAKMSAVGLMCQ-UHFFFAOYSA-N 0.000 description 1
- XAIGCSKGFMPAOU-UHFFFAOYSA-N n-[3-[4-[[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]amino]-1-methylbenzimidazol-2-yl]phenyl]acetamide Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=CC(NC(C)=O)=C1 XAIGCSKGFMPAOU-UHFFFAOYSA-N 0.000 description 1
- NRINOAGBDNGMSM-UHFFFAOYSA-N n-[3-fluoro-4-(2-iodo-4-methylimidazol-1-yl)phenyl]-2-(4-fluorophenyl)-1,6-dimethylimidazo[4,5-c]pyridin-4-amine Chemical compound IC1=NC(C)=CN1C(C(=C1)F)=CC=C1NC1=NC(C)=CC2=C1N=C(C=1C=CC(F)=CC=1)N2C NRINOAGBDNGMSM-UHFFFAOYSA-N 0.000 description 1
- FSIWGSUMMHERBM-UHFFFAOYSA-N n-[3-fluoro-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-2-(4-fluorophenyl)-1-propan-2-ylbenzimidazol-4-amine Chemical compound C1=CC=C2N(C(C)C)C(C=3C=CC(F)=CC=3)=NC2=C1NC(C=C1F)=CC=C1N1C=NC(C)=N1 FSIWGSUMMHERBM-UHFFFAOYSA-N 0.000 description 1
- AOFCSKZWBAWFPS-UHFFFAOYSA-N n-[3-fluoro-4-(4-methylimidazol-1-yl)phenyl]-1,6-dimethyl-2-pyridin-3-ylimidazo[4,5-c]pyridin-4-amine Chemical compound C1=NC(C)=CN1C(C(=C1)F)=CC=C1NC1=NC(C)=CC2=C1N=C(C=1C=NC=CC=1)N2C AOFCSKZWBAWFPS-UHFFFAOYSA-N 0.000 description 1
- IIJXVMDKFXFUDD-UHFFFAOYSA-N n-[3-fluoro-4-(4-methylimidazol-1-yl)phenyl]-2-(2-methoxyphenyl)-1,6-dimethylimidazo[4,5-c]pyridin-4-amine Chemical compound COC1=CC=CC=C1C(N(C1=CC(C)=N2)C)=NC1=C2NC1=CC=C(N2C=C(C)N=C2)C(F)=C1 IIJXVMDKFXFUDD-UHFFFAOYSA-N 0.000 description 1
- IFUIYERWPUEEIR-UHFFFAOYSA-N n-[3-fluoro-4-(4-methylimidazol-1-yl)phenyl]-2-(4-fluorophenyl)-1-methyl-6-propan-2-ylimidazo[4,5-c]pyridin-4-amine Chemical compound N=1C(C(C)C)=CC=2N(C)C(C=3C=CC(F)=CC=3)=NC=2C=1NC(C=C1F)=CC=C1N1C=NC(C)=C1 IFUIYERWPUEEIR-UHFFFAOYSA-N 0.000 description 1
- XFFCCMXGPAYYCB-UHFFFAOYSA-N n-[3-fluoro-4-(4-methylimidazol-1-yl)phenyl]-2-(4-fluorophenyl)-1-methylbenzimidazol-4-amine Chemical compound C1=NC(C)=CN1C(C(=C1)F)=CC=C1NC1=CC=CC2=C1N=C(C=1C=CC(F)=CC=1)N2C XFFCCMXGPAYYCB-UHFFFAOYSA-N 0.000 description 1
- UCXYMVIPPKAXPT-UHFFFAOYSA-N n-[3-fluoro-4-(4-methylimidazol-1-yl)phenyl]-2-(4-fluorophenyl)-1-methylimidazo[4,5-c]pyridin-4-amine Chemical compound C1=NC(C)=CN1C(C(=C1)F)=CC=C1NC1=NC=CC2=C1N=C(C=1C=CC(F)=CC=1)N2C UCXYMVIPPKAXPT-UHFFFAOYSA-N 0.000 description 1
- ODSOKBSZDGWOQO-UHFFFAOYSA-N n-[3-fluoro-4-(4-methylimidazol-1-yl)phenyl]-2-(4-fluorophenyl)-3,5-dimethylimidazo[4,5-b]pyridin-7-amine Chemical compound C1=NC(C)=CN1C(C(=C1)F)=CC=C1NC1=CC(C)=NC2=C1N=C(C=1C=CC(F)=CC=1)N2C ODSOKBSZDGWOQO-UHFFFAOYSA-N 0.000 description 1
- IAECBSDJAZKHCR-UHFFFAOYSA-N n-[3-fluoro-4-(4-methylimidazol-1-yl)phenyl]-2-(4-fluorophenyl)-3-methyl-5-propan-2-ylimidazo[4,5-b]pyridin-7-amine Chemical compound C=12N=C(C=3C=CC(F)=CC=3)N(C)C2=NC(C(C)C)=CC=1NC(C=C1F)=CC=C1N1C=NC(C)=C1 IAECBSDJAZKHCR-UHFFFAOYSA-N 0.000 description 1
- RIRNXFFFMVMOCK-UHFFFAOYSA-N n-[3-fluoro-4-(4-methylimidazol-1-yl)phenyl]-2-(4-fluorophenyl)-3-methylimidazo[4,5-b]pyridin-7-amine Chemical compound C1=NC(C)=CN1C(C(=C1)F)=CC=C1NC1=CC=NC2=C1N=C(C=1C=CC(F)=CC=1)N2C RIRNXFFFMVMOCK-UHFFFAOYSA-N 0.000 description 1
- HIZFUGUBEPIUHB-UHFFFAOYSA-N n-[3-fluoro-4-(4-methylimidazol-1-yl)phenyl]-2-(4-fluorophenyl)-5-methoxy-3-methylimidazo[4,5-b]pyridin-7-amine Chemical compound C=12N=C(C=3C=CC(F)=CC=3)N(C)C2=NC(OC)=CC=1NC(C=C1F)=CC=C1N1C=NC(C)=C1 HIZFUGUBEPIUHB-UHFFFAOYSA-N 0.000 description 1
- AKNXXAJURDLYNI-UHFFFAOYSA-N n-[3-fluoro-4-(5-methyl-1,2,4-triazol-1-yl)phenyl]-2-(4-fluorophenyl)-1,6-dimethylimidazo[4,5-c]pyridin-4-amine Chemical compound CC1=NC=NN1C(C(=C1)F)=CC=C1NC1=NC(C)=CC2=C1N=C(C=1C=CC(F)=CC=1)N2C AKNXXAJURDLYNI-UHFFFAOYSA-N 0.000 description 1
- OEMSIWQRNQLBSN-UHFFFAOYSA-N n-[3-fluoro-4-(5-methyl-1,2,4-triazol-1-yl)phenyl]-2-(4-fluorophenyl)-1-methylimidazo[4,5-c]pyridin-4-amine Chemical compound CC1=NC=NN1C(C(=C1)F)=CC=C1NC1=NC=CC2=C1N=C(C=1C=CC(F)=CC=1)N2C OEMSIWQRNQLBSN-UHFFFAOYSA-N 0.000 description 1
- CCVISICJHGLCAP-UHFFFAOYSA-N n-[3-fluoro-4-(5-methyl-1,2,4-triazol-1-yl)phenyl]-2-(4-fluorophenyl)-1-propan-2-ylimidazo[4,5-c]pyridin-4-amine Chemical compound N1=CC=C2N(C(C)C)C(C=3C=CC(F)=CC=3)=NC2=C1NC(C=C1F)=CC=C1N1N=CN=C1C CCVISICJHGLCAP-UHFFFAOYSA-N 0.000 description 1
- WMLSVUDEUGBUOW-UHFFFAOYSA-N n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-1-methyl-2-[2-(trifluoromethyl)phenyl]imidazo[4,5-c]pyridin-4-amine Chemical compound C=1C=C(N2N=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=NC=CC=1N(C)C=2C1=CC=CC=C1C(F)(F)F WMLSVUDEUGBUOW-UHFFFAOYSA-N 0.000 description 1
- WKNXPTOSYALWDM-UHFFFAOYSA-N n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-2-(2-methylpropyl)-1,3-benzoxazol-4-amine Chemical compound COC1=CC(NC=2C=3N=C(CC(C)C)OC=3C=CC=2)=CC=C1N1C=NC(C)=N1 WKNXPTOSYALWDM-UHFFFAOYSA-N 0.000 description 1
- XJPKQCATKUTLAR-UHFFFAOYSA-N n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-2-(2-methylpropyl)-1-(2,2,2-trifluoroethyl)benzimidazol-4-amine Chemical compound COC1=CC(NC=2C=3N=C(CC(C)C)N(CC(F)(F)F)C=3C=CC=2)=CC=C1N1C=NC(C)=N1 XJPKQCATKUTLAR-UHFFFAOYSA-N 0.000 description 1
- XIKTUFADIBIODL-UHFFFAOYSA-N n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-2-(3-methoxyphenyl)-1,6-dimethylimidazo[4,5-c]pyridin-4-amine Chemical compound COC1=CC=CC(C=2N(C3=CC(C)=NC(NC=4C=C(OC)C(=CC=4)N4N=C(C)N=C4)=C3N=2)C)=C1 XIKTUFADIBIODL-UHFFFAOYSA-N 0.000 description 1
- LVRIEYNKGOBFCT-UHFFFAOYSA-N n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-2-(3-methoxyphenyl)-1-methylbenzimidazol-4-amine Chemical compound COC1=CC=CC(C=2N(C3=CC=CC(NC=4C=C(OC)C(=CC=4)N4N=C(C)N=C4)=C3N=2)C)=C1 LVRIEYNKGOBFCT-UHFFFAOYSA-N 0.000 description 1
- QKENOWCZXGZUHE-UHFFFAOYSA-N n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-2-(3-methoxyphenyl)-1-methylimidazo[4,5-c]pyridin-4-amine Chemical compound COC1=CC=CC(C=2N(C3=CC=NC(NC=4C=C(OC)C(=CC=4)N4N=C(C)N=C4)=C3N=2)C)=C1 QKENOWCZXGZUHE-UHFFFAOYSA-N 0.000 description 1
- DPTVEUTUNCWZAV-UHFFFAOYSA-N n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-2-(3-methoxyphenyl)-1-propan-2-ylbenzimidazol-4-amine Chemical compound COC1=CC=CC(C=2N(C3=CC=CC(NC=4C=C(OC)C(=CC=4)N4N=C(C)N=C4)=C3N=2)C(C)C)=C1 DPTVEUTUNCWZAV-UHFFFAOYSA-N 0.000 description 1
- PAYVQDQHMXZDEG-UHFFFAOYSA-N n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-2-(3-methoxyphenyl)-1-propan-2-ylimidazo[4,5-c]pyridin-4-amine Chemical compound COC1=CC=CC(C=2N(C3=CC=NC(NC=4C=C(OC)C(=CC=4)N4N=C(C)N=C4)=C3N=2)C(C)C)=C1 PAYVQDQHMXZDEG-UHFFFAOYSA-N 0.000 description 1
- NFJQXSPUZNRRBM-UHFFFAOYSA-N n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-2-(oxan-4-yl)-1-propan-2-ylbenzimidazol-4-amine Chemical compound C=1C=C(N2N=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1N(C(C)C)C=2C1CCOCC1 NFJQXSPUZNRRBM-UHFFFAOYSA-N 0.000 description 1
- DIIIRXMTLYUTIT-UHFFFAOYSA-N n-[3-methoxy-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-2-methyl-1-propan-2-ylbenzimidazol-4-amine Chemical compound COC1=CC(NC=2C=3N=C(C)N(C(C)C)C=3C=CC=2)=CC=C1N1C=NC(C)=N1 DIIIRXMTLYUTIT-UHFFFAOYSA-N 0.000 description 1
- BBYCLPSSRHOZFH-UHFFFAOYSA-N n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-1,2-dimethylbenzimidazol-4-amine Chemical compound COC1=CC(NC=2C=3N=C(C)N(C)C=3C=CC=2)=CC=C1N1C=NC(C)=C1 BBYCLPSSRHOZFH-UHFFFAOYSA-N 0.000 description 1
- LRQJTZQAUITTSY-UHFFFAOYSA-N n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-1-methyl-2-(2-methylpropyl)benzimidazol-4-amine Chemical compound COC1=CC(NC=2C=3N=C(CC(C)C)N(C)C=3C=CC=2)=CC=C1N1C=NC(C)=C1 LRQJTZQAUITTSY-UHFFFAOYSA-N 0.000 description 1
- QLZMAXICYDXQJA-UHFFFAOYSA-N n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-1-methyl-2-(2-methylpropylsulfanyl)benzimidazol-4-amine Chemical compound COC1=CC(NC=2C=3N=C(SCC(C)C)N(C)C=3C=CC=2)=CC=C1N1C=NC(C)=C1 QLZMAXICYDXQJA-UHFFFAOYSA-N 0.000 description 1
- FRNXRMREIJYPGA-UHFFFAOYSA-N n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-1-methyl-2-(3,3,3-trifluoropropyl)benzimidazol-4-amine Chemical compound COC1=CC(NC=2C=3N=C(CCC(F)(F)F)N(C)C=3C=CC=2)=CC=C1N1C=NC(C)=C1 FRNXRMREIJYPGA-UHFFFAOYSA-N 0.000 description 1
- XSVRBGYICUUYAI-UHFFFAOYSA-N n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-1-methyl-2-(oxan-4-ylmethyl)benzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1N(C)C=2CC1CCOCC1 XSVRBGYICUUYAI-UHFFFAOYSA-N 0.000 description 1
- JKJFZWSTCVFYGS-UHFFFAOYSA-N n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-1-methyl-2-(piperidin-4-ylmethyl)benzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1N(C)C=2CC1CCNCC1 JKJFZWSTCVFYGS-UHFFFAOYSA-N 0.000 description 1
- AEUCEFXTCLUDBY-UHFFFAOYSA-N n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-1-methyl-2-[(1-methylpiperidin-4-yl)methyl]benzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1N(C)C=2CC1CCN(C)CC1 AEUCEFXTCLUDBY-UHFFFAOYSA-N 0.000 description 1
- LQJWDFACJZHKPP-UHFFFAOYSA-N n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-1-methyl-2-phenoxybenzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1N(C)C=2OC1=CC=CC=C1 LQJWDFACJZHKPP-UHFFFAOYSA-N 0.000 description 1
- HHSQCZLNCAOSEB-UHFFFAOYSA-N n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-1-methyl-2-piperidin-1-ylbenzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1N(C)C=2N1CCCCC1 HHSQCZLNCAOSEB-UHFFFAOYSA-N 0.000 description 1
- DYVGYMVFVBSWBP-UHFFFAOYSA-N n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-1-methyl-2-propan-2-yloxybenzimidazol-4-amine Chemical compound COC1=CC(NC=2C=3N=C(OC(C)C)N(C)C=3C=CC=2)=CC=C1N1C=NC(C)=C1 DYVGYMVFVBSWBP-UHFFFAOYSA-N 0.000 description 1
- FGEFIOZZNPAYEK-UHFFFAOYSA-N n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-1-propan-2-yl-2-[6-(trifluoromethyl)pyridin-3-yl]benzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1N(C(C)C)C=2C1=CC=C(C(F)(F)F)N=C1 FGEFIOZZNPAYEK-UHFFFAOYSA-N 0.000 description 1
- FPPPOXPVUAHPPQ-UHFFFAOYSA-N n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-2-(1-methylpiperidin-4-yl)-1,3-benzoxazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1OC=2C1CCN(C)CC1 FPPPOXPVUAHPPQ-UHFFFAOYSA-N 0.000 description 1
- RCSXZCSMRDNFEL-UHFFFAOYSA-N n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-2-(2-methoxyphenyl)-1,3-benzoxazol-4-amine Chemical compound COC1=CC=CC=C1C(OC1=CC=C2)=NC1=C2NC1=CC=C(N2C=C(C)N=C2)C(OC)=C1 RCSXZCSMRDNFEL-UHFFFAOYSA-N 0.000 description 1
- DXBXAUHLQOQXBB-UHFFFAOYSA-N n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-2-(2-methylphenyl)-1h-benzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1NC=2C1=CC=CC=C1C DXBXAUHLQOQXBB-UHFFFAOYSA-N 0.000 description 1
- KLANZYRAJYUNCV-UHFFFAOYSA-N n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-2-(2-methylpropyl)-1,3-benzoxazol-4-amine Chemical compound COC1=CC(NC=2C=3N=C(CC(C)C)OC=3C=CC=2)=CC=C1N1C=NC(C)=C1 KLANZYRAJYUNCV-UHFFFAOYSA-N 0.000 description 1
- FYBNSZAREGIYIO-UHFFFAOYSA-N n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-2-(3-methoxyphenyl)-1-methylbenzimidazol-4-amine Chemical compound COC1=CC=CC(C=2N(C3=CC=CC(NC=4C=C(OC)C(=CC=4)N4C=C(C)N=C4)=C3N=2)C)=C1 FYBNSZAREGIYIO-UHFFFAOYSA-N 0.000 description 1
- QKKWNFHOLUIAOV-UHFFFAOYSA-N n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-2-(3-methoxypropyl)-1-methylbenzimidazol-4-amine Chemical compound C1=CC=C2N(C)C(CCCOC)=NC2=C1NC(C=C1OC)=CC=C1N1C=NC(C)=C1 QKKWNFHOLUIAOV-UHFFFAOYSA-N 0.000 description 1
- ZZBYFSBXAMGDPO-UHFFFAOYSA-N n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-2-(4-methoxyphenyl)-1-methylbenzimidazol-4-amine Chemical compound C1=CC(OC)=CC=C1C(N(C1=CC=C2)C)=NC1=C2NC1=CC=C(N2C=C(C)N=C2)C(OC)=C1 ZZBYFSBXAMGDPO-UHFFFAOYSA-N 0.000 description 1
- MYZLFSKRQVJWDO-UHFFFAOYSA-N n-[3-methoxy-4-(5-methyl-1,2,4-triazol-1-yl)phenyl]-1-methyl-2-(phenoxymethyl)benzimidazol-4-amine Chemical compound C=1C=C(N2C(=NC=N2)C)C(OC)=CC=1NC(C=1N=2)=CC=CC=1N(C)C=2COC1=CC=CC=C1 MYZLFSKRQVJWDO-UHFFFAOYSA-N 0.000 description 1
- SNUSCFLGIMDYSK-UHFFFAOYSA-N n-[4-(4-bromoimidazol-1-yl)-3-methoxyphenyl]-2-(4-fluorophenyl)-1-methylbenzimidazol-4-amine Chemical compound C=1C=C(N2C=C(Br)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=C(F)C=C1 SNUSCFLGIMDYSK-UHFFFAOYSA-N 0.000 description 1
- KXSDIWGELZQDDZ-UHFFFAOYSA-N n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methyl-2-(3-propan-2-yloxyphenyl)benzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=CC(OC(C)C)=C1 KXSDIWGELZQDDZ-UHFFFAOYSA-N 0.000 description 1
- WCXZWRTYGSCJOF-UHFFFAOYSA-N n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methyl-2-[2-(trifluoromethoxy)phenyl]benzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=CC=C1OC(F)(F)F WCXZWRTYGSCJOF-UHFFFAOYSA-N 0.000 description 1
- APCZSKUZEIYFTL-UHFFFAOYSA-N n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methyl-2-[2-(trifluoromethyl)phenyl]benzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=CC=C1C(F)(F)F APCZSKUZEIYFTL-UHFFFAOYSA-N 0.000 description 1
- DRUOAYJZBOGIBA-UHFFFAOYSA-N n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methyl-2-[2-methyl-5-(trifluoromethyl)phenyl]benzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC(C(F)(F)F)=CC=C1C DRUOAYJZBOGIBA-UHFFFAOYSA-N 0.000 description 1
- ANLAERGMLRYGPC-UHFFFAOYSA-N n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methyl-2-[3-(trifluoromethoxy)phenyl]benzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=CC(OC(F)(F)F)=C1 ANLAERGMLRYGPC-UHFFFAOYSA-N 0.000 description 1
- AWSDPAYBZOARKP-UHFFFAOYSA-N n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methyl-2-[3-(trifluoromethyl)phenyl]benzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=CC(C(F)(F)F)=C1 AWSDPAYBZOARKP-UHFFFAOYSA-N 0.000 description 1
- RVOHGJMGUCWKDQ-UHFFFAOYSA-N n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methyl-2-[4-(trifluoromethoxy)phenyl]benzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=C(OC(F)(F)F)C=C1 RVOHGJMGUCWKDQ-UHFFFAOYSA-N 0.000 description 1
- RAQXMOORVMRJGQ-UHFFFAOYSA-N n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methyl-2-[4-(trifluoromethyl)phenyl]benzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=C(C(F)(F)F)C=C1 RAQXMOORVMRJGQ-UHFFFAOYSA-N 0.000 description 1
- FEZUDUGXVJTXKA-UHFFFAOYSA-N n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-1-methyl-2-phenylbenzimidazol-4-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=NC=1NC(C=1N=2)=CC=CC=1N(C)C=2C1=CC=CC=C1 FEZUDUGXVJTXKA-UHFFFAOYSA-N 0.000 description 1
- FDKCXGUUFCODHW-UHFFFAOYSA-N n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-2-(3-methoxyphenyl)-1,3-benzoxazol-4-amine Chemical compound COC1=CC=CC(C=2OC3=CC=CC(NC=4N=C(OC)C(=CC=4)N4C=C(C)N=C4)=C3N=2)=C1 FDKCXGUUFCODHW-UHFFFAOYSA-N 0.000 description 1
- JFQHEWVAEIWYNT-UHFFFAOYSA-N n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-2-(3-methoxyphenyl)-1-methylbenzimidazol-4-amine Chemical compound COC1=CC=CC(C=2N(C3=CC=CC(NC=4N=C(OC)C(=CC=4)N4C=C(C)N=C4)=C3N=2)C)=C1 JFQHEWVAEIWYNT-UHFFFAOYSA-N 0.000 description 1
- TUKSZSBYBGCUKG-UHFFFAOYSA-N n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-2-(4-methoxy-2-methylphenyl)-1-methylbenzimidazol-4-amine Chemical compound CC1=CC(OC)=CC=C1C(N(C1=CC=C2)C)=NC1=C2NC1=CC=C(N2C=C(C)N=C2)C(OC)=N1 TUKSZSBYBGCUKG-UHFFFAOYSA-N 0.000 description 1
- AMRBGCCQSMHPGH-UHFFFAOYSA-N n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-2-(4-methoxyphenyl)-1-methylbenzimidazol-4-amine Chemical compound C1=CC(OC)=CC=C1C(N(C1=CC=C2)C)=NC1=C2NC1=CC=C(N2C=C(C)N=C2)C(OC)=N1 AMRBGCCQSMHPGH-UHFFFAOYSA-N 0.000 description 1
- AEUIEAUMBFMOLJ-UHFFFAOYSA-N n-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-2-[3-methoxy-5-(trifluoromethyl)phenyl]-1-methylbenzimidazol-4-amine Chemical compound FC(F)(F)C1=CC(OC)=CC(C=2N(C3=CC=CC(NC=4N=C(OC)C(=CC=4)N4C=C(C)N=C4)=C3N=2)C)=C1 AEUIEAUMBFMOLJ-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 1
- KQTXIZHBFFWWFW-UHFFFAOYSA-L silver(I) carbonate Inorganic materials [Ag]OC(=O)O[Ag] KQTXIZHBFFWWFW-UHFFFAOYSA-L 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000004544 spot-on Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 229960005137 succinic acid Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229940042055 systemic antimycotics triazole derivative Drugs 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- PSRHRFNKESVOEL-UHFFFAOYSA-N tert-butyl 4-(2-oxoethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CC=O)CC1 PSRHRFNKESVOEL-UHFFFAOYSA-N 0.000 description 1
- QENITIZROAJKEO-UHFFFAOYSA-N tert-butyl 4-[[4-[3-methoxy-4-(4-methylimidazol-1-yl)anilino]-1-methylbenzimidazol-2-yl]methyl]piperidine-1-carboxylate Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(C=1N=2)=CC=CC=1N(C)C=2CC1CCN(C(=O)OC(C)(C)C)CC1 QENITIZROAJKEO-UHFFFAOYSA-N 0.000 description 1
- 150000003510 tertiary aliphatic amines Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- APEJMQOBVMLION-VOTSOKGWSA-N trans-cinnamamide Chemical class NC(=O)\C=C\C1=CC=CC=C1 APEJMQOBVMLION-VOTSOKGWSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- the present invention is concerned with novel substituted benzoxazole, benzimidazole, oxazolopyridine and imidazopyridine derivatives useful as gamma secretase modulators.
- the invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
- AD Alzheimer's Disease
- AD Alzheimer's disease
- specific neuropathological lesions in the limbic and cerebral cortices include intracellular neurofibrillary tangles consisting of hyperphosphorylated tau protein and the extracellular deposition of fibrillar aggregates of amyloid beta peptides (amyloid plaques).
- amyloid beta A-beta, Abeta or Aß
- a variant thereof, which is the Aß1-42-peptide (Abeta-42) is believed to be the major causative agent for amyloid formation.
- Another variant is the Aß1-40-peptide (Abeta-40).
- Amyloid beta is the proteolytic product of a precursor protein, beta amyloid precursor protein (beta-APP or APP).
- AD ⁇ -amyloid precursor protein
- APP ⁇ -amyloid precursor protein
- presenilin proteins 1 and 2 ⁇ -amyloid precursor protein
- late onset forms of AD have been correlated with a specific allele of the apolipoprotein E (ApoE) gene, and, more recently, the finding of a mutation in alpha2-macroglobulin, which may be linked to at least 30 % of the AD population.
- ApoE apolipoprotein E
- a ⁇ amyloidogenic peptides
- a ⁇ amyloidogenic peptides
- a ⁇ 42 amyloidogenic peptides
- AD amyloid cascade hypothesis
- a ⁇ peptides The release of A ⁇ peptides is modulated by at least two proteolytic activities referred to as ⁇ - and ⁇ -secretase cleavage at the N-terminus (Met-Asp bond) and the C-terminus (residues 37-42) of the A ⁇ peptide, respectively.
- ⁇ -secretase cleaves first, leading to the secretion of s-APP ⁇ (s ⁇ ) and the retention of a 11 kDa membrane-bound carboxy terminal fragment (CTF). The latter is believed to give rise to A ⁇ peptides following cleavage by ⁇ -secretase.
- a ⁇ 42 The amount of the longer isoform, A ⁇ 42, is selectively increased in patients carrying certain mutations in a particular protein (presenilin), and these mutations have been correlated with early-onset familial Alzheimer's disease. Therefore, Aß42 is believed by many researchers to be the main culprit of the pathogenesis of Alzheimer's disease.
- the gamma ( ⁇ )-secretase activity resides within a multiprotein complex containing at least four components: the presenilin (PS) heterodimer, nicastrin, aph-1 and pen-2.
- PS presenilin
- the PS heterodimer consists of the amino- and carboxyterminal PS fragments generated by endoproteolysis of the precursor protein. The two aspartates of the catalytic site are at the interface of this heterodimer.
- nicastrin serves as a gamma-secretase-substrate receptor.
- the functions of the other members of gamma-secretase are unknown, but they are all required for activity ( Steiner, 2004. Curr. Alzheimer Research 1(3): 175-181 ).
- US 2008/0280948 A1 relates to aminophenyl derivatives which are modulators for amyloid beta.
- WO-2009/005729 relates to heterocyclic compounds and their use as gamma secretase modulators.
- WO-2008/097538 encompasses 2-[4-imidazolyl)-phenyl]vinyl-heterocycle derivatives which selectively attenuate production of Abeta(1-42) and are useful in the treatment of Alzheimer's disease.
- WO-2004/017963 discloses benzimidazoles as coagulation factor Xa inhibitors for the treatment of thromboembolic illnesses.
- WO-2005/115990 discloses cinnamide compounds that are useful for the treatment of neurodegenerative diseases caused by amyloid ⁇ proteins such as Alzheimer's disease, senile dementia, Down's syndrome and amyloidosis.
- WO-2007/044895 discloses diaromatic amines and their use in lubricating oil compositions and stabilizer-containing compositions.
- WO-2008/156580 discloses triazole derivatives for treating diseases associated with deposition of A ⁇ in the brain, in particular Alzheimer's disease.
- the compounds of the present invention are useful as gamma secretase modulators.
- the compounds according to the invention and the pharmaceutically acceptable compositions thereof, may be useful in the treatment or prevention of Alzheimer's disease.
- the present invention concerns novel compounds of Formula (I): and stereoisomeric forms thereof, wherein R 1 is hydrogen, cyano, CF 3 , halo, or C 1-4 alkyl optionally substituted with one or more substituents each independently selected from the group consisting of hydroxyl and C 1-4 alkyloxy; R 2 is hydrogen, C 1-4 alkyl or halo; X is CR 5 or N; R 5 is hydrogen or halo; A 1 is CR 6 or N; R 6 is hydrogen, halo or C 1-4 alkyloxy; A 2 , A 3 and A 4 each independently are CH, CF or N; provided that no more than two of A 1 , A 2 , A 3 and A 4 are N; Y 1 is CH or N; Y 2 is CR 4 or N; Y 3 is CH or N; provided that only one of Y 1 , Y 2 and Y 3 may represent N; R 4 is hydrogen, halo, C 1-4 alkyloxy, cyano, cycloC 3
- the present invention also concerns methods for the preparation of compounds of Formula (I) and pharmaceutical compositions comprising them.
- the present compounds surprisingly were found to modulate the ⁇ -secretase activity in vitro and in vivo, and are therefore useful in the treatment or prevention of Alzheimer's disease, traumatic brain injury, mild cognitive impairment (MCI), senility, dementia, dementia with Lewy bodies, cerebral amyloid angiopathy, multi-infarct dementia, Down's syndrome, dementia associated with Parkinson's disease and dementia associated with beta-amyloid, preferably Alzheimer's disease and other disorders with Beta-amyloid pathology (eg glaucoma).
- MCI mild cognitive impairment
- senility dementia
- dementia with Lewy bodies dementia with Lewy bodies
- cerebral amyloid angiopathy multi-infarct dementia
- Down's syndrome dementia associated with Parkinson's disease and dementia associated with beta-amyloid
- Beta-amyloid pathology eg glaucoma
- the compounds are suitable in the treatment or prevention of Alzheimer's disease, cerebral amyloid angiopathy, multi-infarct dementia, dementia pugilistica or Down syndrome.
- the present invention also concerns to the use of a compound according to the general Formula (I), the stereoisomeric forms thereof and the pharmaceutically acceptable acid or base addition salts and the solvates thereof, for the manufacture of a medicament for the modulation of ⁇ -secretase activity.
- One advantage of the compounds or a part of the compounds of the present invention may lie in their enhanced CNS-penetration.
- substituted is used in the present invention, it is meant, unless otherwise is indicated or is clear from the context, to indicate that one or more hydrogens, in particular from 1 to 4 hydrogens, preferably from 1 to 3 hydrogens, more preferably 1 hydrogen, on the atom or radical indicated in the expression using "substituted” are replaced with a selection from the indicated group, provided that the normal valency is not exceeded, and that the substitution results in a chemically stable compound, i.e. a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into a therapeutic agent.
- halo or "halogen” as a group or part of a group is generic for fluoro, chloro, bromo, iodo unless otherwise is indicated.
- C 1-6 alkyl refers to a hydrocarbyl radical of Formula C n H 2n+1 wherein n is a number ranging from 1 to 6.
- C 1-6 alkyl groups comprise from 1 to 6 carbon atoms, preferably from 1 to 4 carbon atoms, more preferably from 1 to 3 carbon atoms, still more preferably 1 to 2 carbon atoms.
- Alkyl groups may be linear or branched and may be substituted as indicated herein. When a subscript is used herein following a carbon atom, the subscript refers to the number of carbon atoms that the named group may contain.
- C 1-6 alkyl includes all linear, or branched alkyl groups with between 1 and 6 carbon atoms, and thus includes such as for example methyl, ethyl, n -propyl, i -propyl, 2-methyl-ethyl, butyl and its isomers (e.g. n -butyl, isobutyl and tert -butyl), pentyl and its isomers, hexyl and its isomers, and the like.
- C 2-6 alkyl as a group or part of a group refers to a hydrocarbyl radical of Formula C n H 2n+1 wherein n is a number ranging from 2 to 6.
- C 2-6 alkyl groups comprise from 2 to 6 carbon atoms, in particular from 2 to 4 carbon atoms, more in particular from 2 to 3 carbon atoms.
- Alkyl groups may be linear or branched and may be substituted as indicated herein.
- C 2-6 alkyl includes all linear, or branched alkyl groups with between 2 and 6 carbon atoms, and thus includes such as for example ethyl, n -propyl, i -propyl, 2-methyl-ethyl, butyl and its isomers (e.g. n- butyl, iso butyl and tert -butyl), pentyl and its isomers, hexyl and its isomers, and the like.
- C 1-4 alkyl refers to a hydrocarbyl radical of Formula C n H 2n+1 wherein n is a number ranging from 1 to 4.
- C 1-4 alkyl groups comprise from 1 to 4 carbon atoms, preferably from 1 to 3 carbon atoms, more preferably 1 to 2 carbon atoms.
- C 1-3 alkyl refers to a hydrocarbyl radical of Formula C n H 2n+1 wherein n is a number ranging from 1 to 3.
- Alkyl groups may be linear or branched and may be substituted as indicated herein.
- C 1-4 alkyl includes all linear, or branched alkyl groups with between 1 and 4 carbon atoms, and thus includes such as for example methyl, ethyl, n -propyl, i- propyl, 2-methyl-ethyl, butyl and its isomers (e.g. n -butyl, iso butyl and tert -butyl), and the like.
- C 1-6 alkyloxy refers to a radical having the Formula -OR b wherein R b is C 1-6 alkyl.
- suitable alkyloxy include methyloxy, ethyloxy, propyloxy, isopropyloxy, butyloxy, isobutyloxy, sec- butyloxy, tert -butyloxy, pentyloxy, and hexyloxy.
- C 1-4 alkyloxy refers to a radical having the Formula -OR c wherein R c is C 1-4 alkyl.
- suitable alkyloxy include methyloxy (also methoxy), ethyloxy (also ethoxy), propyloxy, isopropyloxy, butyloxy, isobutyloxy, sec -butyloxy and tert -butyloxy.
- C 2-6 alkenyl is a straight or branched hydrocarbon radical having from 2 to 6 carbon atoms containing a double bond such as ethenyl, propenyl, butenyl, pentenyl, 1-propen-2-yl, hexenyl and the like.
- cycloC 3-7 alkyl alone or in combination, refers to a cyclic saturated hydrocarbon radical having from 3 to 7 carbon atoms.
- suitable cycloC 3-7 alkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyL
- cycloC 3-7 alkyloxy alone or in combination, refers to a radical having the Formula -OR d , wherein R d is cycloC 3-7 alkyl.
- suitable cycloC 3-7 alkyloxy include cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy and cycloheptyloxy.
- each definition is independent.
- stereoisomeric forms as used hereinbefore defines all the possible isomeric forms that the compounds of Formula (I) may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms. More in particular, stereogenic centers may have the R- or S-configuration; substituents on bivalent cyclic (partially) saturated radicals may have either the cis- or trans-configuration. Compounds encompassing double bonds can have an E or Z-stereochemistry at said double bond. Stereoisomeric forms of the compounds of Formula (I) are embraced within the scope of this invention.
- salts of the compounds of Formula (I) are those wherein the counterion is pharmaceutically acceptable.
- salts of acids and bases which are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound. All salts, whether pharmaceutically acceptable or not are included within the ambit of the present invention.
- the pharmaceutically acceptable acid and base addition salts as mentioned hereinabove or hereinafter are meant to comprise the therapeutically active non-toxic acid and base addition salt forms which the compounds of Formula (I) are able to form.
- the pharmaceutically acceptable acid addition salts can conveniently be obtained by treating the base form with such appropriate acid.
- Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid, sulfuric, nitric, phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic (i.e. ethanedioic), malonic, succinic (i.e.
- salt forms can be converted by treatment with an appropriate base into the free base form.
- the compounds of Formula (I) containing an acidic proton may also be converted into their non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases.
- Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g.
- primary, secondary and tertiary aliphatic and aromatic amines such as methylamine, ethylamine, propylamine, isopropylamine, the four butylamine isomers, dimethylamine, diethylamine, diethanolamine, dipropylamine, diisopropylamine, di- n- butylamine, pyrrolidine, piperidine, morpholine, trimethylamine, triethylamine, tripropylamine, quinuclidine, pyridine, quinoline and isoquinoline; the benzathine, N- methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.
- the salt form can be converted by treatment with acid into the free acid form.
- solvate comprises the hydrates and solvent addition forms which the compounds of formula (I) are able to form, as well as the salts thereof. Examples of such forms are e.g. hydrates, alcoholates and the like.
- the compounds of Formula (I) as prepared in the processes described below may be synthesized in the form of racemic mixtures of enantiomers that can be separated from one another following art-known resolution procedures.
- a manner of separating the enantiomeric forms of the compounds of Formula (I) involves liquid chromatography using a chiral stationary phase.
- Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically.
- a compound according to the invention is inherently intended to comprise all isotopic combinations of its chemical elements.
- a chemical element in particular when mentioned in relation to a compound according to formula (I), comprises all isotopes and isotopic mixtures of this element.
- hydrogen when hydrogen is mentioned, it is understood to refer to 1 H, 2 H, 3 H and mixtures thereof
- the most commonly used positron emitting (PET) radioactive isotopes are 11 C, 18 F, 15 O and 13 N, all of which are accelerator produced and have half-lives of 20, 100, 2 and 10 minutes respectively. Since the half-lives of these radioactive isotopes are so short, it is only feasible to use them at institutions which have an accelerator on site for their production, thus limiting their use.
- the most widely used of these are 18 F, 99m Tc, 201 Tl and 123 I.
- the handling of these radioactive isotopes, their production, isolation and incorporation in a molecule are known to the skilled person.
- the radioactive atom is selected from the group of hydrogen, carbon, nitrogen, sulfur, oxygen and halogen.
- the radioactive isotope is selected from the group of 3 H, 11 C, 18 F, 122 I, 123 I, 125 I, 131 I, 75 Br, 76 Br, 77 Br and 82 Br.
- a compound means one compound or more than one compound.
- the invention relates to compounds of Formula (I) and stereoisomeric forms thereof, wherein R 1 is hydrogen, cyano, CF 3 , halo, or C 1-4 alkyl optionally substituted with one or more substituents each independently selected from the group consisting of hydroxyl and C 1-4 alkyloxy; R 2 is hydrogen, C 1-4 alkyl or halo; X is CR 5 or N; R 5 is hydrogen or halo; A 1 is CR 6 or N; R 6 is hydrogen, halo or C 1-4 alkyloxy; A 2 , A 3 and A 4 each independently are CH, CF or N; provided that no more than two of A 1 , A 2 , A 3 and A 4 are N; Y 1 is CH or N; Y 2 is CR 4 or N; Y 3 is CH or N; provided that only one of Y 1 , Y 2 and Y 3 may represent N; R 4 is hydrogen, halo, C 1-4 alkyloxy, cyano, cyclo
- the invention relates to compounds of Formula (I) and stereoisomeric forms thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein one or more, preferably all, of the following restrictions apply:
- the invention relates to compounds of Formula (I) and stereoisomeric forms thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein one or more, preferably all, of the following restrictions apply:
- the invention relates to compounds of Formula (I) and stereoisomeric forms thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein one or more, preferably all, of the following restrictions apply:
- the invention relates to compounds of Formula (I) and stereoisomeric forms thereof, wherein R 1 is hydrogen, C 1-4 alkyl, cyano, CF 3 , or halo; R 2 is hydrogen or C 1-4 alkyl; X is CR 5 or N; R 5 is hydrogen or halo; A 1 is CR 6 or N; R 6 is hydrogen, halo or C 1-4 alkyloxy; A 2 , A 3 and A 4 each independently are CH, CF or N; provided that no more than two of A 1 , A 2 , A 3 and A 4 are N; Y 1 is CH or N; Y 2 is CR 4 or N; Y 3 is CH or N; provided that only one of Y 1 , Y 2 and Y 3 may represent N; R 4 is hydrogen, halo, C 1-4 alkyloxy, cyano, cycloC 3-7 alkyl, C 2-4 alkenyl, or C 1-4 alkyl optionally substituted with one or more substituents each independently
- the invention relates to compounds of Formula (I) and stereoisomeric forms thereof, wherein R 1 is hydrogen, C 1-4 alkyl, cyano, CF 3 , or halo; R 2 is hydrogen or C 1-4 alkyl; X is CR 5 or N; wherein R 5 is H or halo; A 1 is CR 6 or N; R 6 is hydrogen, halo or C 1-4 alkyloxy; A 2 , A 3 and A 4 each independently are CH, CF or N; provided that no more than two of A 1 , A 2 , A 3 and A 4 are N; Y 1 is CH or N; Y 2 is CR 4 or N; Y 3 is CH or N; provided that only one of Y 1 , Y 2 and Y 3 may represent N; R 3 is C 2-6 alkyl substituted with one or more substituents selected from halo; C 1-6 alkyl optionally substituted with one or more substituents selected from piperidinyl, Ar, C 1-6 alkyl
- the invention relates to compounds of Formula (I) and stereoisomeric forms thereof, wherein , R 1 is hydrogen, C 1-4 alkyl, cyano, CF 3 , or halo; R 2 is hydrogen or C 1-4 alkyl; X is CR 5 or N; R 5 is hydrogen or halo; A 1 is CR 6 or N; R 6 is hydrogen, halo or C 1-4 alkyloxy; A 2 , A 3 and A 4 each independently are CH, CF or N; provided that no more than two of A 1 , A 2 , A 3 and A 4 are N; Y 1 is CH or N; Y 2 is CR 4 ; Y 3 is CH; R 4 is hydrogen, halo, C 1-4 alkyloxy, cyano, or C 1-4 alkyl optionally substituted with one or more halo substituents; R 3 is C 2-6 alkyl substituted with one or more halo substituents; C 1-6 alkyl optionally substituted with one or more substituent
- the invention relates to compounds of Formula (I) and stereoisomeric forms thereof, wherein R 1 is hydrogen, C 1-4 alkyl, cyano, CF 3 , or halo; R 2 is hydrogen or C 1-4 alkyl; X is CR 5 or N; wherein R 5 is H or halo; A 1 is CR 6 or N; R 6 is hydrogen, halo or C 1-4 alkyloxy; A 2 , A 3 and A 4 each independently are CH, CF or N; provided that no more than two of A 1 , A 2 , A 3 and A 4 are N; Y 1 is CH or N; Y 2 is CR 4 ; Y 3 is CH; R 3 is C 2-6 alkyl substituted with one or more substituents selected from halo; C 1-6 alkyl optionally substituted with one or more substituents selected from piperidinyl, Ar, C 1-6 alkyloxy, tetrahydropyranyl, cycloC 3-7 alkyloxy and
- the invention relates to compounds of Formula (I) and stereoisomeric forms thereof, wherein R 1 is hydrogen, C 1-4 alkyl, cyano or halo; R 2 is hydrogen or C 1-4 alkyl; X is CH or N; A 1 is CR 6 or N; R 6 is hydrogen, halo or C 1-4 alkyloxy; A 2 , A 3 and A 4 each independently are CH, CF or N; provided that no more than two of A 1 , A 2 , A 3 and A 4 are N; Y 1 is CH or N; Y 2 is CR 4 ; Y 3 is CH or N; provided that only one of Y 1 and Y 3 may represent N; R 3 is C 2-6 alkyl substituted with one or more halo substituents; C 1-6 alkyl optionally substituted with one or more substituents each independently selected from the group consisting of piperidinyl, Ar, C 1-6 alkyloxy, tetrahydropyranyl and cycloC 3-7 alky
- the invention relates to compounds of Formula (I) and stereoisomeric forms thereof, wherein R 1 is hydrogen, C 1-4 alkyl, cyano or halo; R 2 is hydrogen or C 1-4 alkyl; X is CH or N; A 1 is CR 6 or N; R 6 is hydrogen, halo or C 1-4 alkyloxy; A 2 , A 3 and A 4 each independently are CH, CF or N; provided that no more than two of A 1 , A 2 , A 3 and A 4 are N; Y 1 is CH or N; Y 2 is CR 4 ; Y 3 is CH; R 3 is C 2-6 alkyl substituted with one or more halo substituents; C 1-6 alkyl optionally substituted with one or more substituents each independently selected from the group consisting of piperidinyl, Ar, C 1-6 alkyloxy, tetrahydropyranyl and cycloC 3-7 alkyl; cycloC 3-7 alkyl; piperidinyl;
- the invention relates to compounds of Formula (I) and stereoisomeric forms thereof, wherein R 1 is hydrogen, methyl, cyano or bromo; R 2 is hydrogen or methyl; XisCHorN; A 1 is CR 6 or N; R 6 is hydrogen, F or methoxy; A 2 , A 3 and A 4 each independently are CH, CF or N; provided that no more than two of A 1 , A 2 , A 3 and A 4 are N; Y 1 is CH or N; Y 2 is CR 4 ; Y 3 is CH; R 3 is 3,3,3-trifluoropropyl; C 1-6 alkyl optionally substituted with one or more substituents each independently selected from the group consisting of piperidinyl, Ar, methoxy, tetrahydropyranyl and cyclopropyl; hexyl; pentyl; piperidinyl; morpholinyl; O-Ar; isopropyloxy; isobutylthio; Ar
- the invention relates to compounds of Formula (I) and stereoisomeric forms thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein one or more, preferably all, of the following restrictions apply:
- the invention relates to compounds of Formula (I) and stereoisomeric forms thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein one or more, preferably all, of the following restrictions apply:
- the invention relates to compounds according to any of the other embodiments, wherein R 1 is methyl and wherein R 2 is hydrogen.
- the invention relates to compounds according to any of the other embodiments, wherein R 1 is hydrogen and wherein R 2 is methyl.
- the invention relates to compounds according to any of the other embodiments, wherein R 1 is hydrogen, wherein R 2 is methyl and wherein X is N.
- the invention relates to compounds according to any of the other embodiments, wherein R 1 is hydrogen, C 1-4 alkyl, cyano or halo.
- the invention relates to compounds according to any of the other embodiments, wherein X is CR 5 .
- the invention relates to compounds according to any of the other embodiments, wherein X is N.
- the invention relates to compounds according to any of the other embodiments, wherein X is N or CH.
- the invention relates to compounds according to any of the other embodiments, wherein X is CH.
- the invention relates to compounds according to any of the other embodiments, wherein Y 1 is CH or N; Y 2 is CR 4 ; and Y 3 is CH or N; provided that only one of Y 1 and Y 3 may represent N;.
- the invention relates to compounds according to any of the other embodiments, wherein Y 1 is CH; Y 2 is CR 4 ; and Y 3 is CH.
- the invention relates to compounds according to any of the other embodiments, wherein Y 1 is N; Y 2 is CR 4 ; and Y 3 is CH.
- the invention relates to compounds according to any of the other embodiments, wherein Y 1 is CH; Y 2 is N; and Y 3 is CH.
- the invention relates to compounds according to any of the other embodiments, wherein Y 1 is CH; Y 2 is CR 4 ; and Y 3 is N.
- the invention relates to compounds according to any of the other embodiments, wherein R 3 is C 2-6 alkyl substituted with one or more halo substituents; C 1-6 alkyl optionally substituted with one or more substituents each independently selected from the group consisting of piperidinyl, Ar, C 1-6 alkyloxy, tetrahydropyranyl, cycloC 3-7 alkyloxy and cycloC 3-7 alkyl; cycloC 3-7 alkyl substituted with one or more phenyl substituents optionally substituted with one or more halo substituents; cycloC 3-7 alkyl; piperidinyl; morpholinyl; pyrrolidinyl; tetrahydropyranyl; O-Ar; NR 7 R 8 ; C 1-6 alkyloxy; C 1-6 alkylthio; Ar; CH 2 -O-Ar; S-Ar; NCH 3 -Ar; NH-Ar; or
- the invention relates to compounds according to any of the other embodiments, wherein R 3 is C 2-6 alkyl substituted with one or more halo substituents; C 1-6 alkyl optionally substituted with one or more substituents each independently selected from the group consisting of Ar, C 1-6 alkyloxy, cycloC 3-7 alkyloxy and cycloC 3-7 alkyl; Ar; or CH 2 -O-Ar; wherein each Ar independently is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C 1-4 alkyloxy, cyano, C 1-4 alkyl and C 1-4 alkyl substituted with one or more halo substituents.
- the invention relates to compounds according to any of the other embodiments, wherein R 3 is isobutyl; cyclopropylmethyl; 3,3,3-trifluoropropyl; C 2-4 alkyl substituted with methoxy; CH 2 -O-Ar; or Ar.
- the invention relates to compounds according to any of the other embodiments, wherein R 3 is Ar.
- each Ar independently is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C 1-4 alkyloxy, cyano, NR 7 R 8 , morpholinyl, C 1-4 alkyl and C 1-4 alkyl substituted with one or more halo substituents; or a 5- or 6-membered heteroaryl selected from the group consisting of pyridinyl, oxazolyl, thiophenyl, thiazolyl and oxadiazolyl; wherein said 5- or 6-membered heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of halo, C 1-4 alkyloxy, cyano, C 1-4 alkyl and C 1-4 alkyl substituted with one or more halo substituents.
- the invention relates to compounds according to any of the other embodiments, wherein each Ar independently is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C 1-4 alkyloxy, cyano, NR 7 R 8 , morpholinyl, C 1-4 alkyl and C 1-4 alkyl substituted with one or more halo substituents; or pyridinyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C 1-4 alkyloxy, cyano, C 1-4 alkyl and C 1-4 alkyl substituted with one or more halo substituents.
- the invention relates to compounds according to any of the other embodiments, wherein each Ar independently is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C 1-4 alkyloxy, cyano, NR 7 R 8 , morpholinyl, C 1-4 alkyl and C 1-4 alkyl substituted with one or more halo substituents; or a 5- or 6-membered heteroaryl selected from the group consisting ofpyridinyl, pyrimidinyl, oxazolyl, furanyl, thiophenyl, pyrazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridazinyl and pyrazinyl; wherein said 5- or 6-membered heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of halo, C 1-4 alkyloxy, cyan
- the invention relates to compounds according to any of the other embodiments, wherein R 4 is hydrogen, halo, C 1-4 alkyloxy, cyano, cycloC 3-7 alkyl, C 2-4 alkenyl, or C 1-4 alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo and C 1-4 alkyloxy.
- the invention relates to compounds according to any of the other embodiments, wherein R 4 is hydrogen, halo, C 1-4 alkyloxy, cyano, or C 1-4 alkyl optionally substituted with one or more halo substituents.
- the invention relates to compounds according to any of the other embodiments, wherein R 4 is hydrogen, halo, or C 1-4 alkyl optionally substituted with one or more halo substituents.
- the invention relates to compounds according to any of the other embodiments, wherein R 4 is hydrogen, halo, methyl, cyano or CF 3 .
- the invention relates to compounds according to any of the other embodiments, wherein R 4 is hydrogen, F or CF 3 .
- the invention relates to compounds according to any of the other embodiments, wherein Z is O.
- the invention relates to compounds according to any of the other embodiments, wherein Z is NR 9 .
- the invention relates to compounds according to any of the other embodiments, wherein Z is NR 9 and wherein R 9 is C 1-6 alkyl optionally substituted with one or more substituents each independently selected from the group consisting of C 1-4 alkyloxy and CF 3 .
- the invention relates to compounds according to any of the other embodiments, wherein R 9 is C 1-3 alkyl.
- the invention relates to compounds according to any of the other embodiments or any combination of the other embodiments, wherein each R 8 is selected independently from hydrogen or C 1-4 alkyl.
- the invention relates to compounds according to any of the other embodiments, wherein A 1 is N, CH, CF or COCH 3 .
- the invention relates to compounds according to any of the other embodiments, wherein A 2 is CH.
- the invention relates to compounds according to any of the other embodiments, wherein A 3 is CH or N.
- the invention relates to compounds according to any of the other embodiments, wherein A 4 is CH.
- the invention relates to compounds according to any of the other embodiments, wherein A 2 , A 3 and A 4 each independently are CH or N; provided that no more than two of A 1 , A 2 , A 3 and A 4 are N.
- the invention relates to compounds according to any of the other embodiments, wherein A 3 and A 4 are CH.
- the invention relates to compounds according to any of the other embodiments, wherein A 2 is CH, CF or N; and A 3 and A 4 each independently are CH or N; provided that no more than two of A 1 , A 2 , A 3 and A 4 are N;
- the invention relates to compounds according to any of the other embodiments, wherein A 1 is N, CH, CF or COCH 3 ; A 2 is CH; A 3 is CH or N; and A 4 is CH.
- the invention relates to compounds according to any of the other embodiments, wherein C 1-6 alkyl is restricted to C 1-4 alkyl.
- the compound of Formula (I) is selected from the group comprising:
- the compound of Formula (I) is selected from the group comprising:
- the compound of Formula (I) is selected from the group comprising:
- the compound of Formula (I) is 2-(4-fluorophenyl)- N -[6-methoxy-5-(4-methyl-1 H -imidazol-1-yl)-2-pyridinyl]-1-methyl-1 H -benzimidazol-4-amine, including the pharmaceutically acceptable addition salts and the solvates thereof.
- the compound of Formula (I) is 2-(4-fluoro-3-methoxyphenyl)- N -[6-methoxy-5-(4-methyl-1 H -imidazol-1-yl)-2-pyridinyl]-1-methyl-1 H -benzimidazol-4-amine .2HCl .H 2 O.
- the compound of Formula (I) is 2-(4-fluoro-3-methoxyphenyl)- N -[6-methoxy-5-(4-methyl-1 H -imidazol-1-yl)-2-pyridinyl]-1-methyl-1 H -benzimidazol-4-amine, including the pharmaceutically acceptable addition salts and the solvates thereof.
- the present invention also encompasses processes for the preparation of compounds of Formula (I) and subgroups thereof.
- reactive functional groups for example hydroxy, amino, or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions.
- Conventional protecting groups can be used in accordance with standard practice, for example, see T. W. Greene and P. G. M. Wuts in "Protective Groups in Organic Chemistry", John Wiley and Sons, 1999.
- the compounds of Formula (I) and the subgroups thereof can be prepared by a succession of steps as described hereunder. They are generally prepared from starting materials which are either commercially available or prepared by standard means obvious to those skilled in the art. The compounds of the present invention can be also prepared using standard synthetic processes commonly used by those skilled in the art of organic chemistry.
- a compound of formula (I) can be prepared via a coupling reaction between an intermediate of formula (II-a) and an intermediate of formula (III-a), or via a coupling reaction between an intermediate of formula (II-b) and an intermediate of formula (III-b).
- halo is defined as Cl, Br or I.
- This reaction may be performed in the presence of a suitable base such as, for example, Cs 2 CO 3 or sodium tert -butoxide.
- the reaction can be performed in a reaction-inert solvent such as, for example, toluene, N,N -dimethylformamide (DMF), 1,2-dimethoxyethane (DME), tert -butanol or dioxane.
- the reaction typically is performed in the presence of a catalyst system comprising of a suitable catalyst such as tris(dibenzylideneacetone)dipalladium (Pd 2 (dba) 3 ), palladium(II) acetate (Pd(OAc) 2 ) and a ligand such as (9,9-dimethyl-9 H -xanthene-4,5-diyl)bis[diphenylphosphine] (Xantphos), [1,1'-binaphthalene]-2,2'-diylbis[diphenylphosphine] (BINAP), bis(2-diphenylphosphinophenyl)ether (DPEphos), or dicyclohexyl[2',4',6'-tris(1-methylethyl)[1,1'-biphenyl]-2-yl]-phosphine (X-phos).
- a suitable catalyst such as tris(dibenzylideneacetone)
- Palladium traces present after work-up of the reaction can optionally be removed by treatment of a solution of the compound of formula (I) in a suitable solvent or in a mixture of solvents, such as, for example DCM and MeOH, with N -acetyl-L-cysteine or thiol-functionalized silica.
- a compound of formula (I) wherein Y 1 or Y 3 is N can be prepared via an aromatic nucleophilic substitution between intermediates of formula (II-a) and (III-a).
- This reaction may be performed under basic or acidic conditions, e.g., in the presence of HCl or methanesulfonic acid in a reaction-inert solvent such as, for example, 2-propanol. Reaction rate and yield may be enhanced by microwave assisted heating.
- R 3 groups containing suitable functional groups such as, for example, halo, (protected) amines, alcohols, or ketones, can be used to incorporate further substitution patterns in compounds of formula (I).
- An intermediate of formula (II-a) can be prepared by a reduction of an intermediate of formula (IV) as shown in Scheme 2 below, wherein all variables are as defined before.
- the reduction of (IV) to (II-a) can be conducted by a conventional method such as, for example, a reductive hydrogenation or reduction with a metal or a metal salt and an acid [for example a metal such as iron, or a metal salt such as SnCl 2 and acid such as an inorganic acid (HCl, H 2 SO 4 or the like) or an organic acid (acetic acid or the like)], or other well-known methods for converting a nitro-group to the corresponding amine.
- An intermediate of formula (II-a) can also be prepared by a copper catalysed reaction of an intermediate of formula (V) with a (un)substituted imidazole or triazole of formula (VI) according to Scheme 3, wherein halo is defined as Br or I and wherein all other variables are defined as mentioned hereabove.
- the reaction may be performed under a protecting atmosphere such as, for example, N 2 atmosphere. Stirring, elevated temperatures (for example between 70-200 °C) and/or pressure may enhance the rate of the reaction.
- the reaction typically is performed in an organic solvent such as, for example, dimethylsulfoxide (DMSO) or dimethylformamide (DMF).
- the reaction is performed in the presence of a base such as, for example K 2 CO 3 , Cs 2 CO 3 , or triethylamine (Et 3 N), and/or a ligand such as N,N '-dimethylethylenediamine or 1,10-phenanthroline.
- a copper catalyst such as copper salts, for example, copper(I)oxide, copper(I)iodide, or copper(I)bromide, can be used in catalytic or stoichiometric amounts.
- the amino-group in intermediate (V) can be protected before the reaction, and can be deprotected after reaction via the use of a suitable amino-protecting group in accordance with standard practice, for example, see T. W. Greene and P. G. M. Wuts in "Protective Groups in Organic Chemistry", John Wiley and Sons, 1999 .
- An intermediate of formula (II-a) can also be prepared by conversion of the halo-substitutent in intermediate (II-b) into an amino-group or a masked amino functionality, which can subsequently be converted into an amino-group, according to Scheme 4.
- Scheme 4 typical reaction conditions known to those skilled in the art can be used.
- halo is defined as Cl, Br or I, and all other variables are defined as mentioned hereabove.
- An intermediate of formula (IV) can be prepared via a nucleophilic aromatic substitution of an intermediate of formula (VII) with a (un)substituted imidazole or triazole of formula (VI) according to Scheme 5, wherein halo is defined as F, Cl, or Br and wherein all other variables are defined as mentioned hereabove.
- the reaction may be performed under a protecting atmosphere such as, for example, N 2 atmosphere. Stirring, elevated temperatures (for example between 70-170 °C) and/or pressure may enhance the rate of the reaction.
- the reaction typically is performed in an organic solvent such as, for example, DMSO, DMF, or N -methylpyrrolidinone (NMP) in the presence of a base such as, for example K 2 CO 3 , Cs 2 CO 3 , or Et 3 N.
- organic solvent such as, for example, DMSO, DMF, or N -methylpyrrolidinone (NMP)
- NMP N -methylpyrrolidinone
- An intermediate of formula (II-b) can be prepared from intermediate of formula (II-a) via a Sandmeyer reaction according to Scheme 6 by conversion of (II-a) into the corresponding diazonium salt followed by treatment with a reagent such as, for example, KI, CuBr, or CuCl.
- a reagent such as, for example, KI, CuBr, or CuCl.
- Typical reaction conditions known to those skilled in the art can be used in Scheme 6. All variables in Scheme 6 are defined as before.
- An intermediate of formula (II-b) wherein A 1 and/or A 3 are N can be prepared via a nucleophilic aromatic substitution of an intermediate (VIII) wherein A 1 and/or A 3 are N, with a (un)substituted imidazole or triazole of formula (VI) according to Scheme 7, wherein LG is defined as F,Cl, Br, or NO 2 , wherein halo is defined as Br or I, and wherein all other variables are defined as hereinbefore.
- the reaction may be performed under similar conditions as described for experimental procedure 5.
- An intermediate of formula (II-b) wherein X represents CH hereby named an intermediate of formula (II-b2)
- a reaction inert solvent such as THF
- a suitable base such as Et 3 N
- An intermediate of formula (XII) can subsequently be prepared via alkylation of an intermediate of formula (X) with an intermediate of formula (XI), in the presence of a reaction inert solvent such as, for example, DMF, and a suitable base such as, for example, Cs 2 CO 3 or K 2 CO 3 , and optionally in the presence of a catalytic amount of a iodide salt such as, for example, KI or NaI.
- a condensation reaction of intermediate (XII) with an ammonia source such as, for example, ammonium acetate (NH 4 OAc) subsequently yields a compound of formula (II-b2).
- halo is defined as Cl, Br, or I
- halo2 is defined as Cl or Br
- all other variables are defined as mentioned hereinbefore.
- An intermediate of formula (III-a), wherein R 3 is carbon-linked to the heterocycle, and wherein Z is N-R 9 , hereby named an intermediate of formula (III-a1), can be prepared by an acylation of an intermediate (XIII) with an intermediate of formula (XIV) followed by a condensation, according to Scheme 9.
- the acylation reaction can be carried out in a solvent such as, for example, pyridine or a reaction inert solvent such as, for example, DMF.
- the reaction may be performed in the presence of a base such as, for example, Et 3 N.
- the subsequent condensation reaction can be carried out by heating the crude acylated product in a solvent such as, for example, acetic acid.
- halo is defined as Cl, Br or I, and all other variables are defined as before.
- intermediate (XIII) can be condensed to intermediate (III-a1) directly by using a carboxylic acid of formula R 3 -COOH.
- This reaction may be performed under dehydrating conditions such as, for example, heating in a solvent such as, for example, polyphosphoric acid.
- An intermediate of formula (III-a1) can also be prepared by treatment of an intermediate of formula (XIII) with an aldehyde of formula (XV).
- the reaction typically can be performed in the presence of a reducing agent such as, for example, sodium metabisulfite.
- the reaction typically may be performed in a reaction inert solvent such as, for example, N,N -dimethylacetamide (DMA), according to Scheme 10.
- a reaction inert solvent such as, for example, N,N -dimethylacetamide (DMA), according to Scheme 10.
- halo is defined as Cl or Br and all other variables are defined as mentioned before.
- An intermediate of formula (III-a1) can also be prepared by treatment of an intermediate of formula (XVI) with an aldehyde of formula (XV).
- This reaction may be performed in the presence of a reducing agent such as, for example, sodium dithionite.
- the reaction typically can be performed in a reaction inert solvent such as, for example, ethanol.
- halo is defined as Cl or Br and all other variables are defined as mentioned hereinbefore.
- an intermediate of formula (III-a1) wherein R 9 is different from H hereby named an intermediate of formula (III-a2)
- an intermediate of formula (III-a3) can also be prepared from an intermediate of formula (IIIa1) wherein R 9 is H, hereby named an intermediate of formula (III-a3).
- the group R 9a can be introduced via N -alkylation, leading predominantly to an intermediate of formula (III-a2) wherein R 9a is a substituent as defined before, except hydrogen, as described in Scheme 12.
- An intermediate of formula (XIII) can be prepared via reduction of an intermediate of formula (XVI) as is shown in Scheme 13, wherein halo is defined as Br or Cl, and wherein all other variables are as defined before.
- the reduction of (XVI) to (XIII) can be conducted by a conventional method such as, for example, a reductive hydrogenation or reduction with a metal or a metal salt and an acid [for example a metal such as iron, or a metal salt such as SnCl 2 and acid such as an inorganic acid (hydrochloric acid, sulfuric acid or the like) or an organic acid (acetic acid or the like)], or other well-known methods for converting a nitro-group to the corresponding amine.
- An intermediate of formula (XVI) can be prepared via a substitution reaction of an intermediate of formula (XVII) with an amine of formula R 9 -NH 2 as is shown in Scheme 14 below, wherein halo is defined as Br, I or Cl, wherein halo2 is defined as F, Cl or Br, and wherein all other variables are as defined before.
- An Intermediate of formula (III-b), wherein R 3 is carbon-linked to the heterocycle and Z is N-R 9 can be prepared as shown in Scheme 15.
- acylation of intermediate (XVIII) with an activated carboxylic acid derivative such as, for example, a carboxylic acid chloride
- intermediate (XIX) which can be condensed to a intermediate of formula (XX).
- a one step preparation of intermediate (XX) can also be performed via condensation of an intermediate of formula (XVIII) with a carboxylic acid of formula R 9 -COOH under dehydrating conditions, such as heating in a solvent such as, for example, polyphosphoric acid.
- an intermediates of formula (III-b1) can be prepared as set out below in Scheme 16.
- a base such as, for example, lithium hexamethyldisilazide
- a reaction-inert solvent such as, for example, toluene or (methyl)tetrahydrofuran
- an alkylating agent such as, for example, CH 3 I
- an intermediate of formula (XXIII) Treatment of an intermediate of formula (XXIII) with a halogenating agent such as, for example, phosphoroxychloride (POCl 3 ) gives an intermediate of formula (XXIV).
- a halogenating agent such as, for example, phosphoroxychloride (POCl 3 ) gives an intermediate of formula (XXIV).
- This intermediate can be converted to an intermediate of formula (XXV) via reaction with amines, alcohols, thiols, or via Suzuki reactions with aryl- or alkyl-boronates.
- a reducing agent such as, for example, iron in acetic acid, or other known methods for converting a nitro-group into the corresponding amine, gives the required intermediate of formula (III-b1).
- a reducing agent such as, for example, iron in acetic acid, or other known methods for converting a nitro-group into the corresponding amine
- An intermediate of formula (III-a1) can also be prepared as set out in Scheme 17.
- Condensation of an intermediate of formula (XIII) with urea, carbonyldiimidazole, phosgene or a phosgene equivalent such as e.g. diphosgene or triphosgene gives an intermediate of formula (XXVI).
- Treatment of an intermediate of formula (XXVI) with a halogenating agent such as, for example, POCl 3 gives an intermediate of formula (XXVII).
- An intermediate of formula (XXVII) can be converted to an intermediate of formula (III-a1) via reaction with amines, alcohols, thiols, or via Suzuki reactions with aryl- or alkyl-boronates.
- halo is defined as Br, I or Cl, and all other variables are defined as mentioned before. All reaction steps in Scheme 17, can be performed by using typical reaction conditions known to those skilled in the art.
- Intermediates of formula (III-a), wherein R 3 is restricted to C 1-6 alkylthio and wherein Z is N-R 9 , hereby named an intermediate of formula (III-a3), can be prepared as set out below in Scheme 18.
- Condensation of an intermediate of formula (XIII) with thiourea or 1,1'-thiocarbonyldiimidazole via heating in a reaction inert solvent, such as, for example THF yields an intermediate of formula (XXVIII).
- an intermediate of formula (XXVIII) may be alkylated, for example by a C 1-6 alkyl-iodide, in the presence of a base such as, for example, K 2 CO 3 .
- This reaction step typically can be performed in a reaction inert solvent such as, for example, acetone, to give an intermediate of formula (III-a3).
- a reaction inert solvent such as, for example, acetone
- halo is defined as Br, I or Cl
- R 3a is defined as C 1-6 alkylthio
- all other substituents are defined as mentioned hereinbefore.
- an intermediate of formula (III-a4) can be prepared as set out below in Scheme 19.
- Acylation of an intermediate of formula (XXIX) with an activated carboxylic acid derivative such as, for example, a carboxylic acid chloride with formula R 3 -COCl gives an intermediate of formula (XXX).
- an intermediate of formula (XXX) can be O-arylated to a benzoxazole intermediate of formula (III-a4).
- halo is defined as Br, I or Cl
- halo2 is defined as Cl, Br or I
- all other variables are as defined before.
- An intermediate of formula (III-b) can also be prepared by conversion of the halo-substitutent in an intermediate of formula (III-a), wherein halo is defined as Cl, Br or I, and wherein all other variables are defined as mentioned hereabove, into an amino-group or a masked amino functionality, which can subsequently be converted into an amino-group, according to Scheme 20.
- Typical well-known reaction conditions known to those skilled in the art can be used in Scheme 20.
- a compound of formula (I), wherein Z is N-R 9 , hereby named a compound of formula (I-a), can be prepared, starting from a coupling reaction between an intermediate of formula (XXVII) with an intermediate of formula (II-a) according to the conditions described under experimental procedure 1, to give an intermediate of formula (XXXI), followed by conversion of (XXXI) to a compound of formula (I-a) via reaction with amines, alcohols, thiols, or via Suzuki reactions with aryl- or alkyl-boronates.
- This last reaction in Scheme 21 can be performed by using typical reaction conditions known to those skilled in the art.
- a compound of formula (I), wherein R 3 is carbon-linked to the heterocycle, and wherein Z is N-R 9 , hereby named a compound of formula (I-b), can be prepared, starting from a coupling reaction between an intermediate of formula (XVI) with an intermediate of formula (II-a) according to the conditions described under experimental procedure 1, to give an intermediate of formula (XXXII).
- the intermediate of formula (XXXII) can either be directly converted into a compound of formula (I-b) according to the conditions described under experimental procedure 11, or (XXXII) can first be reduced to an intermediate of formula (XXXIII) according to the conditions described under experimental procedure 13, followed by the conversion of (XXXIII) to a compound of formula (I-b) according to the conditions described under experimental procedure 10.
- the free base can be dissolved in DIPE or Et 2 O and subsequently, a 6 N HCl solution in 2-propanol or a 1 N HCl solution in Et 2 O can be added dropwise. The mixture typically is stirred for 10 minutes after which the product can be filtered off.
- the HCl salt usually is dried in vacuo.
- the compounds of the present invention modulate the ⁇ -secretase activity.
- the compounds according to the invention and the pharmaceutically acceptable compositions thereof are therefore useful in the treatment or prevention of Alzheimer's disease (AD), traumatic brain injury, mild cognitive impairment (MCI), senility, dementia, dementia with Lewy bodies, cerebral amyloid angiopathy, multi-infarct dementia, Down's syndrome, dementia associated with Parkinson's disease and dementia associated with beta-amyloid, preferably Alzheimer's disease.
- AD Alzheimer's disease
- MCI mild cognitive impairment
- senility dementia
- dementia with Lewy bodies dementia with Lewy bodies
- cerebral amyloid angiopathy dementia with Lewy bodies
- multi-infarct dementia dementia associated with Parkinson's disease
- dementia associated with beta-amyloid preferably Alzheimer's disease.
- the term "modulation of ⁇ -secretase activity" refers to an effect on the processing of APP by the ⁇ -secretase-complex. Preferably it refers to an effect in which the overall rate of processing of APP remains essentially as without the application of said compounds, but in which the relative quantities of the processed products are changed, more preferably in such a way that the amount of the Aß42-peptide produced is reduced.
- a different Abeta species can be produced (e.g. Abeta-38 or other Abeta peptide species of shorter amino acid sequence instead of Abeta-42) or the relative quantities of the products are different (e.g. the ratio of Abeta-40 to Abeta-42 is changed, preferably increased).
- ⁇ -secretase complex is also involved in the processing of the Notch-protein.
- Notch is a signaling protein which plays a crucial role in developmental processes (e.g. reviewed in Schweisguth F (2004) Curr. Biol. 14, R129 ).
- ⁇ -secretase modulators it seems particularly advantageous not to interfere with the Notch-processing activity of the ⁇ -secretase activity in order to avoid putative undesired side-effects.
- ⁇ -secretase inhibitors show side effects due to concomitant inhibition of Notch processing
- ⁇ -secretase modulators may have the advantage of selectively decreasing the production of highly aggregatable and neurotoxic forms of A ⁇ , i.e.
- treatment is intended to refer to all processes, wherein there may be a slowing, interrupting, arresting, or stopping of the progression of a disease, but does not necessarily indicate a total elimination of all symptoms.
- the invention relates to a compound according to the general Formula (I), the stereoisomeric forms thereof and the pharmaceutically acceptable acid or base addition salts and the solvates thereof, for use as a medicament.
- the invention also relates to a compound according to the general Formula (I), the stereoisomeric forms thereof and the pharmaceutically acceptable acid or base addition salts and the solvates thereof, for the treatment or prevention of diseases or conditions selected from Alzheimer's disease, traumatic brain injury, mild cognitive impairment, senility, dementia, dementia with Lewy bodies, cerebral amyloid angiopathy, multi-infarct dementia, or Down's syndrome.
- diseases or conditions selected from Alzheimer's disease, traumatic brain injury, mild cognitive impairment, senility, dementia, dementia with Lewy bodies, cerebral amyloid angiopathy, multi-infarct dementia, or Down's syndrome.
- the invention also relates to a compound according to the general Formula (I), the stereoisomeric forms thereof and the pharmaceutically acceptable acid or base addition salts and the solvates thereof, for the treatment or prevention of diseases or conditions selected from AD, MCI, senility, dementia, dementia with Lewy bodies, cerebral amyloid angiopathy, multi-infarct dementia, or Down's syndrome.
- diseases or conditions selected from AD, MCI, senility, dementia, dementia with Lewy bodies, cerebral amyloid angiopathy, multi-infarct dementia, or Down's syndrome.
- said disease or condition is preferably Alzheimer's disease.
- the invention also relates to a compound according to the general Formula (I), the stereoisomeric forms thereof and the pharmaceutically acceptable acid or base addition salts and the solvates thereof, for use in treating said diseases.
- the invention also relates to a compound according to the general formula (I), the stereoisomeric forms thereof and the pharmaceutically acceptable acid or base addition salts and the solvates thereof, for use in the treatment or prevention, in particular treatment, of ⁇ -secretase mediated diseases or conditions.
- the invention also relates to the use of a compound according to the general Formula (I), the stereoisomeric forms thereof and the pharmaceutically acceptable acid or base addition salts and the solvates thereof, for the manufacture of a medicament.
- the invention also relates to the use of a compound according to the general Formula (I), the stereoisomeric forms thereof and the pharmaceutically acceptable acid or base addition salts and the solvates thereof, for the manufacture of a medicament for the modulation of ⁇ -secretase activity.
- the invention also relates to the use of a compound according to the general Formula (I), the stereoisomeric forms thereof and the pharmaceutically acceptable acid or base addition salts and the solvates thereof, for the manufacture of a medicament for the treatment or prevention of any one of the disease conditions mentioned hereinbefore.
- the invention also relates to the use of a compound according to the general Formula (I), the stereoisomeric forms thereof and the pharmaceutically acceptable acid or base addition salts and the solvates thereof, for the manufacture of a medicament for the treatment of any one of the disease conditions mentioned hereinbefore.
- IC 50 value for the inhibition of the production of Aß42-peptide of less than 1000 nM, preferably less than 100 nM, more preferably less than 50 nM, even more preferably less than 20 nM as determined by a suitable assay, such as the assays used in the Examples below.
- the compounds of the present invention can be administered to mammals, preferably humans for the treatment or prevention of any one of the diseases mentioned hereinbefore.
- Said methods comprise the administration, i.e. the systemic or topical administration, preferably oral administration, of an effective amount of a compound of Formula (I), a stereoisomeric form thereof and a pharmaceutically acceptable addition salt or solvate thereof, to warm-blooded animals, including humans.
- An effective therapeutic daily amount would be from about 0.005 mg/kg to 50 mg/kg, in particular 0.01 mg/kg to 50 mg/kg body weight, more in particular from 0.01 mg/kg to 25 mg/kg body weight, preferably from about 0.01 mg/kg to about 15 mg/kg, more preferably from about 0.01 mg/kg to about 10 mg/kg, even more preferably from about 0.01 mg/kg to about 1 mg/kg, most preferably from about 0.05 mg/kg to about 1 mg/kg body weight.
- a method of treatment may also include administering the active ingredient on a regimen of between one and four intakes per day.
- the compounds according to the invention are preferably formulated prior to administration.
- suitable pharmaceutical formulations are prepared by known procedures using well known and readily available ingredients.
- the compounds of the present invention may be administered alone or in combination with one or more additional therapeutic agents.
- Combination therapy includes administration of a single pharmaceutical dosage formulation which contains a compound of Formula (I) and one or more additional therapeutic agents, as well as administration of the compound of Formula (I) and each additional therapeutic agents in its own separate pharmaceutical dosage formulation.
- a compound of Formula (I) and a therapeutic agent may be administered to the patient together in a single oral dosage composition such as a tablet or capsule, or each agent may be administered in separate oral dosage formulations.
- the active ingredient While it is possible for the active ingredient to be administered alone, it is preferable to present it as a pharmaceutical composition.
- the carrier or diluent must be "acceptable” in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipients thereof.
- the subject compounds may be formulated into various pharmaceutical forms for administration purposes.
- the compounds according to the invention in particular the compounds according to Formula (I), a pharmaceutically acceptable acid or base addition salt thereof, a stereo chemically isomeric form thereof, or any subgroup or combination thereof may be formulated into various pharmaceutical forms for administration purposes.
- compositions there may be cited all compositions usually employed for systemically administering drugs.
- compositions of this invention an effective amount of the particular compound, optionally in addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
- a pharmaceutically acceptable carrier which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
- These pharmaceutical compositions are desirable in unitary dosage form suitable, in particular, for administration orally, rectally, percutaneously, by parenteral injection or by inhalation.
- any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms in which case solid pharmaceutical carriers are obviously employed.
- the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included.
- Injectable solutions for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution.
- Injectable solutions for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution.
- Injectable solutions containing compounds of Formula (I) may be formulated in an oil for prolonged action.
- Appropriate oils for this purpose are, for example, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, synthetic glycerol esters of long chain fatty acids and mixtures of these and other oils.
- Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. Also included are solid form preparations that are intended to be converted, shortly before use, to liquid form preparations.
- the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions.
- These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment. Acid or base addition salts of compounds of Formula (I) due to their increased water solubility over the corresponding base or acid form, are more suitable in the preparation of aqueous compositions.
- Unit dosage form refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
- unit dosage forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, suppositories, injectable solutions or suspensions and the like, and segregated multiples thereof
- compositions comprising said compounds for administration orally are especially advantageous.
- ⁇ -, ⁇ - or ⁇ -cyclodextrins or their derivatives in particular hydroxyalkyl substituted cyclodextrins, e.g. 2-hydroxypropyl- ⁇ -cyclodextrin or sulfobutyl- ⁇ -cyclodextrin.
- co-solvents such as alcohols may improve the solubility and/or the stability of the compounds according to the invention in pharmaceutical compositions.
- the pharmaceutical composition will preferably comprise from 0.05 to 99 % by weight, more preferably from 0.1 to 70 % by weight, even more preferably from 0.1 to 50 % by weight of the compound of formula (I), and, from 1 to 99.95 % by weight, more preferably from 30 to 99.9 % by weight, even more preferably from 50 to 99.9 % by weight of a pharmaceutically acceptable carrier, all percentages being based on the total weight of the composition.
- DCM dichloromethane
- MeOH means methanol
- LCMS Liquid Chromatography/Mass spectrometry
- HPLC high-performance liquid chromatography
- sol means solution; “sat.” means saturated; “aq.” means aqueous; “r.t.” means room temperature;
- AcOH means acetic acid;
- m.p.” means melting point;
- RP means reversed phase;
- BDS means base deactivated silica;
- min means minute(s);
- h means hour(s);
- I.D.” means internal diameter;
- EtOAc means ethyl acetate;
- Et 3 N means triethylamine;
- BINAP means [1,1'-binaphthalene]-2,2'-diylbis[diphenylphosphine] (racemic);
- intermediate 46 was prepared according to the procedures as described in example A9.
- a stainless steel autoclave was loaded with intermediate 12 (370 mg, 1.21 mmol), copper(I)oxide (10 mg), and a 0.5 M sol. of NH 3 in dioxane (30 ml, 15 mmol).
- the autoclave was closed and the r.m. was heated at 150 °C for 18 h.
- the r.m. was cooled, a sat. aq. NH 4 OH sol. (5 ml) was added, and the r.m. was heated at 150 °C for another 18 h
- the r.m. was cooled and concentrated in vacuo .
- the residue was partitioned between DCM and a saturated aq. NH 4 Cl sol.
- the organic layer was dried (MgSO 4 ), filtered and concentrated in vacuo. Yield: 240 mg of intermediate 24 (82 %), which was used as such in the next reaction step.
- a 1 M sol. of LiHMDS in THF (4.94 ml, 4.94 mmol) was added dropwise at 0 °C under a N 2 atmosphere to a sol. of intermediate 22 (290 mg, 0.99 mmol) in THF (15 ml).
- the r.m. was stirred at 0 °C for 30 min, and then 2-iodopropane (1.68 g, 9.9 mmol) was added.
- the r.m. was stirred overnight at 55 °C.
- the r.m. was transferred to a microwave vial, and additional amounts of a 1 M sol. of LiHMDS in THF (2 ml, 2 mmol) and 2-iodopropane (0.84 g, 5 mmol)was added.
- Benzylamine (17 g, 159 mmol) was added to a sol. of 1-bromo-3-fluoro-2-nitro-benzene (10 g, 45.5 mmol) in THF (100 ml). The r.m. was stirred at r.t. overnight. The formed precipitate was removed by filtration and the filtrate was concentrated under reduced pressure. The residue was dissolved in DCM and the resulting sol. was washed subsequently with an aq. AcOH sol., a saturated aq. NaHCO 3 sol., and water. The organic layer was dried (MgSO 4 ), filtered and concentrated in vacuo.
- N -Iodosuccinimide (26.7 g, 119 mmol) and TFA (2.5 ml, 32.4 mmol) were added to a suspension of 2,4-dichloro-pyridin-3-ylamine (17.6 g, 108 mmol) in CH 3 CN (150 ml).
- the reaction mixture was stirred at r.t. for 16 h., and then heated to 40 °C for 6 h.
- the r.m. was diluted with EtOAc and washed with a sat. aq. Na 2 S 2 O 3 sol.
- the aq. phase was extracted with EtOAc, and the combined organic layers were dried (MgSO 4 ), filtered and the solvent was evaporated in vacuo.
- the residue was purified by flash column chromatography over silica gel (eluent: DCM). The product fractions were collected and the solvent was evaporated. Yield: 22 g of intermediate 57 (71 %).
- Isopropenylboronic acid pinacol ester (867 mg, 5.16 mmol) and Pd(PPh 3 ) 4 (298 mg, 0.258 mmol) were added to a sol. of intermediate 61 (2.0 g, 5.16 mmol) in dioxane (8 ml) and an aq. NaHCO 3 sol. (4 ml).
- the r.m. was stirred and heated at 160 °C for 10 min. under microwave irradiation.
- the r.m. was cooled to r.t. and filtered over diatomaceous earth using EtOAc. The filtrate was evaporated.
- POCl 3 (1.05 ml, 11.5 mmol) was added to a sol. of intermediate 72 (1.7 g, 5.2 mmol) in DCE (16 ml). The r.m. was stirred and heated at 150 °C for 35 min. under microwave irradiation. The r.m. was diluted with DCM and washed with a sat. aq. NaHCO 3 sol. The organic phase was dried (MgSO 4 ), filtered and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel (eluent: DCM/MeOH 100/0 to 90/10). The product fractions were collected and the solvent was evaporated.
- 2-Methyl-2-propanol, sodium salt (0.299 g, 3.1 mmol), BINAP (97 mg, 0.16 mmol), Pd(OAc) 2 (23 mg, 0.1 mmol) and intermediate 24 (332 mg, 1.24 mmol) were added to a sol. of 1-(4-bromo-2-methoxyphenyl)-4-methyl-1H-imidazole (250 mg, 1.04 mmol) in toluene (10 ml) and the mixture was purged with N 2 for 5 min. The r.m. was stirred and heated at 100 °C overnight under a N 2 atmosphere. Then, the r.m.
- 2-Methyl-2-propanol, sodium salt (207 mg, 2.15 mmol), BINAP (25 mg, 0.04 mmol), Pd(OAc) 2 (6 mg, 0.027 mmol) and 1-(4-bromo-2-methoxyphenyl)-4-methyl-1 H- imidazole (215 mg, 0.81 mmol) were added to a sol. of intermediate 52 (139 mg, 0.54 mmol) in toluene (10 ml), and the mixture was purged with N 2 . The r.m. was stirred and heated at 150 °C for 1 h under microwave irradiation. Then, the r.m.
- the residue was purified by RP preparative HPLC [RP Vydac Denali C18 (10 ⁇ m, 250 g, I.D. 5 cm); mobile phase: a gradient of (0.25 % NH 4 HCO 3 soL in water)/MeOH].
- the product fractions were collected and worked up.
- the residue was dissolved in hot 2-propanol and treated with a 6 N HCl sol. in 2-propanol.
- the resulting precipitate was collected by filtration and dried. Yield: 168 mg of compound 184 (61 %) as HCl salt (.2HCl.H 2 O).
- 3-Acetamidophenylboronic acid 46 mg, 0.26 mmol
- K 2 CO 3 89 mg, 0.64 mmol
- Pd(PPh 3 ) 4 37 mg, 0.032 mmol
- the r.m. was stirred and heated at 150 °C for 20 min under microwave irradiation.
- Extra 3-acetamidophenyl-boronic acid 23 mg
- DMF 0.5 ml
- the LC measurement was performed using an Acquity UPLC (Waters) system comprising a binary pump, a sample organizer, a column heater (set at 55 °C), a diode-array detector (DAD) and a column as specified in the respective methods below.
- Flow from the column was split to a MS spectrometer
- the MS detector was configured with an electrospray ionization source Mass spectra were acquired by scanning from 100 to 1000 in 0.18 seconds (sec) using a dwell time of 0.02 seconds
- the capillary needle voltage was 3.5 kV and the source temperature was maintained at 140 °C. Nitrogen was used as the nebulizer gas
- Data acquisition was performed with a Waters-Micromass MassLynx-Openlynx data system.
- the HPLC measurement was performed using an Agilent 1100 series liquid chromatography system comprising a binary pump with degasser, an autosampler, a column oven, a UV detector and a column as specified in the respective methods below. Flow from the column was split to a MS spectrometer.
- the MS detector was configured with an electrospray ionization source.
- the capillary voltage was 3 kV, the quadrupole temperature was maintained at 100 °C and the desolvation temperature was 300 °C. Nitrogen was used as the nebulizer gas.
- Data acquisition was performed with an Agilent Chemstation data system.
- the HPLC measurement was performed using an Alliance HT 2790 (Waters) system comprising a quaternary pump with degasser, an autosampler, a column oven (set at 40 °C, unless otherwise indicated), a diode-array detector (DAD) and a column as specified in the respective methods below.
- Flow from the column was split to a MS spectrometer.
- the MS detector was configured with an electrospray ionization source. Mass spectra were acquired by scanning from 100 to 1000 in 1 sec using a dwell time of 0.1 sec.
- the capillary needle voltage was 3 kV and the source temperature was maintained at 140 °C. Nitrogen was used as the nebulizer gas.
- Data acquisition was performed with a Waters-Micromass MassLynx-Openlynx data system.
- Reversed phase UPLC was carried out on a BEH C18 column (1.7 ⁇ m, 2.1 x 50 mm; Waters Acquity) with a flow rate of 0.8 ml/min.
- Two mobile phases (mobile phase A: 0.1 % formic acid in H 2 O/MeOH 95/5; mobile phase B: MeOH) were used to run a gradient condition from 95 % A and 5 % B to 5 % A and 95 % B in 1.3 min and hold for 0.2 min.
- An injection volume of 0.5 ⁇ l was used.
- Cone voltage was 10 V for positive and 20 V for negative ionization mode.
- Reversed phase HPLC was carried out on an Xterra MS C18 column (3.5 ⁇ m, 4.6 x 100 mm) with a flow rate of 1.6 ml/min.
- Three mobile phases (mobile phase A: 95% 25 mM NH 4 OAc + 5 % CH 3 CN; mobile phase B: CH 3 CN; mobile phase C: MeOH) were employed to run a gradient condition from 100%Ato 1 % A, 49 % B and 50 % C in 6.5 min, to 1 % A and 99 % B in 1 min and hold these conditions for 1 min and reequilibrate with 100 % A for 1.5 min.
- An injection volume of 10 ⁇ l was used. Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.
- Reversed phase UPLC Ultra Performance Liquid Chromatography
- BEH bridged ethylsiloxane/silica hybrid
- Waters Acquity with a flow rate of 0.8 ml/min.
- Two mobile phases 25 mM NH 4 OAc in H 2 O/CH 3 CN 95/5; mobile phase B: CH 3 CN
- Cone voltage was 30 V for positive ionization mode and 30 V for negative ionization mode.
- Reversed phase HPLC was carried out on an Xterra MS C18 column (3.5 ⁇ m, 4.6 x 100 mm) with a flow rate of 1.6 ml/min.
- Three mobile phases (mobile phase A: 95% 25 mM NH 4 OAc + 5 % CH 3 CN; mobile phase B: CH 3 CN; mobile phase C: MeOH) were employed to run a gradient condition from 100 % A to 1 % A, 49 % B and 50 % C in 6.5 min, to 1 % A, 99 % B in 0.5 min and keep these conditions for 1 min.
- An injection volume of 10 ⁇ l was used. Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.
- melting points were determined with a DSC823e (Mettler-Toledo). Melting points were measured with a temperature gradient of 30 °C/minute. Maximum temperature was 400 °C. Values are peak values.
- SKNBE2 cells carrying the APP 695 - wild type, grown in Dulbecco's Modified Eagle's Medium/Nutrient mixture F-12 (DMEM/NUT-mix F-12) (HAM) provided by Gibco (cat no. 31330-38) containing 5 % Serum/Fe supplemented with 1 % non-essential amino acids. Cells were grown to near confluency.
- DMEM/NUT-mix F-12 Dulbecco's Modified Eagle's Medium/Nutrient mixture F-12
- Gibco catalog no. 31330-38
- the screening was performed using the assay as described in Citron et al (1997) Nature Medicine 3: 67. Briefly, cells were plated in a 96-well plate at about 10 5 cells/ml one day prior to addition of compounds. Compounds were added to the cells in Ultraculture (Lonza, BE12-725F) supplemented with 1 % glutamine (Invitrogen, 25030-024) for 18 hours. The media were assayed by two sandwich ELISAs, for Aß42 and Aßtotal. Toxicity of the compounds was assayed by WST-1 cell proliferation reagent (Roche, 1 644 807) according to the manufacturer's protocol.
- Enzyme-Linked-Immunosorbent-Assay (ELISA) kits were used (Innotest® ⁇ -Amyloid (1-42) , Innogenetics N.V., Ghent, Belgium).
- the A ⁇ 42 ELISA was performed essentially according to the manufacturer's protocol. Briefly, the standards (dilutions of synthetic A ⁇ 1-42) were prepared in polypropylene Eppendorf with final concentrations of 8000 down to 3.9 pg/ml (1/2 dilution step).
- samples, standards and blanks 100 ⁇ l were added to the anti-A ⁇ 42-coated plate supplied with the kit (the capture antibody selectively recognizes the C-terminal end of the antigen).
- the plate was allowed to incubate 3 h at 25 °C in order to allow formation of the antibody-amyloid complex.
- a selective anti-A ⁇ -antibody conjugate biotinylated 3D6 was added and incubated for a minimum of 1 hour in order to allow formation of the antibody-Amyloid-antibody-complex.
- a Streptavidine-Peroxidase-Conjugate was added, followed 30 minutes later by an addition of 3,3',5,5'-tetramethylbenzidine (TMB)/peroxide mixture, resulting in the conversion of the substrate into a coloured product.
- TMB 3,3',5,5'-tetramethylbenzidine
- This reaction was stopped by the addition of sulfuric acid (0.9 N) and the colour intensity was measured by means of photometry with an ELISA-reader with a 450 nm filter.
- samples and standards were added to a 6E10-coated plate.
- the plate was allowed to incubate overnight at 4 °C in order to allow formation of the antibody-amyloid complex.
- a selective anti-Aß-antibody conjugate biotinylated 4G8 was added and incubated for a minimum of 1 hour in order to allow formation of the antibody-Amyloid-antibody-complex.
- Streptavidine-Peroxidase-Conjugate was added, followed 30 minutes later by an addition of Quanta Blu fluorogenic peroxidase substrate according to the manufacturer's instructions (Pierce Corp., Rockford, Il).
- the sigmoidal dose response curves were analysed by computerised curve-fitting, with percent of inhibition plotted against compound concentration.
- a 4-parameter equation (model 205) in XL fit was used to determine the IC 50 .
- the top and the bottom of the curve were fixed to 100 and 0, respectively, and the hill slope was fixed to 1.
- the IC 50 represents the concentration of a compound that is required for inhibiting a biological effect by 50 % (Here, it is the concentration where Aß peptide level is reduced by 50 %).
- the IC 50 values are shown in Table 3a : To obtain the values reported in Table 3b, the data were calculated as percentage of the maximum amount of amyloid Beta 42 measured in the absence of the test compound.
- the sigmoidal dose response curves were analyzed using non-linear regression analysis with percentage of the control plotted against the log concentration of the compound. A 4-parameter equation was used to determine the IC 50 .
- the values reported in Table 3b are averaged IC 50 values.
- the IC 50 values are shown in Table 3b :
- SKNBE2 cells carrying the APP 695 - wild type, grown in Dulbecco's Modified Eagle's Medium/Nutrient mixture F-12 (DMEM/NUT-mix F-12) (HAM) provided by Invitrogen (cat no. 10371-029) containing 5 % Serum/Fe supplemented with 1 % non-essential amino acids, 1-glutamine 2 mM, Hepes 15 mM, penicillin 50 U/ml (units/ml) en streptomycin 50 ⁇ g/ml. Cells were grown to near confluency.
- DMEM/NUT-mix F-12 Dulbecco's Modified Eagle's Medium/Nutrient mixture F-12
- HAM Dulbecco's Modified Eagle's Medium/Nutrient mixture F-12
- Invitrogen cat no. 10371-029
- the screening was performed using a modification of the assay as described in Citron et al (1997) Nature Medicine 3: 67. Briefly, cells were plated in a 384-well plate at 10 4 cells/well in Ultraculture (Lonza, BE12-725F) supplemented with 1 % glutamine (Invitrogen, 25030-024), 1 % non-essential amino acid (NEAA), penicillin 50 U/ml en streptomycin 50 ⁇ g/ml in the presence of test compound at different test concentrations. The cell/compound mixture was incubated overnight at 37 °C, 5 % CO 2 . The next day the media were assayed by two sandwich immuno-assays, for Aß42 and Aßtotal.
- Alphalisa is a sandwich assay using biotinylated antibody attached to streptavidin coated donorbeads and antibody conjugated to acceptor beads. In the presence of antigen, the beads come into close proximity. The excitation of the donor beads provokes the release of singlet oxygen molecules that trigger a cascade of energy transfer in the acceptor beads, resulting in light emission.
- monoclonal antibody specific to the C-terminus of Aß42 JRF/cAß42/266 was coupled to the receptor beads and biotinylated antibody specific to the N -terminus of Aß (JRF/AßN/25) was used to react with the donor beads.
- monoclonal antibody specifc to the N -terminus of Aß JRF/AßN/25) was coupled to the receptor beads and biotinylated antibody specific to the mid region of Aß (biotinylated 4G8) was used to react with the donor beads.
- a ⁇ 42 lowering agents of the invention can be used to treat AD in mammals such as humans or alternatively demonstrating efficacy in animal models such as, but not limited to, the mouse, rat, or guinea pig.
- the mammal may not be diagnosed with AD, or may not have a genetic predisposition for AD, but may be transgenic such that it overproduces and eventually deposits A ⁇ in a manner similar to that seen in humans afflicted with AD.
- a ⁇ 42 lowering agents can be administered in any standard form using any standard method.
- a ⁇ 42 lowering agents can be in the form of liquid, tablets or capsules that are taken orally or by injection.
- a ⁇ 42 lowering agents can be administered at any dose that is sufficient to significantly reduce levels of A ⁇ 42 in the blood, blood plasma, serum, cerebrospinal fluid (CSF), or brain.
- CSF cerebrospinal fluid
- non-transgenic rodents e.g. mice or rats were used.
- two to three month old Tg2576 mice expressing APP695 containing the "Swedish" variant can be used or a transgenic mouse model developed by Dr. Fred Van Leuven (K.U.Leuven, Belgium) and co-workers, with neuron-specific expression of a clinical mutant of the human amyloid precursor protein [V717I] (Moechars et al., 1999 J. Biol. Chem. 274, 6483).
- Young transgenic mice have high levels of A ⁇ in the brain but no detectable A ⁇ deposition.
- mice start to display spontaneous, progressive accumulation of ⁇ -amyloid (A ⁇ ) in the brain, eventually resulting in amyloid plaques within the subiculum, hippocampus and cortex.
- Animals treated with the A ⁇ 42 lowering agent were examined and compared to those untreated or treated with vehicle and brain levels of soluble A ⁇ 42 and total A ⁇ would be quantitated by standard techniques, for example, using ELISA. Treatment periods varied from hours (h) to days and were adjusted based on the results of the A ⁇ 42 lowering once a time course of onset of effect could be established.
- a typical protocol for measuring A ⁇ 42 lowering in vivo is shown but it is only one of many variations that could be used to optimize the levels of detectable A ⁇ .
- a ⁇ 42 lowering compounds were formulated in 20 % of Captisol® (a sulfobutyl ether of ⁇ -cyclodextrin) in water or 20 % hydroxypropyl ⁇ cyclodextrin.
- Captisol® a sulfobutyl ether of ⁇ -cyclodextrin
- the A ⁇ 42 lowering agents were administered as a single oral dose or by any acceptable route of administration to overnight fasted animals. After 4 h, the animals were sacrificed and A ⁇ 42 levels were analysed.
- Blood was collected by decapitation and exsanguinations in EDTA-treated collection tubes. Blood was centrifuged at 1900 g for 10 minutes (min) at 4 °C and the plasma recovered and flash frozen for later analysis. The brain was removed from the cranium and hindbrain. The cerebellum was removed and the left and right hemisphere were separated. The left hemisphere was stored at -18 °C for quantitative analysis of test compound levels. The right hemisphere was rinsed with phosphate-buffered saline (PBS) buffer and immediately frozen on dry ice and stored at -80 °C until homogenization for biochemical assays.
- PBS phosphate-buffered saline
- Mouse brains were resuspended in 10 volumes of 0.4 % DEA (diethylamine) /50 mM NaCl pH 10 (for non-transgenic animals) or 0.1 % 3-[(3-cholamidopropyl)-dimethyl-ammonio]-1-propanesulfonate (CHAPS) in tris buffered saline (TBS) (for transgenic animals) containing protease inhibitors (Roche-11873580001 or 04693159001) per gram of tissue, e.g. for 0.158 g brain, add 1.58 ml of 0.4 % DEA. All samples were sonicated for 30 seconds on ice at 20 % power output (pulse mode).
- DEA diethylamine
- NaCl pH 10 for non-transgenic animals
- CHAPS 3-[(3-cholamidopropyl)-dimethyl-ammonio]-1-propanesulfonate
- TBS tris buffered s
- the obtained supernatants were purified with Water Oasis HLB reverse phase columns (Waters Corp., Milford, MA) to remove non-specific immunoreactive material from the brain lysates prior subsequent A ⁇ detection.
- Water Oasis HLB reverse phase columns Waters Corp., Milford, MA
- all solutions were passed through the columns at a rate of approximately 1 ml per min, so the vacuum pressure was adjusted accordingly throughout the procedure.
- Columns were preconditioned with 1 ml of 100 % MeOH, before equilibration with 1 ml of H 2 O.
- Non-neutralized brain lysates were loaded onto the columns. The loaded samples were then washed twice with the first wash performed with 1 ml of 5 % MeOH, and the second wash with 1 ml of 30 % MeOH.
- Enzyme-Linked-Immunosorbent-Assay (ELISA) kits were used (e.g. Innotest® ⁇ -Amyloid (1-42) , Innogenetics N.V., Ghent, Belgium).
- the A ⁇ 42 ELISA was performed using the plate provided with the kit only. Briefly, the standards (a dilution of synthetic A ⁇ 1-42) were prepared in 1.5 ml Eppendorf tube in Ultraculture, with final concentrations ranging from 25000 to 1.5 pg/ml.
- a Streptavidine-Peroxidase-Conjugate was added, followed 50 min later by an addition of Quanta Blu fluorogenic peroxidase substrate according to the manufacturer's instructions (Pierce Corp., Rockford, Il). A kinetic reading was performed every 5 min for 30 min (excitation 320 nm/emission 420 nm).
- samples and standards were added to JRF/rAß/2-coated plate. The plate was allowed to incubate overnight at 4 °C in order to allow formation of the antibody-amyloid complex. The ELISA was then performed as for Aß42 detection.
- a ⁇ 42 lowering agents of the invention can be used to treat AD in mammals such as humans or alternatively demonstrating efficacy in animal models such as, but not limited to, the mouse, rat, or guinea pig.
- the mammal may not be diagnosed with AD, or may not have a genetic predisposition for AD, but may be transgenic such that it overproduces and eventually deposits A ⁇ in a manner similar to that seen in humans afflicted with AD.
- a ⁇ 42 lowering agents can be administered in any standard form using any standard method.
- a ⁇ 42 lowering agents can be in the form of liquid, tablets or capsules that are taken orally or by injection.
- a ⁇ 42 lowering agents can be administered at any dose that is sufficient to significantly reduce levels of A ⁇ 42 in the blood, blood plasma, serum, cerebrospinal fluid (CSF), or brain.
- CSF cerebrospinal fluid
- a typical protocol for measuring A ⁇ 42 lowering in vivo is shown but it is only one of many variations that could be used to optimize the levels of detectable A ⁇ .
- a ⁇ 42 lowering compounds were formulated in 20 % of Captisol® (a sulfobutyl ether of ⁇ -cyclodextrin) in water or 20 % hydroxypropyl ⁇ cyclodextrin.
- Captisol® a sulfobutyl ether of ⁇ -cyclodextrin
- the A ⁇ 42 lowering agents were administered as a single oral dose or by any acceptable route of administration to overnight fasted animals. After 4 h, the animals were sacrificed and A ⁇ 42 levels were analysed.
- Blood was collected by decapitation and exsanguinations in EDTA-treated collection tubes. Blood was centrifuged at 1900 g for 10 minutes (min) at 4 °C and the plasma recovered and flash frozen for later analysis. The brain was removed from the cranium and hindbrain. The cerebellum was removed and the left and right hemisphere were separated. The left hemisphere was stored at -18 °C for quantitative analysis of test compound levels. The right hemisphere was rinsed with phosphate-buffered saline (PBS) buffer and immediately frozen on dry ice and stored at -80 °C until homogenization for biochemical assays.
- PBS phosphate-buffered saline
- Enzyme-Linked-Immunosorbent-Assays were used. Briefly, the standards (a dilution of synthetic A ⁇ 1-40 and A ⁇ 1-42, Bachem) were prepared in 1.5 ml Eppendorf tube in Ultraculture, with final concentrations ranging from 10000 to 0.3 pg/ml. The samples and standards were co-incubated with HRPO-labelled N -terminal antibody for Aß42 detection and with the biotinylated mid-domain antibody 4G8 for Aßtotal detection.
- conjugate/sample or conjugate/standards mixtures were then added to the antibody-coated plate (the capture antibodies selectively recognize the C-terminal end of Aß42, antibody JRF/cAß42/26, for Aß42 detection and the N -terminus of Aß, antibody JRF/rAß/2, for Aßtotal detection).
- the plate was allowed to incubate overnight at 4 °C in order to allow formation of the antibody-amyloid complex.
- the ELISA for Aß42 quantification was finished by addition of Quanta Blu fluorogenic peroxidase substrate according to the manufacturer's instructions (Pierce Corp., Rockford, Il). A reading was performed after 10 to 15 min (excitation 320/emission 420).
- Notch is a signaling protein which plays a crucial role in developmental processes, and thus compounds are preferred which do not show an effect on the Notch-processing activity of the ⁇ -secretase-complex.
- the Notch substrate comprised of mouse Notch fragment (V1711-E1809), an N-terminal methionine and a C-terminal FLAG sequence (DYDDDDK), was expressed in E . coli and purified on a column containing an anti-FLAG M2 affinity matrix.
- a typical Notch cell-free assay consisted of 0.3-0.5 ⁇ M Notch substrate, an enriched preparation of ⁇ secretase and 1 ⁇ M of a test compound (compounds 8, 15, 92, 108, 114 and 130 of the present invention).
- GPI ⁇ secretase inhibitor
- Recombinant Notch substrate was pre-treated with 17 ⁇ M DTT (1,4-dithiothreitol) and 0.02 % SDS (Sodium Dodecyl Sulfate) and heated at 65 °C for 10 min. The mixture of substrate, gamma secretase and compound/DMSO was incubated at 37 °C for 6 to 22 hours (h). 6 h incubation was sufficient to produce the maximal amount of NICD and the cleaved product remained stable for an additional 16 h. Reaction products were processed for SDS PAGE (Sodium Dodecyl Sulfate-Poly Acrylamide Gel Electrophoresis) and western blotting. Blots were probed with an anti-Flag M2 antibody, followed by LI-COR infrared secondary antibody, and analyzed with the Odyssey Infrared Imaging System (LI-COR® Biosciences).
- SDS PAGE Sodium Dodecyl Sulfate-Poly Acrylamide Gel Electrophoresis
- N2-CHO cells were seeded at 1x10 5 /well in 24-well plates the day before transfection. On the second day, cells were double transfected with 3 ⁇ g/well pTP1-Luc (expressing firefly luciferase) and 0.3 ng/well pCMV-RLuc (expressing Renilla luciferase). After 6 h incubation, transfected N2-CHO cells were washed and DL-CHO cells (2 x 10 5 cells/well) were added.
- the luciferase assay was carried out according to manufacture's instructions. Briefly, cells were washed with PBS (Phosphate Buffered Saline), lysed with Passive Lysis Buffer (Promega), and incubated at room temperature for 20 min. Lysates were mixed with Dual-Glo Luciferase Reagent and the firefly luciferase activity was measured by reading the luminescence signal in the EnVision 2101 Multilabel reader. Dual-Glo Stop & Glo Reagent was then added to each well and the Renilla luciferase signal was measured.
- PBS Phosphate Buffered Saline
- Passive Lysis Buffer Promega
- An aqueous suspension is prepared for oral administration so that each milliliter contains 1 to 5 mg of active ingredient , 50 mg of sodium carboxymethyl cellulose, 1 mg of sodium benzoate; 500 mg of sorbitol and water ad 1 ml.
- a parenteral composition is prepared by stirring 1.5 % (weight/volume) of active ingredient in 0.9 % NaCl solution or in 10 % by volume propylene glycol in water.
- active ingredient can be replaced with the same amount of any of the compounds according to the present invention, in particular by the same amount of any of the exemplified compounds.
Abstract
Description
- The present invention is concerned with novel substituted benzoxazole, benzimidazole, oxazolopyridine and imidazopyridine derivatives useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
- Alzheimer's Disease (AD) is a progressive neurodegenerative disorder marked by loss of memory, cognition, and behavioral stability. AD afflicts 6-10 % of the population over age 65 and up to 50 % over age 85. It is the leading cause of dementia and the third leading cause of death after cardiovascular disease and cancer. There is currently no effective treatment for AD. The total net cost related to AD in the U.S. exceeds $100 billion annually.
- AD does not have a simple etiology, however, it has been associated with certain risk factors including (1) age, (2) family history and (3) head trauma; other factors include environmental toxins and low levels of education. Specific neuropathological lesions in the limbic and cerebral cortices include intracellular neurofibrillary tangles consisting of hyperphosphorylated tau protein and the extracellular deposition of fibrillar aggregates of amyloid beta peptides (amyloid plaques). The major component of amyloid plaques are the amyloid beta (A-beta, Abeta or Aß) peptides of various lengths. A variant thereof, which is the Aß1-42-peptide (Abeta-42), is believed to be the major causative agent for amyloid formation. Another variant is the Aß1-40-peptide (Abeta-40). Amyloid beta is the proteolytic product of a precursor protein, beta amyloid precursor protein (beta-APP or APP).
- Familial, early onset autosomal dominant forms of AD have been linked to missense mutations in the β-amyloid precursor protein (β-APP or APP) and in the presenilin proteins 1 and 2. In some patients, late onset forms of AD have been correlated with a specific allele of the apolipoprotein E (ApoE) gene, and, more recently, the finding of a mutation in alpha2-macroglobulin, which may be linked to at least 30 % of the AD population. Despite this heterogeneity, all forms of AD exhibit similar pathological findings. Genetic analysis has provided the best clues for a logical therapeutic approach to AD. All mutations found to date, affect the quantitative or qualitative production of the amyloidogenic peptides known as Abeta-peptides (Aβ), specifically Aβ42, and have given strong support to the "amyloid cascade hypothesis" of AD (Tanzi and Bertram, 2005, Cell 120, 545). The likely link between Aβ peptide generation and AD pathology emphasizes the need for a better understanding of the mechanisms of Aβ production and strongly warrants a therapeutic approach at modulating Aβ levels.
- The release of Aβ peptides is modulated by at least two proteolytic activities referred to as β- and γ-secretase cleavage at the N-terminus (Met-Asp bond) and the C-terminus (residues 37-42) of the Aβ peptide, respectively. In the secretory pathway, there is evidence that β-secretase cleaves first, leading to the secretion of s-APPβ (sβ) and the retention of a 11 kDa membrane-bound carboxy terminal fragment (CTF). The latter is believed to give rise to Aβ peptides following cleavage by γ-secretase. The amount of the longer isoform, Aβ42, is selectively increased in patients carrying certain mutations in a particular protein (presenilin), and these mutations have been correlated with early-onset familial Alzheimer's disease. Therefore, Aß42 is believed by many researchers to be the main culprit of the pathogenesis of Alzheimer's disease.
- It has now become clear that the γ-secretase activity cannot be ascribed to a single protein, but is in fact associated with an assembly of different proteins.
- The gamma (γ)-secretase activity resides within a multiprotein complex containing at least four components: the presenilin (PS) heterodimer, nicastrin, aph-1 and pen-2. The PS heterodimer consists of the amino- and carboxyterminal PS fragments generated by endoproteolysis of the precursor protein. The two aspartates of the catalytic site are at the interface of this heterodimer. It has recently been suggested that nicastrin serves as a gamma-secretase-substrate receptor. The functions of the other members of gamma-secretase are unknown, but they are all required for activity (Steiner, 2004. Curr. Alzheimer Research 1(3): 175-181).
- Thus, although the molecular mechanism of the second cleavage-step has remained elusive until now, the γ-secretase-complex has become one of the prime targets in the search for compounds for the treatment of Alzheimer's disease.
- Various strategies have been proposed for targeting gamma-secretase in Alzheimer's disease, ranging from targeting the catalytic site directly, developing substrate-specific inhibitors and modulators of gamma-secretase activity (Marjaux et al., 2004. Drug Discovery Today: Therapeutic Strategies, Volume 1, 1-6). Accordingly, a variety of compounds were described that have secretases as targets (Lamer, 2004. Secretases as therapeutics targets in Alzheimer's disease: patents 2000 - 2004. Expert Opin. Ther. Patents 14, 1403-1420).
- Indeed, this finding was recently supported by biochemical studies in which an effect of certain NSAIDs on γ-secretase was shown (Weggen et al (2001) Nature 414, 6860, 212 and
WO 01/78721 US 2002/0128319 ; Morihara et al (2002) J. Neurochem. 83, 1009; Eriksen (2003) J. Clin. Invest. 112 , 440). Potential limitations for the use of NSAIDs to prevent or treat AD are their inhibition activity of COX enzymes, which can lead to unwanted side effects, and their low CNS penetration (Peretto et al., 2005, J. Med. Chem. 48, 5705-5720). -
US 2008/0280948 A1 relates to aminophenyl derivatives which are modulators for amyloid beta. -
WO-2009/005729 relates to heterocyclic compounds and their use as gamma secretase modulators. -
WO-2008/097538 encompasses 2-[4-imidazolyl)-phenyl]vinyl-heterocycle derivatives which selectively attenuate production of Abeta(1-42) and are useful in the treatment of Alzheimer's disease. -
WO-2004/017963 discloses benzimidazoles as coagulation factor Xa inhibitors for the treatment of thromboembolic illnesses. -
WO-2005/115990 discloses cinnamide compounds that are useful for the treatment of neurodegenerative diseases caused by amyloid β proteins such as Alzheimer's disease, senile dementia, Down's syndrome and amyloidosis. -
WO-2007/044895 discloses diaromatic amines and their use in lubricating oil compositions and stabilizer-containing compositions. -
WO-2008/156580 discloses triazole derivatives for treating diseases associated with deposition of Aβ in the brain, in particular Alzheimer's disease. - There is a strong need for novel compounds which modulate γ-secretase activity thereby opening new avenues for the treatment of Alzheimer's disease. It is an object of the present invention to overcome or ameliorate at least one of the disadvantages of the prior art, or to provide a useful alternative. It is accordingly an object of the present invention to provide such novel compounds.
- It has been found that the compounds of the present invention are useful as gamma secretase modulators. The compounds according to the invention and the pharmaceutically acceptable compositions thereof, may be useful in the treatment or prevention of Alzheimer's disease.
- The present invention concerns novel compounds of Formula (I):
R1 is hydrogen, cyano, CF3, halo, or C1-4alkyl optionally substituted with one or more substituents each independently selected from the group consisting of hydroxyl and C1-4alkyloxy;
R2 is hydrogen, C1-4alkyl or halo;
X is CR5 or N;
R5 is hydrogen or halo;
A1 is CR6 or N;
R6 is hydrogen, halo or C1-4alkyloxy;
A2, A3 and A4 each independently are CH, CF or N;
provided that no more than two of A1, A2, A3 and A4 are N;
Y1 is CH or N;
Y2 is CR4 or N;
Y3 is CH or N;
provided that only one of Y1, Y2 and Y3 may represent N;
R4 is hydrogen, halo, C1-4alkyloxy, cyano, cycloC3-7alkyl, C2-4alkenyl, or C1-4alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo and C1-4alkyloxy;
R3 is C2-6alkyl substituted with one or more halo substituents;
C1-6alkyl optionally substituted with one or more substituents each independently selected from the group consisting of piperidinyl, morpholinyl, pyrrolidinyl, Ar, C1-6alkyloxy, tetrahydropyranyl, cycloC3-7alkyloxy and cycloC3-7alkyl;
cycloC3-7alkyl substituted with one or more phenyl substituents optionally substituted with one or more halo substituents;
cycloC3-7alkyl; piperidinyl; morpholinyl; pyrrolidinyl; tetrahydropyranyl; O-Ar; NR7R8; C1-6alkyloxy; C1-6alkylthio; Ar; CH2-O-Ar; S-Ar; NCH3-Ar; NH-Ar; or 1,6-dihydro-1-methyl-6-oxo-3-pyridinyl;
wherein each piperidinyl, morpholinyl and pyrrolidinyl may be substituted with one or more substituents each independently selected from the group consisting of C1-4alkyl, C2-6alkenyl, C1-4alkylcarbonyl, halo and C1-4alkyloxycarbonyl;
wherein each Ar independently is
phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C1-4alkyloxy, cyano, NR7R8, morpholinyl, C1-4alkyl, C1-4alkyloxy substituted with one or more halo substituents, and C1-4alkyl substituted with one or more halo substituents; or a 5- or 6-membered heteroaryl selected from the group consisting ofpyridinyl, pyrimidinyl, oxazolyl, furanyl, thiophenyl, pyrazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridazinyl and pyrazinyl; wherein said 5-or 6-membered heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of halo, C1-4alkyloxy, cyano, C1-4alkyl, C1-4alkyloxy substituted with one or more halo substituents, and C1-4alkyl substituted with one or more halo substituents;
each R7 is selected independently from hydrogen or C1-4alkyl;
each R8 is selected independently from hydrogen, C1-4alkyl or C1-4alkylcarbonyl;
Z is O or NR9;
R9 is hydrogen, or C1-6alky optionally substituted with one or more substituents each independently selected from the group consisting of halo, cyano, phenyl, cycloC3-7alkyl and C1-4alkyloxy;
and the pharmaceutically acceptable addition salts, and the solvates thereof. - The present invention also concerns methods for the preparation of compounds of Formula (I) and pharmaceutical compositions comprising them.
- The present compounds surprisingly were found to modulate the γ-secretase activity in vitro and in vivo, and are therefore useful in the treatment or prevention of Alzheimer's disease, traumatic brain injury, mild cognitive impairment (MCI), senility, dementia, dementia with Lewy bodies, cerebral amyloid angiopathy, multi-infarct dementia, Down's syndrome, dementia associated with Parkinson's disease and dementia associated with beta-amyloid, preferably Alzheimer's disease and other disorders with Beta-amyloid pathology (eg glaucoma).
- In view of the aforementioned pharmacology of the compounds of Formula (I), it follows that they are suitable for use as a medicament.
- More especially the compounds are suitable in the treatment or prevention of Alzheimer's disease, cerebral amyloid angiopathy, multi-infarct dementia, dementia pugilistica or Down syndrome.
- The present invention also concerns to the use of a compound according to the general Formula (I), the stereoisomeric forms thereof and the pharmaceutically acceptable acid or base addition salts and the solvates thereof, for the manufacture of a medicament for the modulation of γ-secretase activity.
- Use of a compound of Formula (I) for the modulation of γ-secretase activity resulting in a decrease in the relative amount of Aß42-peptides produced are preferred.
- One advantage of the compounds or a part of the compounds of the present invention may lie in their enhanced CNS-penetration.
- The present invention will now be further described. In the following passages, different aspects of the invention are defined in more detail. Each aspect so defined may be combined with any other aspect or aspects unless clearly indicated to the contrary. In particular, any feature indicated as being preferred or advantageous may be combined with any other feature or features indicated as being preferred or advantageous.
- When describing the compounds of the invention, the terms used are to be construed in accordance with the following definitions, unless a context dictates otherwise.
- Whenever the term "substituted" is used in the present invention, it is meant, unless otherwise is indicated or is clear from the context, to indicate that one or more hydrogens, in particular from 1 to 4 hydrogens, preferably from 1 to 3 hydrogens, more preferably 1 hydrogen, on the atom or radical indicated in the expression using "substituted" are replaced with a selection from the indicated group, provided that the normal valency is not exceeded, and that the substitution results in a chemically stable compound, i.e. a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into a therapeutic agent.
- The term "halo" or "halogen" as a group or part of a group is generic for fluoro, chloro, bromo, iodo unless otherwise is indicated.
- The term "C1-6alkyl" as a group or part of a group refers to a hydrocarbyl radical of Formula CnH2n+1 wherein n is a number ranging from 1 to 6. C1-6alkyl groups comprise from 1 to 6 carbon atoms, preferably from 1 to 4 carbon atoms, more preferably from 1 to 3 carbon atoms, still more preferably 1 to 2 carbon atoms. Alkyl groups may be linear or branched and may be substituted as indicated herein. When a subscript is used herein following a carbon atom, the subscript refers to the number of carbon atoms that the named group may contain. Thus, for example, C1-6alkyl includes all linear, or branched alkyl groups with between 1 and 6 carbon atoms, and thus includes such as for example methyl, ethyl, n-propyl, i-propyl, 2-methyl-ethyl, butyl and its isomers (e.g. n-butyl, isobutyl and tert-butyl), pentyl and its isomers, hexyl and its isomers, and the like.
- The term "C2-6alkyl" as a group or part of a group refers to a hydrocarbyl radical of Formula CnH2n+1 wherein n is a number ranging from 2 to 6. C2-6alkyl groups comprise from 2 to 6 carbon atoms, in particular from 2 to 4 carbon atoms, more in particular from 2 to 3 carbon atoms. Alkyl groups may be linear or branched and may be substituted as indicated herein. Thus, for example, C2-6alkyl includes all linear, or branched alkyl groups with between 2 and 6 carbon atoms, and thus includes such as for example ethyl, n-propyl, i-propyl, 2-methyl-ethyl, butyl and its isomers (e.g. n-butyl, isobutyl and tert-butyl), pentyl and its isomers, hexyl and its isomers, and the like.
- The term "C1-4alkyl" as a group or part of a group refers to a hydrocarbyl radical of Formula CnH2n+1 wherein n is a number ranging from 1 to 4. C1-4alkyl groups comprise from 1 to 4 carbon atoms, preferably from 1 to 3 carbon atoms, more preferably 1 to 2 carbon atoms. The term "C1-3alkyl" as a group or part of a group refers to a hydrocarbyl radical of Formula CnH2n+1 wherein n is a number ranging from 1 to 3. Alkyl groups may be linear or branched and may be substituted as indicated herein. Thus, for example, C1-4alkyl includes all linear, or branched alkyl groups with between 1 and 4 carbon atoms, and thus includes such as for example methyl, ethyl, n-propyl, i-propyl, 2-methyl-ethyl, butyl and its isomers (e.g. n-butyl, isobutyl and tert-butyl), and the like.
- The term "C1-6alkyloxy" as a group or part of a group refers to a radical having the Formula -ORb wherein Rb is C1-6alkyl. Non-limiting examples of suitable alkyloxy include methyloxy, ethyloxy, propyloxy, isopropyloxy, butyloxy, isobutyloxy, sec-butyloxy, tert-butyloxy, pentyloxy, and hexyloxy.
- The term "C1-4alkyloxy" as a group or part of a group refers to a radical having the Formula -ORc wherein Rc is C1-4alkyl. Non-limiting examples of suitable alkyloxy include methyloxy (also methoxy), ethyloxy (also ethoxy), propyloxy, isopropyloxy, butyloxy, isobutyloxy, sec-butyloxy and tert-butyloxy.
- In the framework of this application, C2-6alkenyl is a straight or branched hydrocarbon radical having from 2 to 6 carbon atoms containing a double bond such as ethenyl, propenyl, butenyl, pentenyl, 1-propen-2-yl, hexenyl and the like.
- The term "cycloC3-7alkyl" alone or in combination, refers to a cyclic saturated hydrocarbon radical having from 3 to 7 carbon atoms. Non-limiting examples of suitable cycloC3-7alkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyL
- The term "cycloC3-7alkyloxy" alone or in combination, refers to a radical having the Formula -ORd, wherein Rd is cycloC3-7alkyl. Non-limiting examples of suitable cycloC3-7alkyloxy include cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy and cycloheptyloxy.
- The term "thiophenyl" is equivalent to "thienyl".
- The chemical names of the compounds of the present invention were generated according to the nomenclature rules agreed upon by the Chemical Abstracts Service.
- In case of tautomeric forms, it should be clear that the other non-depicted tautomeric form is also included within the scope of the present invention.
- When any variable occurs more than one time in any constituent, each definition is independent.
- It will be appreciated that some of the compounds of Formula (I) and their pharmaceutically acceptable addition salts and stereoisomeric forms may contain one or more centers of chirality and exist as stereoisomeric forms.
- The term "stereoisomeric forms" as used hereinbefore defines all the possible isomeric forms that the compounds of Formula (I) may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms. More in particular, stereogenic centers may have the R- or S-configuration; substituents on bivalent cyclic (partially) saturated radicals may have either the cis- or trans-configuration. Compounds encompassing double bonds can have an E or Z-stereochemistry at said double bond. Stereoisomeric forms of the compounds of Formula (I) are embraced within the scope of this invention.
- When a specific stereoisomeric form is indicated, this means that said form is substantially free, i.e. associated with less than 50 %, preferably less than 20 %, more preferably less than 10 %, even more preferably less than 5 %, further preferably less than 2 % and most preferably less than 1 % of the other isomer(s).
- When a specific regioisomeric form is indicated, this means that said form is substantially free, i.e. associated with less than 50 %, preferably less than 20 %, more preferably less than 10 %, even more preferably less than 5 %, further preferably less than 2 % and most preferably less than 1 % of the other isomer(s).
- For therapeutic use, salts of the compounds of Formula (I) are those wherein the counterion is pharmaceutically acceptable. However, salts of acids and bases which are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound. All salts, whether pharmaceutically acceptable or not are included within the ambit of the present invention.
- The pharmaceutically acceptable acid and base addition salts as mentioned hereinabove or hereinafter are meant to comprise the therapeutically active non-toxic acid and base addition salt forms which the compounds of Formula (I) are able to form. The pharmaceutically acceptable acid addition salts can conveniently be obtained by treating the base form with such appropriate acid. Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid, sulfuric, nitric, phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic (i.e. ethanedioic), malonic, succinic (i.e. butanedioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic; salicylic, p-aminosalicylic, pamoic and the like acids. Conversely said salt forms can be converted by treatment with an appropriate base into the free base form.
- The compounds of Formula (I) containing an acidic proton may also be converted into their non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases. Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. primary, secondary and tertiary aliphatic and aromatic amines such as methylamine, ethylamine, propylamine, isopropylamine, the four butylamine isomers, dimethylamine, diethylamine, diethanolamine, dipropylamine, diisopropylamine, di-n-butylamine, pyrrolidine, piperidine, morpholine, trimethylamine, triethylamine, tripropylamine, quinuclidine, pyridine, quinoline and isoquinoline; the benzathine, N-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like. Conversely the salt form can be converted by treatment with acid into the free acid form.
- The term solvate comprises the hydrates and solvent addition forms which the compounds of formula (I) are able to form, as well as the salts thereof. Examples of such forms are e.g. hydrates, alcoholates and the like.
- The compounds of Formula (I) as prepared in the processes described below may be synthesized in the form of racemic mixtures of enantiomers that can be separated from one another following art-known resolution procedures. A manner of separating the enantiomeric forms of the compounds of Formula (I) involves liquid chromatography using a chiral stationary phase. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably if a specific stereoisomer is desired, said compound would be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.
- In the framework of this application, a compound according to the invention is inherently intended to comprise all isotopic combinations of its chemical elements. In the framework of this application, a chemical element, in particular when mentioned in relation to a compound according to formula (I), comprises all isotopes and isotopic mixtures of this element. For example, when hydrogen is mentioned, it is understood to refer to 1H, 2H, 3H and mixtures thereof
- A compound according to the invention therefore inherently comprises a compound with one or more isotopes of one or more element, and mixtures thereof, including a radioactive compound, also called radiolabelled compound, wherein one or more non-radioactive atoms has been replaced by one of its radioactive isotopes. By the term "radiolabelled compound" is meant any compound according to formula (I), or a pharmaceutically acceptable salt thereof, which contains at least one radioactive atom. For example, a compound can be labelled with positron or with gamma emitting radioactive isotopes. For radioligand-binding techniques, the 3H-atom or the 125I-atom is the atom of choice to be replaced. For imaging, the most commonly used positron emitting (PET) radioactive isotopes are 11C, 18F, 15O and 13N, all of which are accelerator produced and have half-lives of 20, 100, 2 and 10 minutes respectively. Since the half-lives of these radioactive isotopes are so short, it is only feasible to use them at institutions which have an accelerator on site for their production, thus limiting their use. The most widely used of these are 18F, 99mTc, 201Tl and 123I. The handling of these radioactive isotopes, their production, isolation and incorporation in a molecule are known to the skilled person.
- In particular, the radioactive atom is selected from the group of hydrogen, carbon, nitrogen, sulfur, oxygen and halogen. In particular, the radioactive isotope is selected from the group of 3H, 11C, 18F, 122I, 123I, 125I, 131I, 75Br, 76Br, 77Br and 82Br.
- As used in the specification and the appended claims, the singular forms "a", "an," and "the" also include plural referents unless the context clearly dictates otherwise. By way of example, "a compound" means one compound or more than one compound.
- The terms described above and others used in the specification are well understood to those in the art.
- Preferred features of the compounds of this invention are now set forth.
- The present invention concerns novel compounds of Formula (I):
R1 is hydrogen, cyano, CF3, halo, or C1-4alkyl optionally substituted with one or more substituents each independently selected from the group consisting of hydroxyl and C1-4alkyloxy;
R2 is hydrogen, C1-4alkyl or halo;
X is CR5 or N;
R5 is hydrogen or halo;
A1 is CR6 or N;
R6 is hydrogen, halo or C1-4alkyloxy;
A2, A3 and A4 each independently are CH, CF or N;
provided that no more than two of A1, A2, A3 and A4 are N;
Y1 is CH or N;
Y2 is CR4 or N;
Y3 is CH or N;
provided that only one of Y1, Y2 and Y3 may represent N;
R4 is hydrogen, halo, C1-4alkyloxy, cyano, cycloC3-7alkyl, C2-4alkenyl, or C1-4alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo and C1-4alkyloxy;
R3 is C2-6alkyl substituted with one or more halo substituents;
C1-6alkyl optionally substituted with one or more substituents each independently selected from the group consisting of piperidinyl, morpholinyl, pyrrolidinyl, Ar, C1-6alkyloxy, tetrahydropyranyl, cycloC3-7alkyloxy and cycloC3-7alkyl; cycloC3-7alkyl substituted with one or more phenyl substituents optionally substituted with one or more halo substituents;
cycloC3-7alkyl; piperidinyl; morpholinyl; pyrrolidinyl; tetrahydropyranyl; O-Ar; NR7R8; C1-6alkyloxy; C1-6alkylthio; Ar; CH2-O-Ar; S-Ar; NCH3-Ar; NH-Ar; or 1,6-dihydro-1-methyl-6-oxo-3-pyridinyl;
wherein each piperidinyl, morpholinyl and pyrrolidinyl may be substituted with one or more substituents each independently selected from the group consisting of C1-4alkyl, C2-6alkenyl, C1-4alkylcarbonyl, halo and C1-4alkyloxycarbonyl;
wherein each Ar independently is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C1-4alkyloxy, cyano, NR7R8, morpholinyl, C1-4alkyl, C1-4alkyloxy substituted with one or more halo substituents, and C1-4alkyl substituted with one or more halo substituents; or a 5- or 6-membered heteroaryl selected from the group consisting of pyridinyl, pyrimidinyl, oxazolyl, furanyl, thiophenyl, pyrazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridazinyl and pyrazinyl; wherein said 5-or 6-membered heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of halo, C1-4alkyloxy, cyano, C1-4alkyl, C1-4alkyloxy substituted with one or more halo substituents, and C1-4alkyl substituted with one or more halo substituents;
each R7 is selected independently from hydrogen or C1-4alkyl;
each R8 is selected independently from hydrogen, C1-4alkyl or C1-4alkylcarbonyl;
Z is O or NR9;
R9 is hydrogen, or C1-6alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, cyano, phenyl, cycloC3-7alkyl and C1-4alkyloxy;
and the pharmaceutically acceptable addition salts, and the solvates thereof. - In an embodiment, the invention relates to compounds of Formula (I) and stereoisomeric forms thereof, wherein
R1 is hydrogen, cyano, CF3, halo, or C1-4alkyl optionally substituted with one or more substituents each independently selected from the group consisting of hydroxyl and C1-4alkyloxy;
R2 is hydrogen, C1-4alkyl or halo;
X is CR5 or N;
R5 is hydrogen or halo;
A1 is CR6 or N;
R6 is hydrogen, halo or C1-4alkyloxy;
A2, A3 and A4 each independently are CH, CF or N;
provided that no more than two of A1, A2, A3 and A4 are N;
Y1 is CH or N;
Y2 is CR4 or N;
Y3 is CH or N;
provided that only one of Y1, Y2 and Y3 may represent N;
R4 is hydrogen, halo, C1-4alkyloxy, cyano, cycloC3-7alkyl, C2-4alkenyl, or C1-4alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo and C1-4alkyloxy;
R3 is C2-6alkyl substituted with one or more halo substituents;
C1-6alkyl optionally substituted with one or more substituents each independently selected from the group consisting of piperidinyl, morpholinyl, pyrrolidinyl, Ar, C1-6alkyloxy, tetrahydropyranyl, cycloC3-7alkyloxy and cycloC3-7alkyl; cycloC3-7alkyl substituted with one or more phenyl substituents optionally substituted with one or more halo substituents;
cycloC3-7alkyl; piperidinyl; morpholinyl; pyrrolidinyl; tetrahydropyranyl; O-Ar;
NR7R8; C1-6alkyloxy; C1-6alkylthio; Ar; CH2-O-Ar; S-Ar; NCH3-Ar; NH-Ar; or 1,6-dihydro-1-methyl-6-oxo-3-pyridinyl;
wherein each piperidinyl, morpholinyl and pyrrolidinyl may be substituted with one or more substituents each independently selected from the group consisting of C1-4alkyl, C2-6alkenyl, C1-4alkylcarbonyl, halo and C1-4alkyloxycarbonyl;
wherein each Ar independently is
phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C1-4alkyloxy, cyano, NR7R8, morpholinyl, C1-4alkyl, C1-4alkyloxy substituted with one or more halo substituents, and C1-4alkyl substituted with one or more halo substituents; or a 5- or 6-membered heteroaryl selected from the group consisting of pyridinyl, pyrimidinyl, oxazolyl, furanyl, thiophenyl, pyrazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridazinyl and pyrazinyl; wherein said 5-or 6-membered heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of halo, C1-4alkyloxy, cyano, C1-4alkyl and C1-4alkyl substituted with one or more halo substituents;
each R7 is selected independently from hydrogen or C1-4alkyl;
each R8 is selected independently from hydrogen, C1-4alkyl or C1-4alkylcarbonyl;
Z is O or NR9;
R9 is hydrogen, or C1-6alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, phenyl and C1-4alkyloxy;
and the pharmaceutically acceptable addition salts, and the solvates thereof. - In an embodiment, the invention relates to compounds of Formula (I) and stereoisomeric forms thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein one or more, preferably all, of the following restrictions apply:
- (a) R1 is hydrogen, cyano, halo, or C1-4alkyl optionally substituted with one or more substituents each independently selected from the group consisting of hydroxyl and C1-4alkyloxy;
- (b) R5 is hydrogen;
- (c) Y1 is CH or N; Y2 is CR4 or N; Y3 is CH; provided that only one of Y1 and Y2 may represent N;
- (d) R4 is hydrogen, halo, C1-4alkyloxy, cycloC3-7alkyl, C2-4alkenyl, or C1-4alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo and C1-4alkyloxy;
- (e) R3 is C2-6alkyl substituted with one or more halo substituents; C1-6alkyl optionally substituted with one or more substituents each independently selected from the group consisting of piperidinyl, Ar, C1-6alkyloxy, tetrahydropyranyl and cycloC3-7alkyl; cycloC3-7alkyl substituted with one or more phenyl substituents optionally substituted with one or more halo substituents; cycloC3-7alkyl; piperidinyl; morpholinyl; tetrahydropyranyl; O-Ar; C1-6alkyloxy; C1-6alkylthio; Ar; CH2-O-Ar; NH-Ar; or 1,6-dihydro-1-methyl-6-oxo-3-pyridinyl;
wherein each piperidinyl and morpholinyl may be substituted with one or more substituents each independently selected from the group consisting of C1-4alkyl, C1-4alkylcarbonyl, halo and C1-4alkyloxycarbonyl;
wherein each Ar independently is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C1-4alkyloxy, cyano, NR7R8, C1-4alkyl, C1-4alkyloxy substituted with one or more halo substituents, and C1-4alkyl substituted with one or more halo substituents; or
a 5- or 6-membered heteroaryl selected from the group consisting of pyridinyl and thiophenyl; wherein said 5- or 6-membered heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of halo and C1-4alkyl substituted with one or more halo substituents; - (f) each R8 is selected independently from C1-4alkyl or C1-4alkylcarbonyl.
- In an embodiment, the invention relates to compounds of Formula (I) and stereoisomeric forms thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein one or more, preferably all, of the following restrictions apply:
- (a) R1 is hydrogen, cyano, Br, or methyl optionally substituted with one or more substituents each independently selected from the group consisting of hydroxyl and methoxy;
- (b) R2 is hydrogen, methyl or I;
- (c) X is CH or N;
- (d) R6 is hydrogen, F or methoxy;
- (d) Y1 is CH or N; Y2 is CR4 or N; Y3 is CH; provided that only one of Y1 and Y2 may represent N;
- (e) R4 is hydrogen, F, methoxy, cyclopropyl, 1-propen-2-yl, or C1-4alkyl optionally substituted with one or more substituents each independently selected from the group consisting of F and methoxy;
- (f) R3 is n-propyl substituted with one or more F substituents; C1-4alkyl optionally substituted with one or more substituents each independently selected from the group consisting of piperidinyl, Ar, methoxy, tetrahydropyranyl and cyclopropyl; cyclopropyl substituted with one or more phenyl substituents optionally substituted with one or more Cl substituents; cyclopentyl; cyclohexyl; piperidinyl; morpholinyl; tetrahydropyranyl; O-Ar; C1-4alkyloxy; C1-4alkylthio; Ar; CH2-O-Ar; NH-Ar; or 1,6-dihydro-1-methyl-6-oxo-3-pyridinyl;
wherein each piperidinyl and morpholinyl may be substituted with one or more substituents each independently selected from the group consisting of methyl, methylcarbonyl, F and tert-butyloxycarbonyl;
wherein each Ar independently is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, methoxy, ethoxy, isopropoxy, cyano, NR7R8, methyl, isopropyl, methoxy substituted with one or more F substituents, and C1-4alkyl substituted with one or more F substituents; or a 5- or 6-membered heteroaryl selected from the group consisting of pyridinyl and thiophenyl; wherein said 5- or 6-membered heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of F and C1-4alkyl substituted with one or more F substituents; - (g) each R7 is selected independently from hydrogen or methyl;
- (h) each R8 is selected independently from methyl or methylcarbonyl;
- (i) R9 is hydrogen, or C1-4alkyl optionally substituted with one or more substituents each independently selected from the group consisting of F, phenyl and methoxy.
- In an embodiment, the invention relates to compounds of Formula (I) and stereoisomeric forms thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein one or more, preferably all, of the following restrictions apply:
- (a) R1 is C1-4alkyl; in particular methyl;
- (b) R2 is hydrogen;
- (c) X is CH or N;
- (d) A1 is CR6;
- (e) R6 is hydrogen, methoxy or halo; in particular hydrogen, methoxy or F;
- (f) A2 is CH or N;
- (g) A3 and A4 are CH;
- (h) Y1 is CH or N; Y2 is CR4; Y3 is CH;
- (i) R4 is hydrogen, halo or C1-4alkyl; in particular hydrogen, F, methyl or isopropyl;
- (j) R3 is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C1-4alkyloxy, NR7R8 and C1-4alkyl substituted with one or more halo substituents; in particular phenyl substituted with one or more substituents each independently selected from the group consisting of F, Cl, methoxy, NR7R8 and CF3;
- (k) R7 is hydrogen;
- (l) R8 is C1-4alkylcarbonyl; in particular methylcarbonyl;
- (m) Z is NR9;
- (n) R9 is C1-6alkyl; in particular C1-4alkyl; more in particular methyl or isopropyl.
- In an embodiment, the invention relates to compounds of Formula (I) and stereoisomeric forms thereof, wherein
R1 is hydrogen, C1-4alkyl, cyano, CF3, or halo;
R2 is hydrogen or C1-4alkyl;
X is CR5 or N;
R5 is hydrogen or halo;
A1 is CR6 or N;
R6 is hydrogen, halo or C1-4alkyloxy;
A2, A3 and A4 each independently are CH, CF or N;
provided that no more than two of A1, A2, A3 and A4 are N;
Y1 is CH or N;
Y2 is CR4 or N;
Y3 is CH or N;
provided that only one of Y1, Y2 and Y3 may represent N;
R4 is hydrogen, halo, C1-4alkyloxy, cyano, cycloC3-7alkyl, C2-4alkenyl, or C1-4alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo and C1-4alkyloxy;
R3 is C2-6alkyl substituted with one or more halo substituents; C1-6alkyl optionally substituted with one or more substituents each independently selected from the group consisting ofpiperidinyl, Ar, C1-6alkyloxy, tetrahydropyranyl, cycloC3-7alkyloxy and cycloC3-7alkyl; cycloC3-7alkyl; piperidinyl; morpholinyl; pyrrolidinyl; tetrahydropyranyl; O-Ar; NR7R8; C1-6alkyloxy; C1-6alkylthio; Ar; CH2-O-Ar; S-Ar; NCH3-Ar; or NH-Ar;
wherein each piperidinyl, morpholinyl and pyrrolidinyl may be substituted with one or more substituents each independently selected from the group consisting of C1-4alkyl, C2-6alkenyl, C1-4alkylcarbonyl, halo and C1-4alkyloxycarbonyl;
wherein each Ar independently is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C1-4alkyloxy, cyano, NR7R8, morpholinyl, C1-4alkyl and C1-4alkyl substituted with one or more halo substituents; or a 5- or 6-membered heteroaryl selected from the group consisting of pyridinyl, pyrimidinyl, oxazolyl, furanyl, thiophenyl, pyrazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridazinyl and pyrazinyl; wherein said 5- or 6-membered heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of halo, C14alkyloxy, cyano, C1-4alkyl and
C1-4alkyl substituted with one or more halo substituents;
each R7 is selected independently from hydrogen or C1-4alkyl;
each R8 is selected independently from hydrogen or C1-4alkyl;
Z is O or NR9;
R9 is hydrogen, or C1-6alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, phenyl and C1-4alkyloxy; and the pharmaceutically acceptable addition salts, and the solvates thereof - In an embodiment, the invention relates to compounds of Formula (I) and stereoisomeric forms thereof, wherein
R1 is hydrogen, C1-4alkyl, cyano, CF3, or halo;
R2 is hydrogen or C1-4alkyl;
X is CR5 or N; wherein R5 is H or halo;
A1 is CR6 or N;
R6 is hydrogen, halo or C1-4alkyloxy;
A2, A3 and A4 each independently are CH, CF or N; provided that no more than two of A1, A2, A3 and A4 are N;
Y1 is CH or N;
Y2 is CR4 or N;
Y3 is CH or N;
provided that only one of Y1, Y2 and Y3 may represent N;
R3 is C2-6alkyl substituted with one or more substituents selected from halo; C1-6alkyl optionally substituted with one or more substituents selected from piperidinyl, Ar, C1-6alkyloxy, tetrahydropyranyl, cycloC3-7alkyloxy and cycloC3-7alkyl; cycloC3-7alkyl; piperidinyl; morpholinyl; pyrrolidinyl; tetrahydropyranyl; O-Ar; NR7R8; C1-6alkyloxy; C1-6alkylthio; Ar; CH2-O-Ar; S-Ar; NCH3-Ar; or NH-Ar;
wherein each piperidinyl, morpholinyl and pyrrolidinyl may optionally be substituted with one or more substituents selected from C1-4alkyl, C2-6alkenyl, C1-4alkylcarbonyl, halo and C1-4alkyloxycarbonyl;
wherein each Ar independently is phenyl optionally substituted with one or more substituents each independently selected from halo, C1-4alkyloxy, cyano, NR7R8, morpholinyl, C1-4alkyl and C1-4alkyl substituted with one or more substituents selected from halo; or a 5- or 6-membered heteroaryl selected from pyridinyl, pyrimidinyl, oxazolyl, furanyl, thiophenyl, pyrazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridazinyl, or pyrazinyl, wherein said 5- or 6-membered heteroaryl is optionally substituted with 1 or more substituents each independently selected from halo, C1-4alkyloxy, cyano, C1-4alkyl and C1-4alkyl substituted with one or more substituents selected from halo;
wherein each R7 is selected independently from hydrogen or C1-4alkyl;
wherein each R8 is selected independently from hydrogen or C1-4alkyl;
R4 is hydrogen, halo, C1-4alkyloxy, cyano, cycloC3-7alkyl, C2-4alkenyl, or C1-4alkyl optionally substituted with one or more substituents selected from halo or C1-4alkyloxy; Z is O or NR9; wherein R9 is hydrogen, C1-6alkyl optionally substituted with one or more substituents selected from halo, phenyl and C1-4alkyloxy;
and the pharmaceutically acceptable addition salts, and the solvates thereof. - In an embodiment, the invention relates to compounds of Formula (I) and stereoisomeric forms thereof, wherein ,
R1 is hydrogen, C1-4alkyl, cyano, CF3, or halo;
R2 is hydrogen or C1-4alkyl;
X is CR5 or N;
R5 is hydrogen or halo;
A1 is CR6 or N;
R6 is hydrogen, halo or C1-4alkyloxy;
A2, A3 and A4 each independently are CH, CF or N;
provided that no more than two of A1, A2, A3 and A4 are N;
Y1 is CH or N;
Y2 is CR4;
Y3 is CH;
R4 is hydrogen, halo, C1-4alkyloxy, cyano, or C1-4alkyl optionally substituted with one or more halo substituents;
R3 is C2-6alkyl substituted with one or more halo substituents; C1-6alkyl optionally substituted with one or more substituents each independently selected from the group consisting of piperidinyl, Ar, C1-6alkyloxy, tetrahydropyranyl, cycloC3-7alkyloxy and cycloC3-7alkyl; cycloC3-7alkyl; piperidinyl; morpholinyl; pyrrolidinyl; tetrahydropyranyl; O-Ar; NR7R8; C1-6alkyloxy; C1-6alkylthio; Ar; CH2-O-Ar; S-Ar; NCH3-Ar; or NH-Ar;
wherein each piperidinyl, morpholinyl and pyrrolidinyl may be substituted with one or more substituents each independently selected from the group consisting of C1-4alkyl, C2-6alkenyl, C1-4alkylcarbonyl, halo and C1-4alkyloxycarbonyl;
wherein each Ar independently is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C1-4alkyloxy, cyano, NR7R8, morpholinyl, C1-4alkyl and C1-4alkyl substituted with one or more halo substituents; or a 5- or 6-membered heteroaryl selected from the group consisting ofpyridinyl, pyrimidinyl, oxazolyl, furanyl, thiophenyl, pyrazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridazinyl and pyrazinyl; wherein said 5- or 6-membered heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of halo, C1-4alkyloxy, cyano, C1-4alkyl and C1-4alkyl substituted with one or more halo substituents;
each R7 is selected independently from hydrogen or C1-4alkyl;
each R8 is selected independently from hydrogen or C1-4alkyl;
Z is O or NR9;
R9 is hydrogen, or C1-6alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, phenyl and C1-4alkyloxy; and the pharmaceutically acceptable addition salts, and the solvates thereof. - In an embodiment, the invention relates to compounds of Formula (I) and stereoisomeric forms thereof, wherein
R1 is hydrogen, C1-4alkyl, cyano, CF3, or halo;
R2 is hydrogen or C1-4alkyl;
X is CR5 or N; wherein R5 is H or halo;
A1 is CR6 or N;
R6 is hydrogen, halo or C1-4alkyloxy;
A2, A3 and A4 each independently are CH, CF or N; provided that no more than two of A1, A2, A3 and A4 are N;
Y1 is CH or N; Y2 is CR4; Y3 is CH;
R3 is C2-6alkyl substituted with one or more substituents selected from halo; C1-6alkyl optionally substituted with one or more substituents selected from piperidinyl, Ar, C1-6alkyloxy, tetrahydropyranyl, cycloC3-7alkyloxy and cycloC3-7alkyl; cycloC3-7alkyl; piperidinyl; morpholinyl; pyrrolidinyl; tetrahydropyranyl; O-Ar; NR7R8; C1-6alkyloxy; C1-6alkylthio; Ar; CH2-O-Ar; S-Ar; NCH3-Ar, or NH-Ar;
wherein each piperidinyl, morpholinyl and pyrrolidinyl may optionally be substituted with one or more substituents selected from C1-4alkyl, C2-6alkenyl, C1-4alkylcarbonyl, halo and C1-4alkyloxycarbonyl;
wherein each Ar independently is phenyl optionally substituted with one or more substituents each independently selected from halo, C1-4alkyloxy, cyano, NR7R8, morpholinyl, C1-4alkyl and C1-4alkyl substituted with one or more substituents selected from halo; or a 5- or 6-membered heteroaryl selected from pyridinyl, pyrimidinyl, oxazolyl, furanyl, thiophenyl, pyrazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridazinyl, or pyrazinyl, wherein said 5- or 6-membered heteroaryl is optionally substituted with 1 or more substituents each independently selected from halo, C1-4alkyloxy, cyano, C1-4alkyl and C1-4alkyl substituted with one or more substituents selected from halo;
wherein R7 is hydrogen or C1-4alkyl;
wherein R8 is hydrogen or C1-4alkyl;
R4 is hydrogen, halo, C1-4alkyloxy, cyano, or C1-4alkyl optionally substituted with one or more substituents selected from halo;
Z is O or NR9; wherein R9 is hydrogen, C1-6alkyl optionally substituted with one or more substituents selected from halo, phenyl and C1-4alkyloxy;
and the pharmaceutically acceptable addition salts, and the solvates thereof. - In an embodiment, the invention relates to compounds of Formula (I) and stereoisomeric forms thereof, wherein
R1 is hydrogen, C1-4alkyl, cyano or halo;
R2 is hydrogen or C1-4alkyl;
X is CH or N;
A1 is CR6 or N;
R6 is hydrogen, halo or C1-4alkyloxy;
A2, A3 and A4 each independently are CH, CF or N;
provided that no more than two of A1, A2, A3 and A4 are N;
Y1 is CH or N;
Y2 is CR4;
Y3 is CH or N;
provided that only one of Y1 and Y3 may represent N;
R3 is C2-6alkyl substituted with one or more halo substituents; C1-6alkyl optionally substituted with one or more substituents each independently selected from the group consisting of piperidinyl, Ar, C1-6alkyloxy, tetrahydropyranyl and cycloC3-7alkyl; cycloC3-7alkyl; piperidinyl; morpholinyl; O-Ar; C1-6alkyloxy; C1-6alkylthio; Ar; or NH-Ar;
wherein each piperidinyl and morpholinyl may be substituted with one or more substituents each independently selected from the group consisting of C1-4alkyl, C1-4alkylcarbonyl, halo and C1-4alkyloxycarbonyl;
wherein each Ar independently is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C1-4alkyloxy and C1-4alkyl; or pyridinyl;
R4 is hydrogen, halo, cyano, or C1-4alkyl optionally substituted with one or more halo substituents;
Z is O or NR9;
R9 is hydrogen, or C1-6alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, phenyl and C1-4alkyloxy; and the pharmaceutically acceptable addition salts, and the solvates thereof. - In an embodiment, the invention relates to compounds of Formula (I) and stereoisomeric forms thereof, wherein
R1 is hydrogen, C1-4alkyl, cyano or halo;
R2 is hydrogen or C1-4alkyl;
X is CH or N;
A1 is CR6 or N;
R6 is hydrogen, halo or C1-4alkyloxy;
A2, A3 and A4 each independently are CH, CF or N;
provided that no more than two of A1, A2, A3 and A4 are N;
Y1 is CH or N;
Y2 is CR4;
Y3 is CH;
R3 is C2-6alkyl substituted with one or more halo substituents; C1-6alkyl optionally substituted with one or more substituents each independently selected from the group consisting of piperidinyl, Ar, C1-6alkyloxy, tetrahydropyranyl and cycloC3-7alkyl; cycloC3-7alkyl; piperidinyl; morpholinyl; O-Ar; C1-6alkyloxy; C1-6alkylthio; Ar; or NH-Ar;
wherein each piperidinyl and morpholinyl may be substituted with one or more substituents each independently selected from the group consisting of C1-4alkyl, C1-4alkylcarbonyl, halo and C1-4alkyloxycarbonyl;
wherein each Ar independently is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C1-4alkyloxy and C1-4alkyl; or pyridinyl;
R4 is hydrogen, halo, cyano, or C1-4alkyl optionally substituted with one or more halo substituents;
Z is O or NR9;
R9 is hydrogen, or C1-6alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, phenyl and C1-4alkyloxy; and the pharmaceutically acceptable addition salts, and the solvates thereof - In another embodiment, the invention relates to compounds of Formula (I) and stereoisomeric forms thereof, wherein
R1 is hydrogen, methyl, cyano or bromo;
R2 is hydrogen or methyl;
XisCHorN;
A1 is CR6 or N;
R6 is hydrogen, F or methoxy;
A2, A3 and A4 each independently are CH, CF or N;
provided that no more than two of A1, A2, A3 and A4 are N;
Y1 is CH or N;
Y2 is CR4;
Y3 is CH;
R3 is 3,3,3-trifluoropropyl; C1-6alkyl optionally substituted with one or more substituents each independently selected from the group consisting of piperidinyl, Ar, methoxy, tetrahydropyranyl and cyclopropyl; hexyl; pentyl; piperidinyl; morpholinyl; O-Ar; isopropyloxy; isobutylthio; Ar; or NH-Ar;
wherein each piperidinyl and morpholinyl may be substituted with one or more substituents each independently selected from the group consisting of methyl, methylcarbonyl, F and tert-butyloxycarbonyl;
wherein each Ar independently is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of Cl, F, methyloxy, ethyloxy, methyl and isobutyl; or pyridinyl;
R4 is hydrogen, F, methyl, cyano or CF3;
Z is O or NR9;
R9 is hydrogen, or C1-4alkyl optionally substituted with one or more substituents each independently selected from the group consisting of F, phenyl and methoxy;
and the pharmaceutically acceptable addition salts, and the solvates thereof. - In an embodiment, the invention relates to compounds of Formula (I) and stereoisomeric forms thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein one or more, preferably all, of the following restrictions apply:
- (a) R1 is C1-4alkyl; in particular methyl;
- (b) R2 is hydrogen;
- (c) X is CH;
- (d) A1 is CR6;
- (e) R6 is F or methoxy; in particular methoxy;
- (f) A2 is N or CH; in particular N;
- (g) A3 and A4 are CH;
- (h) Y1 is CH or N;
- (i) Y2 is CR4;
- (j) Y3 is CH;
- (k) R4 is hydrogen or methyl;
- (l) R3 is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo and methoxy; in particular R3 is phenyl substituted with one or more substituents each independently selected from the group consisting of halo and methoxy; more in particular R3 is phenyl substituted with one or two substituents each independently selected from the group consisting of halo and methoxy; even more in particular R3 is phenyl substituted with one or two substituents each independently selected from the group consisting of F and methoxy;
- (m) Z is NR9;
- (n) R9 is C1-6alkyl; in particular C1-4alkyl; more in particular methyl.
- In an embodiment, the invention relates to compounds of Formula (I) and stereoisomeric forms thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein one or more, preferably all, of the following restrictions apply:
- (a) R1 is C1-4alkyl; in particular methyl;
- (b) R2 is hydrogen;
- (c) X is CH;
- (d) A1 is COCH3; A2 is N; A3 is CH; A4 is CH;
- (e) Y1, Y2 and Y3 are CH;
- (f) R3 is phenyl optionally substituted with one or more halo substituents; in particular phenyl substituted with one or more halo substituents; more in particular phenyl substituted with one halo substituent; even more in particular phenyl substituted with one fluoro substituent;
- (g) Z is NR9;
- (h) R9 is C1-6alkyl; in particular C1-4alkyl; more in particular methyl.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein R1 is methyl and wherein R2 is hydrogen.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein R1 is hydrogen and wherein R2 is methyl.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein R1 is hydrogen, wherein R2 is methyl and wherein X is N.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein R1 is hydrogen, C1-4alkyl, cyano or halo.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein X is CR5.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein X is N.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein X is N or CH.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein X is CH.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein Y1 is CH or N; Y2 is CR4; and Y3 is CH or N;
provided that only one of Y1 and Y3 may represent N;. - In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein Y1 is CH; Y2 is CR4; and Y3 is CH.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein Y1 is N; Y2 is CR4; and Y3 is CH.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein Y1 is CH; Y2 is N; and Y3 is CH.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein Y1 is CH; Y2 is CR4; and Y3 is N.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein R3 is C2-6alkyl substituted with one or more halo substituents; C1-6alkyl optionally substituted with one or more substituents each independently selected from the group consisting of piperidinyl, Ar, C1-6alkyloxy, tetrahydropyranyl, cycloC3-7alkyloxy and cycloC3-7alkyl; cycloC3-7alkyl substituted with one or more phenyl substituents optionally substituted with one or more halo substituents; cycloC3-7alkyl; piperidinyl; morpholinyl; pyrrolidinyl; tetrahydropyranyl; O-Ar; NR7R8; C1-6alkyloxy; C1-6alkylthio; Ar; CH2-O-Ar; S-Ar; NCH3-Ar; NH-Ar; or 1,6-dihydro-1-methyl-6-oxo-3-pyridinyl.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein
R3 is C2-6alkyl substituted with one or more halo substituents; C1-6alkyl optionally substituted with one or more substituents each independently selected from the group consisting of Ar, C1-6alkyloxy, cycloC3-7alkyloxy and cycloC3-7alkyl; Ar; or CH2-O-Ar; wherein each Ar independently is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C1-4alkyloxy, cyano, C1-4alkyl and C1-4alkyl substituted with one or more halo substituents. - In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein R3 is isobutyl; cyclopropylmethyl; 3,3,3-trifluoropropyl; C2-4alkyl substituted with methoxy; CH2-O-Ar; or Ar.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein R3 is Ar.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein each Ar independently is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C1-4alkyloxy, cyano, NR7R8, morpholinyl, C1-4alkyl and C1-4alkyl substituted with one or more halo substituents; or a 5- or 6-membered heteroaryl selected from the group consisting of pyridinyl, oxazolyl, thiophenyl, thiazolyl and oxadiazolyl; wherein said 5- or 6-membered heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of halo, C1-4alkyloxy, cyano, C1-4alkyl and C1-4alkyl substituted with one or more halo substituents.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein each Ar independently is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C1-4alkyloxy, cyano, NR7R8, morpholinyl, C1-4alkyl and C1-4alkyl substituted with one or more halo substituents; or pyridinyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C1-4alkyloxy, cyano, C1-4alkyl and C1-4alkyl substituted with one or more halo substituents.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein each Ar independently is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C1-4alkyloxy, cyano, NR7R8, morpholinyl, C1-4alkyl and C1-4alkyl substituted with one or more halo substituents; or a 5- or 6-membered heteroaryl selected from the group consisting ofpyridinyl, pyrimidinyl, oxazolyl, furanyl, thiophenyl, pyrazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridazinyl and pyrazinyl; wherein said 5- or 6-membered heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of halo, C1-4alkyloxy, cyano, C1-4alkyl and C1-4alkyl substituted with one or more halo substituents.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein R4 is hydrogen, halo, C1-4alkyloxy, cyano, cycloC3-7alkyl, C2-4alkenyl, or C1-4alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo and C1-4alkyloxy.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein R4 is hydrogen, halo, C1-4alkyloxy, cyano, or C1-4alkyl optionally substituted with one or more halo substituents.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein R4 is hydrogen, halo, or C1-4alkyl optionally substituted with one or more halo substituents.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein R4 is hydrogen, halo, methyl, cyano or CF3.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein R4 is hydrogen, F or CF3.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein Z is O.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein Z is NR9.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein Z is NR9 and wherein R9 is C1-6alkyl optionally substituted with one or more substituents each independently selected from the group consisting of C1-4alkyloxy and CF3.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein R9 is C1-3alkyl.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments or any combination of the other embodiments, wherein each R8 is selected independently from hydrogen or C1-4alkyl.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein A1 is N, CH, CF or COCH3.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein A2 is CH.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein A3 is CH or N.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein A4 is CH.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein A2, A3 and A4 each independently are CH or N; provided that no more than two of A1, A2, A3 and A4 are N.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein A3 and A4 are CH.
- In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein
A2 is CH, CF or N; and
A3 and A4 each independently are CH or N; provided that no more than two of A1, A2, A3 and A4 are N; - In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein
A1 is N, CH, CF or COCH3;
A2 is CH;
A3 is CH or N; and
A4 is CH. - In a further embodiment, the invention relates to compounds according to any of the other embodiments, wherein C1-6alkyl is restricted to C1-4alkyl.
- In an embodiment the compound of Formula (I) is selected from the group comprising:
- 2-(4-fluorophenyl)-N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-4-benzoxazolamine,
- 2-cyclohexyl-N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-4-benzoxazolamine,
- 2-(4-fluorophenyl)-N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1-methyl-1H-benzimidazo 1-4-amine,
- 2-cyclopentyl-N-[3-methoxy-4-(4-methyl-1H-ilnidazol-1-yl)phenyl]-4-benzoxazo lamine,
- N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-(2-methylpropyl)-4-benzoxazolamine,
- N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-(3-pyridinyl)-4-benzoxazo lamine,
- 2-(4-fluorophenyl)-N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1-(1-methylethyl)-1H-benzimidazol-4-amine,
- 4-[4-[[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]amino]-2-benzoxazolyl]-1-piperidinecarboxylic acid, 1,1-dimethylethyl ester
- 2-(2-chlorophenyl)-N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-4-benzoxazolamine,
- 2-(4-fluorophenyl)-N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1-(phenylmethyl)-1H-benzimidazol-4-amine,
- 2-cyclohexyl-N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-(4-fluorophenyl)-N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1H-benzimidazol-4-amine,
- N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-(4-methoxyphenyl)-1-methyl-1H-benzimidazol-4-amine,
- 2-(2,4-difluorophenyl)-N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-(2,6-dimethyl-4-morpholinyl)-N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)-phenyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-(2-fluorophenyl)-N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1-methyl-1H-benzimidazol-4-amine,
- N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-(2-methoxyphenyl)-4-benzoxazolamine,
- 1-acetyl-4-[4-[[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]amino]-2-benzoxazolyl]-piperidine,
- 2-[(4-fluorophenyl)methyl]-N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-4-benzoxazolamine,
- N-[4-(4-bromo-1H-imidazol-1-yl)-3-methoxyphenyl]-2-(4-fluorophenyl)-1-methyl-1H-benzimidazol-4-amine,
- N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-(1-methyl-4-piperidinyl)-4-benzoxazolamine,
- N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1-methyl-2-(2-methylpropyl)-1H-benzimidazol-4-amine,
- 2-(4-fluorophenyl)-N-[5-methoxy-6-(4-methyl-1H-imidazol-1-yl)-3-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-(4-fluorophenyl)-N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1-methyl-1H-benzimidazol-4-amine,
- 1-[4-[[2-(4-fluorophenyl)-1-methyl-1H-benzimidazol-4-yl]amino]-2-methoxy-phenyl]-1H-imidazole-4-carbonitrile,
- 2-(4-fluorophenyl)-N-[4-(1H-imidazol-1-yl)-3-methoxyphenyl]-1-methyl-1H-benzimidazol-4-amine,
- N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-(2-methylphenyl)-1-(phenylmethyl)-1H-benzimidazol-4-amine,
- 2-(1,1-dimethylethyl)-N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-4-benzoxazolamine,
- 2-(4-fluorophenyl)-1-methyl-N-[5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1H-benzimidazol-4-amine,
- 2-(4-fluorophenyl)-N-[3-methoxy-4-(1H-1,2,4-triazol-1-yl)phenyl]-1-methyl-1H-benzimidazol-4-amine,
- N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1-methyl-2-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-benzimidazol-4-amine,
- 2-[(4-fluorophenyl)methyl]-N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-(4-fluorophenyl)-N-[4-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-(4-fluorophenyl)-1-methyl-N-[4-(4-methyl-1H-imidazol-1-yl)phenyl]-1H-benzimidazol-4-amine,
- 2-(4-fluorophenyl)-1-methyl-N-[2-(4-methyl-1H-imidazol-1-yl)-5-pyrimidinyl]-1H-benzimidazol-4-amine,
- N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-(2-methylphenyl)-1H-benzimidazol-4-amine,
- 2-(4,4-difluoro-1-piperidinyl)-N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1-methyl-1H-benzimidazol-4-amine,
- N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1-methyl-2-phenoxy-1H-benzimidazol-4-amine,
- N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1-methyl-2-(1-piperidinyl)-1H-benzimidazol-4-amine,
- 2-(4-fluorophenyl)-N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1H-imidazo [4,5-c]pyridin-4-amine,
- 1-(2-methoxyethyl)-N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-(3-methoxyphenyl)-1H-benzimidazol-4-amine,
- 2-(4-fluorophenyl)-N-[3-methoxy-4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1-methyl-1H-benzimidazol-4-amine,
- N-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-(4-fluorophenyl)-1-methyl-1H-benzimidazol-4-amine,
- 2-(4-fluorophenyl)-N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1-methyl-1H-imidazo[4,5-c]pyridin-4-amine,
- 2-(4-fluorophenyl)-N-[3-fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl]-1-methyl-1H-benzimidazol-4-amine,
- N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1-methyl-2-(1-methyl-ethoxy)-1H-benzimidazol-4-amine,
- N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1-methyl-2-[(2-methylpropyl)thio]-1H-benzimidazol-4-amine,
- N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1-methyl-2-(3,3,3-trifluoropropyl)-1H-benzimidazol-4-amine,
- N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1-methyl-2-(4-piperidinyl-methyl)-1H-benzimidazol-4-amine,
- 1-acetyl-4-[[4-[[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]amino]-1-methyl-1H-benzimidazol-2-yl]methyl]-piperidine,
- N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1-methyl-2-[(1-methyl-4-piperidinyl)methyl]-1H-benzimidazol-4-amine,
- 2-(4-fluorophenyl)-1-methyl-N-[6-(4-methyl-1H-imidazol-1-yl)-3-pyridinyl]-1H-benzimidazol-4-amine,
- 2-(4-fluorophenyl)-1-methyl-N-[6-(3-methyl-1H-1,2,4-triazol-1-yl)-3-pyridinyl]-1H-benzimidazol-4-amine,
- N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-(3-methoxyphenyl)-1-methyl-1H-benzimidazol-4-amine,
- N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-2-(2-methylpropyl)-4-benzoxazolamine,
- 2-[4-ethoxy-2-methyl-5-(1-methylethyl)phenyl]-N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-[4-ethoxy-2-methyl-5-(1-methylethyl)phenyl]-N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-4-benzoxazolamine,
- N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-methyl-1-(phenylmethyl)-1H-benzimidazo 1-4-amine,
- 2-(cyclopropylmethyl)-1-ethyl-N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)-phenyl]-1H-benzimidazol-4-amine,
- 2-(4-chloro-3-methoxyphenyl)-N-[3-fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-(4-fluorophenyl)-1-(1-methylethyl)-N-[4-(3-methyl-1H-1,2,4-triazol-1-yl)-phenyl]-1H-benzimidazol-4-amine,
- 2-(4-fluorophenyl)-N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1-(1-methylethyl)-1H-benzimidazol-4-amine,
- 2-(4-fluorophenyl)-N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1-(1-methylethyl)-1H-benzimidazol-4-amine .2 HCl,
- 1-(1,1-dimethylethyl)-2-(4-fluorophenyl)-N-[4-(3-methyl-1H-1,2,4-triazol-1-yl)-phenyl]-1H-benzimidazol-4-amine,
- 1-(1,1-dimethylethyl)-2-(4-fluorophenyl)-N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1H-benzimidazol-4-amine,
- N 2-[4-ethoxy-2-methyl-5-(1-methylethyl)phenyl]-N 4-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1-methyl-1H-benzimidazole-2,4-diamine,
- 2-methyl-N-[4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1-(phenylmethyl)-1H-benzimidazol-4-amine,
- 1,2-bis(2-methylpropyl)-N-[4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1H-benzimidazo 1-4-amine,
- 1-(2-methoxyethyl)-2-(2-methylpropyl)-N-[4-(3-methyl-1H-1,2,4-triazol-1-yl)-phenyl]-1H-benzimidazol-4-amine,
- 2-(2-methylpropyl)-N-[5-(3-methyl-1H-1,2,4-triazol-1-yl)-2-pyridinyl]-4-benzoxazo lamine,
- 2-(4-fluorophenyl)-1-(1-methylethyl)-N-[6-(3-methyl-1H-1,2,4-triazol-1-yl)-3-pyridinyl]-1H-benzimidazol-4-amine,
- N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-2-methyl-1-(1-methyl-ethyl)-1H-benzimidazol-4-amine,
- 2-(4-fluorophenyl)-1-methyl-N-[4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-6-(trifluoromethyl)-1H-benzimidazol-4-amine,
- N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-(3-methoxypropyl)-1-methyl-1H-benzimidazol-4-amine,
- 1-ethyl-N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-(3,3,3-trifluoropropyl)-1H-benzimidazol-4-amine,
- N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-2-(3-methoxyphenyl)-1-methyl-1H-benzimidazol-4-amine,
- 2-(3-methoxyphenyl)-1-methyl-N-[4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1H-benzimidazol-4-amine,
- 2-(4-fluorophenyl)-1-(1-methylethyl)-N-[5-(3-methyl-1H-1,2,4-triazol-1-yl)-2-pyridinyl]-1H-benzimidazol-4-amine,
- 2-methyl-1-(1-methylethyl)-N-[4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1H-benzimidazo 1-4-amine,
- 2-(4-fluorophenyl)-1-(1-methylethyl)-N-[4-(5-methyl-1H-1,2,4-triazol-1-yl)-phenyl]-1H-benzimidazol-4-amine,
- N-[3-fluoro-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-2-(4-fluorophenyl)-1-(1-methylethyl)-1H-benzimidazol-4-amine,
- N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-2-(3-methoxyphenyl)-1-(1-methylethyl)-1H-benzimidazol-4-amine,
- 2-(1,1-dimethylethyl)-N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-(3-chlorophenyl)-N-[3-methoxy-4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-(2-chloro-3-methoxyphenyl)-N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)-phenyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-(3-methoxyphenyl)-1-(1-methylethyl)-N-[4-(3-methyl-1H-1,2,4-triazol-1-yl)-phenyl]-1H-benzimidazol-4-amine,
- 2-(4-chloro-3-methoxyphenyl)-N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-butyl-N-[3-fluoro-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-(4-fluorophenyl)-1-methyl-N-[6-(4-methyl-1H-imidazol-1-yl)-3-ppidazinyl]-1H-benzimidazol-4-amine,
- 2-(4-fluorophenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
- 6-fluoro-N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-2-(3-methoxy-phenyl)-1-methyl-1H-benzimidazol-4-amine,
- 6-fluoro-N-[3-fluoro-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-2-(3-methoxyphenyl)-1-methyl-1H-benzimidazol-4-amine,
- 6-fluoro-2-(3-methoxyphenyl)-1-methyl-N-[4-(3-methyl-1H-1,2,4-triazol-1-yl)-phenyl]-1H-benzimidazol-4-amine,
- 2-(4-fluorophenyl)-N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1-methyl-1H-imidazo[4,5-c]pyridin-4-amine,
- 2-(4-fluorophenyl)-1-methyl-N-[6-(3-methyl-1H-1,2,4-triazol-1-yl)-3-pyridinyl]-6-(trifluoromethyl)-1H-benzimidazol-4-amine,
- N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1,2-dimethyl-1H-benzimidazol-4-amine,
- N-[3-fluoro-4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl]-2-(4-fluorophenyl)-1-(1-methylethyl)-1H-imidazo[4,5-c]pyridin-4-amine,
- N-[3-fluoro-4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl]-2-(4-fluorophenyl)-1-methyl-1H-imidazo[4,5-c]pyridin-4-amine,
- 2-(2,4-difluorophenyl)-N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1-methyl-1H-imidazo[4,5-c]pyridin-4-amine,
- N-[3-methoxy-4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1-methyl-2-(phenoxy-methyl)-1H-benzimidazol-4-amine,
- N-[3-fluoro-4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl]-2-(4-fluorophenyl)-1,6-dimethyl-1H-imidazo[4,5-c]pyridin-4-amine,
- 2-(cyclopropylmethyl)-N-[3-methoxy-4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1-methyl-1H-imidazo[4,5-c]pyridin-4-amine,
- N-[3,5-difluoro-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-2-(4-fluorophenyl)-1-methyl-1H-benzimidazol-4-amine,
- 2-(4-fluorophenyl)-1-methyl-N-[4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1H-benzimidazol-4-amine,
- 2-(2,4-difluorophenyl)-N-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1-methyl-1H-imidazo[4,5-c]pyridin-4-amine,
- N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-2-(2-methylpropyl)-1-(2,2,2-trifluoroethyl)-1H-benzimidazol-4-amine,
- N-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-(4-fluorophenyl)-1,6-dimethyl-1H-imidazo[4,5-c]pyridin-4-amine,
- 2-(4-fluorophenyl)-N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-3-methyl-5-(1-methylethyl)-3H-imidazo[4,5-b]pyridin-7-amine,
- 2-(4-chloro-3-methoxyphenyl)-N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1-methyl-1H-imidazo[4,5-c]pyridin-4-amine,
- 2-(4-fluorophenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-3-methyl-5-(1-methylethyl)-3H-imidazo[4,5-b]pyridin-7-amine,
- 2-(4-fluorophenyl)-N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1-methyl-6-(1-methylethyl)-1H-imidazo[4,5-c]pyridin-4-amine,
- 6-fluoro-2-(4-fluorophenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
- 6-fluoro-2-(4-fluorophenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-(1-methylethyl)-1H-benzimidazol-4-amine,
- 2-(4-fluorophenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-(1-methylethyl)-1H-benzimidazol-4-amine,
- N-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-(4-fluorophenyl)-3,5-dimethyl-3H-imidazo[4,5-b]pyridin-7-amine,
- 2-(4-fluorophenyl)-N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-3,5-dimethyl-3H-imidazo[4,5-b]pyridin-7-amine,
- 2-(4-fluorophenyl)-N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-3-methyl-5-(1-methylethenyl)-3H-imidazo[4,5-b]pyridin-7-amine,
- 1-[4-[[2-(4-fluorophenyl)-1-methyl-1H-benzimidazol-4-yl]amino]-2-methoxyphenyl]-1H-imidazole-4-methanol,
- 2-(4-fluorophenyl)-N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1,6-dimethyl-1H-imidazo[4,5-c]pyridin-4-amine,
- 2-(2,4-difluorophenyl)-N-[2-fluoro-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1-methyl-1H-imidazo[4,5-c]pyridin-4-amine,
- N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-2-(3-methoxyphenyl)-1,6-dimethyl-1H-imidazo[4,5-c]pyridin-4-amine,
- N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1-(1-methylethyl)-2-(tetrahydro-2H-pyran-4-yl)-1H-benzimidazol-4-amine,
- N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1-(1-methylethyl)-2-[6-(trifluoromethyl)-3-pyridinyl]-1H-benzimidazol-4-amine,
- N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-2-(3-methoxyphenyl)-1-methyl-1H-imidazo[4,5-c]pyridin-4-amine,
- N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1-methyl-2-[2-(trifluoromethyl)phenyl]-1H-imidazo[4,5-c]pyridin-4-amine,
- 2-(2,5-difluorophenyl)-1-ethyl-6-fluoro-N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1H-benzimidazol-4-amine,
- N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-2-(3-methoxyphenyl)-1-(1-methylethyl)-1H-imidazo[4,5-c]pyridin-4-amine,
- 2-(2-chlorophenyl)-6-fluoro-N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-(2-chlorophenyl)-N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1-methyl-1H-imidazo[4,5-c]pyridin-4-amine,
- 2-(4-fluorophenyl)-N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-5-(3-methoxypropyl)-3-methyl-3H-imidazo[4,5-b]pyridin-7-amine,
- 2-(2-chlorophenyl)-N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1-(1-methylethyl)-1H-imidazo[4,5-c]pyridin-4-amine,
- 2-(4-fluorophenyl)-N-[3-methoxy-4-[4-(methoxymethyl)-1H-imidazol-1-yl]phenyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-(5-chloro-2-thienyl)-N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1-(1-methylethyl)-1H-benzimidazol-4-amine,
- 2-(4-fluorophenyl)-N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-3-methyl-3H-imidazo[4,5-c]pyridin-7-amine,
- 2-(3-chlorophenyl)-N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1-(1-methylethyl)-1H-benzimidazol-4-amine,
- 2-[1-(4-chlorophenyl)ethyl]-N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-[1-(4-chlorophenyl)cyclopropyl]-N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-(2-chlorophenyl)-6-fluoro-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-(4-fluorophenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1,6-dimethyl-1H-imidazo[4,5-c]pyridin-4-amine,
- 2-(2-chlorophenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1,6-dimethyl-1H-imidazo[4,5-c]pyridin-4-amine,
- 2-(2-chlorophenyl)-N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1,6-dimethyl-1H-imidazo[4,5-c]pyridin-4-amine,
- 2-(2-chlorophenyl)-N-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1,6-dimethyl-1H-imidazo[4,5-c]pyridin-4-amine,
- N-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-(4-fluorophenyl)-1-methyl-1H-imidazo[4,5-c]pyridin-4-amine,
- 5-cyclopropyl-N-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-(4-fluorophenyl)-3-methyl-3H-imidazo[4,5-b]pyridin-7-amine,
- 6-chloro-2-(4-fluorophenyl)-N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1-methyl-1H-imidazo[4,5-c]pyridin-4-amine,
- 4-[[4-[[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]amino]-1-methyl-1H-benzimidazol-2-yl]methyl]-1-piperidinecarboxylic acid 1,1-dimethylethyl ester,
- 5-cyclopropyl-2-(4-fluorophenyl)-N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-3-methyl-3H-imidazo[4,5-b]pyridin-7-amine,
- N-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-(4-fluorophenyl)-3-methyl-5-(1-methylethyl)-3H-imidazo[4,5-b]pyridin-7-amine,
- N-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-(4-fluorophenyl)-1-methyl-6-(1-methylethyl)-1H-imidazo[4,5-c]pyridin-4-amine,
- N-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-(4-fluorophenyl)-3-methyl-3H-imidazo[4,5-b]pyridin-7-amine,
- 2-(4-fluorophenyl)-N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-3-methyl-3H-imidazo[4,5-b]pyridin-7-amine,
- N-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-(4-fluorophenyl)-5-methoxy-3-methyl-3H-imidazo[4,5-b]pyridin-7-amine,
- 2-(4-fluorophenyl)-5-methoxy-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-3-methyl-3H-imidazo[4,5-b]pyridin-7-amine,
- N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-2-(3-methoxyphenyl)-4-benzoxazolamine,
- 2-(3-bromo-4-fluorophenyl)-N-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1,6-dimethyl-1H-imidazo[4,5-c]pyridin-4-amine,
- N-[3-fluoro-4-(2-iodo-4-methyl-1H-imidazol-1-yl)phenyl]-2-(4-fluorophenyl)-1,6-dimethyl-1H-imidazo[4,5-c]pyridin-4-amine,
- 2-(3-ethoxyphenyl)-N-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1,6-dimethyl-1H-imidazo[4,5-c]pyridin-4-amine,
- 5-[4-[[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]amino]-1-methyl-1H-benzimidazol-2-yl]-1-methyl-2(1H)-pyridinone,
- 5-[4-[[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]amino]-1-methyl-1H-benzimidazol-2-yl]-1-methyl-2(1H)-pyridinone,
- N-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-(2-methoxyphenyl)-1,6-dimethyl-1H-imidazo[4,5-c]pyridin-4-amine,
- 2-(2-fluoro-4-methoxyphenyl)-N-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1,6-dimethyl-1H-imidazo[4,5-c]pyridin-4-amine,
- N-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1,6-dimethyl-2-(3-pyridinyl)-1H-imidazo[4,5-c]pyridin-4-amine,
- 2-[3-(dimethylamino)phenyl]-N-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1,6-dimethyl-1H-imidazo[4,5-c]pyridin-4-amine,
- N-[3-[4-[[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]amino]-1,6-dimethyl-1H-imidazo[4,5-c]pyridin-2-yl]phenyl]-acetamide,
- 2-(4-chloro-3-methoxyphenyl)-6-fluoro-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-(4-chloro-3-methoxyphenyl)-N-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1,6-dimethyl-1H-imidazo[4,5-c]pyridin-4-amine,
- 2-(4-chloro-3-methoxyphenyl)-N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1,6-dimethyl-1H-imidazo[4,5-c]pyridin-4-amine,
- 2-(4-chloro-3-methoxyphenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-(4-chloro-3-methoxyphenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-(1-methylethyl)-1H-benzimidazol-4-amine,
- 6-fluoro-N-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-(4-fluorophenyl)-1-(1-methylethyl)-1H-benzimidazol-4-amine,
- 2-(4-fluorophenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-3-methyl-3H-imidazo[4,5-b]pyridin-7-amine,
- 2-(4-fluorophenyl)-N-[6-methoxy-5-(3-methyl-1H-1,2,4-triazol-1-yl)-2-pyrridinyl]-1-(1-methylethyl)-1H-benzimidazol-4-amine,
- 2-(4-fluorophenyl)-N-[6-methoxy-5-(3-methyl-1H-1,2,4-triazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-(4-fluorophenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-3,5-dimethyl-3H-imidazo[4,5-b]pyridin-7-amine,
- 2-(4-fluorophenyl)-6-methoxy-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-(3-bromo-4-fluorophenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-[3-fluoro-5-(trifluoromethyl)phenyl]-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-(3,5-difluorophenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
- N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-2-[3-(trifluoromethyl)phenyl]-1H-benzimidazol-4-amine,
- N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-2-[4-(trifluoromethyl)phenyl]-1H-benzimidazol-4-amine,
- 2-(4-fluoro-3-iodophenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
- N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-2-[2-(trifluoromethoxy)phenyl]-1H-benzimidazol-4-amine,
- 2-(3-fluorophenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
- N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-2-[2-(trifluoromethyl)phenyl]-1H-benzimidazol-4-amine,
- 2-[3-(dimethylamino)phenyl]-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
- N-[3-[4-[[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]amino]-1-methyl-1H-benzimidazol-2-yl]phenyl]-acetamide,
- 2-(3,4-difluorophenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-(2,3-difluorophenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
- N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-2-(3-methoxyphenyl)-1-methyl-1H-benzimidazol-4-amine,
- N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-2-(4-methoxyphenyl)-1-methyl-1H-benzimidazol-4-amine,
- 2-(3-ethoxyphenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-(2-fluoro-5-methoxyphenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine .2HCl.H2O,
- 2-(2-fluoro-5-methoxyphenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
- N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-2-[3-(1-methylethoxy)phenyl]-1H-benzimidazol-4-amine,
- 2-(2-fluoro-4-methoxyphenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
- N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-2-[3-methoxy-5-(trifluoromethyl)phenyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-(4-fluoro-3-methoxyphenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-(4-fluoro-3-methoxyphenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine .2HCl .H2O,
- 2-(4-fluoro-2-methylphenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-(3,5-dimethoxyphenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-[2-fluoro-5-(trifluoromethyl)phenyl]-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-(3-fluoro-5-methoxyphenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
- N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-2-[3-(trifluoromethoxy)phenyl]-1H-benzimidazol-4-amine,
- 2-(2,4-difluorophenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
- N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-2-[4-(trifluoromethoxy)phenyl]-1H-benzimidazol-4-amine,
- 2-[4-fluoro-3-(trifluoromethyl)phenyl]-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-(2-fluorophenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
- N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-2-(4-methoxy-2-methylphenyl)-1-methyl-1H-benzimidazol-4-amine,
- N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-2-[2-methyl-5-(trifluoromethyl)phenyl]-1H-benzimidazol-4-amine,
- N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-2-phenyl-1H-benzimidazol-4-amine,
- 2-[4-(dimethylamino)phenyl]-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine, and
- 3-[4-[[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]amino]-1-methyl-1H-benzimidazol-2-yl]-benzonitrile,
including any stereochemically isomeric form thereof,
and the pharmaceutically acceptable addition salts and the solvates thereof. - In an embodiment the compound of Formula (I) is selected from the group comprising:
- N-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-(4-fluorophenyl)-1,6-dimethyl-1H-imidazo[4,5-c]pyridin-4-amine,
- N-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-(4-fluorophenyl)-1,6-dimethyl-1H-imidazo[4,5-c]pyridin-4-amine .2CH3SO3H,
- N-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-(4-fluorophenyl)-1,6-dimethyl-1H-imidazo[4,5-c]pyridin-4-amine .2HCl,
- 2-(4-fluorophenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-(4-fluorophenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine .2HCl,
- 2-(2,3-difluorophenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine .2HCl .H2O,
- 2-(2,3-difluorophenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-(4-fluoro-3-methoxyphenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine .2HCl .H2O,
- 2-(4-fluoro-3-methoxyphenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-(3,5-dimethoxyphenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine .2HCl .H2O, and
- 2-(3,5-dimethoxyphenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
- In an embodiment the compound of Formula (I) is selected from the group comprising:
- N-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-(4-fluorophenyl)-1,6-dimethyl-1H-imidazo[4,5-c]pyridin-4-amine,
- 2-(4-fluorophenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
- 2-(4-fluoro-3-methoxyphenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine .2HCl. H2O,
- 2-(2,3-difluorophenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine .2HCl. H2O, and
- 2-(3,5-dimethoxyphenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine .2HCl .H2O.
- In an embodiment the compound of Formula (I) is 2-(4-fluorophenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine, including the pharmaceutically acceptable addition salts and the solvates thereof.
- In an embodiment the compound of Formula (I) is 2-(4-fluorophenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine.
- In an embodiment the compound of Formula (I) is 2-(4-fluoro-3-methoxyphenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine .2HCl .H2O.
- In an embodiment the compound of Formula (I) is 2-(4-fluoro-3-methoxyphenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine, including the pharmaceutically acceptable addition salts and the solvates thereof.
- All possible combinations of the above-indicated interesting embodiments are considered to be embraced within the scope of this invention.
- The present invention also encompasses processes for the preparation of compounds of Formula (I) and subgroups thereof. In the reactions described, it can be necessary to protect reactive functional groups, for example hydroxy, amino, or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups can be used in accordance with standard practice, for example, see T. W. Greene and P. G. M. Wuts in "Protective Groups in Organic Chemistry", John Wiley and Sons, 1999.
- The compounds of Formula (I) and the subgroups thereof can be prepared by a succession of steps as described hereunder. They are generally prepared from starting materials which are either commercially available or prepared by standard means obvious to those skilled in the art. The compounds of the present invention can be also prepared using standard synthetic processes commonly used by those skilled in the art of organic chemistry.
- The general preparation of some typical examples is shown below:
-
- A compound of formula (I) can be prepared via a coupling reaction between an intermediate of formula (II-a) and an intermediate of formula (III-a), or via a coupling reaction between an intermediate of formula (II-b) and an intermediate of formula (III-b). In Scheme 1, halo is defined as Cl, Br or I. This reaction may be performed in the presence of a suitable base such as, for example, Cs2CO3 or sodium tert-butoxide. The reaction can be performed in a reaction-inert solvent such as, for example, toluene, N,N-dimethylformamide (DMF), 1,2-dimethoxyethane (DME), tert-butanol or dioxane. The reaction typically is performed in the presence of a catalyst system comprising of a suitable catalyst such as tris(dibenzylideneacetone)dipalladium (Pd2(dba)3), palladium(II) acetate (Pd(OAc)2) and a ligand such as (9,9-dimethyl-9H-xanthene-4,5-diyl)bis[diphenylphosphine] (Xantphos), [1,1'-binaphthalene]-2,2'-diylbis[diphenylphosphine] (BINAP), bis(2-diphenylphosphinophenyl)ether (DPEphos), or dicyclohexyl[2',4',6'-tris(1-methylethyl)[1,1'-biphenyl]-2-yl]-phosphine (X-phos). Preferably this reaction is carried out under an inert atmosphere, such as a nitrogen or an argon atmosphere. Reaction rate and yield may be enhanced by microwave assisted heating.
- Palladium traces present after work-up of the reaction can optionally be removed by treatment of a solution of the compound of formula (I) in a suitable solvent or in a mixture of solvents, such as, for example DCM and MeOH, with N-acetyl-L-cysteine or thiol-functionalized silica.
- In an alternative procedure, only valid when Y1 or Y3 is N in the definition of (III-a), a compound of formula (I) wherein Y1 or Y3 is N, can be prepared via an aromatic nucleophilic substitution between intermediates of formula (II-a) and (III-a). This reaction may be performed under basic or acidic conditions, e.g., in the presence of HCl or methanesulfonic acid in a reaction-inert solvent such as, for example, 2-propanol. Reaction rate and yield may be enhanced by microwave assisted heating.
- R3 groups containing suitable functional groups such as, for example, halo, (protected) amines, alcohols, or ketones, can be used to incorporate further substitution patterns in compounds of formula (I).
- An intermediate of formula (II-a) can be prepared by a reduction of an intermediate of formula (IV) as shown in Scheme 2 below, wherein all variables are as defined before. The reduction of (IV) to (II-a) can be conducted by a conventional method such as, for example, a reductive hydrogenation or reduction with a metal or a metal salt and an acid [for example a metal such as iron, or a metal salt such as SnCl2 and acid such as an inorganic acid (HCl, H2SO4 or the like) or an organic acid (acetic acid or the like)], or other well-known methods for converting a nitro-group to the corresponding amine.
- An intermediate of formula (II-a) can also be prepared by a copper catalysed reaction of an intermediate of formula (V) with a (un)substituted imidazole or triazole of formula (VI) according to Scheme 3, wherein halo is defined as Br or I and wherein all other variables are defined as mentioned hereabove. The reaction may be performed under a protecting atmosphere such as, for example, N2 atmosphere. Stirring, elevated temperatures (for example between 70-200 °C) and/or pressure may enhance the rate of the reaction. The reaction typically is performed in an organic solvent such as, for example, dimethylsulfoxide (DMSO) or dimethylformamide (DMF). Optionally, the reaction is performed in the presence of a base such as, for example K2CO3, Cs2CO3, or triethylamine (Et3N), and/or a ligand such as N,N'-dimethylethylenediamine or 1,10-phenanthroline. A copper catalyst such as copper salts, for example, copper(I)oxide, copper(I)iodide, or copper(I)bromide, can be used in catalytic or stoichiometric amounts. The amino-group in intermediate (V) can be protected before the reaction, and can be deprotected after reaction via the use of a suitable amino-protecting group in accordance with standard practice, for example, see T. W. Greene and P. G. M. Wuts in "Protective Groups in Organic Chemistry", John Wiley and Sons, 1999.
- An intermediate of formula (II-a) can also be prepared by conversion of the halo-substitutent in intermediate (II-b) into an amino-group or a masked amino functionality, which can subsequently be converted into an amino-group, according to Scheme 4. In Scheme 4, typical reaction conditions known to those skilled in the art can be used. In Scheme 4, halo is defined as Cl, Br or I, and all other variables are defined as mentioned hereabove.
- An intermediate of formula (IV) can be prepared via a nucleophilic aromatic substitution of an intermediate of formula (VII) with a (un)substituted imidazole or triazole of formula (VI) according to Scheme 5, wherein halo is defined as F, Cl, or Br and wherein all other variables are defined as mentioned hereabove. The reaction may be performed under a protecting atmosphere such as, for example, N2 atmosphere. Stirring, elevated temperatures (for example between 70-170 °C) and/or pressure may enhance the rate of the reaction. The reaction typically is performed in an organic solvent such as, for example, DMSO, DMF, or N-methylpyrrolidinone (NMP) in the presence of a base such as, for example K2CO3, Cs2CO3, or Et3N.
- An intermediate of formula (II-b) can be prepared from intermediate of formula (II-a) via a Sandmeyer reaction according to Scheme 6 by conversion of (II-a) into the corresponding diazonium salt followed by treatment with a reagent such as, for example, KI, CuBr, or CuCl. Typical reaction conditions known to those skilled in the art can be used in Scheme 6. All variables in Scheme 6 are defined as before.
- An intermediate of formula (II-b) wherein A1 and/or A3 are N, hereby named an intermediate of formula (II-b1), can be prepared via a nucleophilic aromatic substitution of an intermediate (VIII) wherein A1 and/or A3 are N, with a (un)substituted imidazole or triazole of formula (VI) according to Scheme 7, wherein LG is defined as F,Cl, Br, or NO2, wherein halo is defined as Br or I, and wherein all other variables are defined as hereinbefore. The reaction may be performed under similar conditions as described for experimental procedure 5.
- An intermediate of formula (II-b) wherein X represents CH, hereby named an intermediate of formula (II-b2), can also be prepared via acylation of intermediate (IX) to yield intermediate (X) in the presence of a reaction inert solvent, such as THF, and optionally a suitable base, such as Et3N, according to Scheme 8. An intermediate of formula (XII), can subsequently be prepared via alkylation of an intermediate of formula (X) with an intermediate of formula (XI), in the presence of a reaction inert solvent such as, for example, DMF, and a suitable base such as, for example, Cs2CO3 or K2CO3, and optionally in the presence of a catalytic amount of a iodide salt such as, for example, KI or NaI. A condensation reaction of intermediate (XII) with an ammonia source such as, for example, ammonium acetate (NH4OAc) subsequently yields a compound of formula (II-b2). In Scheme 8, halo is defined as Cl, Br, or I, halo2 is defined as Cl or Br, and all other variables are defined as mentioned hereinbefore.
- For the construction of the imidazole ring in an intermediate of formula (II-b2), the order of introduction of R2 and R1 can be reversed. This type of reaction is described in
US2006/0004013 for 1-(4-bromo-2-methoxyphenyl)-4-methyl-1H-Imidazole. - An intermediate of formula (III-a), wherein R3 is carbon-linked to the heterocycle, and wherein Z is N-R9, hereby named an intermediate of formula (III-a1), can be prepared by an acylation of an intermediate (XIII) with an intermediate of formula (XIV) followed by a condensation, according to Scheme 9. The acylation reaction can be carried out in a solvent such as, for example, pyridine or a reaction inert solvent such as, for example, DMF. The reaction may be performed in the presence of a base such as, for example, Et3N. The subsequent condensation reaction can be carried out by heating the crude acylated product in a solvent such as, for example, acetic acid. In Scheme 9, halo is defined as Cl, Br or I, and all other variables are defined as before.
- In a similar condensation procedure, intermediate (XIII) can be condensed to intermediate (III-a1) directly by using a carboxylic acid of formula R3-COOH. This reaction may be performed under dehydrating conditions such as, for example, heating in a solvent such as, for example, polyphosphoric acid.
- An intermediate of formula (III-a1), can also be prepared by treatment of an intermediate of formula (XIII) with an aldehyde of formula (XV). The reaction typically can be performed in the presence of a reducing agent such as, for example, sodium metabisulfite. The reaction typically may be performed in a reaction inert solvent such as, for example, N,N-dimethylacetamide (DMA), according to Scheme 10. In Scheme 10, halo is defined as Cl or Br and all other variables are defined as mentioned before.
- An intermediate of formula (III-a1), can also be prepared by treatment of an intermediate of formula (XVI) with an aldehyde of formula (XV). This reaction may be performed in the presence of a reducing agent such as, for example, sodium dithionite. The reaction typically can be performed in a reaction inert solvent such as, for example, ethanol. In Scheme 11, halo is defined as Cl or Br and all other variables are defined as mentioned hereinbefore.
- Alternatively, an intermediate of formula (III-a1) wherein R9 is different from H, hereby named an intermediate of formula (III-a2), can also be prepared from an intermediate of formula (IIIa1) wherein R9 is H, hereby named an intermediate of formula (III-a3). The group R9a can be introduced via N-alkylation, leading predominantly to an intermediate of formula (III-a2) wherein R9a is a substituent as defined before, except hydrogen, as described in Scheme 12.
- An intermediate of formula (XIII) can be prepared via reduction of an intermediate of formula (XVI) as is shown in Scheme 13, wherein halo is defined as Br or Cl, and wherein all other variables are as defined before. The reduction of (XVI) to (XIII) can be conducted by a conventional method such as, for example, a reductive hydrogenation or reduction with a metal or a metal salt and an acid [for example a metal such as iron, or a metal salt such as SnCl2 and acid such as an inorganic acid (hydrochloric acid, sulfuric acid or the like) or an organic acid (acetic acid or the like)], or other well-known methods for converting a nitro-group to the corresponding amine.
- An intermediate of formula (XVI) can be prepared via a substitution reaction of an intermediate of formula (XVII) with an amine of formula R9-NH2 as is shown in Scheme 14 below, wherein halo is defined as Br, I or Cl, wherein halo2 is defined as F, Cl or Br, and wherein all other variables are as defined before.
- An Intermediate of formula (III-b), wherein R3 is carbon-linked to the heterocycle and Z is N-R9, hereby named an intermediate of formula (III-b1), can be prepared as shown in Scheme 15. In a first step, acylation of intermediate (XVIII) with an activated carboxylic acid derivative such as, for example, a carboxylic acid chloride, yields intermediate (XIX) which can be condensed to a intermediate of formula (XX). Alternatively, a one step preparation of intermediate (XX) can also be performed via condensation of an intermediate of formula (XVIII) with a carboxylic acid of formula R9-COOH under dehydrating conditions, such as heating in a solvent such as, for example, polyphosphoric acid.
- Deprotonation of an intermediate of formula (XX) with a base such, for example, lithium hexamethyldisilazide, in a reaction-inert solvent such as, for example, toluene or (methyl)tetrahydrofuran, followed by treatment with an alkylating agent such as, for example, CH3I, leads to an intermediate of formula (XXI).
- Reduction of an intermediate of formula (XXI) via reductive hydrogenation, or treatment of (XXI) with a reducing agent such as, for example, iron in acetic acid, or other well-known methods for converting a nitro-group into the corresponding amine yields the required intermediate of formula (III-b1).
-
- Alternatively, an intermediates of formula (III-b1) can be prepared as set out below in Scheme 16. Deprotonation of an intermediate of formula (XXII) with a base such as, for example, lithium hexamethyldisilazide, typically in a reaction-inert solvent such as, for example, toluene or (methyl)tetrahydrofuran, followed by treatment with an alkylating agent such as, for example, CH3I, leads to an intermediate of formula (XXIII). Treatment of an intermediate of formula (XXIII) with a halogenating agent such as, for example, phosphoroxychloride (POCl3) gives an intermediate of formula (XXIV). This intermediate can be converted to an intermediate of formula (XXV) via reaction with amines, alcohols, thiols, or via Suzuki reactions with aryl- or alkyl-boronates. As in Scheme 15, reduction of an intermediate of formula (XXV) via reductive hydrogenation, or treatment of an intermediate of formula (XXV) with a reducing agent such as, for example, iron in acetic acid, or other known methods for converting a nitro-group into the corresponding amine, gives the required intermediate of formula (III-b1). In scheme 16, all variables are defined as mentioned before.
- An intermediate of formula (III-a1), can also be prepared as set out in Scheme 17. Condensation of an intermediate of formula (XIII) with urea, carbonyldiimidazole, phosgene or a phosgene equivalent such as e.g. diphosgene or triphosgene, gives an intermediate of formula (XXVI). Treatment of an intermediate of formula (XXVI) with a halogenating agent such as, for example, POCl3, gives an intermediate of formula (XXVII). An intermediate of formula (XXVII) can be converted to an intermediate of formula (III-a1) via reaction with amines, alcohols, thiols, or via Suzuki reactions with aryl- or alkyl-boronates. In scheme 17, halo is defined as Br, I or Cl, and all other variables are defined as mentioned before. All reaction steps in Scheme 17, can be performed by using typical reaction conditions known to those skilled in the art.
- Intermediates of formula (III-a), wherein R3 is restricted to C1-6alkylthio and wherein Z is N-R9, hereby named an intermediate of formula (III-a3), can be prepared as set out below in Scheme 18. Condensation of an intermediate of formula (XIII) with thiourea or 1,1'-thiocarbonyldiimidazole via heating in a reaction inert solvent, such as, for example THF, yields an intermediate of formula (XXVIII). Subsequently, an intermediate of formula (XXVIII) may be alkylated, for example by a C1-6alkyl-iodide, in the presence of a base such as, for example, K2CO3. This reaction step typically can be performed in a reaction inert solvent such as, for example, acetone, to give an intermediate of formula (III-a3). In Scheme 18, halo is defined as Br, I or Cl, R3a is defined as C1-6alkylthio, and all other substituents are defined as mentioned hereinbefore.
- Intermediates of formula (III-a), wherein R3 is carbon-linked to the heterocycle and , wherein Z is O, hereby named an intermediate of formula (III-a4), can be prepared as set out below in Scheme 19. Acylation of an intermediate of formula (XXIX) with an activated carboxylic acid derivative such as, for example, a carboxylic acid chloride with formula R3-COCl gives an intermediate of formula (XXX). Subsequently, an intermediate of formula (XXX) can be O-arylated to a benzoxazole intermediate of formula (III-a4). In scheme 19, halo is defined as Br, I or Cl, halo2 is defined as Cl, Br or I, and all other variables are as defined before.
- An intermediate of formula (III-b) can also be prepared by conversion of the halo-substitutent in an intermediate of formula (III-a), wherein halo is defined as Cl, Br or I, and wherein all other variables are defined as mentioned hereabove, into an amino-group or a masked amino functionality, which can subsequently be converted into an amino-group, according to Scheme 20. Typical well-known reaction conditions known to those skilled in the art can be used in Scheme 20.
- A compound of formula (I), wherein Z is N-R9, hereby named a compound of formula (I-a), can be prepared, starting from a coupling reaction between an intermediate of formula (XXVII) with an intermediate of formula (II-a) according to the conditions described under experimental procedure 1, to give an intermediate of formula (XXXI), followed by conversion of (XXXI) to a compound of formula (I-a) via reaction with amines, alcohols, thiols, or via Suzuki reactions with aryl- or alkyl-boronates. This last reaction in Scheme 21, can be performed by using typical reaction conditions known to those skilled in the art.
- A compound of formula (I), wherein R3 is carbon-linked to the heterocycle, and wherein Z is N-R9, hereby named a compound of formula (I-b), can be prepared, starting from a coupling reaction between an intermediate of formula (XVI) with an intermediate of formula (II-a) according to the conditions described under experimental procedure 1, to give an intermediate of formula (XXXII). The intermediate of formula (XXXII) can either be directly converted into a compound of formula (I-b) according to the conditions described under experimental procedure 11, or (XXXII) can first be reduced to an intermediate of formula (XXXIII) according to the conditions described under experimental procedure 13, followed by the conversion of (XXXIII) to a compound of formula (I-b) according to the conditions described under experimental procedure 10.
- Intermediates of formula (V), (VI), (VII), (VIII), (IX), (XI), (XIV), (XV), (XVII), (XXII) and formula (XXIX) are commercially available or can be easily prepared by those skilled in the art.
- Where necessary or desired, any one or more of the following further steps in any order may be performed :
- Intermediates of formula (III-a) or (III-b) and compounds of formula (I), any subgroup thereof, addition salts; solvates, and stereochemical isomeric forms thereof can be converted into further intermediates and compounds according to the invention using procedures known in the art.
- In order to obtain the HCl salt forms of the compounds, several procedures known to those skilled in the art can be used. In a typical procedure, for example, the free base can be dissolved in DIPE or Et2O and subsequently, a 6 N HCl solution in 2-propanol or a 1 N HCl solution in Et2O can be added dropwise. The mixture typically is stirred for 10 minutes after which the product can be filtered off. The HCl salt usually is dried in vacuo.
- It will be appreciated by those skilled in the art that in the processes described above the functional groups of intermediate compounds may need to be blocked by protecting groups. In case the functional groups of intermediate compounds were blocked by protecting groups, they can be deprotected after a reaction step.
- It has been found that the compounds of the present invention modulate the γ-secretase activity. The compounds according to the invention and the pharmaceutically acceptable compositions thereof are therefore useful in the treatment or prevention of Alzheimer's disease (AD), traumatic brain injury, mild cognitive impairment (MCI), senility, dementia, dementia with Lewy bodies, cerebral amyloid angiopathy, multi-infarct dementia, Down's syndrome, dementia associated with Parkinson's disease and dementia associated with beta-amyloid, preferably Alzheimer's disease.
- As used herein, the term "modulation of γ-secretase activity" refers to an effect on the processing of APP by the γ-secretase-complex. Preferably it refers to an effect in which the overall rate of processing of APP remains essentially as without the application of said compounds, but in which the relative quantities of the processed products are changed, more preferably in such a way that the amount of the Aß42-peptide produced is reduced. For example a different Abeta species can be produced (e.g. Abeta-38 or other Abeta peptide species of shorter amino acid sequence instead of Abeta-42) or the relative quantities of the products are different (e.g. the ratio of Abeta-40 to Abeta-42 is changed, preferably increased).
- It has been previously shown that the γ-secretase complex is also involved in the processing of the Notch-protein. Notch is a signaling protein which plays a crucial role in developmental processes (e.g. reviewed in Schweisguth F (2004) Curr. Biol. 14, R129). With respect to the use of γ-secretase modulators in therapy, it seems particularly advantageous not to interfere with the Notch-processing activity of the γ-secretase activity in order to avoid putative undesired side-effects. While γ-secretase inhibitors show side effects due to concomitant inhibition of Notch processing, γ-secretase modulators may have the advantage of selectively decreasing the production of highly aggregatable and neurotoxic forms of Aβ, i.e. Aβ42, without decreasing the production of smaller, less aggregatable forms of Aβ, i.e. Aβ38 and without concomitant inhibition of Notch processing. Thus, compounds are preferred which do not show an effect on the Notch-processing activity of the γ-secretase-complex.
- As used herein, the term "treatment" is intended to refer to all processes, wherein there may be a slowing, interrupting, arresting, or stopping of the progression of a disease, but does not necessarily indicate a total elimination of all symptoms.
- The invention relates to a compound according to the general Formula (I), the stereoisomeric forms thereof and the pharmaceutically acceptable acid or base addition salts and the solvates thereof, for use as a medicament.
- The invention also relates to a compound according to the general Formula (I), the stereoisomeric forms thereof and the pharmaceutically acceptable acid or base addition salts and the solvates thereof, for the treatment or prevention of diseases or conditions selected from Alzheimer's disease, traumatic brain injury, mild cognitive impairment, senility, dementia, dementia with Lewy bodies, cerebral amyloid angiopathy, multi-infarct dementia, or Down's syndrome.
- The invention also relates to a compound according to the general Formula (I), the stereoisomeric forms thereof and the pharmaceutically acceptable acid or base addition salts and the solvates thereof, for the treatment or prevention of diseases or conditions selected from AD, MCI, senility, dementia, dementia with Lewy bodies, cerebral amyloid angiopathy, multi-infarct dementia, or Down's syndrome.
- In an embodiment, said disease or condition is preferably Alzheimer's disease.
- The invention also relates to a compound according to the general Formula (I), the stereoisomeric forms thereof and the pharmaceutically acceptable acid or base addition salts and the solvates thereof, for use in treating said diseases.
The invention also relates to a compound according to the general formula (I), the stereoisomeric forms thereof and the pharmaceutically acceptable acid or base addition salts and the solvates thereof, for use in the treatment or prevention, in particular treatment, of γ-secretase mediated diseases or conditions. - The invention also relates to the use of a compound according to the general Formula (I), the stereoisomeric forms thereof and the pharmaceutically acceptable acid or base addition salts and the solvates thereof, for the manufacture of a medicament.
- The invention also relates to the use of a compound according to the general Formula (I), the stereoisomeric forms thereof and the pharmaceutically acceptable acid or base addition salts and the solvates thereof, for the manufacture of a medicament for the modulation of γ-secretase activity.
- The invention also relates to the use of a compound according to the general Formula (I), the stereoisomeric forms thereof and the pharmaceutically acceptable acid or base addition salts and the solvates thereof, for the manufacture of a medicament for the treatment or prevention of any one of the disease conditions mentioned hereinbefore.
- The invention also relates to the use of a compound according to the general Formula (I), the stereoisomeric forms thereof and the pharmaceutically acceptable acid or base addition salts and the solvates thereof, for the manufacture of a medicament for the treatment of any one of the disease conditions mentioned hereinbefore.
- In the invention, particular preference is given to compounds of Formula (I), or any subgroup thereof with a IC50 value for the inhibition of the production of Aß42-peptide of less than 1000 nM, preferably less than 100 nM, more preferably less than 50 nM, even more preferably less than 20 nM as determined by a suitable assay, such as the assays used in the Examples below.
- The compounds of the present invention can be administered to mammals, preferably humans for the treatment or prevention of any one of the diseases mentioned hereinbefore.
- In view of the utility of the compound of Formula (I), there is provided a method of treating warm-blooded animals, including humans, suffering from or a method of preventing warm-blooded animals, including humans, to suffer from any one of the diseases mentioned hereinbefore.
- Said methods comprise the administration, i.e. the systemic or topical administration, preferably oral administration, of an effective amount of a compound of Formula (I), a stereoisomeric form thereof and a pharmaceutically acceptable addition salt or solvate thereof, to warm-blooded animals, including humans.
- Those of skill in the treatment of such diseases could determine the effective therapeutic daily amount from the test results presented hereinafter. An effective therapeutic daily amount would be from about 0.005 mg/kg to 50 mg/kg, in particular 0.01 mg/kg to 50 mg/kg body weight, more in particular from 0.01 mg/kg to 25 mg/kg body weight, preferably from about 0.01 mg/kg to about 15 mg/kg, more preferably from about 0.01 mg/kg to about 10 mg/kg, even more preferably from about 0.01 mg/kg to about 1 mg/kg, most preferably from about 0.05 mg/kg to about 1 mg/kg body weight. The amount of a compound according to the present invention, also referred to here as the active ingredient, which is required to achieve a therapeutically effect will of course, vary on case-by-case basis, for example with the particular compound, the route of administration, the age and condition of the recipient, and the particular disorder or disease being treated.
- A method of treatment may also include administering the active ingredient on a regimen of between one and four intakes per day. In these methods of treatment the compounds according to the invention are preferably formulated prior to administration. As described herein below, suitable pharmaceutical formulations are prepared by known procedures using well known and readily available ingredients.
- The compounds of the present invention, that are suitable to treat or prevent Alzheimer's disease or the symptoms thereof, may be administered alone or in combination with one or more additional therapeutic agents. Combination therapy includes administration of a single pharmaceutical dosage formulation which contains a compound of Formula (I) and one or more additional therapeutic agents, as well as administration of the compound of Formula (I) and each additional therapeutic agents in its own separate pharmaceutical dosage formulation. For example, a compound of Formula (I) and a therapeutic agent may be administered to the patient together in a single oral dosage composition such as a tablet or capsule, or each agent may be administered in separate oral dosage formulations.
- While it is possible for the active ingredient to be administered alone, it is preferable to present it as a pharmaceutical composition.
- Accordingly, the present invention further provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound according to Formula (I).
- The carrier or diluent must be "acceptable" in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipients thereof.
- For ease of administration, the subject compounds may be formulated into various pharmaceutical forms for administration purposes. The compounds according to the invention, in particular the compounds according to Formula (I), a pharmaceutically acceptable acid or base addition salt thereof, a stereo chemically isomeric form thereof, or any subgroup or combination thereof may be formulated into various pharmaceutical forms for administration purposes. As appropriate compositions there may be cited all compositions usually employed for systemically administering drugs.
- To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, optionally in addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirable in unitary dosage form suitable, in particular, for administration orally, rectally, percutaneously, by parenteral injection or by inhalation. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable solutions containing compounds of Formula (I) may be formulated in an oil for prolonged action. Appropriate oils for this purpose are, for example, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, synthetic glycerol esters of long chain fatty acids and mixtures of these and other oils. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. Also included are solid form preparations that are intended to be converted, shortly before use, to liquid form preparations. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment. Acid or base addition salts of compounds of Formula (I) due to their increased water solubility over the corresponding base or acid form, are more suitable in the preparation of aqueous compositions.
- It is especially advantageous to formulate the aforementioned pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such unit dosage forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, suppositories, injectable solutions or suspensions and the like, and segregated multiples thereof
- Since the compounds according to the invention are potent orally administrable compounds, pharmaceutical compositions comprising said compounds for administration orally are especially advantageous.
- In order to enhance the solubility and/or the stability of the compounds of Formula (I) in pharmaceutical compositions, it can be advantageous to employ α-, β- or γ-cyclodextrins or their derivatives, in particular hydroxyalkyl substituted cyclodextrins, e.g. 2-hydroxypropyl-β-cyclodextrin or sulfobutyl-β-cyclodextrin. Also co-solvents such as alcohols may improve the solubility and/or the stability of the compounds according to the invention in pharmaceutical compositions.
- Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 % by weight, more preferably from 0.1 to 70 % by weight, even more preferably from 0.1 to 50 % by weight of the compound of formula (I), and, from 1 to 99.95 % by weight, more preferably from 30 to 99.9 % by weight, even more preferably from 50 to 99.9 % by weight of a pharmaceutically acceptable carrier, all percentages being based on the total weight of the composition.
- The following examples illustrate the present invention.
- Hereinafter, the term "DCM" means dichloromethane; "MeOH" means methanol; "LCMS" means Liquid Chromatography/Mass spectrometry; "HPLC" means high-performance liquid chromatography; "sol." means solution; "sat." means saturated; "aq." means aqueous; "r.t." means room temperature; "AcOH" means acetic acid; "m.p." means melting point; "RP" means reversed phase; "BDS" means base deactivated silica; "min" means minute(s); "h" means hour(s); "I.D." means internal diameter; "EtOAc" means ethyl acetate; "Et3N" means triethylamine; "BINAP" means [1,1'-binaphthalene]-2,2'-diylbis[diphenylphosphine] (racemic); "EtOH" means ethanol; "eq" means equivalent; "r.m." means reaction mixture(s); "DIPE" means diisopropyl ether; "q.s." quantum sufficit; "DMA" means N,N-dimethylacetamide; "NMP" means N-methyl-2-pyrrolidinone; "TFA" means trifluoroacetic acid; "THF" means tetrahydrofuran; "DMSO" means dimethyl sulfoxide; "mCPBA" means 3-chlorobenzenecarboperoxoic acid; "DMF" means N,N-dimethyl formamide; "LiHMDS" means lithium hexamethyldisilazane; "X-Phos" means dicyclohexyl[2',4',6'-tris(1-methylethyl)[1,1'-biphenyl]-2-yl]phosphine; "DCE" means 1 ,2-dichloroethane; "HBTU" means 1-[bis(dimethylamino)methylene]-1H-benzotriazol-1-ium 3-oxide hexafluorophosphate; "Pd(PPh3)4" means tetrakis(triphenylphosphine)palladium, "Pd(OAc)2" means palladium(2+) diacetate; "PdCl2(PPh3)2" means dichlorobis(triphenylphosphine)palladium; and "Pd2(dba)3" means tris[µ-[(1,2-η:4,5-η)-(1E,4E)-1,5-diphenyl-1,4-pentadien-3-one]]dipalladium.
-
- A mixture of 1-chloro-2-methoxy-4-nitrobenzene (50 g, 0.26 mol), 4-methyl-1H-imidazole (43.77 g, 0.53 mol) and K2CO3 (36.84 g, 0.26 mol) in DMSO (500 ml) was reacted in an autoclave under N2 atmosphere for 6 h at 150 °C. This reaction was repeated twice with 50 g of 1-chloro-2-methoxy-4-nitrobenzene each. Subsequently, the 3 r.m. (150 g of 1-chloro-2-methoxy-4-nitrobenzene in total) were worked up together. The mixture was poured out into 6 1 of ice-water. The solid was filtered off and washed with H2O. The solid was dissolved in DCM and this sol. was washed with H2O. The separated organic layer was dried (MgSO4), filtered and the solvent was evaporated. The residue was purified over silica gel on a glass filter (eluent: DCM/MeOH from 100/0 to 97/3). The product fractions were collected and the solvent was evaporated. The residue was suspended in DIPE, filtered off and dried in the oven. Yield: 48.54 g of intermediate 1 (26 %).
-
- Intermediate 1 (13.2 g, 56.6 mmol) was dissolved in MeOH (250 ml). Pd/C (0.5 g) was added to the sol. and the resulting suspension was stirred overnight at 50 °C under H2 (atmospheric pressure). After uptake of H2 (1 eq, the catalyst was filtered off. The organic layer was evaporated, yielding intermediate 2a (free base). Intermediate 2a was dissolved in a sol. of HCl/EtOH and stirred for 30 min. The solvent was removed in vacuo. The residue was crystallized from EtOH with a small amount of petroleum ether to yield the desired product. Yield: 4.7 g of intermediate 2 (41 %).
-
- A mixture of 1-fluoro-2-methoxy-4-nitrobenzene (821 mg, 4.8 mmol), 5-methyl-1H-1,2,4-triazole (800 mg, 9.63 mmol), K2CO3 (4.8 mmol) and DMSO (8 ml) was stirred at 120 °C for 1 h. After cooling, the r.m. was poured into ice water. The solid was filtered off, washed with water and dried in vacuo at 50 °C. Yield: 0.554 g of intermediate 3 (49 %). The aq. layer was saturated with NaCl, extracted with DCM and the organic layer was dried (MgSO4), filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: DCM). The desired fraction was collected and the solvent was evaporated. Yield: 0.147 g of intermediate 4 (13 %).
-
- MeOH (50 ml) was added to Pd/C 10 % (150 mg) under N2 atmosphere. Subsequently, a 0.4 % thiophene sol. in DIPE (1 ml) and intermediate 3 (550 mg, 2.348 mmol) were added. The r.m. was stirred at 25°C under H2 atmosphere until 3 eq of H2 was absorbed. The catalyst was filtered off over diatomaceous earth. The filtrate was evaporated and the residue was suspended in DIPE, filtered off and dried in vacuo. Yield: 0.350 g of intermediate 5 (73 %).
-
- A mixture of 3,4-difluoro-nitrobenzene (15.7 g, 96.7 mmol), 5-methyl-1H-1,2,4-triazole (9.94 g, 116 mmol), K2CO3 (20 g, 145 mmol) and DMF (150 ml) was stirred at 75 °C for 2 h. After cooling, the r.m. was poured into ice water. The precipitate was filtered off, and washed with water. The resulting solid was recrystallized from H2O/MeOH to yield intermediate 6 as a monohydrate solid (yield: 9.2 g, 43 %), and a mother liquor. The mother liquor was concentrated in vacuo to yield 3.1 g of a residue containing 44 % of intermediate 6 and 55 % of intermediate 7.
-
- MeOH (150 ml) was added to Pd/C 10 % (2 g) under N2 atmosphere. Subsequently, a 0.4 % thiophene sol. in DIPE (1 ml) and intermediate 6 (9.1 g, 37.9 mmol) were added. The r.m. was stirred at 50 °C under H2 atmosphere until 3 eq of H2 was absorbed. The catalyst was filtered off over diatomaceous earth and the filtrate was evaporated. The residue was partitioned between DCM and H2O. The combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. Yield: 7.23 g of intermediate 8 (99 %).
-
- MeOH (150 ml) was added to Pd/C 10 % (1 g) under N2 atmosphere. Subsequently, a 0.4 % thiophene sol. in DIPE (0.5 ml) and a mixture of intermediate 6 and intermediate 7 in a 4/5 ratio (3.1 g, 12.9 mmol) were added. The r.m. was stirred at 50 °C under H2 atmosphere until 3 eq of H2 was absorbed. The catalyst was filtered off over diatomaceous earth and the filtrate was evaporated. The residue was purified by RP preparative HPLC [RP Shandon Hyperprep® C18 BDS (8 µm, 250 g, I.D. 5 cm); mobile phase: a gradient of (0.25 % NH4HCO3 sol. in water)/MeOH]. The product fractions were collected and worked up. Yield: 1.2 g of intermediate 9 (48 %).
-
- A 8 M methylamine sol. in EtOH (100 ml, 0.8 mol) was added to 1-bromo-3-fluoro-2-nitro-benzene (19.8 g, 90 mmol), cooled on a water bath. The r.m. was stirred at r.t. overnight. Then, the solvent was evaporated and the residue was partitioned between water and DCM. The combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. Yield: 20 g of intermediate 10 (96 %), which was used as such in the next reaction step.
-
- Intermediate 10 (20 g, 86.6 mmol) and iron powder (15 g, 269 mmol) were added to AcOH (150 ml), and the resulting suspension was stirred and heated at 60 °C for 1 h. The r.m. was concentrated in vacuo and the residue was partitioned between DCM and a sat. aq. NaHCO3 sol. The organic layer was dried (MgSO4), filtered and concentrated in vacuo. Yield: 14 g of intermediate 11 (80 %), which was used as such in the next reaction step.
-
- Et3N (8.1 g, 80 mmol) was added to a sol. of intermediate 11 (10 g, 39.8 mmol) in DCM (250 ml). Then 4-fluoro-benzoylchloride (5.5 g, 34.7 mmol) was added dropwise at r.t., and the r.m. was stirred at r.t. overnight. The r.m. was washed with water, and the organic layer was dried (MgSO4), filtered and concentrated in vacuo. The residue was dissolved in AcOH (100 ml), and a concentrated aq. HCl sol. (3 ml) was added. The r.m. was stirred at 100 °C for 2 h. The r.m. was concentrated in vacuo and the residue was dissolved in DCM and washed with a saturated aq. NaHCO3 sol. and water. The organic layer was dried (MgSO4), filtered and concentrated in vacuo. Yield: 12 g of intermediate 12, which was used as such in the next reaction step.
-
- A mixture of intermediate 11 (3 g, 14.9 mmol) and urea (1 g, 17.9 mmol) in THF (30 ml) was stirred at 60 °C for 3 h. Subsequently, the r.m. was concentrated in vacuo and the residue was purified by flash chromatography over silica gel (eluent: DCM/MeOH from 99.5/0.5 to 99/1). The desired fraction was collected and the solvent was evaporated. Yield: 3.4 g of intermediate 13 (100 %).
-
- POCl3 (27.9 ml, 299 mmol) was added slowly to intermediate 13 (3.4 g, 14.9 mmol) while cooling on ice and stirring. Then the r.m. was heated at 100 °C for 3 h. The r.m. was concentrated in vacuo. Yield: 3.1 g of crude intermediate 14, which was used as such in the next reaction step.
-
- A mixture of intermediate 14 (800 mg), NaOH (391 mg, 9.78 mmol), and 4,4-difluoropiperidine, HCl salt (616 mg, 3.91 mmol) in THF (10 ml) was heated at 150 °C under microwave irradiation for 4 h. The r.m. was cooled to r.t., and a sat. aq. NH4Cl sol. was added. The mixture was extracted with DCM. The organic layers were dried (Na2SO4), filtered and concentrated in vacuo. The residue was purified by flash chromatography over silica gel (eluent: EtOAc/heptane from 10/90 to 50/50). The desired fraction was collected and the solvent was evaporated. Yield: 0.2 g of
-
- A mixture of intermediate 14 (1 g), NaOH (489 mg, 12.2 mmol), and phenol (460 mg, 4.89 mmol) in THF (10 ml) was heated at 110°C under microwave irradiation for 4 h. The r.m. was cooled to r.t., and a saturated aq. NH4Cl sol. was added. The mixture was extracted with DCM. The organic layers were dried (Na2SO4), filtered and concentrated in vacuo. The residue was purified by flash chromatography over silica gel (eluent: EtOAc/heptane from 10/90.5 to 50/50). The desired fraction was collected and the solvent was evaporated. Yield: 0.2 g of intermediate 16.
-
- A mixture of intermediate 11 (1 g, 4.97 mmol) and 1.1'-thiocarbonyldiimidazole (1.15 g, 6.47 mmol) in THF (20 ml) was heated at 125 °C under microwave irradiation for 1.5 h. The r.m. was cooled to r.t., and the solvent was evaporated. The residue was dissolved in acetone (30 ml), and 1-iodo-2-methyl-propane (1.83 g, 9.95 mmol), and K2CO3 (1.37 g, 9.95 mmol) were added. The r.m. was heated at 100 °C under microwave irradiation for 0.5 h. The r.m. was cooled and partitioned between DCM and water. The organic layer was dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by flash chromatography over silica gel (eluent: DCM). The desired fraction was collected and the solvent was evaporated. Yield: 0.6 g of intermediate 17 (33 %).
-
- Isopropylamine (12.9 g, 218 mmol) was added to a sol. of 1-bromo-3-fluoro-2-nitro-benzene (8.0 g, 36 mmol) in EtOH (40 ml). The r.m. was stirred at r.t. overnight. Then, the solvent was evaporated and the residue was partitioned between water and DCM. The combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. Yield: 8.3 g of intermediate 18 (88 %), which was used as such in the next reaction step.
-
- Intermediate 18 (8.3 g, 32 mmol) and iron powder (8.95 g, 160 mmol) were added to AcOH (50 ml), and the resulting suspension was stirred and heated at 60 °C for 1 h. The r.m. was concentrated in vacuo and the residue was partitioned between DCM and a saturated aq. NaHCO3 sol. The organic layer was dried (MgSO4) filtered and concentrated in vacuo. Yield: 7.5 g of intermediate 19 (100 %), which was used as such in the next reaction step.
-
- 4-Fluoro-benzaldehyde (2.28 g, 18.3 mmol) and Na2S2O5 (3.73 g, 19.6 mmol) were added to a sol. of intermediate 19 (3 g, 13.1 mmol) in DMA (50 ml). The r.m. was stirred at r.t. overnight. Then, the r.m. was poured into water, which resulted in the precipitation of a solid. The solid was filtered off, washed with water, and suspended in DIPE. The resulting solid was filtered off, washed with DIPE, and dried. Yield: 2.3 g of intermediate 20 (53 %).
-
- Et3N (2.02 g, 20 mmol) and 4-fluoro-benzoylchloride (1.58 g, 10 mmol) were added to a sol. of 3-nitro-benzene-1,2-diamine (1.53 g, 10 mmol)) in DCM (50 ml) and CH3CN (25 ml), and the r.m. was stirred at r.t. for 2 h. The r.m. was diluted with DCM and washed with water. The organic layer was dried (MgSO4), filtered and concentrated in vacuo. The residue was suspended in DIPE, and the resulting solid was filtered off and dried in vacuo. Yield: 2.3 g of intermediate 21 (84 %).
-
- Intermediate 21 (1.35 g, 4.9 mmol) and a concentrated aq. HCl sol. (0.5 ml) were added to AcOH (15 ml), and the resulting mixture was stirred and heated at 150 °C for 0.5 h under microwave irradiation. The r.m. was cooled to r.t., resulting in the formation of a precipitate. The precipitate was filtered off, washed with AcOH, followed by DIPE, and then dried in vacuo. Yield: 1 g of intermediate 22 (69 %).
-
- To a sol. of intermediate 22 (290 mg, 0.99 mmol) in THF (10 ml) was added a 1 M sol. of LiHMDS in THF (2.96 ml, 2.96 mmol) dropwise at 0 °C under a N2 atmosphere. The r.m. was stirred at 0 °C for 30 min, and then CH31 (210 mg, 1.48 mmol) was added. The r.m. was stirred overnight at 55 °C. The mixture was cooled, then washed with brine, and the organic phase was separated, dried (MgSO4), filtered and the solvent was evaporated in vacuo. The residue was suspended in DIPE. The resulting solid was filtered off, washed with DIPE, and dried. Yield: 160 mg of intermediate 23 (60 %).
-
- Intermediate 23 (150 mg, 0.55 mmol) and iron powder (162 mg, 2.9 mmol) were added to AcOH (10 ml), and the resulting suspension was stirred and heated at 60 °C for 1 h. The r.m. was concentrated in vacuo and the residue was partitioned between DCM and a saturated aq. NaHCO3 sol. The organic layer was dried (MgSO4), filtered and concentrated in vacuo. Yield: 120 mg of intermediate 24 (90 %), which was used as such in the next reaction step.
-
- Starting from 3-nitro-benzene-1,2-diamine and 2,4-difluoro-benzoylchloride, intermediate 46 was prepared according to the procedures as described in example A9.
-
- A stainless steel autoclave was loaded with intermediate 12 (370 mg, 1.21 mmol), copper(I)oxide (10 mg), and a 0.5 M sol. of NH3 in dioxane (30 ml, 15 mmol). The autoclave was closed and the r.m. was heated at 150 °C for 18 h. Then, the r.m. was cooled, a sat. aq. NH4OH sol. (5 ml) was added, and the r.m. was heated at 150 °C for another 18 h The r.m. was cooled and concentrated in vacuo. The residue was partitioned between DCM and a saturated aq. NH4Cl sol. The organic layer was dried (MgSO4), filtered and concentrated in vacuo. Yield: 240 mg of intermediate 24 (82 %), which was used as such in the next reaction step.
-
- A 1 M sol. of LiHMDS in THF (4.94 ml, 4.94 mmol) was added dropwise at 0 °C under a N2 atmosphere to a sol. of intermediate 22 (290 mg, 0.99 mmol) in THF (15 ml). The r.m. was stirred at 0 °C for 30 min, and then 2-iodopropane (1.68 g, 9.9 mmol) was added. The r.m. was stirred overnight at 55 °C. The r.m. was transferred to a microwave vial, and additional amounts of a 1 M sol. of LiHMDS in THF (2 ml, 2 mmol) and 2-iodopropane (0.84 g, 5 mmol)was added. The r.m was stirred and heated at 150 °C for 4 h under microwave irradiation. The mixture was cooled, then washed with brine, and the organic phase was separated, dried (MgSO4), filtered and the solvent was evaporated in vacuo. The residue was purified by RP preparative HPLC [RP Shandon Hyperprep® C18 BDS (8 µm, 250 g, I.D. 5 cm); mobile phase: a gradient of (0.25 % NH4HCO3 sol. in water)/CH3CN]. The product fractions were collected and worked up. Yield: 50 mg of intermediate 25 (17 %).
-
- Intermediate 25 (50 mg, 0.167 mmol) and iron powder (49 mg, 0.88 mmol) were added to AcOH (4 ml), and the resulting suspension was stirred and heated at 60 °C for 1 h. The r.m. was concentrated in vacuo and the residue was partitioned between DCM and a sat. aq. NaHCO3 sol. The organic layer was dried (MgSO4), filtered and concentrated in vacuo. Yield: 40 mg of intermediate 26 (89 %), which was used as such in the next reaction step.
-
- 4-Bromo-2-chloropyrimidine (5 g, 25.8 mmol), 4-methyl-1H-imidazole (4.25 g, 51.7 mmol) and K2CO3 (10.72 g, 77.5 mmol) in NMP (100 ml) were heated overnight at 85°C. The mixture was separated between DCM and water. The organic layer was dried (MgSO4), filtered and the solvent was evaporated. Water was added to the residue and the resulting precipitate was collected by filtration and dried in vacuo. Yield 4.7 g of intermediate 27 (76 %).
-
- 2-Methyl-2-propanol, sodium salt (1.69 g, 17.6 mmol), BINAP (195 mg, 0.314 mmol), Pd2(dba)3 (287 mg, 0.31 mmol), intermediate 27 (3 g, 12.5 mmol) and benzophenone imine (2.27 g, 12.5 mmol) in toluene (40 ml; previously deoxygenated) were stirred and heated for 4 h at 120 °C. The mixture was separated between DCM and water. The organic phase was separated, dried (MgSO4), filtered and the solvent was evaporated in vacuo. Yield: 3.4 g of crude intermediate 28.
-
- A 1 N aq. HCl sol. (11 ml, 11 mmol) was added to a sol. of intermediate 28 (3.4 g, 4.1 mmol) in THF (10 ml). The r.m. was stirred at r.t. for 2 h. The solvent was evaporated in vacuo and the residue was separated between DCM and water, basified with an aq. NH4OH sol. till pH 10. The organic phase was separated, dried (MgSO4), filtered and the solvent was evaporated in vacuo. The product was purified by flash column chromatography over silica gel (eluent: DCM/MeOH from 98/2 to 95/5). The product fractions were collected and the solvent was evaporated. Yield: 0.36 g of intermediate 29 (16 % yield over 2 steps).
-
- Cul (8.25 g, 43 mmol) was added under a N2 flow to a sol. of 5-bromo-pyridin-2-ylamine (5 g, 28.9 mmol), 4-methyl-1H-imidazole (5.9 g, 72 mmol), and Cs2CO3 (9.4 g, 28.9 mmol) in DMSO (100 ml). The reaction mixture was heated for 2 nights at 130 °C and was then cooled. CH3CN was added to form a blue precipitate which was removed by filtration. The filtrate was concentrated under reduced pressure, and the residue was separated between DCM and water. The organic phase was separated, dried (MgSO4), filtered and the solvent was evaporated in vacuo. The residue was purified by flash column chromatography over silica gel (eluent: DCM/MeOH from 98/2 to 95/5). The product fractions were collected and the solvent was evaporated. Yield: 0.628 g of intermediate 30. The aq. layer was concentrated under reduced pressure, until some additional product precipitated, which was filtered off, and dried in vacuo, to give 0.16 g of intermediate 30.
-
- Cul (2.64 g, 13.9 mmol) was added under a N2 flow to a sol. of 2-bromo-pyridin-5-ylamine (6 g, 34.7 mmol), 5-methyl-1H-1,2,4-triazole (4.03 g, 48.5 mmol), and CS2CO3 (22.6 g, 69.4 mmol) in DMF (50 ml). The reaction mixture was heated for 2 nights at 120 °C and was then cooled and concentrated in vacuo. The residue was partitioned between DCM and water. The aq. phase was saturated with NaCl and extracted further with DCM and MeOH. The combined organic layers were dried (MgSO4), filtered and the solvent was evaporated in vacuo. The residue was purified by RP preparative HPLC [RP Shandon Hyperprep® C18 BDS (8 µm, 250 g, I.D. 5 cm); mobile phase: a gradient of (0.25 % NH4HCO3 sol. in water)/MeOH/CH3CN]. The product fractions were collected and worked up. Yield: 1150 mg of intermediate 32 (19 %) and 1500 mg of intermediate 31 (25 %).
-
- MeOH (100 ml) was added to Pt/C 5 % (1 g) under N2 atmosphere. Subsequently, a 0.4 % thiophene sol. in DIPE (2 ml) and 4-amino-2-bromo-3-nitro-pyridine (3.5 g, 16 mmol) were added. The r.m. was stirred at 25 °C under H2 atmosphere until 3 eq of H2 was absorbed. The catalyst was filtered off over diatomaceous earth and the filtrate was concentrated in vacuo. Yield: 1.8 g of intermediate 33 (63 %), which was used as such in the next reaction step.
-
- A mixture of intermediate 33 (1.8 g, 9.57 mmol) and 4-fluoro-benzoic acid (1.34 g, 9.57 mmol) in polyphosphoric acid (25 g) was stirred and heated for 1 h at 180 °C. The r.m. was cooled to r.t, and water was added. The resulting sol. was neutralized with K2CO3, and the resulting precipitate was filtered off and washed with water. Yield: 1 g of crude intermediate 34, which was used as such in the next reaction step.
-
- Intermediate 34 (825 mg, 2.8 mmol), CH3I (400 mg, 2.8 mmol), and K2CO3 (830 mg, 6 mmol) were added to DMF (25 ml). The resulting mixture was stirred for 1 h at 50 °C. The r.m. was cooled to r.t. and concentrated in vacuo. The residue was partitioned between DCM and water. The organic layer was dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by RP preparative HPLC [RP Shandon Hyperprep® C18 BDS (8 µm, 250 g, I.D. 5 cm); mobile phase: a gradient of (0.25 % NH4HCO3 sol. in water)/MeOH]. The product fractions were collected and worked up. Yield: 180 mg of intermediate 35 (21 %).
-
- Et3N (0.78 ml, 5.7 mmol) was added to a sol. of 2,4-dichloro-3-nitropyridine (cas 5975-12-2) (1 g, 5.2 mmol) in DMF (10 mL) at 0°C. Then, isopropylamine (0.444 ml, 5.2 mmol) was added, and the r.m. was stirred for 5 min. The r.m. was diluted with EtOAc and the resulting mixture was washed with water and brine. The organic layer was dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel (eluent: DCM/MeOH from 100/0 to 99/1). The product fractions were collected and the solvent was evaporated. Yield: 1.1 g of intermediate 36 (98 %).
-
- 4-Fluorobenzaldehyde (589 mg, 4.74 mmol) and Na2S2O4 (3.0 g, 17.2 mmol) were added to a sol. of intermediate 36 (930 mg, 4.31 mmol) in EtOH (15 ml). The r.m. was heated under microwave conditions for 45 min at 160 °C. The r.m. was cooled to r.t. and filtered through diatomaceous earth. The filtrate was evaporated and the residue was purified by flash column chromatography over silica gel (eluent: DCM/MeOH from 100/0 to 96/4). The product fractions were collected and the solvent was evaporated. Yield: 450 mg of intermediate 37 (36 %).
-
- Na2S2O5 (1.64 g, 8.62 mmol) and 4-fluoro-benzaldehyde (891 mg, 7.18 mmol) were added to a sol. of 3-bromo-5-trifluoromethyl-1,2-diaminobenzene (1.65 g, 6.47 mmol) in DMA (40 ml). The r.m. was stirred overnight at 70 °C. Then, the r.m. was cooled to r.t. and poured into water. The solid was filtered off, washed with water, and suspended in DIPE and drops of 2-propanol. The resulting solid was filtered off, washed with DIPE, and dried. Yield: 1.95 g of intermediate 38 (84 %).
-
- A 1 M sol. of LiHMDS in THF (9.2 ml, 9.2 mmol) was added dropwise at r.t. under a N2 atmosphere to a sol. of intermediate 38 (1.65 g, 4.6 mmol) in THF (50 ml). The r.m. was stirred at r.t. for 30 min, and then CH3I (3.26 g, 23 mmol) was added. The r.m. was stirred at r.t. for 1 h and then washed with a sat. aq. NaHCO3 sol. and brine. The organic phase was separated, dried (MgSO4), filtered and the solvent was evaporated in vacuo. The residue was purified by RP preparative HPLC [RP Shandon Hyperprep® C18 BDS (8 µm, 250 g, I.D. 5 cm); mobile phase: a gradient of (0.25 % NH4HCO3 sol. in water)/MeOH/CH3CN]. The product fractions were collected and worked up. Yield: 720 mg of intermediate 39 (42 %).
-
- 4-(2-Oxo-ethyl)-piperidine-1-carboxylic acid tert-butyl ester (682 mg, 3 mmol) and Na2S2O5 (741 mg, 3.9 mmol) were added to a sol. of intermediate 11 (603 mg, 3 mmol) in DMA (15 ml). The r.m. was stirred overnight at r.t. Then, water was added and the mixture was extracted with EtOAc. The combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel (eluent: DCM/MeOH from 100/0 to 98/2). The product fractions were collected and the solvent was evaporated. Yield: 840 mg of intermediate 40, which was used as such in the next reaction step.
-
- A mixture of formic acid (12.8 ml, 340 mmol) and acetic acid anhydride (8.54 ml, (91 mmol) was stirred at r.t. for 40 min. Subsequently, a soL of 3-amino-6-bromo-2-methoxy-pyridine (5 g, 24.6 mmol) in THF (30 ml) was added dropwise and the resulting r.m. was stirred overnight at 60 °C. The r.m. was cooled and poured into ice-water, resulting in the precipitation of a solid. The solid was filtered off, washed with water, and dried. Yield: 5.2 g of intermediate 42 (76 %).
-
- 1-Chloro-propan-2-one (4.34 g, 46.9 mmol) was added dropwise to a mixture of intermediate 42 (5.2 g, 18.8 mmol), potassium iodide (0.343 g, 2.06 mmol), CS2CO3 (21.4 g, 65.9 mmol) in DMF (50 ml). The r.m. was stirred at r.t. overnight. The r.m. was poured into ice-water and extracted with EtOAc. The combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. The residue was suspended in DIPE and the resulting solid was filtered off, washed with DIPE, and dried. Yield: 4.43 g of intermediate 43 (82 %).
-
- Intermediate 43 (4.4 g, 15.3 mmol) was added to a mixture of ammonium acetate (5.41 g, 70.2 mmol) in AcOH (10 ml). The r.m. was heated at reflux for 1 h. The r.m. was cooled to r.t. and poured into a mixture of ice-water and EtOAc. The mixture was basified with a 50 % w/v (weight/volume percentage solution) aq. NaOH sol. to pH 9: The organic layer was separated, dried (MgSO4), filtered and concentrated in vacuo. The resulting solid product was used as such in the next step. Yield: 3.78 g of crude
-
- 2-Methyl-2-propanol, sodium salt (0.717 g, 7.46 mmol), BINAP (464 mg, 0.75 mmol), Pd2(dba)3 (342 mg, 0.37 mmol), intermediate 44 (1.0 g, 3.73 mmol) and benzophenone imine (0.845 g, 4.66 mmol) in toluene (20 ml; previously deoxygenated) were stirred and heated at 100 °C for 2 h under microwave conditions. The mixture was cooled, and the solvent removed in vacuo. THF (50 ml) and a 1 N aq. HCl sol. (50 ml) were added to the residue, and the mixture was stirred at r.t: for 1 h. The r.m. was basified with a 10 % aq. Na2CO3 sol. and extracted with EtOAc. The organic layers were dried (MgSO4), filtered and the solvent was evaporated in vacuo. The product was purified by flash column chromatography over silica gel (eluent: DCM/MeOH from 100/0 to 95/5). The product fractions were collected and the solvent was evaporated. Yield: 0.6 g of intermediate 45 (52 % yield over 2 reaction steps).
- In an alternative procedure, Cu2O (320 mg, 2.24 mmol) and a 7 N NH3 solution in MeOH (48 ml, 336 mmol) were added to a solution of intermediate 44 (6 g, 22.4 mmol) in ethylene glycol (50 ml). The r.m. was heated in a closed pressure vessel at 100 °C for 12 h. After cooling to r.t., the mixture was diluted with water, and extracted with EtOAc. The organic layer was dried (MgSO4), filtered and the solvent was evaporated in vacuo. The residue was triturated with DIPE. Yield: 4 g of intermediate 45 (87%).
-
- 2-Chlorobenzoylchloride (1.46 g, 8.37 mmol) was added at r.t. to a sol. of 2,6-dibromoaniline (2.0 g, 7.97 mmol) in THF (24 ml). The r.m. was stirred at r.t. overnight. The mixture was diluted with EtOAc (30 ml) and the organic phase was washed with a sat. aq. NaHCO3 sol., dried (MgSO4), filtered and the solvent was evaporated. The residue was triturated in DIPE, filtered off, extensively washed with DIPE and dried in vacuo. Yield: 1.08 g of intermediate 46 (35 %).
-
- A mixture of intermediate 46 (0.5 g, 1.28 mmol), CuI (0.025 g, 0.13 mmol), CS2CO3 (0.63 g, 1.93 mmol), 1,10-phenantroline (0.046 g, 0.257 mmol) in DME (10 ml) was stirred at 90 °C in a sealed tube for 3 days. The mixture was diluted with H2O (10 ml) and DCM (50 ml). The separated organic phase was dried (MgSO4), filtered and the solvent was evaporated in vacuo. The residue was purified by flash column chromatography over silica gel (eluent: heptanes/DCM isocratic 1/2). The product fractions were collected and evaporated off. Yield: 0.18 g of intermediate 47 (46 %).
-
- Cyclohexanecarboxylic acid chloride (0.61 g, 4.18 mmol) was added at r.t. to a sol. of 2,6-dibromoaniline (1.0 g, 3.98 mmol) in THF (12 ml). The r.m. was stirred at r.t. for 4 days. The mixture was diluted with EtOAc (30 ml) and the organic phase was washed with a saturated aq. NaHCO3 sol., dried (MgSO4), filtered and the solvent was evaporated. The residue was triturated in DIPE, filtered off, extensively washed with DIPE and dried in vacuo. Yield: 0.62 g of intermediate 48 (43 %).
-
- A mixture of intermediate 48 (0.15 g, 0.41 mmol), CuI (0.008 g, 0.04 mmol), CS2CO3 (0.203 g, 0.62 mmol) and 1,10-phenantroline (0.015 g, 0.08 mmol) in DME (2 ml) was stirred overnight at 90 °C in a sealed tube. The mixture was diluted with H2O (2 ml) and DCM (2 ml). The separated organic phase was passed through Extrelut® and the filtrate was evaporated in vacuo. The residue was purified by flash column chromatography over silica gel (eluent: heptane/DCM 30/70). The product fractions were collected and the solvent was evaporated. Yield: 0.095 g of intermediate 49 (77 %).
-
- SOCl2 (1.38 ml, 19.0 mmol) was added to a sol. of isopentanoic acid (1.87 g, 18.2 mmol) and pyridine (1.48 ml, 18.3 mmol) in DCM (15 ml) and the r.m. was stirred at r.t. for 2 h. A sol. of 2,6-dibromoaniline (0.92 g, 3.5 mmol) in DCM (5 ml) was added and the r.m. was stirred at r.t. for 2 days. Up to 5 extra equivalents of acyl chloride were prepared and added to the r.m. which was further stirred overnight. The mixture was diluted with DCM (20 ml) and the organic phase was washed with a 1 M HCl sol., then a saturated aq. NaHCO3 sol., dried (MgSO4), filtered and the solvent was evaporated. The crude product was recrystallized from DIPE/CH3CN. Yield: 0.21 g of intermediate 50 (17 %).
-
- A mixture of intermediate 50 (0.21 g, 0.63 mmol), CuI (0.012 g, 0.063 mmol), Cs2CO3 (0.306 g, 0.94 mmol) and 1,10-phenantroline (0.023 g, 0.125 mmol) in DME (3 ml) was stirred overnight at 90 °C in a sealed tube. The mixture was diluted with H2O (20 ml) and DCM (20 ml). The separated organic phase was passed through Extrelut® and the filtrate was evaporated in vacuo. The residue was purified by flash column chromatography over silica gel (eluent: heptane/DCM 30/70). The product fractions were collected and evaporated off. Yield: 0.110 g of intermediate 51 (69 %).
-
- Benzylamine (17 g, 159 mmol) was added to a sol. of 1-bromo-3-fluoro-2-nitro-benzene (10 g, 45.5 mmol) in THF (100 ml). The r.m. was stirred at r.t. overnight. The formed precipitate was removed by filtration and the filtrate was concentrated under reduced pressure. The residue was dissolved in DCM and the resulting sol. was washed subsequently with an aq. AcOH sol., a saturated aq. NaHCO3 sol., and water. The organic layer was dried (MgSO4), filtered and concentrated in vacuo. The crude residue was dissolved in AcOH (100mL) and iron powder (7.62 g, 136 mmol) was added. The resulting suspension was stirred and heated at 60 °C for 1 h. The r.m. was concentrated in vacuo and the residue was partitioned between DCM and a saturated aq. NaHCO3 sol. The organic layer was dried (MgSO4), filtered and concentrated in vacuo. Yield: 6.5 g of intermediate 53 (80 % purity according to LC-MS analysis), which was used as such in the next reaction step.
-
- Et3N (1.21 g, 12 mmol) and 2-methyl-benzoylchloride (923 mg, 5.97 mmol) were added to a sol. of intermediate 53 (2.07 g, 5.97 mmol) in DCM (50 ml), and the r.m. was stirred at r.t. overnight. The r.m. was diluted with DCM and washed with water. The organic layer was dried (MgSO4), filtered and concentrated in vacuo. The residue was dissolved in AcOH (25 ml) and a concentrated aq. HCl sol. (0.5 ml) was added. The resulting mixture was stirred and heated at 100 °C for 18 h. The r.m. was cooled and concentrated in vacuo. The residue was partitioned between DCM and a saturated aq. NaHCO3 sol. The organic layer was washed with water, dried (MgSO4), filtered and concentrated in vacuo. Yield: 2.2 g of intermediate 54 (98 %) which was used as such in the next reaction step.
-
- Na2S2O5 (5.56 g, 29.2 mmol) and 4-fluoro-benzaldehyde (2.91 g, 23.4 mmol) were added to a sol. of 3-bromo-5-fluoro-1,2-diaminobenzene (4.0 g, 19.5 mmol) in DMA (80 ml). The r.m. was stirred overnight at 70 °C. Then, the r.m. was cooled to r.t. and poured into water. The solid was filtered off, washed with water, and dried. Yield: 6 g of intermediate 55.
-
- A suspension ofNaH (60 % in mineral oil; 233 mg, 5.82 mmol) was added under a N2 atmosphere to a cooled (5 °C) sol. of intermediate 55 (900 mg, 2.91 mmol) in THF (5 ml). The r.m. was stirred at 5 °C for 30 min, and then isopropyliodide (1.98 g, 11.6 mmol) was added. The r.m. was stirred at 130 °C for 2 h under microwave irradiation. The r.m. was cooled, more THF (q.s.) was added and the mixture was washed with brine. The organic phase was separated, dried (MgSO4), filtered and the solvent was evaporated. The residue was purified by flash column chromatography over silica gel (eluent: heptane/DCM 50/50 to 0/100). The product fractions were collected and the solvent was evaporated. Yield: 350 mg of intermediate 56 (34 %).
-
- N-Iodosuccinimide (26.7 g, 119 mmol) and TFA (2.5 ml, 32.4 mmol) were added to a suspension of 2,4-dichloro-pyridin-3-ylamine (17.6 g, 108 mmol) in CH3CN (150 ml). The reaction mixture was stirred at r.t. for 16 h., and then heated to 40 °C for 6 h. The r.m. was diluted with EtOAc and washed with a sat. aq. Na2S2O3 sol. The aq. phase was extracted with EtOAc, and the combined organic layers were dried (MgSO4), filtered and the solvent was evaporated in vacuo. The residue was purified by flash column chromatography over silica gel (eluent: DCM). The product fractions were collected and the solvent was evaporated. Yield: 22 g of intermediate 57 (71 %).
-
- A sol. of methylamine in THF (2 M, 25 ml, 50 mmol) was added to a sol. of intermediate 57 (4.8 g, 16.6 mmol) in EtOH (20 ml). The r.m. was stirred at 160°C under microwave irradiation for 8 h. Then, the solvent was evaporated and the residue was partitioned between aq. NaHCO3 sol. and DCM. The combined organic layers were dried (Na2SO4), filtered and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel (eluent: heptane/DCM 100/0 to 0/100). The product fractions were collected and the solvent was evaporated. Yield: 950 mg of intermediate 58 (20 %) and 2900 mg of intermediate 59 (62 %).
-
- Et3N (3.61 ml, 26.5 mmol) and 4-fluoro-benzoylchloride (1.68 g, 10.6 mmol) were added to a sol. of intermediate 59 (2.5 g, 8.8 mmol) in DCM (100 ml), and the r.m. was stirred at r.t. for 4 h. The r.m. was concentrated in vacuo. Yield: 2.7 g of crude intermediate 60 (75 %), which was used as such in the next reaction step.
-
- POCl3 (907 mg, 5.9 mmol) was added to a sol. of intermediate 60 (2.0 g, 4.93 mmol) in DCE (15 ml), and the resulting mixture was stirred and heated at 150 °C for 15 min under microwave irradiation. The r.m. was concentrated in vacuo, and the residue was purified by flash column chromatography over silica gel (eluent: DCM/MeOH(NH3) from 100/0 to 97/3). The product fractions were collected and the solvent was evaporated. Yield: 1.56 g of intermediate 61 (81 %).
-
- Isopropenylboronic acid pinacol ester (867 mg, 5.16 mmol) and Pd(PPh3)4 (298 mg, 0.258 mmol) were added to a sol. of intermediate 61 (2.0 g, 5.16 mmol) in dioxane (8 ml) and an aq. NaHCO3 sol. (4 ml). The r.m. was stirred and heated at 160 °C for 10 min. under microwave irradiation. The r.m. was cooled to r.t. and filtered over diatomaceous earth using EtOAc. The filtrate was evaporated. The residue was purified by flash column chromatography over silica gel (eluent: DCM/MeOH(NH3) from 100/0 to 97/3). The product fractions were collected and the solvent was evaporated. Yield: 1.25 g of intermediate 62 (80 %).
-
- MeOH (40 ml) was added to Pt/C 5 % (100 mg) under N2 atmosphere. Subsequently, intermediate 62 (1.25 g, 4.14 mmol) was added. The r.m. was stirred at 25 °C under H2 atmosphere until 1 eq of H2 was absorbed. The catalyst was filtered off over diatomaceous earth and the filtrate was evaporated. Yield: 0.9 g of crude intermediate 63 (71 %), which was used as such in the next reaction step.
-
- Methylboronic acid (93 mg, 1.55 mmol) and Pd(PPh3)4 (71 mg, 0.062 mmol) were added to a sol. of intermediate 61 (600 mg, 0.31 mmol) in dioxane (10 ml) and an aq. NaHCO3 sol. (5 ml). The resulting mixture was stirred and heated at 150 °C for 20 min. under microwave irradiation. The r.m. was cooled to r.t. and partitioned between water and DCM. The organic phase was separated, dried (MgSO4), filtered and the solvent was evaporated in vacuo. Yield: 180 mg ofcrude intermediate 64 which was used as such in the next reaction step.
-
- Zn(CN)2 (36 mg, 0.31 mmol) and Pd(PPh3)4 (30 mg, 0.026 mmol) were added to a sol. of intermediate 61 (200 mg, 0.52 mmol) in DMF (5 ml). The resulting mixture was stirred and heated at 160 °C for 10 min. under microwave irradiation. The r.m. was cooled to r.t. and filtered through diatomaceous earth. The filtrate was concentrated in vacuo and the residue was purified by flash column chromatography over silica gel (eluent: DCM/MeOH(NH3) 100/0 to 97/3). The product fractions were collected and the solvent was evaporated. Yield: 0.14 g of intermediate 74 (95 %).
-
- A mixture of intermediate 61 (200 mg, 0.52 mmol), 4,7-dimethoxy-[1,10]phenanthroline (25 mg, 0.1 mmol), and CS2CO3 (336 mg, 1 mmol) in MeOH (1 ml) was degassed and stirred at 110 °C for 1 h under microwave irradiation. The r.m. was cooled to r.t. and concentrated in vacuo. The residue was partitioned between DCM and water. The organic phase was separated, dried (MgSO4), filtered and the solvent was evaporated in vacuo. The residue was triturated with DIPE. Yield: 100 mg of intermediate 75 (66 %).
-
- THF (40 ml) was added to Pd/C 10 % (0.1 g) under N2 atmosphere. Subsequently, a 0.4 % thiophene sol. in DIPE (1 ml) and intermediate 61 (800 mg, 2.06 mmol) were added. The r.m. was stirred at r.t. under H2 atmosphere until 1 eq of H2 was absorbed. The catalyst was filtered off over diatomaceous earth. The filtrate was evaporated and the residue was used as such in the next step. Yield: 0.45 g of intermediate 76 (83 %).
-
- 4-Fluorobenzaldehyde (1.11 g, 8.93 mmol) and Na2S2O4 (3.89 g, 22.3 mmol) were added to a sol. of 2-chloro-N-6-dimethyl-3-nitro-pyridin-4-amine (1.5 g, 7.44 mmol) in EtOH (15 ml). The r.m. was heated under microwave conditions for 1 h at 160 °C. The r.m. was cooled to r.t. and filtered through diatomaceous earth using EtOAc. This was repeated thrice. The combined filtrates were evaporated and the residue was purified by RP preparative HPLC [RP Vydec Denali C18 (10 µm, 250 g, I.D. 5 cm); mobile phase: a gradient of (0.25 % NH4HCO3 sol. in water)/CH3CN]. The product fractions were collected and worked up. Yield: 1.95 g of intermediate 65 (32 %).
-
- Et3N (1.87 ml, 13.8 mmol) and 4-fluoro-benzoylchloride (873 mg, 5.5 mmol) were added to a sol. of intermediate 58 (1.3 g, 4.6 mmol) in DCM (80 ml, and the r.m. was stirred at r.t. for 4 h. The r.m. was concentrated in vacuo. Yield: 1.5 g of crude intermediate 66 (81 %), which was used as such in the next reaction step.
-
- POCl3 (121 mg, 0.79 mmol) was added to a sol. of intermediate 66 (267 mg, 0.66 mmol) in DCE (2 ml), and the resulting mixture was stirred and heated at 150 °C for 15 min under microwave irradiation. The r.m. was concentrated in vacuo, and the residue was purified by flash column chromatography over silica gel (eluent: DCM/MeOH(NH3) from 100/0 to 97/3). The product fractions were collected and the solvent was evaporated. Yield: 215 mg of intermediate 67 (84 %).
-
- Isopropenylboronic acid pinacol ester (434 mg, 2.58 mmol) and Pd(PPh3)4 (149 mg, 0.129 mmol) was added to a sol. of intermediate 67 (1.0 g, 2.58 mmol) in dioxane (8 ml) and an aq. NaHCO3 sol. (4ml), and the resulting mixture was stirred and heated at 160 °C for 10 min. under microwave irradiation. The r.m. was cooled to r.t. and filtered over diatomaceous earth using EtOAc, and the filtrate was evaporated. The residue was purified by flash column chromatography over silica gel (eluent: DCM/MeOH(NH3) from 100/0 to 97/3). The product fractions were collected and the solvent was evaporated. Yield: 0.72 g of intermediate 68 (92 %).
-
- MeOH (40 ml) was added to Pt/C 5 % (100 mg) under N2 atmosphere. Subsequently, intermediate 68 (0.75 g, 2.49 mmol) was added. The r.m. was stirred at 25 °C under H2 atmosphere until 1 eq of H2 was absorbed. The catalyst was filtered off over diatomaceous earth and the filtrate was evaporated. Yield: 0.55 g of crude intermediate 69 (73 %), which was used as such in the next reaction step.
-
- Cyclopropylboronic acid (86 mg, 1.0 mmol) and Pd(PPh3)4 (78 mg, 0.067 mmol) was added to a sol. of intermediate 67 (260 mg, 0.67 mmol) in dioxane (6 ml) and an aq. NaHCO3 soL (3ml), and the resulting mixture was stirred and heated at 160 °C for 10 min. under microwave irradiation. The r.m. was cooled to r.t. and filtered over diatomaceous earth using EtOAc, and the filtrate was evaporated. The residue was purified by flash column chromatography over silica gel (eluent: DCM/MeOH(NH3) from 100/0 to 97/3). The product fractions were collected and the solvent was evaporated. Yield: 0.15 g of intermediate 77 (74 %).
-
- 4-Methyl-1H-imidazole (37.2 g, 0.452 mol) and K2CO3 (62.5 g, 0.452 mol) were added to a sol. of 3,4-difluoro-nitrobenzene (60 g, 0.377 mol) in DMF (800 ml). The r.m. was heated at 125 °C for 4 h. The mixture was cooled and poured into ice-water. The solid was filtered off, washed (H2O) and dried. Yield: 60.2 g of intermediate 70 (72 %).
-
- MeOH (250 ml) was added to Pd/C 10 % (5 g) under N2 atmosphere. Subsequently, a 0.4 % thiophene sol. in DIPE (1 ml) and intermediate 71 (60.2 g, 272 mmol) were added. The r.m. was stirred at 50 °C under H2 atmosphere until 3 eq of H2 was absorbed. The catalyst was filtered off over diatomaceous earth. The filtrate was evaporated and the residue was purified by flash column chromatography over silica gel (eluent: DCM/MeOH(NH3) from 100/0 to 95/5). The product fractions were collected and the solvent was evaporated. Yield: 36.5 g of intermediate 71 (70 %).
-
- Et3N (2.65 ml, 19 mmol), and 3-amino-4-methylamino-2-chloropyridine (1500 mg, 9.52 mmol) were added to a sol. of HBTU (4.51 g, 11.9 mmol) and 4-chloro-3-methoxy-benzoic acid (1776 mg, 9.52 mmol) in DMF (30ml). The r.m. was stirred at 70 °C for 16 h. The r.m. was diluted with DCM, and the mixture was washed with a sat. aq. Na2CO3.sol. and water. Yield: 1.8 g of crude intermediate 72 (58 %), which was used as such in the next reaction step.
-
- POCl3 (1.05 ml, 11.5 mmol) was added to a sol. of intermediate 72 (1.7 g, 5.2 mmol) in DCE (16 ml). The r.m. was stirred and heated at 150 °C for 35 min. under microwave irradiation. The r.m. was diluted with DCM and washed with a sat. aq. NaHCO3 sol. The organic phase was dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel (eluent: DCM/MeOH 100/0 to 90/10). The product fractions were collected and the solvent was evaporated. The residue was triturated with DIPE, then dissolved in DCM, and washed with a CS2CO3 sol. The organic phase was dried (MgSO4), filtered and concentrated in vacuo. Yield: 400 mg of intermediate 73 (25 %).
-
- MeOH (150 ml) was added to Pt/C 5 % (1 g) under N2 atmosphere. Subsequently, a 0.4 % thiophene sol. in DIPE (2 ml) and 2-bromo-4-methoxy-6-nitroaniline (5 g, 20.2 mmol) were added. The r.m. was stirred at 25 °C under H2 atmosphere until 3 eq of H2 was absorbed. The catalyst was filtered off over diatomaceous earth and the filtrate was concentrated in vacuo. Yield: 4.33 g of intermediate 78 (99 %), which was used as such in the next reaction step.
-
- 4-Fluoro-benzaldehyde (1.17 ml, 11.1 mmol) and Na2S2O5 (2.63 g, 13.8 mmol) were added to a sol. of intermediate 78 (2 g, 9.2 mmol) in DMA (40 ml). The r.m. was stirred at 90 °C overnight. Then, the r.m. was poured into water, resulting in the precipitation of a solid. The solid was filtered off, washed with water, and suspended in DIPE. The resulting solid was filtered off, washed with DIPE, and dried. Yield: 2.9 g of intermediate 79 (98 %).
-
- A suspension of 60% NaH in mineral oil (486 mg, 12.1 mmol) was added under a N2 atmosphere to a sol. of intermediate 79 (2.6 g, 8.1 mmol) in DMF (15 ml) at 5 °C. The r.m. was stirred at 5 °C for 30 min, and then CH3I (1.26 ml, 20.2 mmol) was added. The r.m. was stirred at r.t. for 3 h., and partitioned between EtOAc and water. The organic phase was separated, dried (MgSO4), filtered and the solvent was evaporated in vacuo. The residue was purified by flash column chromatography over silica gel (eluent: DCM/MeOH 100/0 to 99/1). The product fractions were collected and the solvent was evaporated. Yield: 1.25 g of intermediate 80 (46 %).
-
- Concentrated HNO3 (12.5 ml) was added to a sol. of 3,5-dibromo-pyridine N-oxide (4.5 g, 17.8 mmol) in concentrated H2SO4 (16 ml). The r.m. was refluxed for 4 h, then cooled and poured onto ice-water. The precipitate was collected by filtration and dried. Yield: 3.1 g of intermediate 81 (58 %), which was used as such in the next step.
-
- A 2 M sol. of methylamine in THF (7.15 ml, 14.3 mmol) was added to a mixture of intermediate 81 (2.66 g, 8.9 mmol) in THF (100 ml). The r.m. was stirred at 60 °C for 2 days and was then concentrated in vacuo. The residue was partitioned between DCM and an aq. NaHCO3 sol. The organic phase was separated, dried (Na2SO4), filtered and the solvent was evaporated in vacuo. The residue was purified by flash column chromatography over silica gel (eluent: heptane/DCM/MeOH(NH3) 100/0/0 to 0/100/0 to 0/70/30). The product fractions were collected and the solvent was evaporated. Yield: 1.2 g of intermediate 82 (54 %; N-oxide).
-
- 4-Fluorobenzaldehyde (252 mg, 2.0 mmol) and Na2S2O4 (1.18 g, 6.8 mmol) were added to a sol. of intermediate 82 (420 mg, 1.7 mmol) in EtOH (6 ml). The r.m. was heated under microwave conditions at 160 °C for 45 min. The r.m. was cooled to r.t. and diluted with EtOAc. The mixture was washed with an aq. NaHCO3 sol. and brine. The organic phase was separated, dried (MgSO4), filtered and the solvent was evaporated in vacuo. The residue was purified by flash column chromatography over silica gel (eluent: DCM/MeOH(NH3) 100/0 to 97/3). The product fractions were collected and the solvent was evaporated. Yield: 0.35 g of intermediate 83 (68 %).
-
- CuI (1.71 g, 8.9 mmol) and N,N'-dimethylethylenediamine (1.91 ml, 17.92 mmol) were added to a mixture of 2-amino-5-iodopyridine (5.03 g, 22.4 mmol), 3-methyl-1H-1,2,4-triazole (2.42 g, 29.1 mmol), and Cs2CO3 (14.60 g, 44.81 mmol) in DMF (40 ml). The r.m. was heated at 110 °C for 7 h., the r.m. was cooled, EtOAc was added and the mixure was washed with water. The water layer was extracted 5 times with EtOAc. The combined organic layers were dried (MgSO4), filtered and the solvent was evaporated in vacuo. The residue was purified by RP preparative HPLC [RP Shandon Hyperprep® C18 BDS (8 µm, 250 g, I.D. 5 cm); mobile phase: a gradient of (0.25 % NH4HCO3 solution in water)/MeOH/CH3CN]. The product fractions were collected and the solvent was evaporated. Yield: 1.5 g of intermediate 84 (38 %).
-
- Intermediate 84 (3.3 g, 18.8 mmol) was dissolved in THF (20 ml), Et3N (13.1 ml, 94.2 mmol) and acetic anhydride (17.8 ml, 188.4 mmol) were added. The r.m. was stirred at 65 °C for 18 h. The r.m. was cooled to r.t. and concentrated in vacuo. The residue was suspended in DIPE. The resulting solid was filtered off, washed with DIPE, and dried. Yield: 3.25 g of intermediate 85 (79 %).
-
- Intermediate 85 (10 g, 46.0 mmol) was dissolved in DCM (500 ml) and mCPBA (14.75 g, 59.84 mmol) was added. The r.m. was stirred at r.t. for 18 h. DCM and a sol. of 10 % NaHCO3 in water was added. The organic phase was separated, and washed twice with a solution of 10 % NaHCO3 in water. The combined water layers were extracted 10 x with DCM. The combined organic layers were dried (MgSO4), filtered and the solvent was evaporated in vacuo. Yield: 10.1 g of intermediate 86 (94 %; N-oxide).
-
- Intermediate 86 (10.1 g, 43.3 mmol) was dissolved in acetic anhydride (307 ml, 3.25 mol). The r.m. was stirred at 80°C for 2 h. The r.m. was cooled to r.t. and concentrated in vacuo. The residue was suspended in DIPE. The resulting solid was filtered off. Yield: 10.5 g of crude intermediate 87, which was used as such in the next step.
-
- Intermediate 87 (2.5 g, 9.1 mmol) and K2CO3 (1.26 g, 9.1 mmol) were added to MeOH (30 ml). The r.m. was stirred at r.t. for 1 h. The residue was directly purified (without evaporation of the solvent) by flash column chromatography over silica gel (eluent: DCM/MeOH from 100/0 to 90/10). The product fractions were collected and the solvent was evaporated in vacuo. The residue was suspended in DIPE. The solid was filtered off, washed with DIPE, and dried. Yield: 1 g of intermediate 88 (47 %).
-
- Intermediate 88 (1 g, 4.28 mmol), CH3I (0.4 ml, 6.43 mmol), and Ag2CO3 (1.18 g, 4.29 mmol) were added to DMF (50 ml). The resulting mixture was stirred at 60°C for 4 h. The r.m. was cooled to r.t., and filtered through diatomaceous earth and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel (eluent: DCM/EtOAc from 100/0 to 0/100). The product fractions were collected and the solvent was evaporated. Yield: 450 mg of intermediate 89 (42 %).
-
- Intermediate 89 (1.1 g, 4.45 mmol) was dissolved in MeOH (120 ml) and NaOH 10 % in water (30 ml) was added. The r.m. was stirred at 80 °C for 3 h. The r.m. was cooled to r.t. and concentrated in vacuo. The residue was partitioned between DCM and water. The organic layer was dried (MgSO4), filtered and concentrated in vacuo. Yield: 870 mg of intermediate 90 (95 %).
-
- Intermediate 14 (14 g, 40.75 mmol) was partitioned between DCM and an aq. NH4OH solution. The organic layer was dried (MgSO4), filtered and concentrated in vacuo. The residue was dissolved in 2-methyl-2-propanol (750 ml), and intermediate 45 (8.32 g, 40.75 mmol), Pd2(dba)3 (3.73 g, 4.08 mmol), X-Phos (5.83 g, 12.2 mmol) and Cs2CO3 (40 g, 122 mmol) were added. The r.m. was purged with N2, and subsequently heated at reflux for 16 h. The hot mixture was filtered, and the filtrate was concentrated in vacuo. The residue was suspended in DCM, and the resulting mixture filtered over diatomaceous earth. The filtrate was washed with a dilute aq. NaHCO3 sol., followed by water. The organic layer was dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel (eluent: DCM/MeOH(NH3) from 100/0 to 97/3). The product fractions were collected and the solvent was evaporated. The residue was triturated with a mixture of DIPE and 2-propanol. Yield: 4.5 g of intermediate 91 (30 %).
-
- Intermediate 45 (2.02 g, 9.9 mmol), Pd2(dba)3 (635 mg, 0.7 mmol), X-Phos (992 mg, 2.08 mmol) and Cs2CO3 (9.7 g, 29.7 mmol) were added to a sol. of intermediate 10 (2.29 g, 9.9 mmol) in 2-methyl-2-propanol (100 ml) under a N2 atmosphere. The r.m. was purged with N2, and subsequently heated at reflux for 16 h. The hot mixture was filtered, and the filtrate was concentrated in vacuo. The residue was partitioned between DCM and a diluted aq. NaHCO3 solution, followed by water. The organic layer was dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel (eluent: DCM/MeOH(NH3) from 100/0 to 97/3). The product fractions were collected and the solvent was evaporated. Yield: 1.3 g of intermediate 92 (37 %).
-
- A mixture of intermediate 92 (354 mg, 1 mmol) and iron powder (223 mg, 4 mmol) in AcOH was stirred at 60 °C for 1 h. The mixture was cooled and filtered, and the filtrate was concentrated in vacuo. The residue was partitioned between DCM and an aq. K2CO3 solution. The organic layer was dried (MgSO4), filtered and concentrated in vacuo. Yield: 324 mg of crude intermediate 93, which was used as such in the next reaction step.
-
- A mixture of 2-chloro-N-6-dimethyl-3-nitro-pyridin-4-amine (600 mg, 2.98 mmol) and intermediate 71 (1.14 g, 5.95 mmol) in DMA (12 ml) was heated under microwave conditions for 5 h at 140 °C followed by 90 min at 160 °C. The r.m. was cooled to r.t. and poured into water. The resulting precipitate was filtered off, washed with water, and dried. Yield: 528 mg of intermediate 94 (50 %).
-
- A mixture of 2-chloro-N-4,6-dimethyl-3,4-pyridinediamine, (2.99 g, 17.4 mmol) and urea (1.31 g, 21.8 mmol) in xylene (40 ml) was stirred at reflux overnight. The r.m. was cooled, and the resulting precipitate collected by filtration and washed with water. The solid was triturated with DIPE. Yield: 3.15 g of intermediate 95, which was used as such in the next reaction step.
-
- Intermediate 71 (592 mg, 3.1 mmol), Pd2(dba)3 (334 mg, 0.36 mmol), X-Phos (347 mg, 0.73 mmol) and Cs2CO3 (3.56 g, 10.9 mmol) were added to a sol. of intermediate 95 (1 g, 1.7 mmol) in 2-methyl-2-propanol (35 ml) under a N2 atmosphere. The r.m. was heated at 100 °C overnight. More Pd2(dba)3 (334 mg, 0.36 mmol), X-Phos (347 mg, 0.73 mmol) were added and the r.m. was again stirred at 100 °C overnight. Again, extra Pd2(dba)3 (174 mg, 0.18 mmol), X-Phos (167 mg, 0.37 mmol) were added and the r.m. was again stirred at 100 °C overnight. The mixture was cooled and partitioned between DCM and water. The organic layer was dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel (eluent: DCM/MeOH(NH3) from 100/0 to 97/3). The product fractions were collected and the solvent was evaporated. Yield: 300 mg of intermediate 96 (50 %).
-
- POCl3 (10 ml) was added intermediate 96 (1.03 g, 2.8 mmol) and the r.m. was heated at 115 °C for 24 h. The r.m. was concentrated in vacuo. The residue was neutralized with a sat. aq. NaHCO3 sol., and extracted with EtOAc The organic layer was dried (MgSO4), filtered and concentrated in vacuo. Yield: 635 mg of crude intermediate 97 which was used as such in the next reaction step.
-
- A mixture of 1-fluoro-2-methoxy-4-nitrobenzene (2.45 g, 14.3 mmol), 4-hydroxymethyl-1H-imidazole (1.54 g, 15.7 mmol) and K2CO3 (3.95 g, 28.6 mmol) in DMF (20 ml) was stirred at 100 °C for 16 h. The mixture was concentrated in vacuo, and the residue was partitioned between EtOAc and water. Undissolved material was collected by filtration and dissolved in a mixture of THF and CH3CN. The combined organic layers were dried (MgSO4), filtered and the solvent was evaporated. The residue was triturated in DIPE/2-propanol, filtered off and dried. Yield: 1.2 g of intermediate 98 which was used as such in the next reaction step.
-
- MeOH (100 ml) was added to Pd/C 10 % (0.5g) under N2 atmosphere. Subsequently, a 0.4 % thiophene sol. in DIPE (2 ml) and intermediate 98 (1.2 g, 3.4 mmol) were added. The r.m. was stirred at 25 °C under H2 atmosphere until 3 eq of H2 was absorbed. The catalyst was filtered off over diatomaceous earth. The filtrate was evaporated. Yield: 0.56 g of intermediate 99, which was used as such in the next reaction step.
-
- A mixture of intermediate 61 (500 mg, 1.29 mmol), 3-methoxy-propyne (99 mg, 1.4 mmol), PdCl2(PPh3)2 (36 mg, 0.05 mmol) and CuI (9 mg, 0.049 mmol) in Et3N (6 ml) was stirred at 50 °C for 20 h under a N2 atmosphere. The mixture was concentrated in vacuo, and the residue was partitioned between DCM and water. The organic layer was dried (MgSO4), filtered, and concentrated in vacuo. The residue was purified by column chromatography over silicagel (eluent: DCM/MeOH 99/1). The product fractions were collected and the solvent was evaporated in vacuo. Yield: 440 mg of intermediate 100 (quantitative).
-
- Intermediate 5 (62 mg, 0.3 mmol), Pd2(dba)3 (28 mg, 0.03 mmol), X-phos (28 mg, 0.06 mmol) and Cs2CO3 (300 mg, 0.91 mmol) were added to a solution of intermediate 100 (100 mg, 0.3 mmol) in 2-methyl-2-propanol (15 ml) under a N2 atmosphere. The r.m. was heated at 100 °C for 20 h. Then, the r.m. was cooled, water was added and the mixture was extracted with DCM. The combined organic layers were dried (MgSO4), filtered and the solvent was evaporated. The residue was purified by flash chromatography over silicagel (eluent: DCM/MeOH(NH3) from 100/0 to 99/1). The product fractions were collected and the solvent was evaporated in vacuo. Yield: 140 mg of intermediate 41 (93 %).
-
- 2-Methyl-2-propanol, sodium salt (0.299 g, 3.1 mmol), BINAP (97 mg, 0.16 mmol), Pd(OAc)2 (23 mg, 0.1 mmol) and intermediate 24 (332 mg, 1.24 mmol) were added to a sol. of 1-(4-bromo-2-methoxyphenyl)-4-methyl-1H-imidazole (250 mg, 1.04 mmol) in toluene (10 ml) and the mixture was purged with N2 for 5 min. The r.m. was stirred and heated at 100 °C overnight under a N2 atmosphere. Then, the r.m. was cooled to r.t., water was added, and the mixture was extracted with DCM. The combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel (eluent: DCM/MeOH(NH3) from 100/0 to 97/3). The product fractions were collected and the solvent was evaporated. The residue was triturated with DIPE. The solid was collected and dried in vacuo. Yield: 0.28 g of compound 1 (63 %).
-
- Pd2(dba)3 (14 mg, 0.015 mmol) and X-Phos (34 mg, 0.06 mmol) were added to a N2 purged mixture of 1-(4-bromo-2-methoxyphenyl)-4-methyl-1H-imidazole (51 mg, 0.19 mmol), intermediate 26 (40 mg, 0.15 mmol), and Cs2CO3 (97 mg, 0.3 mmol) in toluene (5 ml). The r.m. was heated at 100 °C overnight under a N2 atmosphere. Then, the solvent was evaporated and the residue was partitioned between water and DCM. The combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by RP preparative HPLC [RP Shandon Hyperprep® C18 BDS (8 µm, 250 g, I.D. 5 cm); mobile phase: a gradient of (0.25 % NH4HCO3 sol. in water)/MeOH/CH3CN]. The product fractions were collected and worked up. Yield: 30 mg of compound 2 (44 %).
-
- 2-Methyl-2-propanol, sodium salt (207 mg, 2.15 mmol), BINAP (25 mg, 0.04 mmol), Pd(OAc)2 (6 mg, 0.027 mmol) and 1-(4-bromo-2-methoxyphenyl)-4-methyl-1H-imidazole (215 mg, 0.81 mmol) were added to a sol. of intermediate 52 (139 mg, 0.54 mmol) in toluene (10 ml), and the mixture was purged with N2. The r.m. was stirred and heated at 150 °C for 1 h under microwave irradiation. Then, the r.m. was cooled to r.t., water was added, and the mixture was extracted with DCM. The combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by RP preparative HPLC [RP Shandon Hyperµprep® C18 BDS (8 µm, 250 g, I.D. 5 cm); mobile phase: a gradient of (0.25 % NH4HCO3 sol. in water)/MeOH/CH3CN]. The product fractions were collected and worked up. Yield: 67 mg of compound 3 (28 %).
-
- Intermediate 5 (340 mg, 1.66 mmol), Pd2(dba)3 (152 mg, 0.166 mmol), X-Phos (173 mg, 0.366 mmol) and Cs2CO3 (1.63 g, 5 mmol) were added to a sol. of intermediate 12 (508 mg, 1.66 mmol) in 2-methyl-2-propanol (25 ml) under a N2 atmosphere. The r.m. was heated at 110 °C for 2 h. Then, the r.m. was cooled to r.t., water was added and the mixture was extracted with DCM. The combined organic layers were dried (MgSO4), filtered and the solvent was evaporated. The residue was purified by RP preparative HPLC [RP Shandon Hyperprep® C18 BDS (8 µm, 250 g, I.D. 5 cm); mobile phase: a gradient of (0.25 % NH4HCO3 sol. in water)/MeOH/CH3CN]. The product fractions were collected and worked up. The residue was triturated with DIPE. The solid was collected and dried in vacuo. Yield: 0.31 g of compound 4 (44 %).
-
- Intermediate 30 (155 mg, 0.89 mmol), Pd2(dba)3 (71 mg, 0.077 mmol), X-Phos (81 mg, 0.17 mmol) and Cs2CO3 (757 mg, 2.32 mmol) were added to a sol. of intermediate 12 (236 mg, 0.77 mmol) in 2-methyl-2-propanol (5 ml) under a N2 atmosphere. The r.m. was heated at 110 °C for 20 h. Then, the r.m. was cooled to r.t., water was added and the mixture was extracted with DCM. The combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel (eluent: DCM/MeOH(NH3) from 100/0 to 98/2). The product fractions were collected and the solvent was evaporated. The residue was partitioned between an aq. NH4OH sol. and DCM. The combined organic layers were dried (MgSO4), filtered and the solvent was evaporated. Yield: 0.05 g of compound 5 (16 %).
-
- Intermediate 29 (70 mg, 0.4 mmol), Pd2(dba)3 (50 mg, 0.055 mmol), X-Phos (58 mg, 0.12 mmol) and Cs2CO3 (537 mg, 1.65 mmol) were added to a sol. of intermediate 12 (168 mg, 0.55 mmol) in 2-methyl-2-propanol (5 ml) under a N2 atmosphere. The r.m. was heated at 110 °C for 20 h. Then, the r.m. was cooled to r.t., water was added and the mixture was extracted with DCM. The combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel (eluent: DCM/MeOH(NH3) from 100/0 to 98/2). Yield: 0.075 g of compound 6 (34 %).
-
- 1-(4-aminophenyl)-4-methyl-1H-imidazole (130 mg, 0.75 mmol), Pd2(dba)3 (60 mg, 0.065 mmol), X-Phos (69 mg, 0.144 mmol) and Cs2CO3 (641 mg, 1.97 mmol) were added to a sol. of intermediate 12 (200 mg, 0.65 mmol) in 2-methyl-2-propanol (5 ml) under a N2 atmosphere. The r.m. was heated at 110 °C for 20 h. Then, the r.m. was cooled to r.t., water was added and the mixture was extracted with DCM. The combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel (eluent: DCM/MeOH(NH3) from 100/0 to 98/2). The product fractions were collected and concentrated in vacuo. The residue was purified further by RP preparative SFC [RP Shandon Hyperprep® C18 BDS (8 µm, 250 g, I.D. 5 cm); mobile phase: 35 % MeOH (with 0.2% isopropylamine), 65 % CO2. The product fractions were collected and worked up. Yield: 0.052 g of compound 7 (20 %).
-
- Intermediate 2a (93 mg, 0.457 mmol), Pd2(dba)3 (42 mg, 0.046 mmol), X-Phos (58 mg, 0.1 mmol) and Cs2CO3 (456 mg, 1.4 mmol) were added to a sol. of intermediate 35 (140 mg, 0.457 mmol) in 2-methyl-2-propanol (5 ml) under a N2 atmosphere. The r.m. was heated at 110 °C for 20 h. Then, the r.m. was cooled to r.t., water was added and the mixture was extracted with DCM. The combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel (eluent: DCM/MeOH from 100/0 to 99/1). The residue was treated with DIPE and a drop CH3CN to provide a solid. Yield: 0.063 g of compound 8 (32 %).
-
- Intermediate 2a (2.01 g, 6.17 mmol), Pd2(dba)3 (188 mg, 0.206 mmol), dicyclohexyl[2',4',6'-tris(1-methylethyl)[1,1'-biphenyl]-2-yl]phosphine (216 mg, 0.453 mmol) and Cs2CO3 (1.63 g, 5 mmol) were added to a sol. of intermediate 40 (840 mg, 1.83 mmol) in 2-methyl-2-propanol (40 ml) under a N2 atmosphere. The r.m. was heated for 20 h at 110 °C. Then, the r.m. was cooled to r.t., water was added and the mixture was extracted with DCM. The combined organic layers were dried (MgSO4), filtered and the solvent was evaporated. The residue was purified by flash column chromatography over silica gel (eluent: DCM/MeOH(NH3) from 100/0 to 96/4). The product fractions were collected and the solvent was evaporated. Yield: 0.685 g of compound 212 (70 %).
-
- Compound 212 (660 mg, 1.24 mmol) was added to to a mixture of DCM (5 ml) and TFA (5 ml). The r.m. was stirred at r.t. for 6 h. The r.m. was concentrated in vacuo, and the residue was partitioned between DCM and a sat. aq. NaHCO3 sol. The organic layer was dried (MgSO4), filtered and concentrated in vacuo. Yield 430 mg of compound 9 (80 %), which was used as such in the following steps. 80 mg was purified further by RP preparative HPLC [RP Shandon Hyperprep® C18 BDS (10 µm, 250 g, I.D. 5 cm); mobile phase: a gradient of (0.25 % NH4HCO3 sol. in water)/MeOH/CH3CN]. The product fractions were collected and worked up to yield: 47 mg of pure compound 9.
-
- To a sol. of compound 9 (65 mg, 0.15 mmol) in DCM (5 ml) was added acetic acid anhydride (16 mg, 0.15 mmol). The r.m. was stirred at r.t. for 30 min. The r.m. was treated with water (1 ml) and then dried by filtration over an Isolute® HM-N filter. The organic layer was evaporated. The residue was purified by RP preparative HPLC [RP Shandon Hyperprep® C18 BDS (10 µm, 250 g, I.D. 5 cm); mobile phase: a gradient of (0.25 % NH4HCO3 sol. in water)/MeOH/CH3CN]. The product fractions were collected and worked up. Yield 41 mg of compound 10 (58 %).
-
- A mixture of compound 9 (70 mg, 0.163 mmol), a formaldehyde sol. in water (37 weight %, 0.054 ml, 0.65 mmol), in DCE (1.5 ml) and MeOH (1.5 ml) was cooled to 0 °C. Sodium triacetoxyborohydride (69 mg, 0.325 mmol) was added to this mixture, and the r.m. was stirred at r.t. for 16 h. Then, the r.m. was partitioned between DCM and water. The organic layer was dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by by RP preparative HPLC [RP Shandon Hyperprep® C 18 BDS (10 µm, 250 g, I.D. 5 cm); mobile phase: a gradient of (0.25 % NH4HCO3 sol. in water)/MeOH]. The product fractions were collected and worked up. Yield 8 mg of compound 11 (10 %).
-
- Intermediate 2a (123 mg, 0.61 mmol), Pd2(dba)3 (56 mg, 0.061 mmol), X-Phos (63 mg, 0.13 mmol) and Cs2CO3 (592 mg, 1.82 mmol) were added to a sol. of intermediate 15 (200 mg, 0.61 mmol) in 2-methyl-2-propanol (15 ml) under a N2 atmosphere. The r.m. was heated at 110 °C for 6 h. Then, the r.m. was cooled to r.t., water was added and the mixture was extracted with EtOAc. The combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by by RP preparative HPLC [RP Shandon Hyperprep® C18 BDS (8 µm, 250 g, I.D. 5 cm); mobile phase: a gradient of (0.25 % NH4HCO3 sol. in water)/MeOH/CH3CN]. The product fractions were collected and worked up. Yield 90 mg of compound 12 (33 %).
-
- Cs2CO3 (472 mg, 1.45 mmol), X-Phos (46 mg, 0.097 mmol) and Pd2(dba)3 (44 mg, 0.048 mmol), were added to a sol. of intermediate 37 (140 mg, 0.483 mmol) and intermediate 9 (93 mg, 0.483 mmol) in 2-methyl-2-propanol (5 ml) under a N2 atmosphere. The r.m. was heated at 100 °C for 16 h. Then, the r.m. was cooled to r.t., water was added and the mixture was extracted with DCM. The combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by by RP preparative HPLC [RP Vydac DenaliC18 (10 µm, 250 g, I.D. 5 cm); mobile phase: a gradient of (0.25 % NH4HCO3 sol. in water)/MeOH]. The product fractions were collected and worked up. Yield 51 mg of compound 13 (24 %).
-
- Intermediate 31 (113 mg, 0.643 mmol), Cs2CO3 (629 mg, 1.93 mmol), X-Phos (61 mg, 0.129 mmol) and Pd2(dba)3 (59 mg, 0.064 mmol), were added to a sol. of intermediate 39 (240 mg, 0.643 mmol) in 2-methyl-2-propanol (10 ml) under a N2 atmosphere. The r.m. was heated at 110 °C for 16 h. Then, the r.m. was cooled to r.t., water was added and the mixture was extracted with DCM. The combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel (eluent: DCM/MeOH from 100/0 to 98/2). The residue was treated with DIPE to provide a solid. Yield: 0.2 g of compound 14 (66 %).
-
- Intermediate 45 (232 mg, 0.819 mmol), Cs2CO3 (801 mg, 2.46 mmol), X-Phos (86 mg, 0.18 mmol) and Pd2(dba)3 (75 mg, 0.082 mmol), were added to a sol. of intermediate 12 (250 mg, 0.819 mmol) in 2-methyl-2-propanol (15 ml) under a N2 atmosphere. The r.m. was heated at 110 °C for 6 h. Then, the r.m. was cooled to r.t., water was added and the mixture was extracted with DCM. The combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by RP preparative HPLC [RP Shandon Hyperprep® C18 BDS (8 µm, 250 g, I.D. 5 cm); mobile phase: a gradient of (0.25 % NH4HCO3 sol. in water)/ CH3CN]. The product fractions were collected and worked up. Yield 45 mg of compound 15 (13 %).
-
- Intermediate 2a (0.178 g, 0.875 mmol), Pd2(dba)3 (0.053 g, 0.058 mmol), X-Phos (0.061 g, 0.128 mmol) and Cs2CO3 (0.570 g, 1.75 mmol) were added to a sol. of intermediate 47 (0.18 g, 0.583 mmol) in 2-Methyl-2-propanol (5 ml) and the r.m. was heated at 110 °C overnight. Then H2O was added and the product was extracted with DCM The organic phase was dried (MgSO4) and evaporated off. The residue was purified by preparative HPLC [RP Shandon Hyperprep® C18 BDS (8 µm, 250 g, I.D. 5 cm); mobile phase: (0.5 % NH4Ac sol. in water + 10% CH3CN, MeOH]. The product fractions were collected and worked up. Yield: 0.072 g of compound 16 (28.6 %).
-
- Intermediate 2a (0.123 g, 0.607 mmol), Pd2(dba)3 (0.028 g, 0.030 mmol), X-Phos (0.032 g, 0.067 mmol) and Cs2CO3 (0.296 g, 0.91 mmol) were added to a sol. of intermediate 49 (0.085 g, 0.303 mmol) in 2-methyl-2-propanol (5 ml) and the r.m. was heated at 110 °C for 20 h. Then H2O was added and the product was extracted with DCM The organic phase was dried (MgSO4) and evaporated off. The residue was purified by preparative HPLC [RP Shandon Hyperprep® C 18 BDS (8 µm, 250 g, I.D. 5 cm); mobile phase: (0.25 % NH4CO3 sol. in water, MeOH). The product fractions were collected and worked up. Yield: 0.015 g of compound 17 (12 %).
-
- Intermediate 2a (0.160 g, 0.787 mmol), Pd2(dba)3 (0.036 g, 0.039 mmol), X-Phos (0.041 g, 0.086 mmol) and CsCO3 (0.384 g, 1.18 mmol) were added to a sol. of intermediate 51 (0.1 g, 0.394 mmol) in 2-Methyl-2-propanol (5 ml) and the r.m. was heated at 110 °C for 20 h. Then H2O was added and the product was extracted with DCM The organic phase was dried (MgSO4) and evaporated off. The residue was purified by flash colum chromatography (eluent: DCM/MeOH(NH3) from 100/0 to 98/2). The product fractions were collected and concentrated in vacuo. Yield: 0.110 g of compound 18 (71 %).
-
- Intermediate 2a (0.244 g, 1.2 mmol), Pd2(dba)3 (0.092 g, 0.1 mmol), BINAP (0.093 g, 0.15 mmol) and Cs2CO3 (0.977 g, 3 mmol) were added to a sol. of intermediate 54 (0.377 g, 1 mmol) in DMF (15 ml) and the r.m. was heated at 150 °C for 5 h under microwave irradiation. The r.m. was cooled to r.t. and the solvent was removed under reduced pressure. The residue was partitioned between DCM and water. The organic phase was dried (MgSO4) and concentrated in vacuo. The residue was purified by preparative HPLC [RP Shandon Hyperprep® C18 BDS (8 µm, 250 g, I.D. 5 cm); mobile phase: (0.25 % NH4CO3 sol. in water, MeOH/CH3CN). The product fractions were collected and worked up. Yield: 0.155 g of compound 46 (31 %).
-
- MeOH (50 ml) was added to Pd/C 10 % (20 mg) under N2 atmosphere. Subsequently, compound 46 (143 mg, 0.286 mmol) was added. The r.m. was stirred at 25 °C under H2 atmosphere until 1 eq of H2 was absorbed. The catalyst was filtered off over diatomaceous earth and the filtrate was evaporated. The residue was purified by flash column chromatography over silica gel (eluent: DCM/MeOH(NH3) from 100/0 to 95/5). The product fractions were collected and evaporated. The residue was treated with DIPE/2-propanol to provide a solid. This was purified further by RP preparative HPLC [RP Shandon Hyperprep® C18 BDS (8 µm, 250 g, I.D. 5 cm); mobile phase: a gradient of (0.25 % NH4HCO3 sol, in water)/MeOH/CH3CN]. The product fractions were collected and worked up. Yield: 41 mg of compound 45 (35 %).
-
- Intermediate 45 (81 mg, 0.40 mmol), Cs2CO3 (390 mg, 1.2 mmol), X-Phos (46 mg, 0.096 mmol) and Pd2(dba)3 (30 mg, 0.032 mmol), were added to a sol. of intermediate 56 (140 mg, 0.40 mmol) in 2-methyl-2-propanol (10 ml) under a N2 atmosphere. The r.m. was heated at 100 °C for 3 h. Then, the r.m. was cooled to r.t., water was added and the mixture was extracted with DCM. The combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by flash colum chromatography (eluent: DCM/MeOH(NH3) from 100/0 to 96/4). The product fractions were collected and concentrated in vacuo. The residue was suspended in DIPE. The solid was filtered off, washed with DIPE and dried. Yield 120 mg of compound 106 (63 %).
-
- Intermediate 5 (118 mg, 0.58 mmol), Cs2CO3 (709 mg, 2.18 mmol), X-Phos (69 mg, 0.145 mmol) and Pd2(dba)3 (66 mg, 0.073 mmol), were added to a sol. of intermediate 56 (200 mg, 0.66 mmol) in 2-methyl-2-propanol (8 ml) under a N2 atmosphere. The r.m. was heated at 100 °C for 16 h. Then, the r.m. was cooled to r.t., water was added and the mixture was extracted with DCM. The combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by flash colum chromatography (eluent: DCM/MeOH(NH3) from 100/0 to 97/3). The product fractions were collected and concentrated in vacuo. Yield 186 mg of compound 107 (60 %).
-
- Intermediate 71 (1.2 g, 6.3 mmol), Cs2CO3 (7.22 g, 22.2 mmol), X-Phos (704 mg, 1.48 mmol) and Pd2(dba)3 (677 mg, 0.74 mmol), were added to a sol. of intermediate 65 (2.32 g, 7.39 mmol) in 2-methyl-2-propanol (50 ml) under a N2 atmosphere. The r.m. was heated at 100 °C for 16 h. Then, the r.m. was cooled to r.t., water was added and the mixture was extracted with DCM. The combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by flash colum chromatography (eluent: DCM/MeOH(NH3) from 100/0 to 97/3). The product fractions were collected and concentrated in vacuo. Yield 1.96 g of compound 108 (62 %).
- Intermediate 71 (6.24 g, 32.6 mmol) and methanesulfonic acid (10.5 g, 109 mmol) were added to a solution of intermediate 65 (10 g, 36.3 mmol) in 2-propanol (88 ml). The r.m. was heated at 90 °C for 36 h. Then, the r.m. was cooled slowly to r.t., and the resulting precipitate was collected by filtration. The solid was partitioned between DCM and a sat. aq. NaHCO3 sol. The organic layer was dried (MgSO4), filtered and concentrated in vacuo. Yield 11.2 g of compound 108 (85 %).
-
- Intermediate 5 (195 mg, 0.96 mmol), Cs2CO3 (1.1 g, 3.38 mmol), X-Phos (107 mg, 0.23 mmol) and Pd2(dba)3 (103 mg, 0.11 mmol), were added to a sol. of intermediate 62 (340 mg, 1.13 mmol) in 2-methyl-2-propanol (15 ml) under a N2 atmosphere. The r.m. was heated at 100 °C for 16 h. Then, the r.m. was cooled to r.t., water was added and the mixture was extracted with DCM. The combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by flash colum chromatography (eluent: DCM/MeOH(NH3) from 100/0 to 97/3). The product fractions were collected and concentrated in vacuo. Yield 310 mg of compound 109 (59 %).
-
- MeOH (40 ml) was added to Pt/C 5 % (100 mg) under N2 atmosphere. Subsequently, compound 109 (310 mg, 0.66 mmol) was added. The r.m. was stirred at 25 °C under H2 atmosphere until 1 eq of H2 was absorbed. The catalyst was filtered off over diatomaceous earth and the filtrate was concentrated in vacuo. The residue was purified by flash colum chromatography (eluent: DCM/MeOH(NH3) from 100/0 to 97/3). The product fractions were collected and concentrated in vacuo. The residue was triturated with diethylether. Yield: 250 mg of compound 110.
-
- Intermediate 45 (118 mg, 0.58 mmol), Cs2CO3 (709 mg, 2.18 mmol), X-Phos (69 mg, 0.145 mmol) and Pd2(dba)3 (66 mg, 0.073 mmol), were added to a sol. of intermediate 63 (200 mg, 0.66 mmol) in 2-methyl-2-propanol (8 ml) under a N2 atmosphere. The r.m. was heated at 100 °C for 16 h. Then, the r.m. was cooled to r.t., water was added and the mixture was extracted with DCM. The combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by flash colum chromatography (eluent: DCM/MeOH(NH3) from 100/0 to 97/3). The product fractions were collected and concentrated in vacuo. Yield 166 mg of compound 111 (53 %).
-
- Intermediate 71 (187 mg, 0.98 mmol), Cs2CO3 (957 mg, 2.94 mmol), X-Phos (93 mg, 0.196 mmol) and Pd2(dba)3 (89 mg, 0.098 mmol), were added to a sol. of intermediate 64 (270 mg, 0.98 mmol) in 2-methyl-2-propanol (10 ml) under a N2 atmosphere. The r.m. was heated at 100 °C for 20 h. Then, the r.m. was cooled to r.t., water was added and the mixture was extracted with DCM. The combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by flash colum chromatography (eluent: DCM/MeOH(NH3) from 100/0 to 99/1). The product fractions were collected and concentrated in vacuo. The residue was triturated with DIPE/CH3CN. Yield 37 mg of compound 112 (9 %).
-
- Intermediate 5 (55 mg, 0.27 mmol), Cs2CO3 (284 mg, 0.87 mmol), X-Phos (28 mg, 0.058 mmol) and Pd2(dba)3 (26 mg, 0.029 mmol), were added to a sol. of intermediate 64 (80 mg, 0.29 mmol) in 2-methyl-2-propanol (10 ml) under a N2 atmosphere. The r.m. was heated at 100 °C for 20 h. Then, the r.m. was cooled to r.t., water was added and the mixture was extracted with DCM. The combined organic layers were dried (MgSO4), filtered and evaporated. The residue was purified by preparative HPLC [RP Vydac Denali C18 (10 µm, 250 g, I.D. 5 cm); mobile phase: (0.25 % NH4CO3 sol. in water, MeOH/CH3CN). The product fractions were collected and worked up. The residue was triturated with DIPE. Yield: 27 mg of compound 113 (21 %).
-
- Intermediate 5 (139 mg, 0.68 mmol), Cs2CO3 (635 mg, 1.95 mmol), X-Phos (68 mg, 0.143 mmol) and Pd2(dba)3 (59 mg, 0.065 mmol), were added to a sol. of intermediate 73 (200 mg, 0.65 mmol) in 2-methyl-2-propanol (10 ml) under a N2 atmosphere. The r.m. was heated at 75 °C for 16 h. Then, the r.m. was cooled to r.t., water was added and the mixture was extracted with DCM. The combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by flash colum chromatography (eluent: DCM/MeOH(NH3) from 100/0 to 99/1). The product fractions were collected and concentrated in vacuo. The residue was triturated with DIPE. Yield 70 mg of compound 114 (22 %).
-
- 3-Acetamidophenylboronic acid (134 mg, 0.75 mmol) and Pd(PPh3)4 (115 mg, 0.1 mmol) were added to a mixture of intermediate 91 (184 mg, 0.5 mmol) and K2CO3 (207 mg, 1.5 mmol) in dioxane (10 ml) and DMF (2.5 ml). The r.m. was stirred and heated in a closed vessel at 140 °C for 20 h. The r.m. was cooled and concentrated in vacuo. The residue was dissolved in a minimal amount of DCM, and then filtered over diatomaceous earth. The organic layer was evaporated. The residue was purified by RP preparative HPLC [RP Vydac Denali C18 (10 µm, 250 g, I.D. 5 cm); mobile phase: a gradient of (0.25 % NH4HCO3 sol. in water)/MeOH]. The product fractions were collected and worked up. Yield 158 mg of compound 174 (64 %).
-
- 4-Fluoro-3-methoxyphenylboronic acid (127 mg, 0.75 mmol) and Pd(PPh3)4 (115 mg, 0.1 mmol) were added to a mixture of intermediate 91 (184 mg, 0.5 mmol) and K2CO3 (207 mg, 1.5 mmol) in dioxane (10 ml) and DMF (2.5 ml). The r.m. was stirred and heated in a closed vessel at 140 °C for 20 h. The r.m. was cooled and concentrated in vacuo. The residue was dissolved in a minimal amount of DCM, and then filtered over diatomaceous earth. The organic layer was evaporated. The residue was purified by RP preparative HPLC [RP Vydac Denali C18 (10 µm, 250 g, I.D. 5 cm); mobile phase: a gradient of (0.25 % NH4HCO3 soL in water)/MeOH]. The product fractions were collected and worked up. The residue was dissolved in hot 2-propanol and treated with a 6 N HCl sol. in 2-propanol. The resulting precipitate was collected by filtration and dried. Yield: 168 mg of compound 184 (61 %) as HCl salt (.2HCl.H2O).
-
- Na2S2O5 (0.4 g, 2.11 mmol) and 3-bromo-4-fluoro-benzaldehyde (243 mg, 1.2 mmol) were added to a sol. of intermediate 93 (324 mg, 1 mmol) in DMA (10 ml). The r.m. was stirred overnight at 80 °C. Then, the r.m. was cooled to r.t. and poured into water. The mixture was extracted with DCM. The combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by flash column chromatography (eluent: DCM/MeOH(NH3) from 100/0 to 96/4). The product fractions were collected and concentrated in vacuo. The residue was triturated with DIPE. Yield: 110 mg of compound 133 (22 %).
-
- 3-Acetamidophenylboronic acid (46 mg, 0.26 mmol), K2CO3 (89 mg, 0.64 mmol) and Pd(PPh3)4 (37 mg, 0.032 mmol) were added to a sol. of intermediate 97 (80 mg, 0.21 mmol) in dioxane (3.2 ml) and DMF (0.8 ml). The r.m. was stirred and heated at 150 °C for 20 min under microwave irradiation. Extra 3-acetamidophenyl-boronic acid (23 mg), Pd(PPh3)4 (19 mg), and DMF (0.5 ml) were added, and the r.m. was stirred and heated at 150 °C for 20 min under microwave irradiation. The mixture was cooled to r.t. and partitioned between H2O and EtOAc. The organic layers were separated, dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by flash column chromatography (eluent: DCM/MeOH(NH3) from 100/0 to 95/5). The product fractions were collected and concentrated. Yield: 50 mg of compound 141 (50 %).
-
- A 2 M sol. of lithium diisopropylamide in THF (1.6 ml, 3.2 mmol) was added at -40 °C to a solution of compound 108 (460 mg, 1.07 mmol) in THF (35 ml). The r.m. was stirred at -40 °C for 1 h., and subsequently I2 (271 mg, 1.07 mmol) in THF (5 ml) was added. The r.m. was allowed to warm to r.t., and was then partitioned between DCM and water. The organic layer was separated, dried (MgSO4), filtered and concentrated in vacuo. The reaction was repeated using 100 mg of compound 108. The crude residues obtained from both reactions were combined and purified by flash column chromatography (eluent: DCM/MeOH(NH3) from 100/0 to 95/5). The product fractions were collected and concentrated in vacuo. Yield: 52 mg of compound 154 (7 %).
-
- SOCl2 (62 mg, 0.52 mmol) was added to a sol. of compound 118 (prepared according to example B4 from intermediate 99 and intermediate 12) (80 mg, 0.17 mmol) in DCM (5 ml). The r.m. was stirred at r.t. for 1 h and then MeOH (10 ml) was added. The r.m. was stirred at r.t. overnight and then DCM (100 ml) was added. The mixture was first washed with a sat. aq. NaHCO3 sol., and then with water. The organic layer was dried (MgSO4), filtered and the solvent was evaporated. The residue was purified by preparative HPLC [RP Vydac Denali C18 (10 µm, 250 g, I.D. 5 cm); mobile phase: (0.25 % NH4CO3 sol. in water, MeOH). The product fractions were collected and worked up. Yield: 26 mg of compound 119 (33 %).
-
- A mixture of intermediate 41 (140 mg, 0.28 mmol), and Raney nickel (20 mg), in THF (40 ml) was stirred at r.t. under H2 (atmospheric pressure). After uptake of H2 (2 eq), the catalyst was filtered off over diatomaceous earth. The solvent was evaporated and the residue was partitioned between DCM and water. The organic layer was dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by preparative HPLC [RP Vydac Denali C18 (10 µm, 250 g, I.D. 5 cm); mobile phase: (0.25 % NH4CO3 sol. in water, MeOH)]. The product fractions were collected, concentrated in vacuo, and the residue was purified further by preparative HPLC [RP Vydac Denali C18 (10 µm, 250 g, I.D. 5 cm); mobile phase: (0.25 % NH4CO3 sol. in water, CH3CN)]. The product fractions were collected and concentrated under reduced pressure. Yield: 14 mg of compound 208 (10 %).
-
- 2-Fluoro-5-trifluoromethyl-benzaldehyde (189 mg, 0.98 mmol) and Na2S2O4 (427 mg, 2.46 mmol) were added to a sol. of intermediate 92 (290 mg, 0.82 mmol) in EtOH (15 ml). The r.m. was heated under microwave conditions at 160 °C for 45 min. The r.m. was cooled to r.t. and filtered over diatomaceous earth, eluting with EtOAc. The filtrate was concentrated in vacuo. The residue was partitioned between DCM and water. The organic phase was separated, dried (MgSO4), filtered and the solvent was evaporated in vacuo. The residue was purified by flash column chromatography over silica gel (eluent: DCM/MeOH(NH3) 100/0 to 97/3). The product fractions were collected and the solvent was evaporated. The residue was dissolved in 2-propanol and DIPE and treated with a 6N HCl sol. in 2-propanol. The resulting precipitate was collected by filtration and dried. Yield: 86 mg of compound 187 (18 %) as HCl salt (.2HCl.H2O).
- Compounds 1 to 212 in tables 1a, 1b, 1c and 1d were prepared by analogy to one of the above Examples. In case no salt form is indicated, the compound was obtained as a free base 'Co. No.' means compound number 'Pr.' refers to the Example number according to which protocol the compound was synthesized. B1* means that the compound was synthesized according to the protocol as described in B1, but that an intermediate of formula (II-a) was reacted with an intermediate of formula (III-a) mstead of an intermediate of formula (II-b) with (III-b) as was exemplified in B1
Table 1a Co. No. Pr. R1 X A1 R3 Z R4 salt form 19 B4 CH3 CH COCH3 CH3 NCH3 H 20 B4 CH3 N CH CH3 NCH(CH3)2 H 21 B4 CH3 N COCH3 CH3 NCH(CH3)2 H 22 B4 CH3 CH COCH3 CH3 H 23 B4 CH3 N CH CH3 H 24 B4 CH3 N CF NCH3 H 25 B1* CH3 CH COCH3 NCH3 H .2 HCl 26 B4 CH3 N CH H 27 B4 CH3 N CH H .2 HCl 18 B16 CH3 CH COCH3 O H 28 B4 CH3 N COCH3 O H 29 B1* CH3 CH COCH3 NCH3 H 30 B4 CH3 CH COCH3 O H 31 B4 CH3 CH COCH3 NCH3 H 32 B1* CH3 CH COCH3 NCH3 H 33 B4 CH3 CH COCH3 NCH3 H 34 B4 CH3 CH COCH3 NCH3 H 35 B1* CH3 CH COCH3 NCH2CH3 H 36 B1* CH3 CH COCH3 NCH2CH3 H 37 B4 CH3 CH COCH3 O H 17 B15 CH3 CH COCH3 O H 38 B1 CH3 CH COCH3 NCH3 H 39 B4 CH3 CH COCH3 NCH3 H 9 B9.a2 CH3 CH COCH3 NCH3 H 11 B9.c CH3 CH COCH3 NCH3 H 10 B9.b CH3 CH COCH3 NCH3 H 40 B4 CH3 CH COCH3 O H 41 B4 CH3 CH COCH3 O H 42 B4 CH3 CH COCH3 O H 212 B9.a1 CH3 CH COCH3 NCH3 H 12 B10 CH3 CH COCH3 NCH3 H 43 B17.a CH3 CH COCH3 NCH3 H .2 HCl 44 B1 CH3 CH COCH3 NCH3 H 45 B17.b CH3 CH COCH3 NH H 46 B17.a CH3 CH COCH3 H 47 B1 CH3 CH COCH3 NCH3 H 48 B4 CH3 CH COCH3 O H 49 B1* CH3 CH COCH3 NCH3 H 50 B4 CH3 N CH NCH3 H 51 B4 CH3 N CH NCH(CH3)2 H 52 B4 CH3 N COCH3 NCH3 H 53 B4 CH3 N COCH3 NCH(CH3)2 H 54 B4 CH3 CH COCH3 N(CH2)2OCH3 H .2 HCl 55 B4 CH3 N CH NCH3 F 56 B4 CH3 N COCH3 NCH3 F 57 B4 CH3 N CF NCH3 F 58 B4 CH3 N COCH3 NCH3 H 59 B4 CH3 N COCH3 O H 60 B4 CH3 CH COCH3 NCH3 H 61 B4 CH3 CH COCH3 NCH3 H 62 B17.b CH3 CH COCH3 NH H 63 B17.a H CH COCH3 NCH3 H 64 B4 H N COCH3 NCH3 H 65 B4 H N CF NCH3 H 7 B7 CH3 CH CH NCH3 H 66 B1 CH3 CH COCH3 NCH3 H 1 B1 CH3 CH COCH3 NCH3 H 67 B4 CH3 CH CF NCH3 H 68 B12 CH3 CH N NCH3 H 69 B4 CH3 N CH NCH3 CF3 4 B4 CH3 N COCH3 NCH3 H 70 B4 CH3 N N NCH3 H 14 B12 CH3 N N NCH3 CF3 71 B1* Br CH COCH3 NCH3 H 72 B1* CN CH COCH3 NCH3 H 2 B2 CH3 CH COCH3 NCH(CH3)2 H 73 B4 CH3 N CH NCH(CH3)2 H .2 HCl 74 B4 CH3 N CF NCH(CH3)2 H .2 HCl 75 B4 CH3 N COCH3 NCH(CH3)2 H .2 HCl 76 B12 CH3 N N NCH(CH3)2 H 77 B4 CH3 N CH NC(CH3)3 H 78 B4 CH3 N COCH3 NC(CH3)3 H 2 HCl 79 B1 CH3 CH CONCH3 H 80 B4 CH3 CH COCH3 O H 81 B17.a CH3 CH COCH3 NCH3 H 2 HCl 82 B4 CH3 CH COCH3 O H 3 B3 CH3 CH COCH3 NCH3 H 16 B14 CH3 CH COCH3 O H 83 B1* H N CF NCH3 H 84 B4 CH3 N COCH3 NCH3 H 85 B1* CH3 N COCH3 NCH3 H 86 B4 CH3 CH COCH3 O H 103 B4 CH3 N CH NCH3 H 105 B4 CH3 N COCH3 NCH2CF3 H 117 B4 CH3 CH COCH3 NCH(CH3)2 H .2HCl .3H2O 118 B4 CH2OH CH COCH3 NCH3 H 119 B31 CH2OCH3 CH COCH3 NCH3 H 120 B4 CH3 N COCH3 NCH(CH3)2 H .2HCl 121 B4 CH3 N COCH3 NCH(CH3)2 H 122 B4 CH3 N COCH3 NCH3 H .2HCl 123 B4 CH3 N COCH3 NCH3 H .2HCl 124 B18 CH3 CH CF NCH3 H 125 B1* CH3 CH CF NCH(CH3)2 F 126 B4 CH3 N COCH3 NCH(CH3)2 H .2HCl 127 B4 CH3 N COCH3 NCH2CH3 F 128 B4 CH3 N COCH3 NCH3 F Table 1b Co. No Pr. R1 X R2 A1 A2 A3 A4 Y1 Z R3 R4 87 B13 CH3 N H CH N CH CH CH O H 88 B4 H N CH3 CH CH CH CH CH NCH(CH3)2 H 5 B5 CH3 CH H CH N CH CH CH NCH3 H 89 B13 CH3 N H CH N CH CH CH NCH(CH3)2 H 101 B11 H N CH3 COCH3 CH CH CH N NCH3 H 99 B4 H N CH3 COCH3 CH CH CH CH NCH3 H 90 B8 CH3 CH H COCH3 CH CH CH N NH H 91 B8 H N CH3 COCH3 CH CH CH CH NCH3 H 8 B8 CH3 CH H COCH3 CH CH CH N NCH3 H 92 B11 CH3 N H COCH3 CH CH CH N NCH3 H 115 B18 CH3 CH H COCH3 N CH CH CH NCH3 F 116 B18 CH3 CH H COCH3 N CH CH CH NCH(CH3)2 H 106 B18 CH3 CH H COCH3 N CH CH CH NCH(CH3)2 F 93 B13 CH3 CH H COCH3 CH CH N CH NCH3 H 94 B1* CH3 CH H COCH3 CH N CH CH NCH3 H 15 B13 CH3 CH H COCH3 N CH CH CH NCH3 H 210 B13 CH3 CH H COCH3 N CH CH CH NCH3 H 107 B19 CH3 N H COCH3 CH CH CH N NCH3 CH(CH3)2 98 B11 CH3 N H COCH3 CH CH CH N NCH3 H 96 B4 H N CH3 COCH3 CH CH CH CH NCH3 H 114 B25 CH3 N H COCH3 CH CH CH N NCH3 H 108 B20 CH3 CH H CF CH CH CH N NCH3 CH3 211 B20 CH3 CH H CF CH CH CH N NCH3 CH3 209 B20 CH3 CH H CF CH CH CH N NCH3 CH3 97 B11 H N CH3 CF CH CH CH N NCH3 H 102 B4 CH3 N H CF CH CF CH CH NCH3 H 100 B11 H N CH3 CF CH CH CH N NCH3 CH3 13 B11 H N CH3 CF CH CH CH N NCH(CH3)2 H 104 B11 CH3 CH H CF CH CH CH N NCH3 H 6 B6 CH3 CH H N CH N CH CH NCH3 H 95 B4 CH3 CH H N N CH CH CH NCH3 H 129 B24 CH3 N H CH CF CH CH N NCH3 H 130 B23 CH3 N H COCH3 CH CH CH N NCH3 H 131 B18 CH3 CH H COCH3 N CH CH CH NCH(CH3)2 H 132 B26 CH3 CH H COCH3 N CH CH CH NCH3 H 133 B28 CH3 CH H COCH3 N CH CH CH NCH3 H 134 B1* CH3 CH H COCH3 N CH CH CH NCH3 H 135 B20.b CH3 N H COCH3 CH CH CH N NCH3 CH3 1361 B20.b CH3 CH H CF CH CH CH N NCH3 CH3 137 B23 CH3 CH H CF CH CH CH N NCH3 H 138 B29 CH3 CH H CF CH CH CH N NCH3 CH3 139 B20.a CH3 CH H CF CH CH CH N NCH3 CH3 140 B18 CH3 CH H COCH3 N CH CH CH NCH3 F 141 B29 CH3 CH H CF CH CH CH N NCH3 CH3 142 B29 CH3 CH H CF CH CH CH N NCH3 CH3 143 B29 CH3 CH H CF CH CH CH N NCH3 CH3 144 B29 CH3 CH H CF CH CH CH N NCH3 CH3 145 B23 CH3 N H COCH3 CH CH CH N NCH3 H 146 B18 CH3 CH H COCH3 N CH CH CH NCH3 H 147 B19 CH3 N H COCH3 CH CH CH N NCH3 CH3 148 B24 CH3 N CH3 COCH3 CH CH CH N NCH3 H 149 B19 CH3 CH H COCH3 N CH CH N NCH3 CH3 150 B19 CH3 CH H COCH3 N CH CH N NCH3 CH3 151 B4 CH3 CH H COCH3 N CH CH CH NCH3 F 152 B14 CH3 CH H COCH3 N CH CH CH O H 153 B29 CH3 CH H CF CH CH CH N NCH3 CH3 154 B30 CH3 CH I CF CH CH CH N NCH3 CH3 155 B33 CH3 CH H CF CH CH CH N NCH3 CH3 156 B23 CH3 N H COCH3 CH CH CH N NCH3 Cl 157 B24 CH3 N CH3 COCH3 CH CH CH N NCH(CH3)2 H 159 B23 CH3 CH H COCH3 N CH CH N NCH3 CH(CH3)2 160 B18 CH3 CH H COCH3 N CH CH CH NCH3 OCH3 161 B18 CH3 N H COCH3 N CH CH CH NCH3 H 162 B18 CH3 N H COCH3 N CH CH CH NCH(CH3)2 H 163 B24 CH3 N H COCH3 CH CH CH N NCH3 CH3 164 B19 CH3 N H COCH3 CH CH CH N NCH3 CH3 165 B27 CH3 CH H COCH3 N CH CH CH NCH3 H 166 B23 CH3 N CH3 COCH3 CH CH CH N NCH(CH3)2 H 167 B27 CH3 CH H COCH3 N CH CH CH NCH3 H 168 B27 CH3 CH H COCH3 N CH CH CH NCH3 H 169 B33 CH3 CH H COCH3 N CH CH CH NCH3 H 170 B27 CH3 CH H COCH3 N CH CH CH NCH3 H 171 B27 CH3 CH H COCH3 N CH CH CH NCH3 H 172 B27 CH3 CH H COCH3 N CH CH CH NCH3 H 173 B26 CH3 CH H COCH3 N CH CH CH NCH3 H 174 B26 CH3 CH H COCH3 N CH CH CH NCH3 H 175 B26 CH3 CH H COCH3 N CH CH CH NCH3 H 176 B27 CH3 CH H COCH3 N CH CH CH NCH3 H 177 B27 CH3 CH H COCH3 N CH CH CH NCH3 H 178 B27 CH3 CH H COCH3 N CH CH CH NCH3 H 179 B27 CH3 CH H COCH3 N CH CH CH NCH3 H 180 B27 CH3 CH H COCH3 N CH CH CH NCH3 H 181 B27 CH3 CH H COCH3 N CH CH CH NCH3 H 182 B27 CH3 CH H COCH3 N CH CH CH NCH3 H 183 B27 CH3 CH H COCH3 N CH CH CH NCH3 H 184 B27 CH3 CH H COCH3 N CH CH CH NCH3 H 185 B27 CH3 CH H COCH3 N CH CH CH NCH3 H 186 B27 CH3 CH H COCH3 N CH CH CH NCH3 H 187 B33 CH3 CH H COCH3 N CH CH CH NCH3 H 188 B26 CH3 CH H COCH3 N CH CH CH NCH3 H 189 B26 CH3 CH H COCH3 N CH CH CH NCH3 H 190 B27 CH3 CH H COCH3 N CH CH CH NCH3 H 191 B26 CH3 CH H COCH3 N CH CH CH NCH3 H 192 B26 CH3 CH H COCH3 N CH CH CH NCH3 H 193 B26 CH3 CH H COCH3 N CH CH CH NCH3 H 194 B26 CH3 CH H COCH3 N CH CH CH NCH3 H 195 B26 CH3 CH H COCH3 N CH CH CH NCH3 H 196 B26 CH3 CH H COCH3 N CH CH CH NCH3 H 197 B26 CH3 CH H COCH3 N CH CH CH NCH3 H 198 B26 CH3 CH H COCH3 N CH CH CH NCH3 H - Compounds 165, 167,168, 170-172, 176-187 and 190 were obtained as HCl salt forms (.2HCl.H2O). Compound 166 was obtained as a HCl salt form (1.5 HCl.1.4H2O). Compounds 210 and 211 were obtained as a HCl salt form (.2HCl). Compound 209 was obtained as a mesylate (.2CH3SO3H) All other compounds in Table 1b were obtained as free bases
Table 1c (all compounds in table 1c were obtained as free bases) Co. No. Pr. R1 X A1 A2 R4 Y3 Z R3 109 B21 CH3 N COCH3 CH N NCH3 110 B21 CH3 N COCH3 CH CH(CH3)2 N NCH3 111 B22 CH3 CH COCH3 N CH(CH3)2 N NCH3 112 B23 CH3 CH CF CH CH3 N NCH3 113 B24 CH3 N COCH3 CH CH3 N NCH3 199 B23 CH3 N COCH3 CH N NCH3 200 B23 CH3 N COCH3 CH H N NCH3 201 B22 CH3 CH COCH3 N H N NCH3 202 B23 CH3 CH COCH3 N OCH3 N NCH3 203 B22 CH3 CH COCH3 N CH3 N NCH3 204 B23 CH3 CH CF CH OCH3 N NCH3 205 B23 CH3 CH CF CH H N NCH3 206 B23 CH3 CH CF CH CH(CH3)2 N NCH3 207 B23 CH3 CH CF CH N NCH3 208 B32 CH3 N COCH3 CH (CH2)3OCH3 N NCH3 Table 1d Co. No. Pr. R1 X A1 A2 Y2 Z R3 158 B19 CH3 N COCH3 CH N NCH3 - The LC measurement was performed using an Acquity UPLC (Waters) system comprising a binary pump, a sample organizer, a column heater (set at 55 °C), a diode-array detector (DAD) and a column as specified in the respective methods below. Flow from the column was split to a MS spectrometer The MS detector was configured with an electrospray ionization source Mass spectra were acquired by scanning from 100 to 1000 in 0.18 seconds (sec) using a dwell time of 0.02 seconds The capillary needle voltage was 3.5 kV and the source temperature was maintained at 140 °C. Nitrogen was used as the nebulizer gas Data acquisition was performed with a Waters-Micromass MassLynx-Openlynx data system.
- The HPLC measurement was performed using an Agilent 1100 series liquid chromatography system comprising a binary pump with degasser, an autosampler, a column oven, a UV detector and a column as specified in the respective methods below. Flow from the column was split to a MS spectrometer. The MS detector was configured with an electrospray ionization source. The capillary voltage was 3 kV, the quadrupole temperature was maintained at 100 °C and the desolvation temperature was 300 °C. Nitrogen was used as the nebulizer gas. Data acquisition was performed with an Agilent Chemstation data system.
- The HPLC measurement was performed using an Alliance HT 2790 (Waters) system comprising a quaternary pump with degasser, an autosampler, a column oven (set at 40 °C, unless otherwise indicated), a diode-array detector (DAD) and a column as specified in the respective methods below. Flow from the column was split to a MS spectrometer. The MS detector was configured with an electrospray ionization source. Mass spectra were acquired by scanning from 100 to 1000 in 1 sec using a dwell time of 0.1 sec. The capillary needle voltage was 3 kV and the source temperature was maintained at 140 °C. Nitrogen was used as the nebulizer gas. Data acquisition was performed with a Waters-Micromass MassLynx-Openlynx data system.
- In addition to general procedure A: Reversed phase UPLC (Ultra Performance Liquid Chromatography) was carried out on a bridged ethylsiloxane/silica hybrid (BEH) C 18 column (1.7 µm, 2.1 x 50 mm; Waters Acquity) with a flow rate of 0.8 ml/min. Two mobile phases (25 mM NH4OAc in H2O/CH3CN 95/5; mobile phase B: CH3CN) were used to run a gradient condition from 95 % A and 5 % B to 5 % A and 95 % B in 1.3 minutes and hold for 0.3 minutes (min). An injection volume of 0.5 µl was used. Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.
- In addition to general procedure A: Reversed phase UPLC was carried out on a BEH C18 column (1.7 µm, 2.1 x 50 mm; Waters Acquity) with a flow rate of 0.8 ml/min. Two mobile phases (mobile phase A: 0.1 % formic acid in H2O/MeOH 95/5; mobile phase B: MeOH) were used to run a gradient condition from 95 % A and 5 % B to 5 % A and 95 % B in 1.3 min and hold for 0.2 min. An injection volume of 0.5 µl was used. Cone voltage was 10 V for positive and 20 V for negative ionization mode.
- In addition to general procedure B: Reversed phase HPLC was carried out on a YMC-Pack ODS-AQ C18 column (4.6 x 50 mm) with a flow rate of 2.6 ml/min. A gradient run was used from 95 % water and 5 % CH3CN to 95 % CH3CN in 4.80 min and was hold for 1.20 min. Mass spectra were acquired by scanning from 100 to 1400. Injection volume was 10 µl. Column temperature was 35 °C.
- In addition to general procedure C: Column heater was set at 60 °C. Reversed phase HPLC was carried out on an Xterra MS C18 column (3.5 µm, 4.6 x 100 mm) with a flow rate of 1.6 ml/min. Three mobile phases (mobile phase A: 95 % 25 mM NH4OAc + 5 % CH3CN; mobile phase B: CH3CN; mobile phase C: MeOH) were employed to run a gradient condition from 100 % A to 50 % B and 50 % C in 6.5 min, to 100 % B in 0.5 min and hold these conditions for 1 min and reequilibrate with 100 % A for 1.5 min. An injection volume of 10 µl was used. Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.
- In addition to general procedure C: Column heater was set at 45 °C. Reversed phase HPLC was carried out on an Atlantis C18 column (3.5 µm, 4.6 x 100 mm) with a flow rate of 1.6 ml/min. Two mobile phases (mobile phase A: 70 % MeOH + 30 % H2O; mobile phase B: 0.1 % formic acid in H2O/MeOH 95/5) were employed to run a gradient condition from 100 % B to 5 % B + 95 % A in 9 min and hold these conditions for 3 min. An injection volume of 10 µl was used. Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.
- In addition to general procedure C: Reversed phase HPLC was carried out on an Xterra MS C18 column (3.5 µm, 4.6 x 100 mm) with a flow rate of 1.6 ml/min. Three mobile phases (mobile phase A: 95% 25 mM NH4OAc + 5 % CH3CN; mobile phase B: CH3CN; mobile phase C: MeOH) were employed to run a gradient condition from 100%Ato 1 % A, 49 % B and 50 % C in 6.5 min, to 1 % A and 99 % B in 1 min and hold these conditions for 1 min and reequilibrate with 100 % A for 1.5 min. An injection volume of 10 µl was used. Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.
- In addition to general procedure A: Reversed phase UPLC (Ultra Performance Liquid Chromatography) was carried out on a bridged ethylsiloxane/silica hybrid (BEH) C 18 column (1.7 µm, 2.1 x 50 mm; Waters Acquity) with a flow rate of 0.8 ml/min. Two mobile phases (25 mM NH4OAc in H2O/CH3CN 95/5; mobile phase B: CH3CN) were used to run a gradient condition from 95 % A and 5 % B to 5 % A and 95 % B in 1.3 min and hold for 0.3 min. An injection volume of 0.5 µl was used. Cone voltage was 30 V for positive ionization mode and 30 V for negative ionization mode.
- In addition to general procedure C: Reversed phase HPLC was carried out on an Xterra MS C18 column (3.5 µm, 4.6 x 100 mm) with a flow rate of 1.6 ml/min. Three mobile phases (mobile phase A: 95% 25 mM NH4OAc + 5 % CH3CN; mobile phase B: CH3CN; mobile phase C: MeOH) were employed to run a gradient condition from 100 % A to 1 % A, 49 % B and 50 % C in 6.5 min, to 1 % A, 99 % B in 0.5 min and keep these conditions for 1 min. An injection volume of 10 µl was used. Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.
- For a number of compounds, melting points (m.p.) were determined with a DSC823e (Mettler-Toledo). Melting points were measured with a temperature gradient of 30 °C/minute. Maximum temperature was 400 °C. Values are peak values.
-
- For Co. No. 137, the [M-H]- peak was detected: Rt 5.98; [M-H]- 415; LCMS Method 5; Melting Point: 225.6 °C.
- For a number of compounds, 1H NMR spectra were recorded on a Bruker DPX-360, on a Bruker DPX-400 or on a Bruker Avance 600 spectrometer with standard pulse sequences, operating at 360 MHz, 400 MHz and 600 MHz respectively, using CHLOROFORM-d (deuterated chloroform, CDCl3) or DMSO-d 6 (deuterated DMSO, dimethyl-d6 sulfoxide) as solvents. Chemical shifts (δ) are reported in parts per million (ppm) relative to tetramethylsilane (TMS), which was used as internal standard.
- Co. No. 1: (360 MHz, DMSO-d 6) δ ppm 2.14 (s, 3 H), 3.74 (s, 3 H), 3.86 (s, 3 H), 6.93 (dd, J=8.5, 2.2 Hz, 1 H), 7.01 (s, 1 H), 7.12-7.23 (m, 5 H), 7.43 (t, 6 J=8.8 Hz, 2 H), 7.63 (d, J=1.3 Hz, 1 H), 7.92 (dd, J=8.6, 5.5 Hz, 2 H), 8.46 (s, 1 H).
- Co. No. 2: (360 MHz, DMSO-d 6) δ ppm 1.59 (d, J=6.9 Hz, 6 H), 2.14 (s, 3 H), 3.74 (s, 3 H), 4.58-4.71 (m, J=6.9, 6.9, 6.9, 6.9 Hz, 1 H), 6.95 (dd, J=8.5, 2.2 6 Hz, 1 H), 7.01 (s, 1 H), 7.12-7.20 (m, 4 H), 7.29-7.37 (m, 1 H), 7.43 (t, J=8.8 Hz, 2 H), 7.63 (d, J=1.3 Hz, 1 H), 7.73 (dd, J=8.5, 5.5 Hz, 2 H), 8.41 (s, 1 H).
- Co. No. 3: (360 MHz, DMSO-d 6) δ ppm 2.14 (s, 3 H), 3.70 (s, 3 H), 3.73 (s, 3 H), 6.93 (dd, J=8.5, 2.3 Hz, 1 H), 7.01 (s, 1 H), 7.12 (d, J=2.3 Hz, 1 H), 7.15-6 7.26 (m, 4 H), 7.35 (td, J=8.5, 2.6 Hz, 1 H), 7.56 (td, J=9.9, 2.5 Hz, 1 H), 7.63 (d, J=1.3 Hz, 1 H), 7.76-7.83 (m, 1 H), 8.50 (s, 1 H).
- Co. No. 4: (360 MHz, DMSO-d 6) δ ppm 2.32 (s, 3 H), 3.78 (s, 3 H), 3.86 (s, 3 H), 6.95 (dd, J=8.7, 2.2 Hz, 1 H), 7.13 (d, J=2.2 Hz, 1 H), 7.17-7.25 (m, 3 H), 6 7.38 (d, J=8.6 Hz, 1 H), 7.43 (t, J=8.8 Hz, 2 H), 7.92 (dd, J=8.6, 5.5 Hz, 2 H), 8.55 (s, 1 H), 8.61 (s, 1 H).
- Co. No. 5: (360 MHz, CDCl3) δ ppm 2.31 (s, 3 H), 3.86 (s, 3 H), 6.93 (s, 1 H), 6.99-7.06 (m, 2 H), 7.26 (t, 2 H), 7.34 (t, J=8.2 Hz, 1 H), 7.53 (dd, J=8.8, 2.7 Hz, 1 H), 7.66 (s, 1 H), 7.76 (dd, J=8.5, 5.3 Hz, 2 H), 7.92 (s, 1 H), 8.24 (d, J=8.0 Hz, 1 H), 8.36 (d, J=2.7 Hz, 1 H).
- Co. No. 6: (600 MHz, CDCl3) δ ppm 2.30 (d, J=1.1 Hz, 3 H), 3.86 (s, 3 H), 6.93 (br. s, 1 H), 7.03 (dd, J=8.1, 0.8 Hz, 1 H), 7.07 (dd, J=8.1, 0.8 Hz, 1 H), 7.24-7.28 (m, 3 H), 7.53-7.56 (m, J=1.1, 1.1, 1.1, 1.1 Hz, 1 H), 7.75 (dd, J=8.7, 5.3 Hz, 2 H), 8.45 (d, J=1.3 Hz, 1 H), 8.67 (s, 2 H).
- Co. No. 7: (600 MHz, CDCl3) δ ppm 2.30 (d, J=1.1 Hz, 3 H), 3.84 (s, 3 H), 6.94 (dd, J=8.0, 0.9 Hz, 1 H), 6.95-6.96 (m, J=1.2, 1.2, 1.2, 1.2 Hz, 1 H), 7.10 (br. s, 1 H), 7.19 (dd, J=8.0, 0.9 Hz, 1 H), 7.22-7.26 (m, 3 H), 7.28 (d, J=8.7 Hz, 2 H), 7.36 (d, J=8.7 Hz, 2 H), 7.69 (d, J=1.4 Hz, 1 H), 7.74 (dd, J=8.7, 5.3 Hz, 2 H).
- Co. No. 8: (400 MHz, DMSO-d 6) δ ppm 2.15 (d, J=1.0 Hz, 3 H), 3.81 (s, 3 H), 3.86 (s, 3 H), 7.04 (s, 1 H), 7.17 (d, J=5.8 Hz, 1 H), 7.23 (d, J=8.6 Hz, 1 H), 6 7.45 (t, J=8.8 Hz, 2 H), 7.66 (s, 1 H), 7.91 (dd, J=8.6, 2.2 Hz, 1 H), 7.96 (dd, J=8.7, 5.5 Hz, 2 H), 8.00-8.02 (m, 2 H), 9.23 (s, 1 H).
- Co. No. 15: (400 MHz, CDCl3) δ ppm 2.29 (d, J=1.01 Hz, 3 H) 3.83 (s, 3 H) 4.06 (s, 3 H) 6.57 (d, J=8.31 Hz, 1 H) 6.86 (t, J=1.01 Hz, 1 H) 7.02 (dd, J=8.06, 0.76 Hz, 1 H) 7.24 (t, J=8.81 Hz, 2 H) 7.31 (t, J=8.06 Hz, 1 H) 7.39 (d, J=8.06 Hz, 1 H) 7.62 (d, J=1.26 Hz, 1 H) 7.74 (dd, J=8.81, 5.29 Hz, 2 H) 7.94 (s, 1 H) 8.16 (d, J=7.81 Hz, 1 H).
- Co. No. 16: (360 MHz, CDCl3) δ ppm 2.31 (s, 3 H), 3.83 (s, 3 H), 6.89 (s, 1 H), 6.91 (s, 1 H), 6.93-6.98 (m, 2 H), 7.16 (dd, J=7.3, 1.5 Hz, 1 H), 7.20 (d, J=9.1 Hz, 1 H), 7.24-7.33 (m, 2 H), 7.41-7.50 (m, 2 H), 7.59 (dd, J=7.4, 1.9 Hz, 1 H), 7.64 (s, 1 H), 8.14 (dd, J=7.2, 2.3 Hz, 1 H).
- Co. No. 17: (360 MHz, CDCl3) δ ppm 1.27-1.50 (m, 3 H), 1.65-1.77 (m, 3 H), 1.84-1.93 (m, 2 H), 2.11-2.20 (m, 2 H), 2.30 (s, 3 H), 2.96 (tt, J=11.4, 3.6 Hz, 1 H), 3.81 (s, 3 H), 6.72 (s, 1 H), 6.85-6.91 (m, 3 H), 7.02-7.08 (m, 1 H), 7.14-7.22 (m, 3 H), 7.63 (s, 1 H).
- Co. No. 18: (360 MHz, CDCl3) δ ppm 1.05 (d, J=6.7 Hz, 6 H), 2.23-2.36 (m, 1 H), 2.30 (s, 3 H), 2.81 (d, J=7.2 Hz, 2 H), 3.81 (s, 3 H), 6.72 (s, 1 H), 6.86-6.91 (m, 3 H), 7.03-7.09 (m, 1 H), 7.16 (d, J=9.1 Hz, 1 H), 7.19-7.24 (m, 2 H), 7.62 (d, J=1.3 Hz, 1 H).
- Co. No. 25: (360 MHz, DMSO-d 6) δ ppm 1.02 (d, J=7.0 Hz, 6 H), 2.27-2.43 (m, 4 H), 3.09 (d, J=7.3 Hz, 2 H), 3.82 (s, 3 H), 3.98 (s, 3 H), 6.94 (dd, J=8.6, 2.2 Hz, 1 H), 7.08 (d, J=2.2 Hz, 1 H), 7.39-7.55 (m, 4 H), 7.66 (s, 1 H), 9.31 (d, J=1.5 Hz, 1 H), 9.53 (br. s, 1 H).
- Co. No. 37: (360 MHz, CDCl3) δ ppm 1.68-1.80 (m, 2 H), 1.81-1.93 (m, 2 H), 1.98-2.10 (m, 2 H), 2.12-2.22 (m, 2 H), 2.30 (s, 3 H), 3.33-3.43 (m, J=8.1, 8.1, 8.1, 8.1 Hz, 1 H), 3.81 (s, 3 H), 6.70 (s, 1 H), 6.85-6.90 (m, 3 H), 7.01-7.07 (m, 1 H), 7.14-7.22 (m, 3 H), 7.63 (d, J=1.3 Hz, 1 H).
- Co. No. 38: (360 MHz, CDCl3) δ ppm 1.32-1.51 (m, 3 H), 1.73-1.87 (m, 3 H), 1.88-2.04 (m, 4 H), 2.30 (s, 3 H), 2.86 (tt, J=11.8, 3.4 Hz, 1 H), 3.75 (s, 3 H), 3.81 (s, 3 H), 6.84-6.90 (m, 2 H), 6.91-6.96 (m, 2 H), 7.04 (s, 1 H), 7.12-7.18 (m, 3 H), 7.62 (s, 1 H). Co. No. 40: (360 MHz, CDCl3) δ ppm 2.06-2.26 (m, 4 H), 2.30 (s, 3 H), 2.36 (s, 3 H), 2.89-3.04 (m, 3 H), 3.64 (br. s, 2 H), 3.79 (s, 3 H), 6.75 (s, 1 H), 6.84-6.91 (m, 3 H), 7.02-7.09 (m, 1 H), 7.17 (d, J=8.8 Hz, 1 H), 7.19-7.23 (m, 2 H), 7.65 (s, 1 H).
- Co. No. 41: (360 MHz, CDCl3) δ ppm 1.85-2.03 (m, 2 H), 2.15 (s, 3 H), 2.16-2.25 (m, 2 H), 2.30 (s, 3 H), 2.95 (ddd, J=13.7, 11.1, 3.1 Hz, 1 H), 3.22 (tt, J=10.7, 4.0 Hz, 1 H), 3.30 (ddd, J=13.8, 11.1, 2.8 Hz, 1 H), 3.82 (s, 3 H), 3.92 (dt, J=13.8, 4.2 Hz, 1 H), 4.56 (dt, J=13.5, 4.2 Hz, 1 H), 6.74 (s, 1 H), 6.86-6.91 (m, 3 H), 7.02-7.08 (m, 1 H), 7.17 (d, J=9.0 Hz, 1 H), 7.20-7.25 (m, 2 H), 7.63 (d, J=1.3 Hz, 1 H).
- Co. No. 42: (360 MHz, CDCl3) δ ppm 1.48 (s, 9 H), 1.84-1.97 (m, 2 H), 2.08-2.18 (m, 2 H), 2.30 (s, 3 H), 2.99 (t, J=12.0 Hz, 2 H), 3.13 (tt, J=11.0, 3.9 Hz, 1 H), 3.82 (s, 3 H), 4.16 (br. s, 2 H), 6.71 (s, 1 H), 6.86-6.91 (m, 3 H), 7.02-7.07 (m, 1 H), 7.16-7.23 (m, 3 H), 7.63 (d, J=1.3 Hz, 1 H).
- Co. No. 44: (600 MHz, DMSO-d 6) δ ppm 1.15 (d, J=6.2 Hz, 6 H), 2.14 (d, J=1.0 Hz, 3 H), 2.61 (dd, J=12.3, 10.4 Hz, 2 H), 3.44 (d, J=12.0 Hz, 2 H), 3.62 (s, 3 6 H), 3.73 (s, 3 H), 3.81-3.87 (m, 2 H), 6.82 (dd, J=8.5, 2.3 Hz, 1 H), 6.96 (dd, J=6.5, 2.4 Hz, 1 H), 6.98 (t, J=1.2 Hz, 1 H), 7.01-7.06 (m, 3 H), 7.13 (d, J=8.5 Hz, 1 H), 7.60 (d, J=1.3 Hz, 1 H), 7.99 (s, 1 H).
- Co. No. 47: (360 MHz, DMSO-d 6) δ ppm 2.14 (s, 3 H), 3.74 (s, 3 H), 3.85 (s, 3 H), 3.85 (s, 3 H), 6.92 (dd, J=8.5, 2.3 Hz, 1 H), 7.01 (s, 1 H), 7.11-7.21 (m, 7 6 H), 7.63 (d, J=1.3 Hz, 1 H), 7.81 (d, J=8.6 Hz, 2 H), 8.42 (s, 1 H).
- Co. No. 48: (360 MHz, CDCl3) δ ppm 2.31 (s, 3 H), 3.81 (s, 3 H), 4.02 (s, 3 H), 6.88 (s, 1 H), 6.91-6.94 (m, 2 H), 7.09-7.19 (m, 5 H), 7.23-7.29 (m, 2 H), 7.49-7.55 (m, 1 H), 7.63 (s, 1 H), 8.12 (dd, J=7.7, 1.8 Hz, 1 H).
- Co. No. 54: (360 MHz, DMSO-d 6) δ ppm 2.35 (s, 3 H) 3.15 (s, 3 H) 3.78 (t, J=4.76 Hz, 2 H) 3.83 (s, 3 H) 3.89 (s, 3 H) 4.62 (t, J=4.76 Hz, 2 H) 7.01 (dd, J=8.78, 2.20 Hz, 1 H) 7.16 (d, J=2.20 Hz, 1 H) 7.30 (dd, J=8.05, 1.83 Hz, 1 H) 7.41-7.57 (m, 5 H) 7.58-7.65 (m, 2 H) 7.66 (s, 1 H) 9.31 (d, J=1.46 Hz, 1 H) 9.44 (br. s, 1 H) 15.01 (br. s, 1 H).
- Co. No. 62: (360 MHz, DMSO-d 6) δ ppm 2.14 (s, 3 H), 3.75 (s, 3 H), 6.93 (dd, J=8.5, 2.3 Hz, 1 H), 7.02 (s, 1 H), 7.06-7.20 (m, 5 H), 7.42 (t, J=8.7 Hz, 2 H), 6 7.64 (s, 1 H), 8.23 (dd, J=8.5, 5.4 Hz, 2 H), 8.38 (s, 1 H), 12.93 (s, 1 H).
- Co. No. 63: (400 MHz, CDCl3) δ ppm 3.81 (s, 3 H) 3.85 (s, 3 H) 6.92-7.01 (m, 3 H) 7.13-7.21 (m, 4 H) 7.21-7.30 (m, 4 H) 7.69-7.79 (m, 3 H).
- Co. No. 66: (360 MHz, DMSO-d 6) δ ppm 2.14 (s, 3 H), 3.70 (d, J=1.6 Hz, 3 H), 3.74 (s, 3 H), 6.93 (dd, J=8.5, 2.3 Hz, 1 H), 7.01 (s, 1 H), 7.12 (d, J=2.2 Hz, 1 6 H), 7.15-7.20 (m, 3 H), 7.24 (t, J=7.7 Hz, 1 H), 7.41-7.51 (m, 2 H), 7.63 (d, J=1.3 Hz, 1 H), 7.63-7.69 (m, 1 H), 7.70-7.75 (m, 1 H), 8.50 (s, 1 H).
- Co. No. 67: (400 MHz, CDCl3) δ ppm 2.31 (s, 3 H), 3.85 (s, 3 H), 6.92 (s, 1 H), 6.99-7.03 (m, 1 H), 7.06 (dd, J=8.7, 2.5 Hz, 1 H), 7.15 (s, 1 H), 7.18-7.30 (m, 6 H), 7.65 (s, 1 H), 7.74 (dd, J=8.5, 5.3 Hz, 2 H).
- Co. No. 70: (400 MHz, DMSO-d 6) δ ppm 2.37 (s, 3 H), 3.86 (s, 3 H), 7.10 (dd, J=6.2, 2.5 Hz, 1 H), 7.19-7.26 (m, 2 H), 7.42 (t, J=8.8 Hz, 2 H), 7.67 (d, J=8.8 6 Hz, 1 H), 7.81 (dd, J=8.8, 2.8 Hz, 1 H), 7.91 (dd, J=8.6, 5.6 Hz, 2 H), 8.41 (d, J=2.7 Hz, 1 H), 8.74 (s, 1 H), 9.06 (s, 1 H).
- Co. No. 71: (360 MHz, DMSO-d 6) δ ppm 3.75 (s, 3 H), 3.86 (s, 3 H), 6.93 (dd, J=8.8, 2.2 Hz, 1 H), 7.13 (d, J=2.2 Hz, 1 H), 7.16-7.25 (m, 4 H), 7.44 (t, J=8.8 6 Hz, 2 H), 7.50 (d, J=1.1 Hz, 1 H), 7.78 (d, J=1.1 Hz, 1 H), 7.92 (dd, J=8.5, 5.5 Hz, 2 H), 8.55 (s, 1 H).
- Co. No. 74: (360 MHz, DMSO-d 6) δ ppm 1.67 (d, J=6.9 Hz, 6 H), 2.35 (s, 3 H), 4.67-4.80 (m, J=6.9, 6.9, 6.9, 6.9 Hz, 1 H), 7.13 (dd, J=8.7, 2.5 Hz, 1 H), 7.18 6 (dd, J=12.8, 2.6 Hz, 1 H), 7.42-7.52 (m, 2 H), 7.55-7.62 (m, 3 H), 7.75 (d, J=7.8 Hz, 1 H), 7.91 (dd, J=8.5, 5.3 Hz, 2 H), 8.76 (d, J=2.0 Hz, 1 H), 9.32 (br. s, 1 H).
- Co. No. 75: (360 MHz, DMSO-d 6) δ ppm 1.69 (d, J=6.95 Hz, 6 H) 2.37 (s, 3 H) 3.84 (s, 3 H) 4.77 (spt, J=6.95 Hz, 1 H) 6.96 (dd, J=8.42, 2.20 Hz, 1 H) 7.08 (d, J=2.20 Hz, 1 H) 7.47-7.55 (m, 3 H) 7.62 (t, J=8.78 Hz, 2 H) 7.67-7.73 (m, 1 H) 7.96 (dd, J=8.78, 5.12 Hz, 2 H) 8.91 (s, 1 H) 9.40 (br. s, 1 H).
- Co. No. 79: (360 MHz, CDCl3) δ ppm 2.31 (s, 3 H), 3.82 (s, 3 H), 5.41 (s, 2 H), 6.80 (d, J=7.9 Hz, 1 H), 6.88 (s, 1 H), 6.94-6.99 (m, 2 H), 7.09-7.20 (m, 7 H), 7.25 (d, J=8.1 Hz, 1 H), 7.30-7.38 (m, 3 H), 7.61-7.68 (m, 3 H).
- Co. No. 80: (400 MHz, DMSO-d 6) δ ppm 2.15 (d, J=1.0 Hz, 3 H), 3.76 (s, 3 H), 6.90 (dd, J=8.5, 2.3 Hz, 1 H), 7.03 (s, 1 H), 7.10 (d, J=2.3 Hz, 1 H), 7.22 (d, 6 J=8.5 Hz, 1 H), 7.25-7.34 (m, 3 H), 7.47 (t, J=8.8 Hz, 2 H), 7.65 (d, J=1.3 Hz, 1 H), 8.25 (dd, J=8.8, 5.4 Hz, 2 H), 8.74 (s, 1 H).
- Co. No. 82: (360 MHz, CDCl3) δ ppm 2.30 (s, 3 H), 3.80 (s, 3 H), 4.25 (s, 2 H), 6.74 (s, 1 H), 6.85-6.89 (m, 3 H), 7.01-7.08 (m, 3 H), 7.16 (d, J=9.0 Hz, 1 H), 7.19-7.22 (m, 2 H), 7.35 (dd, J=8.4, 5.3 Hz, 2 H), 7.62 (d, J= 1. Hz, 1 H).
- Co. No. 86: (360 MHz, CDCl3) δ ppm 2.31 (d, J=1.0 Hz, 3 H), 3.84 (s, 3 H), 6.87 (s, 1 H), 6.88-6.91 (m, 1 H), 6.93-6.97 (m, 2 H), 7.16 (dd, J=7.4, 1.5 Hz, 1 H), 7.21 (d, J=9.0 Hz, 1 H), 7.25-7.32 (m, 2 H), 7.49 (ddd, J=8.0, 4.9,0.9 Hz, 1 H), 7.65 (d, J=1.3 Hz, 1 H), 8.50 (dt, J=8.0, 1.9 Hz, 1 H), 8.77 (dd, J=4.9, 1.7 Hz, 1 H), 9.48 (dd, J=2.2, 0.9 Hz, 1 H).
- Co. No. 92: (360 MHz, DMSO-d 6) δ ppm 2.34 (s, 3 H) 3.85 (s, 3 H) 3.87 (s, 3 H) 7.20 (d, J=5.85 Hz, 1 H) 7.38-7.53 (m, 3 H) 7.92-8.00 (m, 3 H) 8.03 (d, J=5.85 Hz, 1 H) 8.06 (d, J=2.20 Hz, 1 H) 8.65 (s, 1 H) 9.34 (s, 1 H).
- Co. No. 104: (360 MHz, DMSO-d 6) δ ppm 2.17 (s, 3 H) 3.72 (s, 3 H) 7.18 (s, 1 H) 7.24 (d, J=5.85 Hz, 1 H) 7.37 (td, J=8.60, 2.20 Hz, 1 H) 7.46 (t, J=8.97 Hz, 1 H) 7.59 (td, J=9.15, 2.20 Hz, 1 H) 7.78-7.89 (m, 2 H) 7.95 (dd, J=9.15, 1.83 Hz, 1 H) 8.06 (d, J=5.85 Hz, 1 H) 8.39 (dd, J=14.27, 2.20 Hz, 1 H) 9.69 (s, 1 H).
- Co. No. 106: (360 MHz, CDCl3) δ ppm 1.63 (d, J=7.0 Hz, 6 H), 2.30 (s, 3 H), 4.10 (s, 3 H), 4.70 (spt, J=7.0 Hz, 1 H), 6.53 (d, J=8.1 Hz, 1 H), 6.88 (s, 1 H), 6.90 (dd, J=9.1, 2.2 Hz, 1 H), 7.26 (t, J=8.6 Hz, 2 H), 7.43 (d, J=8.1 Hz, 1 H), 7.55-7.68 (m, 3 H), 7.96 (s, 1 H), 8.12 (dd, J=12.8, 2.2 Hz, 1 H).
- Co. No. 107: (360 MHz, CHLOROFORM-d) δ ppm 1.42 (d, J=7.0 Hz, 6 H), 2.49 (s, 3 H), 3.12 (spt, J=7.0 Hz, 1 H), 3.82 (s, 3 H), 4.00 (s, 3 H), 6.74 (s, 1 H), 7.16 (dd, J=8.8, 1.8 Hz, 1 H), 7.22-7.31 (m, 2 H), 7.58 (d, J=8.8 Hz, 1 H), 7.74 (dd, J=8.1, 5.9 Hz, 2 H), 7.78 (s, 1 H), 8.51 (s, 1 H), 8.58 (s, 1 H).
- Co. No. 108: (600 MHz, CDCl3) δ ppm 2.31 (d, J=1.0 Hz, 3 H), 2.65 (s, 3 H), 3.81 (s, 3 H), 6.77 (d, J=0.8 Hz, 1 H), 6.92-6.95 (m, 1 H), 7.24-7.30 (m, 3 H), 7.44 (dd, J=8.7, 2.4 Hz, 1 H), 7.67 (t, J=1.4 Hz, 1 H), 7.74 (dd, J=8.8, 5.2 Hz, 2 H), 7.80 (s, 1 H), 8.35 (dd, J=13.5, 2.4 Hz, 1 H).
- Co. No. 110: (360 MHz, CDCl3) δ ppm 1.34 (d, J=6.95 Hz, 6 H) 2.50 (s, 3 H) 3.10 (spt, J=6.95 Hz, 1 H) 3.91 (s, 3 H) 3.93 (s, 3 H) 6.98-7.08 (m, 3 H) 7.25 (t, J=8.42 Hz, 2 H) 7.33 (s, 1 H) 7.70 (d, J=8.05 Hz, 1 H) 7.78 (dd, J=8.42, 5.31 Hz, 2 H) 8.54 (s, 1 H).
- Co. No. 111: (360 MHz, CDCl3) δ ppm 1.39 (d, J=7.0 Hz, 6 H), 2.31 (s, 3 H), 3.17 (spt, J=6.9 Hz, 1 H), 3.94 (s, 3 H), 4.14 (s, 3 H), 6.60 (d, J=8.1 Hz, 1 H), 6.90 (s, 1 H), 7.20-7.32 (m, 2 H), 7.48 (d, J=8.1 Hz, 1 H), 7.67 (s, 1 H), 7.79 (dd, J=8.1, 5.5 Hz, 2 H), 8.05 (s, 1 H), 8.21 (s, 1 H).
- Co. No. 112: (360 MHz, DMSO-d 6) δ ppm 2.17 (s, 3 H), 2.51 (s, 3 H), 3.85 (s, 3 H), 6.95 (s, 1 H), 7.20 (s, 1 H), 7.33 (dd, J=8.8, 2.2 Hz, 1 H), 7.37-7.47 (m, 3 H), 7.52 (t, J=8.8 Hz, 1 H), 7.84 (s, 1 H), 7.96 (dd, J=8.8, 5.5 Hz, 2 H), 9.36 (s, 1 H).
- Co. No. 113: (360 MHz, CDCl3) δ ppm 2.50 (s, 3 H) 2.60 (s, 3 H) 3.91 (s, 3 H) 3.92 (s, 3 H) 6.93 (s, 1 H) 6.97 (d, J=2.20 Hz, 1 H) 7.08 (dd, J=8.42, 2.20 Hz, 1 H) 7.26 (t, J=8.60 Hz, 2 H) 7.35 (s, 1 H) 7.70 (d, J=8.42 Hz, 1 H) 7.78 (dd, J=8.78, 5.49 Hz, 2 H) 8.55 (s, 1 H).
- Co. No. 114: (360 MHz, DMSO-d 6) δ ppm 2.33 (s, 3 H), 3.85 (s, 3 H), 3.89 (s, 3 H), 3.97 (s, 3 H), 7.21 (d, J=5.9 Hz, 1 H), 7.45 (d, J=8.8 Hz, 1 H), 7.48 (dd, J=8.1, 1.8 Hz, 1 H), 7.62 (d, J=1.8 Hz, 1 H), 7.67 (d, J=8.1 Hz, 1 H), 7.99 (dd, J=8.8, 2.2 Hz, 1 H), 8.03 (d, J=5.9 Hz, 1 H), 8.05 (d, J=2.2 Hz, 1 H), 8.66 (s, 1 H), 9.40 (s, 1 H).
- Co. No. 115: (360 MHz, CDCl3) δ ppm 2.30 (s, 3 H), 3.81 (s, 3 H), 4.10 (s, 3 H), 6.54 (d, J=8.1 Hz, 1 H), 6.70 (dd, J=8.4, 2.2 Hz, 1 H), 6.89 (s, 1 H), 7.21-7.32 (m, 2 H), 7.44 (d, J=8.1 Hz, 1 H), 7.65 (s, 1 H), 7.74 (dd, J=8.2, 5.3 Hz, 2 H), 7.94 (s, 1 H), 8.15 (dd, J=12.8, 2.2 Hz, 1 H).
- Co. No. 116: (360 MHz, CDCl3) δ ppm 1.67 (d, J=7.0 Hz, 6 H), 2.30 (s, 3 H), 4.06 (s, 3 H), 4.73 (spt, J=7.0 Hz, 1 H), 6.57 (d, J=8.1 Hz, 1 H), 6.87 (s, 1 H), 7.21-7.30 (m, 4 H), 7.40 (d, J=8.1 Hz, 1 H), 7.57-7.68 (m, 3 H), 7.89 (s, 1 H), 8.14 (dd, J=6.9, 1.8 Hz, 1 H).
- Co. No. 118: (360 MHz, DMSO-d 6) δ ppm 3.75 (s, 3 H) 3.86 (s, 3 H) 4.39 (d, J=5.49 Hz, 2 H) 4.91 (t, J=5.49 Hz, 1 H) 6.94 (dd, J=8.42, 2.20 Hz, 1 H) 7.09-7.26 (m, 6 H) 7.44 (t, J=8.78 Hz, 2 H) 7.69 (s, 1 H) 7.92 (dd, J=8.78, 5.49 Hz, 2 H) 8.47 (s, 1 H).
- Co. No. 131: (360 MHz, DMSO-d 6) δ ppm 1.60 (d, J=6.95 Hz, 6 H) 2.14 (s, 3 H) 3.94 (s, 3 H) 3.96 (s, 3 H) 4.69 (spt, J=6.95 Hz, 1 H) 6.95 (d, J=8.42 Hz, 1 H) 7.07 (t, J=1.10 Hz, 1 H) 7.18-7.29 (m, 2 H) 7.38 (d, J=8.05 Hz, 1 H) 7.41 (d, J=1.83 Hz, 1 H) 7.60 (d, J=8.42 Hz, 1 H) 7.65 (d, J=8.05 Hz, 1 H) 7.70 (d, J=1.10 Hz, 1 H) 8.21 (d, J=8.05 Hz, 1 H) 9.17 (s, 1 H).
- Co. No. 132: (360 MHz, DMSO-d 6) δ ppm 2.15 (s, 3 H) 3.94 (s, 3 H) 3.97 (s, 3 H) 6.97 (d, J=8.42 Hz, 1 H) 7.08 (s, 1 H) 7.24 (d, J=8.05 Hz, 1 H) 7.31 (t, J=7.87 Hz, 1 H) 7.62 (d, J=8.42 Hz, 1 H) 7.71 (d, J=1.10 Hz, 1 H) 7.94 (dt, J=8.42, 1.83 Hz, 1 H) 8.09-8.17 (m, 2 H) 8.28 (d, J=8.05 Hz, 1 H) 9.24 (s, 1 H).
- Co. No. 133: (360 MHz, DMSO-d 6) δ ppm 2.15 (s, 3 H) 3.88 (s, 3 H) 3.97 (s, 3 H) 6.96 (d, J=8.42 Hz, 1 H) 7.08 (s, 1 H) 7.20 (d, J=7.68 Hz, 1 H) 7.28 (t, J=8.05, 7.68 Hz, 1 H) 7.56-7.67 (m, 2 H) 7.71 (s, 1 H) 7.96 (ddd, J=8.42, 4.76, 2.20 Hz, 1 H) 8.19-8.30 (m, 2 H) 9.20 (s, 1 H).
- Co. No. 135: (360 MHz, CDCl3) δ ppm 2.49 (s, 3 H) 2.63 (s, 3 H) 3.83 (s, 3 H) 3.98 (s, 3 H) 4.02 (s, 3 H) 6.74 (s, 1 H) 7.14-7.24 (m, 2 H) 7.39 (s, 1 H) 7.54 (d, J=8.05 Hz, 1 H) 7.59 (d, J=8.78 Hz, 1 H) 7.73 (s, 1 H) 8.47 (d, J=1.46 Hz, 1 H) 8.51 (s, 1 H).
- Co. No. 136: (360 MHz, CDCl3) δ ppm 2.31 (s, 3 H) 2.65 (s, 3 H) 3.83 (s, 3 H) 4.02 (s, 3 H) 6.76 (s, 1 H) 6.93 (s, 1 H) 7.20 (dd, J=8.23, 1.65 Hz, 1 H) 7.26 (t, J=9.15, 7.68 Hz, 1 H) 7.38 (d, J=1.83 Hz, 1 H) 7.46 (dd, J=8.78, 2.20 Hz, 1 H) 7.54 (d, J=8.05 Hz, 1 H) 7.67 (s, 1 H) 7.79 (s, 1 H) 8.34 (dd, J=13.72, 2.38 Hz, 1 H).
- Co. No. 142: (360 MHz, CDCl3) δ ppm 2.31 (s, 3 H) 2.64 (s, 3 H) 3.05 (s, 6 H) 3.81 (s, 3 H) 6.76 (s, 1 H) 6.89 (dd, J=8.42, 2.56 Hz, 1 H) 6.93 (s, 1 H) 6.96 (d, J=7.32 Hz, 1 H) 7.05 (s, 1 H) 7.25 (t, J=8.42 Hz, 1 H) 7.39 (t, J=7.87 Hz, 1 H) 7.46 (dd, J=8.78, 1.83 Hz, 1 H) 7.66 (s, 1 H) 7.82 (s, 1 H) 8.34 (dd, J=13.90, 2.20 Hz, 1 H).
- Co. No. 150: (360 MHz, CDCl3) δ ppm 2.30 (s, 3 H) 2.65 (s, 3 H) 3.81 (s, 3 H) 3.95 (s, 3 H) 6.79 (s, 1 H) 6.90 (s, 1 H) 7.27 (t, J=8.42 Hz, 2 H) 7.55 (d, J=8.05 Hz, 1 H) 7.66 (s, 1 H) 7.76 (dd, J=8.42, 5.12 Hz, 2 H) 8.27 (s, 1 H) 8.45 (d, J=8.42 Hz, 1 H).
- Co. No. 160: (360 MHz, CDCl3) δ ppm 2.30 (s, 3 H) 3.80 (s, 3 H) 3.92 (s, 3 H) 4.09 (s, 3 H) 6.48 (d, J=1.46 Hz, 1 H) 6.57 (d, J=8.42 Hz, 1 H) 6.88 (s, 1 H) 7.24 (t, J=8.78 Hz, 2 H) 7.41 (d, J=8.42 Hz, 1 H) 7.64 (s, 1 H) 7.73 (dd, J=8.78, 5.49 Hz, 2 H) 7.88 (s, 1 H) 7.96 (d, J=1.46 Hz, 1 H).
- Co. No. 161: (360 MHz, DMSO-d 6) δ ppm 2.33 (s, 3 H) 3.86 (s, 3 H) 3.99 (s, 3 H) 6.96 (d, J=8.42 Hz, 1 H) 7.22 (d, 1 H) 7.27 (t, J=8.05 Hz, 1 H) 7.44 (t, J=8.78 Hz, 2 H) 7.77 (d, J=8.42 Hz, 1 H) 7.94 (dd, J=8.78, 5.49 Hz, 2 H) 8.20 (d, J=7.68 Hz, 1 H) 8.68 (s, 1 H) 9.30 (s, 1 H).
- Co. No. 162: (360 MHz, DMSO-d 6) δ ppm 1.60 (d, J=6.95 Hz, 6 H) 2.33 (s, 3 H) 3.99 (s, 3 H) 4.64 (spt, J=6.95 Hz, 1 H) 6.96 (d, J=8.42 Hz, 1 H) 7.23 (t, J=8.23 Hz, 1 H) 7.34-7.50 (m, 3 H) 7.67-7.80 (m, 3 H) 8.19 (d, J=7.68 Hz, 1 H) 8.68 (s, 1 H) 9.27 (s, 1 H).
- Co. No. 164: (360 MHz, CDCl3) δ ppm 2.49 (s, 3 H) 2.63 (s, 3 H) 3.81 (s, 3 H) 3.98 (s, 3 H) 6.74 (s, 1 H) 7.20 (dd, J=8.78, 2.20 Hz, 1 H) 7.26 (t, J=8.78 Hz, 2 H) 7.59 (d, J=8.42 Hz, 1 H) 7.69-7.79 (m, 3 H) 8.44 (d, J=2.20 Hz, 1 H) 8.51 (s, 1 H).
- Co. No. 165: (360 MHz, DMSO-d 6) δ ppm 2.35 (s, 3 H) 3.97 (s, 3 H) 3.99 (s, 3 H) 7.00 (d, J=8.42 Hz, 1 H) 7.24-7.49 (m, 2 H) 7.53-7.77 (m, 4 H) 7.85 (d, J=8.78 Hz, 1H) 8.32 (dd, J=6.95, 2.20 Hz, 1 H) 9.33 (d, J=1.46 Hz, 1 H) 9.82 (br. s, 1 H) 14.91 (br. s, 1 H).
- Co. No. 167: (360 MHz, DMSO-d 6) δ ppm 2.35 (s, 3 H) 4.00 (s, 6 H) 7.01 (d, J=8.42 Hz, 1 H) 7.47-7.57 (m, 2 H) 7.71 (s, 1 H) 7.89 (d, J=8.42 Hz, 1 H) 7.95 (t, J=7.68 Hz, 1 H) 8.10 (d, J=8.05 Hz, 1 H) 8.30 (d, J=8.05 Hz, 1 H) 8.36 (s, 1 H) 8.44 (dd, J=6.22, 2.20 Hz, 1 H) 9.34 (d, J=1.46 Hz, 1 H) 10.18 (br. s, 1 H) 15.04 (br. s, 1 H).
- Co. No. 170: (360 MHz, DMSO-d 6) δ ppm 2.35 (s, 3 H) 3.77 (s, 3 H) 3.98 (s, 3 H) 6.99 (d, J=8.42 Hz, 1 H) 7.23-7.38 (m, 1 H) 7.41-7.51 (m, 1 H) 7.60-8.01 (m, 6 H) 8.35 (dd, J=7.32, 1.46 Hz, 1 H) 9.34 (d, J=1.46 Hz, 1 H) 9.97 (br. s, 1 H) 15.02 (br. s, 1 H).
- Co. No. 184: (360 MHz, DMSO-d 6) δ ppm 2.36 (s, 3 H) 4.01 (s, 3 H) 4.02 (s, 3 H) 4.05 (s, 3 H) 7.04 (d, J=8.42 Hz, 1 H) 7.52-7.66 (m, 4 H) 7.72 (s, 1 H) 7.86 (d, J=8.05 Hz, 1 H) 7.92 (d, J=8.42 Hz, 1 H) 8.56 (d, J=6.22 Hz, 1 H) 9.36 (d, J=1.46 Hz, 1 H) 10.49 (br. s, 1 H) 15.13 (br. s, 1 H).
- Co. No. 186: (360 MHz, DMSO-d 6) δ ppm 2.35 (d, J=0.73 Hz, 3 H) 3.89 (s, 6 H) 4.00 (s, 3 H) 4.04 (s, 3 H) 6.88 (t, J=1.83 Hz, 1 H) 7.03 (d, J=8.42 Hz, 1 H) 7.17 (d, J=1.83 Hz, 2 H) 7.56 (br. s, 2 H) 7.72 (t, J=0.73 Hz, 1 H) 7.91 (d, J=8.42 Hz, 1 H) 8.52 (br. s, 1 H) 9.35 (d, J=1.83 Hz, 1 H) 10.46 (br. s, 1 H) 15.01 (br. s, 1 H).
- Co. No. 201: (360 MHz, CDCl3) δ ppm 2.31 (s, 3 H) 3.96 (s, 3 H) 4.11 (s, 3 H) 6.63 (d, J=8.05 Hz, 1 H) 6.90 (t, J=1.10 Hz, 1 H) 7.28 (t, J=8.60 Hz, 2 H) 7.50 (d, J=8.05 Hz, 1 H) 7.67 (d, J=1.10 Hz, 1 H) 7.81 (dd, J=8.96, 5.31 Hz, 2 H) 8.10 (s, 1 H) 8.22 (d, J=5.85 Hz, 1 H) 8.32 (d, J=5.85 Hz, 1 H).
- Co. No. 202: (360 MHz, CDCl3) δ ppm 2.30 (s, 3 H) 3.88 (s, 3 H) 4.02 (s, 3 H) 4.11 (s, 3 H) 6.61 (d, J=8.05 Hz, 1 H) 6.89 (t, J=1.10 Hz, 1 H) 7.25 (t, J=8.42 Hz, 2 H) 7.48 (d, J=8.05 Hz, 1 H) 7.63-7.69 (m, 2 H) 7.77 (dd, J=8.78, 5.49 Hz, 2 H) 7.96 (s, 1 H).
- Co. No. 203: (360 MHz, CDCl3) δ ppm 2.31 (d, J=0.73 Hz, 3 H) 2.67 (s, 3 H) 3.93 (s, 3 H) 4.12 (s, 3 H) 6.62 (d, J=8.05 Hz, 1 H) 6.90 (t, J=1.10 Hz, 1 H) 7.26 (t, J=8.78 Hz, 2 H) 7.49 (d, J=8.05 Hz, 1 H) 7.67 (d, J=1.10 Hz, 1 H) 7.79 (dd, J=8.78, 5.12 Hz, 2 H) 8.02 (s, 1 H) 8.14 (s, 1 H).
- Co. No. 207: (360 MHz, CDCl3) δ ppm 0.95-1.03 (m, 2 H) 1.06-1.12 (m, 2 H) 2.01-2.13 (m, 1 H) 2.32 (s, 3 H) 3.87 (s, 3 H) 6.94-6.98 (m, 2 H) 7.15 (dd, J=8.78, 2.20 Hz, 1 H) 7.19-7.29 (m, 3 H) 7.30-7.38 (m, 2 H) 7.70 (t, J=1.46 Hz, 1 H) 7.77 (dd, J=8.78, 5.12 Hz, 2 H).
- Co. No. 209: (360 MHz, CDCl3) δ ppm 2.48 (s, 3 H) 2.69 (s, 3 H) 2.89 (s, 6 H) 3.98 (s, 3 H) 7.04 (s, 1 H) 7.14 (s, 1 H) 7.21-7.34 (m, 5 H) 7.43 (t, J=8.60 Hz, 1 H) 7.71 (dd, J=8.42, 5.12 Hz, 2 H) 9.04 (s, 1 H) 11.34 (s, 1 H)
- Co. No. 210: (360 MHz, DMSO-d 6) δ ppm 2.35 (s, 3 H) 3.97 (s, 3 H) 3.98 (s, 3 H) 7.00 (d, J=8.78 Hz, 1 H) 7.50 (br. s, 2 H) 7.58 (t, J=8.78 Hz, 2 H) 7.71 (s, 1 H) 7.88 (d, J=8.42 Hz, 1 H) 8.05 (dd, J=8.23, 5.67 Hz, 2 H) 8.40 (br. s, 1 H) 9.33 (d, J=1.46 Hz, 1 H) 10.19 (br. s, 1 H) 14.89 (br. s, 1 H).
- Co. No. 211: (360 MHz, DMSO-d 6) δ ppm 2.38 (s, 3 H) 2.59 (s, 3 H) 3.89 (s, 3 H) 7.33 (br. s, 1 H) 7.49 (t, J=8.78 Hz, 2 H) 7.73 (t, J=8.42 Hz, 1 H) 7.80-7.90 (m, 2 H) 7.96 (dd, J=8.78, 5.49 Hz, 2 H) 8.25 (br. s, 1H) 9.49 (s, 1 H) 10.48 (br. s, 1 H).
- Screening was carried out using SKNBE2 cells carrying the APP 695 - wild type, grown in Dulbecco's Modified Eagle's Medium/Nutrient mixture F-12 (DMEM/NUT-mix F-12) (HAM) provided by Gibco (cat no. 31330-38) containing 5 % Serum/Fe supplemented with 1 % non-essential amino acids. Cells were grown to near confluency.
- The screening was performed using the assay as described in Citron et al (1997) Nature Medicine 3: 67. Briefly, cells were plated in a 96-well plate at about 105 cells/ml one day prior to addition of compounds. Compounds were added to the cells in Ultraculture (Lonza, BE12-725F) supplemented with 1 % glutamine (Invitrogen, 25030-024) for 18 hours. The media were assayed by two sandwich ELISAs, for Aß42 and Aßtotal. Toxicity of the compounds was assayed by WST-1 cell proliferation reagent (Roche, 1 644 807) according to the manufacturer's protocol.
- To quantify the amount of Aβ42 in the cell supernatant, commercially available Enzyme-Linked-Immunosorbent-Assay (ELISA) kits were used (Innotest® β-Amyloid(1-42), Innogenetics N.V., Ghent, Belgium). The Aβ42 ELISA was performed essentially according to the manufacturer's protocol. Briefly, the standards (dilutions of synthetic Aβ1-42) were prepared in polypropylene Eppendorf with final concentrations of 8000 down to 3.9 pg/ml (1/2 dilution step). Samples, standards and blanks (100 µl) were added to the anti-Aβ42-coated plate supplied with the kit (the capture antibody selectively recognizes the C-terminal end of the antigen). The plate was allowed to incubate 3 h at 25 °C in order to allow formation of the antibody-amyloid complex. Following this incubation and subsequent wash steps a selective anti-Aβ-antibody conjugate (biotinylated 3D6) was added and incubated for a minimum of 1 hour in order to allow formation of the antibody-Amyloid-antibody-complex. After incubation and appropriate wash steps, a Streptavidine-Peroxidase-Conjugate was added, followed 30 minutes later by an addition of 3,3',5,5'-tetramethylbenzidine (TMB)/peroxide mixture, resulting in the conversion of the substrate into a coloured product. This reaction was stopped by the addition of sulfuric acid (0.9 N) and the colour intensity was measured by means of photometry with an ELISA-reader with a 450 nm filter.
- To quantify the amount of Aßtotal in the cell supernatant, samples and standards were added to a 6E10-coated plate. The plate was allowed to incubate overnight at 4 °C in order to allow formation of the antibody-amyloid complex. Following this incubation and subsequent wash steps a selective anti-Aß-antibody conjugate (biotinylated 4G8) was added and incubated for a minimum of 1 hour in order to allow formation of the antibody-Amyloid-antibody-complex. After incubation and appropriate wash steps, a Streptavidine-Peroxidase-Conjugate was added, followed 30 minutes later by an addition of Quanta Blu fluorogenic peroxidase substrate according to the manufacturer's instructions (Pierce Corp., Rockford, Il).
- To obtain the values reported in Table 3a, the sigmoidal dose response curves were analysed by computerised curve-fitting, with percent of inhibition plotted against compound concentration. A 4-parameter equation (model 205) in XLfit was used to determine the IC50. The top and the bottom of the curve were fixed to 100 and 0, respectively, and the hill slope was fixed to 1. The IC50 represents the concentration of a compound that is required for inhibiting a biological effect by 50 % (Here, it is the concentration where Aß peptide level is reduced by 50 %).
The IC50 values are shown in Table 3a:
The IC50 values are shown in Table 3b: - Screening was carried out using SKNBE2 cells carrying the APP 695 - wild type, grown in Dulbecco's Modified Eagle's Medium/Nutrient mixture F-12 (DMEM/NUT-mix F-12) (HAM) provided by Invitrogen (cat no. 10371-029) containing 5 % Serum/Fe supplemented with 1 % non-essential amino acids, 1-glutamine 2 mM, Hepes 15 mM, penicillin 50 U/ml (units/ml) en streptomycin 50 µg/ml. Cells were grown to near confluency.
- The screening was performed using a modification of the assay as described in Citron et al (1997) Nature Medicine 3: 67. Briefly, cells were plated in a 384-well plate at 104 cells/well in Ultraculture (Lonza, BE12-725F) supplemented with 1 % glutamine (Invitrogen, 25030-024), 1 % non-essential amino acid (NEAA), penicillin 50 U/ml en streptomycin 50 µg/ml in the presence of test compound at different test concentrations. The cell/compound mixture was incubated overnight at 37 °C, 5 % CO2. The next day the media were assayed by two sandwich immuno-assays, for Aß42 and Aßtotal.
- Aßtotal and Aß42 concentrations were quantified in the cell supernatant using the Aphalisa technology (Perkin Elmer). Alphalisa is a sandwich assay using biotinylated antibody attached to streptavidin coated donorbeads and antibody conjugated to acceptor beads. In the presence of antigen, the beads come into close proximity. The excitation of the donor beads provokes the release of singlet oxygen molecules that trigger a cascade of energy transfer in the acceptor beads, resulting in light emission. To quantify the amount of Aβ42 in the cell supernatant, monoclonal antibody specific to the C-terminus of Aß42 (JRF/cAß42/26) was coupled to the receptor beads and biotinylated antibody specific to the N-terminus of Aß (JRF/AßN/25) was used to react with the donor beads. To quantify the amount of Aβtotal in the cell supernatant, monoclonal antibody specifc to the N-terminus of Aß (JRF/AßN/25) was coupled to the receptor beads and biotinylated antibody specific to the mid region of Aß (biotinylated 4G8) was used to react with the donor beads.
- To obtain the values reported in Table 3c, the data were calculated as percentage of the maximum amount of amyloid Beta 42 measured in the absence of the test compound. The sigmoidal dose response curves were analyzed using non-linear regression analysis with percentage of the control plotted against the log concentration of the compound. A 4-parameter equation was used to determine the IC50.
The IC50 values are shown in Table 3c: - Aβ42 lowering agents of the invention can be used to treat AD in mammals such as humans or alternatively demonstrating efficacy in animal models such as, but not limited to, the mouse, rat, or guinea pig. The mammal may not be diagnosed with AD, or may not have a genetic predisposition for AD, but may be transgenic such that it overproduces and eventually deposits Aβ in a manner similar to that seen in humans afflicted with AD.
- Aβ42 lowering agents can be administered in any standard form using any standard method. For example, but not limited to, Aβ42 lowering agents can be in the form of liquid, tablets or capsules that are taken orally or by injection. Aβ42 lowering agents can be administered at any dose that is sufficient to significantly reduce levels of Aβ42 in the blood, blood plasma, serum, cerebrospinal fluid (CSF), or brain.
- To determine whether acute administration of an Aβ42 lowering agent would reduce Aβ42 levels in vivo, non-transgenic rodents, e.g. mice or rats were used. Alternatively, two to three month old Tg2576 mice expressing APP695 containing the "Swedish" variant can be used or a transgenic mouse model developed by Dr. Fred Van Leuven (K.U.Leuven, Belgium) and co-workers, with neuron-specific expression of a clinical mutant of the human amyloid precursor protein [V717I] (Moechars et al., 1999 J. Biol. Chem. 274, 6483). Young transgenic mice have high levels of Aβ in the brain but no detectable Aβ deposition. At approximately 6-8 months of age, the transgenic mice start to display spontaneous, progressive accumulation of β-amyloid (Aβ) in the brain, eventually resulting in amyloid plaques within the subiculum, hippocampus and cortex. Animals treated with the Aβ42 lowering agent were examined and compared to those untreated or treated with vehicle and brain levels of soluble Aβ42 and total Aβ would be quantitated by standard techniques, for example, using ELISA. Treatment periods varied from hours (h) to days and were adjusted based on the results of the Aβ42 lowering once a time course of onset of effect could be established.
- A typical protocol for measuring Aβ42 lowering in vivo is shown but it is only one of many variations that could be used to optimize the levels of detectable Aβ. For example, Aβ42 lowering compounds were formulated in 20 % of Captisol® (a sulfobutyl ether of β-cyclodextrin) in water or 20 % hydroxypropyl β cyclodextrin. The Aβ42 lowering agents were administered as a single oral dose or by any acceptable route of administration to overnight fasted animals. After 4 h, the animals were sacrificed and Aβ42 levels were analysed.
- Blood was collected by decapitation and exsanguinations in EDTA-treated collection tubes. Blood was centrifuged at 1900 g for 10 minutes (min) at 4 °C and the plasma recovered and flash frozen for later analysis. The brain was removed from the cranium and hindbrain. The cerebellum was removed and the left and right hemisphere were separated. The left hemisphere was stored at -18 °C for quantitative analysis of test compound levels. The right hemisphere was rinsed with phosphate-buffered saline (PBS) buffer and immediately frozen on dry ice and stored at -80 °C until homogenization for biochemical assays.
- Mouse brains were resuspended in 10 volumes of 0.4 % DEA (diethylamine) /50 mM NaCl pH 10 (for non-transgenic animals) or 0.1 % 3-[(3-cholamidopropyl)-dimethyl-ammonio]-1-propanesulfonate (CHAPS) in tris buffered saline (TBS) (for transgenic animals) containing protease inhibitors (Roche-11873580001 or 04693159001) per gram of tissue, e.g. for 0.158 g brain, add 1.58 ml of 0.4 % DEA. All samples were sonicated for 30 seconds on ice at 20 % power output (pulse mode). Homogenates were centrifuged at 221.300 x g for 50 min. The resulting high speed supernatants were then transferred to fresh tubes and were optionally further purified before the next step. A portion of the supernatant was neutralized with 10 % 0.5 M Tris-HCl and this was used to quantify Aßtotal.
- The obtained supernatants were purified with Water Oasis HLB reverse phase columns (Waters Corp., Milford, MA) to remove non-specific immunoreactive material from the brain lysates prior subsequent Aβ detection. Using a vacuum manifold, all solutions were passed through the columns at a rate of approximately 1 ml per min, so the vacuum pressure was adjusted accordingly throughout the procedure. Columns were preconditioned with 1 ml of 100 % MeOH, before equilibration with 1 ml of H2O. Non-neutralized brain lysates were loaded onto the columns. The loaded samples were then washed twice with the first wash performed with 1 ml of 5 % MeOH, and the second wash with 1 ml of 30 % MeOH. Finally, the Aβ was eluted from the columns and into 100 x 30 mm glass tubes, with a solution of 90 % MeOH with 2 % NH4OH. The eluate was then transferred into 1.5 ml tubes and concentrated in a speed-vac concentrator on high heat for about 1.5-2 h at 70 °C. The concentrated Aβ was then resuspended in UltraCULTURE General Purpose Serum-Free Medium (Cambrex Corp., Walkersville, MD) plus Protease Inhibitors added.
- To quantify the amount of Aβ42 in the soluble fraction of the brain homogenates, commercially available Enzyme-Linked-Immunosorbent-Assay (ELISA) kits were used (e.g. Innotest® β-Amyloid(1-42), Innogenetics N.V., Ghent, Belgium). The Aβ42 ELISA was performed using the plate provided with the kit only. Briefly, the standards (a dilution of synthetic Aβ1-42) were prepared in 1.5 ml Eppendorf tube in Ultraculture, with final concentrations ranging from 25000 to 1.5 pg/ml. Samples, standards and blanks (60 µl) were added to the anti-Aβ42-coated plate (the capture antibody selectively recognizes the C-terminal end of the antigen). The plate was allowed to incubate overnight at 4 °C in order to allow formation of the antibody-amyloid complex. Following this incubation and subsequent wash steps a selective anti-Aβ-antibody conjugate (biotinylated detection antibody, e.g., biotinylated 4G8 (Covance Research Products, Dedham, MA) was added and incubated for a minimum of 1 h in order to allow formation of the antibody-Amyloid-antibody-complex. After incubation and appropriate wash steps, a Streptavidine-Peroxidase-Conjugate was added, followed 50 min later by an addition of Quanta Blu fluorogenic peroxidase substrate according to the manufacturer's instructions (Pierce Corp., Rockford, Il). A kinetic reading was performed every 5 min for 30 min (excitation 320 nm/emission 420 nm). To quantify the amount of Aßtotal in the soluble fraction of the brain homogenates, samples and standards were added to JRF/rAß/2-coated plate. The plate was allowed to incubate overnight at 4 °C in order to allow formation of the antibody-amyloid complex. The ELISA was then performed as for Aß42 detection.
In this model at least 20 % Aß42 lowering compared to untreated animals would be advantageous.
The results are shown in Table 4a:Co. No. Aβ42 (%Ctrl)_Mean Aβtotal (%Ctrl)_Mean Co. No. Aβ42 (%Ctrl)_Mean Aβtotal (%Ctrl)_Mean Co. No. Aβ42 (%Ctrl)_Mean Aβtotal (%Ctrl)_Mean 1 57 100 54 71 96 91 68 94 3 46 87 56 78 92 92 60 103 4 64 92 61 89 97 94 64 95 5 62 94 67 71 99 95 85 95 6 66 91 70 64 99 96 62 88 7 58 89 71 88 102 97 96 96 8 46 91 73 87 97 104 65 110 15 31 83 74 86 99 106 87 104 18 81 95 75 67 92 108 59 98 36 79 95 76 86 102 115 97 93 38 72 101 80 97 102 130 75 94 44 91 101 82 85 96 131 51 84 45 93 94 85 71 93 164 72 97 - Aβ42 lowering agents of the invention can be used to treat AD in mammals such as humans or alternatively demonstrating efficacy in animal models such as, but not limited to, the mouse, rat, or guinea pig. The mammal may not be diagnosed with AD, or may not have a genetic predisposition for AD, but may be transgenic such that it overproduces and eventually deposits Aβ in a manner similar to that seen in humans afflicted with AD.
- Aβ42 lowering agents can be administered in any standard form using any standard method. For example, but not limited to, Aβ42 lowering agents can be in the form of liquid, tablets or capsules that are taken orally or by injection. Aβ42 lowering agents can be administered at any dose that is sufficient to significantly reduce levels of Aβ42 in the blood, blood plasma, serum, cerebrospinal fluid (CSF), or brain.
- To determine whether acute administration of an Aβ42 lowering agent would reduce Aβ42 levels in vivo, non-transgenic rodents, e.g. mice or rats were used. Animals treated with the Aβ42 lowering agent were examined and compared to those untreated or treated with vehicle and brain levels of soluble Aβ42 and total Aβ were quantitated by standard techniques, for example, using ELISA. Treatment periods varied from hours (h) to days and were adjusted based on the results of the Aβ42 lowering once a time course of onset of effect could be established.
- A typical protocol for measuring Aβ42 lowering in vivo is shown but it is only one of many variations that could be used to optimize the levels of detectable Aβ. For example, Aβ42 lowering compounds were formulated in 20 % of Captisol® (a sulfobutyl ether of β-cyclodextrin) in water or 20 % hydroxypropyl β cyclodextrin. The Aβ42 lowering agents were administered as a single oral dose or by any acceptable route of administration to overnight fasted animals. After 4 h, the animals were sacrificed and Aβ42 levels were analysed.
- Blood was collected by decapitation and exsanguinations in EDTA-treated collection tubes. Blood was centrifuged at 1900 g for 10 minutes (min) at 4 °C and the plasma recovered and flash frozen for later analysis. The brain was removed from the cranium and hindbrain. The cerebellum was removed and the left and right hemisphere were separated. The left hemisphere was stored at -18 °C for quantitative analysis of test compound levels. The right hemisphere was rinsed with phosphate-buffered saline (PBS) buffer and immediately frozen on dry ice and stored at -80 °C until homogenization for biochemical assays.
- Mouse brains from non-transgenic animals were resuspended in 8 volumes of 0.4 % DEA (diethylamine) /50 mM NaCl containing protease inhibitors (Roche-11873580001 or 04693159001) per gram of tissue, e.g. for 0.158 g brain, add 1.264 ml of 0.4 % DEA. All samples were homogenized in the FastPrep-24 system (MP Biomedicals) using lysing matrix D (MPBio #6913-100) at 6m/s for 20 seconds. Homogenates were centrifuged at 221.300 x g for 50 min. The resulting high speed supernatants were then transferred to fresh eppendorf tubes. Nine parts of supernatant were neutralized with 1 part 0.5 M Tris-HCl pH 6.8 and used to quantify Aßtotal and Aß42.
- To quantify the amount of Aßtotal and Aß42 in the soluble fraction of the brain homogenates, Enzyme-Linked-Immunosorbent-Assays were used. Briefly, the standards (a dilution of synthetic Aβ1-40 and Aβ1-42, Bachem) were prepared in 1.5 ml Eppendorf tube in Ultraculture, with final concentrations ranging from 10000 to 0.3 pg/ml. The samples and standards were co-incubated with HRPO-labelled N-terminal antibody for Aß42 detection and with the biotinylated mid-domain antibody 4G8 for Aßtotal detection. 50 µl of conjugate/sample or conjugate/standards mixtures were then added to the antibody-coated plate (the capture antibodies selectively recognize the C-terminal end of Aß42, antibody JRF/cAß42/26, for Aß42 detection and the N-terminus of Aß, antibody JRF/rAß/2, for Aßtotal detection). The plate was allowed to incubate overnight at 4 °C in order to allow formation of the antibody-amyloid complex. Following this incubation and subsequent wash steps the ELISA for Aß42 quantification was finished by addition of Quanta Blu fluorogenic peroxidase substrate according to the manufacturer's instructions (Pierce Corp., Rockford, Il). A reading was performed after 10 to 15 min (excitation 320/emission 420).
- For Aßtotal detection, a Streptavidine-Peroxidase-Conjugate was added, followed 60 min later by an addional wash step and addition of Quanta Blu fluorogenic peroxidase substrate according to the manufacturer's instructions (Pierce Corp., Rockford, Il). A reading was performed after 10 to 15 min (excitation 320 nm/emission 420 nm).
In this model at least 20 % Aß42 lowering compared to untreated animals would be advantageous.
The results are shown in Table 4b:Co. No. Aβ42 (%Ctrl)_Mean Aβtotal (%Ctrl)_Mean Co. No. Aβ42 (%Ctrl)_Mean Aβtotal (%Ctrl)_Mean Co. No. Aβ42 (%Ctrl)_Mean Aβtotal (%Ctrl)_Mean 15 39 82 162 79 97 186 38 88 110 78 106 165 44 85 187 75 96 136 77 104 167 46 84 189 48 95 142 73 98 174 90 104 202 82 102 160 84 78 184 31 88 - The Notch transmembrane domain is cleaved by gamma secretase to release Notch Intracellular C-terminal Domain (NICD). Notch is a signaling protein which plays a crucial role in developmental processes, and thus compounds are preferred which do not show an effect on the Notch-processing activity of the γ-secretase-complex.
- To monitor the effect of compounds on NICD production, a recombinant Notch substrate (N99) was prepared. The Notch substrate, comprised of mouse Notch fragment (V1711-E1809), an N-terminal methionine and a C-terminal FLAG sequence (DYDDDDK), was expressed in E. coli and purified on a column containing an anti-FLAG M2 affinity matrix.
- A typical Notch cell-free assay consisted of 0.3-0.5 µM Notch substrate, an enriched preparation of γ secretase and 1 µM of a test compound (compounds 8, 15, 92, 108, 114 and 130 of the present invention). Controls included a γ secretase inhibitor (GSI), such as (2S)-N-[2-(3,5-difluorophenyl)acetyl]-L-alanyl-2-phenyl-glycine 1,1-dimethylethyl ester (DAPT) or (2S)-2-hydroxy-3-methyl-N-[(1S)-1-methyl-2-oxo-2-[[(1S)-2,3,4,5-tetrahydro-3-methyl-2-oxo-1H-3-benzazepin-1-yl]amino]ethyl]-butanamide (Semagacestat), and DMSO, the final concentration of DMSO being 1 %. Recombinant Notch substrate was pre-treated with 17 µM DTT (1,4-dithiothreitol) and 0.02 % SDS (Sodium Dodecyl Sulfate) and heated at 65 °C for 10 min. The mixture of substrate, gamma secretase and compound/DMSO was incubated at 37 °C for 6 to 22 hours (h). 6 h incubation was sufficient to produce the maximal amount of NICD and the cleaved product remained stable for an additional 16 h. Reaction products were processed for SDS PAGE (Sodium Dodecyl Sulfate-Poly Acrylamide Gel Electrophoresis) and western blotting. Blots were probed with an anti-Flag M2 antibody, followed by LI-COR infrared secondary antibody, and analyzed with the Odyssey Infrared Imaging System (LI-COR® Biosciences).
- In the cell-free Notch assay, no test compounds (compounds 8, 15, 92, 108, 114 and 130) inhibited the cleavage of C99 by gamma secretase, whereas the production of NICD was blocked by the control GSI (DAPT or Semagacestat). Thus it was demonstrated that compounds 8, 15, 92, 108, 114 and 130 did not show an effect on the Notch-processing activity of the γ-secretase-complex (production of NICD).
- The Notch cell-based assay was based on the interaction of Notch and its ligand in a co-culture system and utilized the Dual-Glo Luciferase Assay System (Promega) to monitor NICD production. 2 stable cell lines, N2-CHO and DL-CHO, were established to express full-length mouse Notch2 and Delta respectively. Cells that expressed mouse Notch were also transfected with 2 plasmids, pTP1-Luc and pCMV-RLuc, to express firefly and Renilla luciferase. Expression of firefly luciferase was under the control of TP1 promoter that responded to NICD activation. The CMV promoter that drove the expression of Renilla luciferase did not respond to NICD activation and therefore was used to control for transfection efficiency and compound toxicity.
- N2-CHO cells were seeded at 1x105/well in 24-well plates the day before transfection. On the second day, cells were double transfected with 3 µg/well pTP1-Luc (expressing firefly luciferase) and 0.3 ng/well pCMV-RLuc (expressing Renilla luciferase). After 6 h incubation, transfected N2-CHO cells were washed and DL-CHO cells (2 x 105 cells/well) were added.
- Compounds were pre-mixed with DL-CHO cell suspension in a five-point curve. Typically, compound treatment was performed in duplicate with a serial 1:10 dilution (3 µM-0.3 nM) in DMSO. The final concentration of DMSO in a given culture was 1 %. Controls included non-transfected cells and transfected cells treated with a GSI or DMSO only. Luciferase assays were performed after 16 h co-culture and compound treatment.
- The luciferase assay was carried out according to manufacture's instructions. Briefly, cells were washed with PBS (Phosphate Buffered Saline), lysed with Passive Lysis Buffer (Promega), and incubated at room temperature for 20 min. Lysates were mixed with Dual-Glo Luciferase Reagent and the firefly luciferase activity was measured by reading the luminescence signal in the EnVision 2101 Multilabel reader. Dual-Glo Stop & Glo Reagent was then added to each well and the Renilla luciferase signal was measured.
- The results of the Notch cell-based assay were in agreement with those in the cell-free NICD assay. On the basis of luciferase assay readouts, the average IC50 values of DAPT and Semagacestat from the Notch cell-based assay were 45 nM and 40 nM respectively, whereas compounds 15, 92, 108, 114 and 130 of the present invention were found to be non-inhibitory.
- "Active ingredient" as used throughout these examples relates to a compound of formula (I), including any stereo chemically isomeric form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof; in particular to any one of the exemplified compounds.
Typical examples of recipes for the formulation of the invention are as follows: -
Active ingredient 5 to 50 mg Di-calcium phosphate 20 mg Lactose 30 mg Talcum 10 mg Magnesium stearate 5 mg Potato starch ad 200 mg - An aqueous suspension is prepared for oral administration so that each milliliter contains 1 to 5 mg of active ingredient , 50 mg of sodium carboxymethyl cellulose, 1 mg of sodium benzoate; 500 mg of sorbitol and water ad 1 ml.
- A parenteral composition is prepared by stirring 1.5 % (weight/volume) of active ingredient in 0.9 % NaCl solution or in 10 % by volume propylene glycol in water.
-
Active ingredient 5 to 1000 mg Stearyl alcohol 3 g Lanoline 5 g White petroleum 15 g Water ad 100 g - In this Example, active ingredient can be replaced with the same amount of any of the compounds according to the present invention, in particular by the same amount of any of the exemplified compounds.
Claims (15)
- A compound of formula (I)R1 is hydrogen, cyano, CF3, halo, or C1-4alkyl optionally substituted with one or more substituents each independently selected from the group consisting of hydroxyl and C1-4alkyloxy;R2 is hydrogen, C1-4alkyl or halo;X is CR5 or N;R5 is hydrogen or halo;A1 is CR6 or N;R6 is hydrogen, halo or C1-4alkyloxy;A2, A3 and A4 each independently are CH, CF or N;provided that no more than two of A1, A2, A3 and A4 are N;Y1 is CH or N;Y2 is CR4 or N;Y3 is CH or N;provided that only one of Y1, Y2 and Y3 may represent N;R4 is hydrogen, halo, C1-4alkyloxy, cyano, cycloC3-7alkyl, C2-4alkenyl, or C1-4alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo and C1-4alkyloxy;R3 is C2-6alkyl substituted with one or more halo substituents; C1-6alkyl optionally substituted with one or more substituents each independently selected from the group consisting of piperidinyl, morpholinyl, pyrrolidinyl, Ar, C1-6alkyloxy, tetrahydropyranyl, cycloC3-7alkyloxy and cycloC3-7alkyl; cycloC3-7alkyl substituted with one or more phenyl substituents optionally substituted with one or more halo substituents; cycloC3-7alkyl; piperidinyl; morpholinyl; pyrrolidinyl; tetrahydropyranyl; O-Ar; NR7R8; C1-6alkyloxy; C1-6alkylthio; Ar; CH2-O-Ar; S-Ar; NCH3-Ar; NH-Ar; or 1,6-dihydro-1-methyl-6-oxo-3-pyridinyl;
wherein each piperidinyl, morpholinyl and pyrrolidinyl may be substituted with one or more substituents each independently selected from the group consisting of C1-4alkyl, C2-6alkenyl, C1-4alkylcarbonyl, halo and C1-4alkyloxycarbonyl;
wherein each Ar independently is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C1-4alkyloxy, cyano, NR7R8, morpholinyl, C1-4alkyl, C1-4alkyloxy substituted with one or more halo substituents, and C1-4alkyl substituted with one or more halo substituents; or a 5- or 6-membered heteroaryl selected from the group consisting of pyridinyl, pyrimidinyl, oxazolyl, furanyl, thiophenyl, pyrazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridazinyl and pyrazinyl; wherein said 5-or 6-membered heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of halo, C1-4alkyloxy, cyano, C1-4alkyl, C1-4alkyloxy substituted with one or more halo substituents, and C1-4alkyl substituted with one or more halo substituents;each R7 is selected independently from hydrogen or C1-4alkyl;each R8 is selected independently from hydrogen, C1-4alkyl or C1-4alkylcarbonyl;Z is O or NR9;R9 is hydrogen, or C1-6alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, cyano, phenyl, cycloC3-7alkyl and C1-4alkyloxy;or a pharmaceutically acceptable addition salt or a solvate thereof. - The compound according to claim 1 or a stereoisomeric form thereof, wherein
R1 is hydrogen, C1-4alkyl, cyano, CF3, or halo;
R2 is hydrogen or C1-4alkyl;
X is CR5 or N;
R5 is hydrogen or halo;
A1 is CR6 or N;
R6 is hydrogen, halo or C1-4alkyloxy;
A2, A3 and A4 each independently are CH, CF or N;
provided that no more than two of A1, A2, A3 and A4 are N;
Y1 is CH or N;
Y2 is CR4 or N;
Y3 is CH or N;
provided that only one of Y1, Y2 and Y3 may represent N;
R4 is hydrogen, halo, C1-4alkyloxy, cyano, cycloC3-7alkyl, C2-4alkenyl, or C1-4alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo and C1-4alkyloxy;
R3 is C2-6alkyl substituted with one or more halo substituents; C1-6alkyl optionally substituted with one or more substituents each independently selected from the group consisting of piperidinyl, Ar, C1-6alkyloxy, tetrahydropyranyl, cycloC3-7alkyloxy and cycloC3-7alkyl; cycloC3-7alkyl; piperidinyl; morpholinyl; pyrrolidinyl; tetrahydropyranyl; O-Ar; NR7R8; C1-6alkyloxy; C1-6alkylthio; Ar; CH2-O-Ar; S-Ar; NCH3-Ar; or NH-Ar;
wherein each piperidinyl, morpholinyl and pyrrolidinyl may be substituted with one or more substituents each independently selected from the group consisting of C1-4alkyl, C2-6alkenyl, C1-4alkylcarbonyl, halo and C1-4alkyloxycarbonyl;
wherein each Ar independently is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C1-4alkyloxy, cyano, NR7R8, morpholinyl, C1-4alkyl and C1-4alkyl substituted with one or more halo substituents; or a 5- or 6-membered heteroaryl selected from the group consisting of pyridinyl, pyrimidinyl, oxazolyl, furanyl, thiophenyl, pyrazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridazinyl and pyrazinyl; wherein said 5- or 6-membered heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of halo, C14alkyloxy, cyano, C1-4alkyl and
C1-4alkyl substituted with one or more halo substituents;
each R7 is selected independently from hydrogen or C1-4alkyl;
each R8 is selected independently from hydrogen or C1-4alkyl;
Z is O or NR9;
R9 is hydrogen, or C1-6alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, phenyl and C1-4alkyloxy;
or a pharmaceutically acceptable addition salt or a solvate thereof. - The compound according to claim 1 or a stereoisomeric form thereof, wherein
R1 is hydrogen, C1-4alkyl, cyano, CF3, or halo;
R2 is hydrogen or C1-4alkyl;
X is CR5 or N;
R5 is hydrogen or halo;
A1 is CR6 or N;
R6 is hydrogen, halo or C1-4alkyloxy;
A2, A3 and A4 each independently are CH, CF or N;
provided that no more than two of A1, A2, A3 and A4 are N;
Y1 is CH or N;
Y2 is CR4;
Y3 is CH;
R4 is hydrogen, halo, C1-4alkyloxy, cyano, or C1-4alkyl optionally substituted with one or more halo substituents;
R3 is C2-6alkyl substituted with one or more halo substituents; C1-6alkyl optionally substituted with one or more substituents each independently selected from the group consisting of piperidinyl, Ar, C1-6alkyloxy, tetrahydropyranyl, cycloC3-7alkyloxy and cycloC3-7alkyl; cycloC3-7alkyl; piperidinyl; morpholinyl; pyrrolidinyl; tetrahydropyranyl; O-Ar; NR7R8; C1-6alkyloxy; C1-6alkylthio; Ar; CH2-O-Ar; S-Ar; NCH3-Ar; or NH-Ar;
wherein each piperidinyl, morpholinyl and pyrrolidinyl may be substituted with one or more substituents each independently selected from the group consisting of C1-4alkyl, C2-6alkenyl, C1-4alkylcarbonyl, halo and C1-4alkyloxycarbonyl;
wherein each Ar independently is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C1-4alkyloxy, cyano, NR7R8, morpholinyl, C1-4alkyl and C1-4alkyl substituted with one or more halo substituents; or a 5- or 6-membered heteroaryl selected from the group consisting of pyridinyl, pyrimidinyl, oxazolyl, furanyl, thiophenyl, pyrazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridazinyl and pyrazinyl; wherein said 5- or 6-membered heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of halo, C1-4alkyloxy, cyano, C1-4alkyl and C1-4alkyl substituted with one or more halo substituents;
each R7 is selected independently from hydrogen or C1-4alkyl;
each R8 is selected independently from hydrogen or C1-4alkyl;
Z is O or NR9;
R9 is hydrogen, or C1-6alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, phenyl and C1-4alkyloxy;
or a pharmaceutically acceptable addition salt or a solvate thereof. - The compound according to claim 1 or a stereoisomeric form thereof, wherein
R1 is hydrogen, cyano, halo, or C1-4alkyl optionally substituted with one or more hydroxyl radicals;
R5 is hydrogen;
Y1 is CH or N;
Y2 is CR4 or N;
Y3 is CH;
provided that only one of Y1 and Y2 may represent N;
R4 is hydrogen, halo, C1-4alkyloxy, cycloC3-7alkyl, C2-4alkenyl, or
C1-4alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo and C1-4alkyloxy;
R3 is C2-6alkyl substituted with one or more halo substituents; C1-6alkyl optionally substituted with one or more substituents each independently selected from the group consisting of piperidinyl, Ar, C1-6alkyloxy, tetrahydropyranyl and cycloC3-7alkyl; cycloC3-7alkyl substituted with one or more phenyl substituents optionally substituted with one or more halo substituents; cycloC3-7alkyl; piperidinyl; morpholinyl; tetrahydropyranyl; O-Ar; C1-6alkyloxy; C1-6alkylthio; Ar; CH2-O-Ar; NH-Ar; or 1,6-dihydro-1-methyl-6-oxo-3-pyridinyl;
wherein each piperidinyl and morpholinyl may be substituted with one or more substituents each independently selected from the group consisting of C1-4alkyl, C1-4alkylcarbonyl, halo and C1-4alkyloxycarbonyl;
wherein each Ar independently is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C1-4alkyloxy, cyano, NR7R8, C1-4alkyl, C1-4alkyloxy substituted with one or more halo substituents, and C1-4alkyl substituted with one or more halo substituents; or
a 5- or 6-membered heteroaryl selected from the group consisting of pyridinyl and thiophenyl; wherein said 5- or 6-membered heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of halo and C1-4alkyl substituted with one or more halo substituents;
each R8 is selected independently from C1-4alkyl or C1-4alkylcarbonyl or a pharmaceutically acceptable addition salt or a solvate thereof. - The compound according to claim 1, or a stereoisomeric form thereof, wherein
R1 is methyl;
R2 is hydrogen;
or a pharmaceutically acceptable addition salt or a solvate thereof. - The compound according to claim 1, or a stereoisomeric form thereof, wherein
R1 is C1-4alkyl;
R2 is hydrogen;
X is CH or N;
A1 is CR6;
R6 is hydrogen, methoxy or halo;
A2 is CH or N;
A3 and A4 are CH;
Y1 is CH or N; Y2 is CR4; Y3 is CH;
R4 is hydrogen, halo or C1-4alkyl;
R3 is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C1-4alkyloxy, NR7R8 and C1-4alkyl substituted with one or more halo substituents;
R7 is hydrogen;
R8 is C1-4alkylcarbonyl;
Z is NR9;
R9 is C1-6alkyl;
or a pharmaceutically acceptable addition salt or a solvate thereof. - The compound according to claim 1, or a stereoisomeric form thereof, wherein
R1 is C1-4alkyl;
R2 is hydrogen;
X is CH;
A1 is CR6;
R6 is F or methoxy;
A2 is N or CH;
A3 and A4 are CH;
Y1 is CH or N;
Y2 is CR4;
Y3 is CH;
R4 is hydrogen or methyl;
R3 is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo and methoxy;
Z is NR9;
R9 is C1-6alkyl;
or a pharmaceutically acceptable addition salt or a solvate thereof. - The compound according to claim 1, or a stereoisomeric form thereof, wherein
R1 is C1-4alkyl;
R2 is hydrogen;
X is CH;
A1 is COCH3; A2 is N; A3 is CH; A4 is CH;
Y1, Y2 and Y3 are CH;
R3 is phenyl optionally substituted with one or more halo substituents;
Z is NR9;
R9 is C1-6alkyl;
or a pharmaceutically acceptable addition salt or a solvate thereof. - The compound according to claim 1, wherein the compound is
N-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-(4-fluorophenyl)-1,6-dimethyl-1H-imidazo[4,5-c]pyridin-4-amine,
N-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-(4-fluorophenyl)-1,6-dimethyl-1H-imidazo[4,5-c]pyridin-4-amine .2CH3SO3H,
N-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-(4-fluorophenyl)-1,6-dimethyl-1H-imidazo[4,5-c]pyridin-4-amine .2HCl,
2-(4-fluorophenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
2-(4-fluorophenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine .2HCl,
2-(2,3-difluorophenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine .2HCl .H2O,
2-(2,3-difluorophenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
2-(4-fluoro-3-methoxyphenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine .2HCl .H2O,
2-(4-fluoro-3-methoxyphenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
2-(3,5-dimethoxyphenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine .2HCl .H2O, or
2-(3,5-dimethoxyphenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
including any stereochemically isomeric form thereof or a pharmaceutically acceptable addition salt or a solvate thereof. - The compound according to claim 1, wherein the compound is
2-(4-fluorophenyl)-N-[6-methoxy-5-(4-methyl-1H-imidazol-1-yl)-2-pyridinyl]-1-methyl-1H-benzimidazol-4-amine,
or a pharmaceutically acceptable addition salt or a solvate thereof. - A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as defined in any one of claims 1 to 10.
- A compound as defined in any one of claims 1 to 10 for use as a medicament.
- A compound as defined in any one of claims 1 to 10 for use in the treatment or prevention of a disease or condition selected from Alzheimer's disease, traumatic brain injury, mild cognitive impairment, senility, dementia, dementia with Lewy bodies, cerebral amyloid angiopathy, multi-infarct dementia, Down's syndrome, dementia associated with Parkinson's disease and dementia associated with beta-amyloid.
- The compound according to claim 13 wherein the disease is Alzheimer's disease.
- Use of a compound as defined in any one of claims 1 to 10 for the manufacture of a medicament for the treatment or prevention of a disease or condition selected from Alzheimer's disease, traumatic brain injury, mild cognitive impairment, senility, dementia, dementia with Lewy bodies, cerebral amyloid angiopathy, multi-infarct dementia, Down's syndrome, dementia associated with Parkinson's disease and dementia associated with beta-amyloid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10706973.4A EP2398793B1 (en) | 2009-02-19 | 2010-02-15 | Novel substituted benzoxazole, benzimidazole, oxazolopyridine and imidazopyridine derivatives as gamma secretase modulators |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09153188 | 2009-02-19 | ||
EP09163409 | 2009-06-22 | ||
PCT/EP2010/051843 WO2010094647A1 (en) | 2009-02-19 | 2010-02-15 | Novel substituted benzoxazole, benzimidazole, oxazolopyridine and imidazopyridine derivatives as gamma secretase modulators |
EP10706973.4A EP2398793B1 (en) | 2009-02-19 | 2010-02-15 | Novel substituted benzoxazole, benzimidazole, oxazolopyridine and imidazopyridine derivatives as gamma secretase modulators |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2398793A1 EP2398793A1 (en) | 2011-12-28 |
EP2398793B1 true EP2398793B1 (en) | 2013-12-18 |
Family
ID=42136263
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10706973.4A Active EP2398793B1 (en) | 2009-02-19 | 2010-02-15 | Novel substituted benzoxazole, benzimidazole, oxazolopyridine and imidazopyridine derivatives as gamma secretase modulators |
Country Status (18)
Country | Link |
---|---|
US (1) | US8772504B2 (en) |
EP (1) | EP2398793B1 (en) |
JP (1) | JP5512705B2 (en) |
KR (1) | KR20110124772A (en) |
CN (1) | CN102341388B (en) |
AR (1) | AR075520A1 (en) |
AU (1) | AU2010215579B2 (en) |
BR (1) | BRPI1016120A2 (en) |
CA (1) | CA2749495A1 (en) |
EA (1) | EA020141B1 (en) |
ES (1) | ES2452881T3 (en) |
IL (1) | IL214687A (en) |
MX (1) | MX2011008754A (en) |
MY (1) | MY151983A (en) |
SG (1) | SG173668A1 (en) |
TW (1) | TWI461425B (en) |
WO (1) | WO2010094647A1 (en) |
ZA (1) | ZA201106086B (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009308675A1 (en) | 2008-10-31 | 2010-05-06 | Genentech, Inc. | Pyrazolopyrimidine JAK inhibitor compounds and methods |
CA2742897A1 (en) | 2008-11-06 | 2010-05-14 | Astrazeneca Ab | Modulators of amyloid beta. |
PA8854101A1 (en) | 2008-12-18 | 2010-07-27 | Ortho Mcneil Janssen Pharm | IMIDAZOL BICYCLIC DERIVATIVES REPLACED AS MODULATORS OF GAMMA SECRETASA |
CN102325765B (en) | 2009-02-06 | 2014-12-24 | 杨森制药公司 | Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators |
TWI461425B (en) | 2009-02-19 | 2014-11-21 | Janssen Pharmaceuticals Inc | Novel substituted benzoxazole, benzimidazole, oxazolopyridine and imidazopyridine derivatives as gamma secretase modulators |
CN102439005B (en) | 2009-05-07 | 2015-07-22 | 杨森制药公司 | Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators |
UA110324C2 (en) | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
KR20120050450A (en) | 2009-07-15 | 2012-05-18 | 얀센 파마슈티칼즈, 인코포레이티드 | Substituted triazole and imidazole derivatives as gamma secretase modulators |
CA2776480A1 (en) * | 2009-10-20 | 2011-04-28 | Pfizer Inc. | Novel heteroaryl imidazoles and heteroaryl triazoles as gamma-secretase modulators |
US9145399B2 (en) | 2010-01-15 | 2015-09-29 | Janssen Pharmaceuticals, Inc. | Substituted bicyclic triazole derivatives as gamma secretase modulators |
EP2547338A2 (en) * | 2010-03-17 | 2013-01-23 | F. Hoffmann-La Roche AG | Imidazopyridine compounds, compositions and methods of use |
BR112013006016A2 (en) | 2010-09-15 | 2016-06-07 | Hoffmann La Roche | azabenzothiazole compounds, compositions and methods of use |
WO2012066061A1 (en) | 2010-11-19 | 2012-05-24 | F. Hoffmann-La Roche Ag | Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors |
AU2012230348A1 (en) | 2011-03-24 | 2013-08-29 | Cellzome Limited | Novel substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators |
ES2602794T3 (en) | 2011-03-31 | 2017-02-22 | Pfizer Inc | Novel bicyclic pyridinones |
IN2014MN00258A (en) | 2011-07-15 | 2015-09-25 | Janssen Pharmaceuticals Inc | |
KR101383239B1 (en) * | 2012-04-30 | 2014-04-10 | 한국화학연구원 | 4-(Benzimidazol-2-ylamino)pyrrolidine derivatives inhibiting beta-secretase's activity and pharmaceutical composition containing the same as an active ingredient |
JP6106745B2 (en) | 2012-05-16 | 2017-04-05 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | Substituted 3,4-dihydro-2H-pyrido [1,2-a] pyrazine-1,6-dione derivatives useful in the treatment of (especially) Alzheimer's disease |
UA110688C2 (en) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Bicyclic pirydynony |
US10112943B2 (en) | 2012-12-20 | 2018-10-30 | Janssen Pharmaceutica Nv | Substituted imidazoles as gamma secretase modulators |
AU2014206834B2 (en) | 2013-01-17 | 2017-06-22 | Janssen Pharmaceutica Nv | Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators |
EP2818472A1 (en) * | 2013-06-27 | 2014-12-31 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators |
US10562897B2 (en) | 2014-01-16 | 2020-02-18 | Janssen Pharmaceutica Nv | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators |
US9868744B2 (en) | 2014-04-25 | 2018-01-16 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
KR20160142401A (en) | 2014-04-25 | 2016-12-12 | 화이자 인코포레이티드 | Heteroaromatic compounds and their use as dopamine d1 ligands |
CA2946990A1 (en) * | 2014-04-28 | 2015-11-05 | Pfizer Inc. | Heterocyclic compounds and their use as dopamine d1 ligands |
WO2015177326A1 (en) | 2014-05-23 | 2015-11-26 | F. Hoffmann-La Roche Ag | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors |
JP6628805B2 (en) | 2015-02-03 | 2020-01-15 | ファイザー・インク | New cyclopropabenzofuranylpyridopyrazinedione |
CN107922437B (en) * | 2015-09-09 | 2021-12-10 | 豪夫迈·罗氏有限公司 | Bridged piperidine derivatives |
JP6980751B2 (en) * | 2016-07-14 | 2021-12-15 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Condensed pyrimidine derivative |
KR102191461B1 (en) * | 2016-08-23 | 2020-12-15 | 주식회사 엘지화학 | Novel ligand compound and transition metal compound comprising the same |
CN110650959B (en) | 2017-05-22 | 2023-04-18 | 豪夫迈·罗氏有限公司 | Therapeutic compounds and compositions and methods of use thereof |
CN107188853B (en) * | 2017-05-27 | 2020-02-14 | 中国矿业大学 | Tetraphenyl vinyl blue light material containing benzimidazole unit, preparation method and application |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DZ3262A1 (en) | 1999-06-10 | 2000-12-12 | Warner Lambert Co | METHOD FOR INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS USING ISOINDOLINE DERIVATIVES |
CA2406383A1 (en) | 2000-04-13 | 2001-10-25 | Mayo Foundation For Medical Education And Research | A.beta.42 lowering agents |
US20030229105A1 (en) * | 2002-05-21 | 2003-12-11 | Cyclacel Limited | Treatment of autoimmune disorders |
SE0202462D0 (en) * | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel use |
DE10238002A1 (en) | 2002-08-20 | 2004-03-04 | Merck Patent Gmbh | benzimidazole derivatives |
BRPI0410348A (en) * | 2003-05-14 | 2006-05-30 | Torreypines Therapeutics Inc | compounds and uses thereof in amyloid-beta modulation |
DE602005023965D1 (en) | 2004-03-08 | 2010-11-18 | Prosidion Ltd | PYRROLOPYRIDINE-2-CARBOXYLIC HYDRAZIDE AS INHIBITORS OF GLYCOPE PHOSPHORYLASE |
MY149038A (en) | 2004-05-26 | 2013-07-15 | Eisai R&D Man Co Ltd | Cinnamide compound |
JPWO2006046575A1 (en) | 2004-10-26 | 2008-05-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Amorphous form of cinamide compound |
US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
WO2007044895A2 (en) | 2005-10-11 | 2007-04-19 | Chemtura Corporation | Diaromatic amines |
JP2009539762A (en) | 2006-03-13 | 2009-11-19 | ファイザー・プロダクツ・インク | Tetralin antagonist of H3 receptor |
GB0606774D0 (en) | 2006-04-03 | 2006-05-10 | Novartis Ag | Organic compounds |
US7893058B2 (en) | 2006-05-15 | 2011-02-22 | Janssen Pharmaceutica Nv | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
JP2010511019A (en) | 2006-12-01 | 2010-04-08 | ガラパゴス・ナムローゼ・フェンノートシャップ | Imidazopyridine compounds useful for the treatment of degenerative and inflammatory diseases |
CN101631786A (en) | 2006-12-20 | 2010-01-20 | 先灵公司 | Novel jnk inhibitor |
US8183276B2 (en) | 2007-02-08 | 2012-05-22 | Christian Fischer | Therapeutic agents |
EP2155737A1 (en) | 2007-05-07 | 2010-02-24 | Schering Corporation | Gamma secretase modulators |
KR101138045B1 (en) * | 2007-05-11 | 2012-04-24 | 에프. 호프만-라 로슈 아게 | Hetarylanilines as modulators for amyloid beta |
US8242150B2 (en) | 2007-06-13 | 2012-08-14 | Merck Sharp & Dohme Corp. | Triazole derivatives for treating alzheimer'S disease and related conditions |
CA2692253A1 (en) | 2007-06-29 | 2009-01-08 | Schering Corporation | Gamma secretase modulators |
US7935815B2 (en) | 2007-08-31 | 2011-05-03 | Eisai R&D Management Co., Ltd. | Imidazoyl pyridine compounds and salts thereof |
JP2010538068A (en) | 2007-09-06 | 2010-12-09 | シェーリング コーポレイション | Gamma secretase modulator |
MX2010006243A (en) | 2007-12-06 | 2010-08-31 | Schering Corp | Gamma secretase modulators. |
MX2010006378A (en) | 2007-12-11 | 2010-09-07 | Schering Corp | Gamma secretase modulators. |
CN101952275B (en) | 2008-02-22 | 2014-06-18 | 弗·哈夫曼-拉罗切有限公司 | Modulators for amyloid protein beta |
US20100137320A1 (en) | 2008-02-29 | 2010-06-03 | Schering Corporation | Gamma secretase modulators |
WO2010010188A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
EP2367817A4 (en) | 2008-12-03 | 2012-05-09 | Via Pharmaceuticals Inc | Inhibitors of diacylglycerol acyltransferase |
PA8854101A1 (en) | 2008-12-18 | 2010-07-27 | Ortho Mcneil Janssen Pharm | IMIDAZOL BICYCLIC DERIVATIVES REPLACED AS MODULATORS OF GAMMA SECRETASA |
TW201030002A (en) | 2009-01-16 | 2010-08-16 | Bristol Myers Squibb Co | Bicyclic compounds for the reduction of beta-amyloid production |
CN102325765B (en) | 2009-02-06 | 2014-12-24 | 杨森制药公司 | Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators |
TWI461425B (en) | 2009-02-19 | 2014-11-21 | Janssen Pharmaceuticals Inc | Novel substituted benzoxazole, benzimidazole, oxazolopyridine and imidazopyridine derivatives as gamma secretase modulators |
JP2012051806A (en) | 2009-02-26 | 2012-03-15 | Eisai R & D Management Co Ltd | Imidazolylpyrazine derivative |
US20120053165A1 (en) | 2009-03-03 | 2012-03-01 | Pfizer Inc. | Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators |
WO2010126745A1 (en) | 2009-04-27 | 2010-11-04 | High Point Pharmaceuticals, Llc | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS β-SECRETASE INHIBITORS |
CN102439005B (en) | 2009-05-07 | 2015-07-22 | 杨森制药公司 | Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators |
KR20120050450A (en) | 2009-07-15 | 2012-05-18 | 얀센 파마슈티칼즈, 인코포레이티드 | Substituted triazole and imidazole derivatives as gamma secretase modulators |
ES2602794T3 (en) | 2011-03-31 | 2017-02-22 | Pfizer Inc | Novel bicyclic pyridinones |
-
2010
- 2010-02-12 TW TW099104538A patent/TWI461425B/en not_active IP Right Cessation
- 2010-02-15 CN CN201080008839.XA patent/CN102341388B/en not_active Expired - Fee Related
- 2010-02-15 SG SG2011058245A patent/SG173668A1/en unknown
- 2010-02-15 ES ES10706973.4T patent/ES2452881T3/en active Active
- 2010-02-15 EA EA201171066A patent/EA020141B1/en not_active IP Right Cessation
- 2010-02-15 WO PCT/EP2010/051843 patent/WO2010094647A1/en active Application Filing
- 2010-02-15 BR BRPI1016120A patent/BRPI1016120A2/en not_active IP Right Cessation
- 2010-02-15 EP EP10706973.4A patent/EP2398793B1/en active Active
- 2010-02-15 JP JP2011550537A patent/JP5512705B2/en not_active Expired - Fee Related
- 2010-02-15 US US13/144,557 patent/US8772504B2/en active Active
- 2010-02-15 MY MYPI2011003788 patent/MY151983A/en unknown
- 2010-02-15 CA CA2749495A patent/CA2749495A1/en not_active Abandoned
- 2010-02-15 AU AU2010215579A patent/AU2010215579B2/en not_active Ceased
- 2010-02-15 KR KR1020117021607A patent/KR20110124772A/en not_active Application Discontinuation
- 2010-02-15 MX MX2011008754A patent/MX2011008754A/en not_active Application Discontinuation
- 2010-02-18 AR ARP100100483A patent/AR075520A1/en unknown
-
2011
- 2011-08-16 IL IL214687A patent/IL214687A/en not_active IP Right Cessation
- 2011-08-18 ZA ZA2011/06086A patent/ZA201106086B/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2011008754A (en) | 2011-09-09 |
BRPI1016120A2 (en) | 2016-04-12 |
CA2749495A1 (en) | 2010-08-26 |
SG173668A1 (en) | 2011-09-29 |
ZA201106086B (en) | 2015-04-29 |
KR20110124772A (en) | 2011-11-17 |
US8772504B2 (en) | 2014-07-08 |
EA201171066A1 (en) | 2012-04-30 |
WO2010094647A1 (en) | 2010-08-26 |
CN102341388B (en) | 2014-05-07 |
TW201040177A (en) | 2010-11-16 |
AU2010215579A1 (en) | 2011-08-04 |
TWI461425B (en) | 2014-11-21 |
AR075520A1 (en) | 2011-04-06 |
CN102341388A (en) | 2012-02-01 |
US20120022090A1 (en) | 2012-01-26 |
JP5512705B2 (en) | 2014-06-04 |
EP2398793A1 (en) | 2011-12-28 |
IL214687A (en) | 2015-01-29 |
AU2010215579B2 (en) | 2014-04-10 |
ES2452881T3 (en) | 2014-04-03 |
JP2012518024A (en) | 2012-08-09 |
IL214687A0 (en) | 2011-11-30 |
EA020141B1 (en) | 2014-08-29 |
MY151983A (en) | 2014-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2398793B1 (en) | Novel substituted benzoxazole, benzimidazole, oxazolopyridine and imidazopyridine derivatives as gamma secretase modulators | |
EP2393804B1 (en) | Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators | |
AU2011206634B2 (en) | Novel substituted bicyclic triazole derivatives as gamma secretase modulators | |
EP2379552B1 (en) | Substituted bicyclic imidazole derivatives as gamma secretase modulators | |
EP2427453B1 (en) | Substituted indazole and aza-indazole derivatives as gamma secretase modulators | |
EP2454239B1 (en) | Substituted triazole and imidazole derivatives as gamma secretase modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20110919 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA RS |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: JANSSEN PHARMACEUTICALS, INC. |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20130603 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA RS |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: JANSSEN PHARMACEUTICALS, INC. Owner name: CELLZOME LIMITED |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 645579 Country of ref document: AT Kind code of ref document: T Effective date: 20140115 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602010012502 Country of ref document: DE Effective date: 20140213 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2452881 Country of ref document: ES Kind code of ref document: T3 Effective date: 20140403 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20131218 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140318 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 645579 Country of ref document: AT Kind code of ref document: T Effective date: 20131218 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140418 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140418 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602010012502 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 Ref country code: LU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140215 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 |
|
26N | No opposition filed |
Effective date: 20140919 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602010012502 Country of ref document: DE Effective date: 20140919 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140319 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20100215 Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 8 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20211230 Year of fee payment: 13 Ref country code: SE Payment date: 20211229 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20220110 Year of fee payment: 13 Ref country code: DE Payment date: 20211230 Year of fee payment: 13 Ref country code: CH Payment date: 20220114 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20220111 Year of fee payment: 13 Ref country code: FR Payment date: 20220118 Year of fee payment: 13 Ref country code: ES Payment date: 20220304 Year of fee payment: 13 Ref country code: BE Payment date: 20220118 Year of fee payment: 13 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602010012502 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20230228 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20230215 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230216 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230228 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230228 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230215 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230215 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230215 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230215 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230228 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230901 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230228 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20240405 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230216 |